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Abstract
Abstract
Interferon (IFN)-y plays a central role in the pathogenesis of atherosclerosis. The Janus 
kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is the 
most widely used mechanism for IFN-y signalling and STAT1 Ser727 phosphorylation 
is known to be required for its full transcriptional activity. Agonists for peroxisome 
proliferator-activated receptors (PPARs) and liver X receptors (LXRs) as well as statins 
have been shown to exert profound anti-inflammatory actions and protective effects in 
atherosclerosis. However, the molecular mechanisms involved in the IFN-y-stimulated 
STAT1 Ser727 phosphorylation and the anti-inflammatory actions of these therapeutic 
agents, particularly in relation to IFN-y responses are yet to be fully elucidated. Studying 
such mechanisms may lead to the identification of new avenues for the treatment of this 
disease, and was therefore the main focus of studies.
Inhibitors for extracellular signal regulated kinase (ERK), c-Jun N-terminal kinase 
(JNK), casein kinase 2 (CK2), phosphoinostide 3’-kinase (PI3K), protein kinase C-8 
(PKC-8) and calcium-calmodulin-dependent protein kinase II (CaMKII) individually 
inhibited the IFN-y-stimulated STAT1 Ser727 phosphorylation. The most extensive 
inhibition was observed for ERK and JNK and hence their roles in IFN-y signalling 
pathway were investigated in more detail. The ERK inhibitor, PD98059 attenuated the 
IFN-y-induced expression of a range of genes implicated in atherosclerosis. A role for 
the ERK- and JNK-cascades in the regulation of STAT1 transactivation and MCP-1 
gene expression by IFN-y was further confirmed through co-transfection assays with 
plasmids specifying for inactive mutant forms of Ras, Raf-1, ERK1, ERK2, MEK1 and 
JNK. The important roles of ERK and JNK in IFN-y signalling were further supported 
by kinase assays that showed that the activity of ERK and JNK was induced 
approximately 3- and 1.5-fold respectively in response to IFN-y.
RT-PCR analysis also revealed an inhibitory effect of agonists for PPARs and LXRs, as 
well as statins, on the IFN-y-induced expression of several genes implicated in 
atherosclerosis with agent-specific actions being observed. These agents were also 
found to inhibit the IFN-y-stimulated STAT1 transactivation and the activation of 
MCP-1 gene promoter. Endogenous ligands for LXRs, but not agonists for PPARs or 
statins, attenuated the IFN-y-induced STAT1 phosphorylation, DNA binding activity 
and nuclear level of this transcription factor. Co-transfection assays revealed that the 
inhibitory effects on STAT1 activity by the LXR endogenous ligands were dependent on 
the corresponding receptor and that the repressive actions of agonists for PPARs and 
LXRs were not dependent on a mechanism involving competing for a limiting amount 
of shared co-activators in the cells.
These studies together reveal novel roles for ERK and JNK, via modulation of STAT1 
Ser727 phosphorylation, in the regulation of gene expression by IFN-y. In addition, the 
work has demonstrated the inhibitory effects of agonists for PPARs and LXRs as well as 
statins on the IFN-y-induced inflammatory gene expression and potential mechanisms 
underlying such regulation.
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CHAPTER ONE: 
GENERAL INTRODUCTION
Chapter 1: General Introduction
Chapter 1: General Introduction 
1.1 Introduction
Cardiovascular disease (CVD) is considered as the most common cause of premature 
death in the UK nowadays (Allender et al., 2008). Atherosclerosis, the principle cause 
of CVD, is characterised by the formation of a lipid-filled plaque within the wall of 
arteries and known to increasingly threaten human health worldwide (Lusis et al., 
2004). There is therefore an ever increasing demand for effective therapies that 
combat this disease.
The development o f the atherosclerotic lesion is a chronic inflammatory process 
orchestrated by cytokines. The study of signalling mechanisms involved in the 
regulation of gene expression by inflammatory cytokines, with respect to 
atherosclerosis, offers the opportunity to uncover potential targets for therapeutic 
intervention in the future.
The development o f the cholesterol-lowering drugs statins, in the past ten years, has 
had a dramatic benefit in reducing the incidence of the disease in high-risk individuals 
(Grundy, 1998). Recent studies have revealed that statins can exert their 
atheroprotective roles through effects independent of their cholesterol-lowing action. 
These, so called ‘pleiotropic effects’, are largely dependent on their anti-inflammatory 
actions. In addition, the nuclear receptors peroxisome proliferators-activated receptors 
(PPARs) and liver X receptors (LXRs) are emerging as crucial regulators of 
inflammation and potential targets for therapeutic intervention of atherosclerosis. The 
study of molecular basis of the anti-inflammatory actions of these potential 
therapeutic agents could lead to the identification of novel targets for the development 
of new therapies to combat atherosclerosis.
The focus of this thesis is on the mechanisms by which the pro-inflammatory cytokine 
interferon (IFN)-y regulates gene expression, and the molecular basis underlying the 
anti-inflammatory effects of agonists for PPARs and LXRs, along with statins, with 
respect to IFN-y actions.
l
Chapter 1: General Introduction
1.2 Cytokines
Cytokines are small proteins (with molecular weight < 30kDa) that have pleiotropic 
regulatory effects on haematopoiesis and cells participating in immunity and 
inflammation. Cytokines exert a multitude of actions on a variety of cells, including 
regulation o f cell proliferation, differentiation, chemotaxis and other effects associated 
with inflammatory responses. The expression of cytokines is generally low during 
normal condition but induced transiently during situation such as inflammation in 
response to various stimuli (e.g. cytokines or hormones) (Abbas and Lichtman, 2003; 
Vilcek, 2003).
Cytokines are broadly classified into families on the basis o f their structural features. 
Families include: interleukins (IL-1 to IL-26); interferons (e.g. IFN-a, IFN-y); 
chemokines (chemotactic cytokines) (CC, CXC, C, and CX3C subfamilies); tumor 
necrosis factors (e.g. TNF-a); transforming growth factor-p family (e.g. TGF-pi); and 
other growth factors [e.g. platelet-derived growth factor (PDGF)] (Table 1.1) (Vilcek, 
2003).
Table 1.1 Division o f cytokines into families based on structural features 
[adapted from Vilcek (2003)]
Family Representative members
Interleukin-2/-4 IL-2, -4, -5, GM-CSF
Interleukin-6/-12 IL-6,-12
Interferons IFN-a,-p,-co,-y,-x
Interleukin-10 IL-10,-19,-20,-22,-24
Interleukin-17 IL-17, -25
Interleukin-1 IL -la, -P, IL-18
Tumor necrosis factors TNF-a, -P, CD40 ligand
Transforming growth 
factor-P TGF-pl
Chemokines CXC subfamily, CC subfamily , C subfamily, CX3C subfamily
Abbreviations: IL: Interleukin; IFN: Interferon; GM-CSF: granulocyte-macrophage colony 
stimulating factor; TNF: Tumor necrosis factor; TGF: Transforming growth factor
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1.3 Interferon-y
The human interferon (IFN) family is divided into type I IFNs (IFN-a, IFN-P, IFN-e, 
IFN-k, IFN-co and IFN-v) and type II IFNs (IFN-y) (Pestka, 2007). Type I IFNs share 
notable sequence homology and are synthesised by most cell types (Meager, 1998). 
Type II IFN, IFN-y is molecularly distinct from the type I IFNs and functions through 
a separate receptor (IFN-yR). IFN-y is produced predominantly by natural killer (NK) 
cells and activated T-lymphocytes but can also be produced by 
monocytes/macrophages, B cells and dendritic cells (Freucht et al., 2001; Schroder et 
al., 2004). The biological properties of IFN-y are discussed in more detail in the 
following sections.
1.3.1 Structure and production of IFN-y
Human IFN-y (molecular mass of 17kDa) is comprised of two self-associated, 
non-covalent, anti-parallel a-subunits, with secondary structure consisting mostly of 
a-helix with no p-sheet (Pestka, 2007).
IFN-y can be produced by an array of cells largely involved in immunity and 
inflammation, including CD4+ T helper cell type 1 (Thl) lymphocytes, CD8+ 
cytotoxic lymphocytes, natural killer (NK) cells, as well as B cells, professional 
antigen-presenting cells (APCs) and NKT cells (Schroder et al., 2004). IFN-y 
produced by NK cells and professional APCs seems to be important in early stage of 
defence against infection, whereas T lymphocytes secrete the majority of the IFN-y in 
the adaptive immune response. The pathogen encountered macrophages evoke the 
secretion of chemokines that attract immune cells (e.g. NK cells) to the site of 
inflammation, as well as IL-12 that promotes IFN-y synthesis in these cells. The 
synergistic combination of IL-12 and IL-18 produced by activated immune cells (e.g. 
macrophages, T cells and NK cells) further stimulate IFN-y production. In contrast, 
IL-4, IL-10, transforming growth factor (TGF)-p and glucocorticoids act as inhibitory 
regulators of IFN-y production (Boehm et al., 1997; Abbas and Lichtman, 2003; 
Schroder et al., 2004).
1.3.2 Biological significance of IFN-y
IFN-y was originally discovered as an antiviral agent. It is now recognised to play a 
far broader and complex function in aspects of immune responses. The biological
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roles of IFN-y can be grouped into four major classes: anti-viral activity, 
immuno-modulation, inflammation, and regulation of cellular state (Table 1.2).
IFN-y displays antiviral activity through the inhibition of several stages of viral 
protein synthesis and replication, as well as a variety of immuno-modulatory and 
inflammatory roles. Mice deficient in IFN-y or IFN-yR display an increased 
susceptibility to bacterial and viral infection (Dalton et al., 1993; Van den Broeck et 
al., 1995). IFN-y exerts its activity on the immune system and inflammation mainly 
through a number of mechanisms including stimulation of antigen presentation by 
inducing the expression of Class I and II major histocompatibility complex (MHC) 
molecules on the surface of macrophages and T-lymphocytes; antigen processing; 
promoting differentiation of naive T helper (ThO) cells towards Thl phenotype; the 
activation of antigen-presenting cells (APCs) (e.g. macrophages) and T-lymphocytes 
by inducing the production of reactive oxygen intermediates and hydrogen peroxide to 
enhance the killing of intracellular parasites; stimulation of cytokine production in 
target cells; and recruitment of leukocytes to the site of inflammation mainly through 
increased expression of chemokines and adhesion molecules in both leukocytes and 
endothelial cells (Boehm et al., 1997; Stark et al., 1998; Schroder et al., 2004).
In addition to its essential roles in immune system and inflammation, IFN-y is also 
known to regulate the cellular state, mainly by influencing the rate of proliferation, 
differentiation and apoptosis. In general, IFN-y inhibits cell growth by modulating the 
expression of certain genes linked to the cell cycle (e.g. Fas) (Dai et al., 1998), and 
can either induce or suppress apoptosis depending on the cell type or state of 
differentiation (Boehm et al., 1997; Stark et al., 1998; Schroder et al., 2004).
The important role of IFN-y in immunity and inflammation imply that the cytokine is 
likely to have a role in disorders associated with a chronic inflammatory reaction. 
Indeed, several studies have suggested a link between the differential expression of 
IFN-y with the pathology of a number of inflammatory diseases, such as rheumatoid 
arthritis (Canete et al., 2000), glomerulosclerosis (Kitching et al., 1999), and 
pancreatitis (Uehara et al., 2003). In particular, IFN-y has been shown to play central 
roles in atherosclerosis (McLaren and Ramji, 2009) by regulating several processes in 
the pathogenesis o f the disease (Harvey and Ramji, 2005) (see section 1.5 for more 
details).
4
Chapterl: General Introduction
Table 1.2 Biological roles of IFN-y
Roles of IFN-y Mechanisms
Anti-viral activity Inhibition of viral protein synthesis Inhibition of viral replication
Immunomodulation Stimulation of antigen presentation and processing Skew differentiation of ThO towards Thl phenotype
Inflammation Recruitment o f leukocyte into inflammatory sites Stimulation of cytokine production
Regulation of cellular state
Inhibition of proliferation
Regulation of apoptosis
Activation o f APCs and T-lymphocytes
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1.4 Atherosclerosis
Atherosclerosis is a chronic, progressive disorder characterised by the accumulation 
of lipids and complex fibrous elements in the large arteries. The disorder is the 
primary cause of CAD, which is major cause of mortality in western societies (Ross, 
1993; Lusis, 2000).
1.4.1 Lesions of atherosclerosis
The pathology of atherosclerosis can be broken down simplistically into three distinct 
phases: early lesion formation (fatty streaks); development of a complex lesion; and 
plaque rupture (Figure 1.1). The earliest recognisable lesion consists of aggregation of 
cholesterol-engorged macrophages (foam cells) and a varying number of 
T-lymphocytes within the innermost layer of the artery wall (intima) (Ross, 1995). 
The early lesions are usually found at sites characterised by changes in blood flow, 
such as branches, bifurcations and curves (Ross, 1993; Lusis, 2000). Such ‘fatty 
streak’ lesions are ubiquitous in young age and not clinically significant (Ross, 1995). 
This initial lesion may proceed to an expanded, intermediate (fibrofatty) lesion 
characterised by layers of lipid-filled macrophages and T cells that alternate with a 
varying number o f smooth muscle cells (SMCs) surrounded by a relatively poorly 
developed extracellular matrix (ECM) (Ross, 1999). If the response continues, the 
condition could lead to the formation of a fibrous cap comprised of numerous SMCs 
surrounded by collagen, elastic fibres and proteoglycans, which encloses proliferating 
SMCs, macrophages and T cells together with a lipid-rich necrotic core (Ross, 1995; 
Lusis, 2000). The more advanced, complex, occlusive lesions called atheroma (also 
known as fibrous plaques) is covered by a fibrous cap, in which numerous SMCs 
characteristically occupy slit-like spaces surrounded by dense layers of connective 
tissue matrix, including collagen and some elastic fibers. Underneath the fibrous cap, 
a deeper layer o f SMCs and numerous macrophages and T lymphocytes are associated 
with a necrotic core. Beneath the core, there may be additional layers of SMCs and 
connective tissue matrix (Lusis, 2000).
Although a sufficiently large lesion has been detected to block blood flow, the most 
important clinical complication arises when the plaque becomes fragile and ruptures. 
Following the rupture, blood from the lumen enters the lipid core of the plaque, where 
the thrombus starts to form. The thrombus is densely packed fibrin covered by an
6
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active surface made up of platelets. Eventually total arterial occlusion due to 
thrombosis leads to a myocardial/cerebral infarction and stroke (Davies, 2000; Lusis 
et al., 2004).
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Figure 1.1 Characteristic stages of atherosclerosis lesions
The lipid-rich macrophages (foam cells) and T-lymphocytes form the earliest lesion 
called the fatty streak. This lesion is the precursor of more advance lesion 
characterised by the complex aggregation of lipid-rich necrotic debris and SMCs. 
Such early atheromas typically have a fibrous cap consisting of a necrotic core 
enclosed by SMCs and ECM. The condition develops into a more complex 
lesion—the fibrous plaque which could be either stable or vulnerable depending on 
the components. The rupture o f the vulnerable plaque could initiate thrombosis, 
ultimately leading to acute infarction or stroke [taken from (Lusis et al., 2004)].
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1.4.2 Atherosclerosis: a chronic inflammatory process
Atherosclerosis is known as a chronic inflammatory process resulting from the 
cellular/molecular interactions between initiators of atherosclerosis (principally 
lipoproteins), cellular components (monocytes/macrophages, T lymphocytes, 
endothelial cells and SMCs), and ECM of the artery wall (Ross, 1999; Fan and 
Watanabe, 2003).
1.4.2.1 Initiators of atherosclerosis
There are many risk factors considered to influence the progression of atherosclerosis, 
including hypercholesterolaemia, hypertension, diabetes mellitus and free radicals 
produced by cigarette smoking, genetic alterations, elevated plasma homocysteine 
concentrations and infection. From these factors, hypercholesterolaemia is regarded to 
be the most important risk factor as well as the principal initiator (Glass and Witztum, 
2001; Steinberg, 2002). Cholesterol is carried in circulation by several lipoprotein 
particles including chylomicrons, very low density lipoproteins (VLDL), low density 
lipoproteins (LDL) and high density lipoproteins (HDL). In humans, LDL particles 
carry the majority of serum cholesterol to peripheral tissues. It has been demonstrated 
that LDL, VLDL and lipoproteins play a critical role in the pro-inflammatory and 
pro-atherogenic reactions while HDL exerts anti-inflammatory and anti-atherogenic 
functions (Ross, 1999; Steinberg, 2002).
When LDL particles are trapped in an arterial wall, they undergo certain modifications 
before they can subsequently be engulfed by macrophages. The LDL-intemalised 
macrophages develop into foam cells contributing to fatty streak formation. Some 
foam cells are also derived from SMCs. Oxidation is thought to be the most important 
and efficient modification for the LDL being internalised by both macrophages and 
SMCs (Navab et al., 1996; Diaz et al., 1997; Griendling and Alexander, 1997). Cells 
are able to protect themselves against cholesterol-overload by down-regulating the 
LDL receptor (LDLR). Extensively oxidized LDL, however is no longer bound by 
LDLR, but rather by scavenger receptors expressed on macrophages and SMCs (Ross, 
1999; Glass and Witztum, 2001).
1.4.2.2 Endothelial dysfunction
Numerous studies in humans and animals led to the response-to-inj ury hypothesis of 
atherosclerosis. The hypothesis suggests that the manifestation of the dysfunction of
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the endothelium (injury) triggers the inflammatory response followed by the 
fibro-proliferative responses, and if unabated and excessive, the process would 
ultimately lead to an advanced, complicated lesion (Ross, 1993). Risk factors 
associated with increased atherogenesis may induce some forms of endothelial 
dysfunction and oxLDL is regarded to be a key factor (Ross, 1995).
Normal endothelial cells provide a non-adherent surface for leukocytes and platelets 
in the blood. One of the earliest atherogenic alterations seems to be the increased 
accumulation of lipoprotein in the ECM of the subendothelial space of the intima, 
probably due to increased permeability to macromolecules of endothelial cells as a 
result of haemodynamic forces generated by the pulsatile flow of blood (Davignon 
and Ganz, 2004). Indeed, the earliest lesions of atherosclerosis characteristically 
develop in branchpoints of artery and other regions of altered blood flow (Gimbrone 
et al., 2000). After being trapped into the sub-endothelial region of the intima, many 
of these lipoprotein particles are oxidised or glycosylated. oxLDL may induce 
expression of genes that seem to activate the inflammatory response (Hansson, 2001). 
For example, both in vitro and in vivo studies have shown that oxLDL activates the 
expression of vascular cell adhesion molecule-1 (VCAM-1) on the endothelium 
(Cybulsky and Gimbrone, 1991; Frostegard et al., 1991). VCAM-1 expression can be 
induced not only by pro-atherogenic molecules, but also by cytokines such as IFN-y 
secreted by macrophages and T lymphocytes. In addition to VCAM-1, the expression 
of P-and E-selectins and other adhesion molecules are also induced through a 
cytokine-dependent pathway (Ross, 1995; Lusis, 2000; Hansson, 2001). Increased 
accumulation of lipoproteins in the sub-endothelial region results in the elevated 
attachment and subsequent adherence of leukocytes to the endothelial cellular surface 
which contributes to the recruitment of monocytes and T lymphocytes to the 
atherosclerotic lesion (Bonetti et al., 2003).
Following stimulation by mediators produced by a range of cells within lesions, 
including macrophages, platelets, SMCs and T lymphocytes, endothelial cells produce 
a number of growth-regulatory molecules and cytokines, such as platelet-derived 
growth factor (PDGF), fibroblast growth factor (FGF), interleukin-1 (IL-1), tumor 
necrosis factor a (TNFa), macrophage-colony stimulating factor (M-CSF) and 
monocyte chemotactic protein-1 (MCP-1) (Glass and Witztum, 2001; Hansson, 2001).
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These molecules act as paracrine stimulators for neighbouring SMCs, macrophages 
and T lymphocytes, and hence play essential roles in lesion progression (Ross, 1995; 
Quehenberger, 2005; Bobryshev, 2006).
1.4.2.3 Monocyte/macrophage recruitment
Circulating monocytes attach to endothelial cells via adhesion molecules produced by 
endothelial cells in response to inflammatory signals, such as oxLDL. The initial 
adhesion involves rolling interaction followed by firmer attachment by means of 
selectins (L-selectin on the surface of monocytes; P-and E-selectins on the luminal 
surface of activated endothelium) and integrins (pi and p2 on monocytes). The strong 
attachment is mediated by the interaction of the integrins with a class of ligands 
belonging to the immunoglobulin superfamily, most importantly intercellular adhesion 
molecule-1 (ICAM-1) and VCAM-1. With the low affinity for ligands in circulating 
monocytes, the integrins need to be activated by chemokine signals in order to 
mediate the firm adhesion of monocytes to the endothelium (Hansson, 2001; 
Quehenberger, 2005; Bobryshev, 2006). Chemokines are a type of key inflammatory 
cytokines that contribute to early lesion development, which not only stimulate firm 
adhesion, but most importantly guide the adherent monocytes and T lymphocytes 
across the endothelia (Burke-Gaffhey et al., 2002; Braunersreuther et al., 2007a).
1.4.2.4 Specific roles of chemokines in atherosclerosis
Chemokines belong to a large superfamily of small chemotactic proteins that have 
been classified into four subfamilies, C, CC, CXC, and CXXXC, depending on the 
relative position of the first two cysteines. They are known to induce leukocyte 
trafficking and activation through seven transmembrane domain, G protein-coupled 
cell-surface receptors on target cells.
MCP-1 (also known as CCL2) is the most characterised CC chemokine which tends to 
attract mononuclear cells and is found at sites of chronic inflammation (Ikeda et al., 
2002). It has been well established that MCP-1 plays a crucial role in inflammatory 
aspect of atherogenesis (Sheikine and Hansson, 2004; Zemecke and Weber, 2005). 
MCP-1 is produced by atheroma-associated cells (endothelial cells, SMCs, T cells and 
macrophages) (Boisvert, 2004). Increased expression and activity of MCP-1 and its 
receptor CCR2 have been identified in atherosclerotic plaques, and elevated plasma 
levels of MCP-1 have been found to be associated with traditional risk factors for
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atherosclerosis (Ohtsuki et al., 2001; Peters and Charo, 2001; Deo et al., 2004). 
Activation of MCP-1/CCR-2 pathway induces the expression of adhesion molecules, 
pro-inflammatory cytokines and chemokines (Jiang et al., 1992; Lu et al., 1998). The 
overwhelming evidence for a pro-atherogenic role of MCP-1 mainly comes from 
studies on transgenic animals. Over-expression of MCP-1 accelerates atherosclerosis 
in hypercholesterolaemic animals (Aiello et al., 1999; Namiki et al., 2002). By 
contrast, MCP-1 or CCR-2 deficiency significantly reduces atherosclerotic lesion 
development in transgenic atherosclerosis-prone mice (Boring et al., 1998; Gu et al., 
1998; Dawson et al., 1999; Gosling et al., 1999; Ni et al., 2001). In addition to its 
pro-inflammatory roles in atherosclerosis, MCP-1 has been shown to induce the 
expression of genes which are thought to reduce plaque stability (matrix 
metalloproteinases (MMP-1)) and stimulate acute thrombosis (tissue factor) (Schecter 
et al., 1997; Yamamoto et al., 2000). The involvement of MCP-1 in advanced lesion 
complication has been confirmed by studies on apolipoprotein-E (apoE)-knockout 
mice (Inoue et al., 2002b).
MCP-1/CCR2 is not the only chemokine/chemokine receptor involved in monocyte 
recruitment and key roles for other chemokines have also been documented. 
Macrophage inflammatory protein-1 (MIP-1) family is another structure-related 
pro-inflammatory CC cheomokine group, among which MIP-1 a (CCL3) and MIP-lp 
(CCL4) are the best known to date (Maurer and von Stebut, 2004). The MIP-1 family 
members orchestrate acute and chronic inflammatory responses at lesion sites mainly 
by recruiting inflammatory cells, most crucially T-cells, but also monocytes, dentritic 
cells and NK cells (Menten et al., 2002). Pro-inflammatory mediators, such as TNF, 
IFN, lipopolysaccharide (LPS) and various infectious pathogens are known to 
stimulate the production of MIP in a range of atheroma-associated-cells, including 
monocyte/macrophages, T-cells and SMCs. A growing body of evidence suggests that 
MIP-1 proteins are key players in the pathogenesis of many inflammatory conditions 
and diseases, including asthma, wound healing, arthritis, multiple sclerosis and 
pneumonia (Maurer and von Stebut, 2004). Braunersreuther (2007b) and Zemecke 
(2006) have independently reported that deficiency of the MIP-1 receptor CCR5 
reduces atherosclerotic lesion formation in atherosclerosis-prone mice. It is worth 
noting that CCR5 is a receptor for several chemokines, including MIP-la, MIP-lp, 
MCP-2 and RANTES, all of which except MIP-lp are also ligands for CCR1
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(Murdoch and Finn, 2000). Interestingly, two previous studies have reported that 
CCR1-/- mice do not show athero-protective immune responses as shown in CCR5-/- 
counterparts (Braunersreuther et al., 2007a; Zemecke et al., 2008). Therefore, it is 
conceivable that MIP-ip might play a pivotal role in lesion development, although 
direct in vivo and clinical evidence is required.
The IFN-y-inducible protein (IP-10) (also known as CXCL10 as it belongs to the 
CXC group) is another major chemokine that is detectable in atherosclerotic lesion 
and its level is found to increase as lesion progresses (Heller et al., 2006). IP-10 is 
known to be highly induced by IFN-y in atheroma-associated cells (i.e. macrophages, 
endothelial cells and SMCs). It is specifically a chemoattractant for activated 
T-lymphocytes, which is another key immune cellular mediator in atherosclerotic 
lesion progression (Luster and Ravetch, 1987). IP-10-/- and apoE-/- mice demonstrate 
significantly less atherosclerotic lesions compared with the apoE-/- control. Moreover, 
the number and activity of regulatory T-lymphocytes (Treg) was significantly enhanced 
in lesions whereas the overall T-lymphocyte numbers were markedly diminished in 
IP 10-deficient mice compared to wild type control (Heller et al., 2006), suggesting 
that this chemokine promotes atherogenesis probably not only by assisting 
recruitment of T cells into lesion site, but also by modulating discrete subsets of 
lymphocytes in the immune system towards a pro-inflammatory phenotype.
In addition to MCP-1, MIP-1 and IP-10, a continuously expanding body of 
chemokines have been found to play important roles in atherogenesis, such as 
interleukin-8 (IL-8)/CXCL8 (potent chemoattractant to macrophages), 
RANTES/CCL5 (towards T-cells), and fractalkine/CXC3CLl (chemoattractant to 
both monocytes and T-cells) (Takahashi et al., 2002; Linton and Fazio, 2003).
1.4.2.5 Macrophages, central players in the developing plaque
Monocyte-derived macrophages, which are present at all stages of atherosclerotic 
lesion development, have a multifunctional role in the progression of the lesion 
(Jonasson et al., 1986; Weber et al., 2008). In human atherosclerotic plaques, -40% of 
the cells express macrophage markers and apoE-knock out mice lacking macrophages 
develop very little atherosclerosis despite high cholesterol levels in the blood (Smith et 
al., 1995), thus demonstrating a central role for macrophages in this disease 
(Quehenberger, 2005; Hansson and Libby, 2006).
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Macrophages express scavenger receptors, such as CD36, CD68, CXCL16, 
lectin-type oxidized low-density lipoprotein receptor 1 (LOX-1), scavenger receptor A 
(SR-A) and SR-B1, which internalize oxLDL leading to foam-cell formation, a 
rate-limiting step in atherosclerosis (Nicoletti et al., 1999; Quehenberger, 2005). After 
the uptake of oxLDL, endosomes loaded with ligand-bound scavenger receptors 
transfer cholesterol ester to lysosomes for intracellular degradation and also to 
peptide-loading compartments for MHC-class-II association. Therefore, scavenger 
receptors can mediate uptake of modified antigens for presentation to antigen-specific 
T cells and subsequently initiate the adaptive immune response (Janeway and 
Medzhitov, 2002). The induced expression of inflammatory cytokines, chemokines 
and co-stimulatory molecules in macrophages provide the additional antigen-specific 
stimuli and co-stimulatory molecules to activate antigen-specific T cells (Glass and 
Witztum, 2001; Li and Glass, 2002). Macrophages thus act as an important link 
between innate and adaptive immunity involved in atherogenesis.
Macrophages have two mechanisms for disposing of excess cholesterol in order to 
maintain cholesterol homeostasis: enzymatic modification to more soluble forms and 
the cholesterol efflux pathway. Cholesterol 27 hydroxylase, highly expressed in 
macrophages, is thought to convert cholesterol to the more soluble 27-OH-cholesterol. 
The expression of cholesterol 27 hydroxylase has also been observed to enhance 
cholesterol efflux (Escher et al., 2003). One of the principal components of the 
cholesterol efflux system is ATP-binding cassette transporter Al (ABCA1) that 
facilitates the transport of cholesterol from cells to HDL which ultimately returns the 
cholesterol to the liver (Singaraja et al., 2002). ApoE can serve as an acceptor of 
cholesterol transported by the ABCA1-dependent pathway (Greenow et al., 2005). 
Due to its atheroprotective property, enhancement of this particular cholesterol efflux 
pathway in macrophages is thought to have important therapeutic significance 
(Cuchel and Rader, 2006).
1.4.2.6 Roles of macrophages in plaque destabilisation
Increased macrophage density has long been known to correlate with weakened 
atherosclerotic plaque cap (Lendon et al., 1991). Indeed, macrophages have now been 
shown to contribute to the destabilisation of the plaque in a number of ways. First, as 
macrophage foam cells undergo apoptosis themselves, their contents contribute to the
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necrotic core (Li and Glass, 2002). Macrophages have also been shown to release the 
pro-thrombotic molecules, such as tissue factor (TF) and complement proteins (e.g. 
complement C3b) into the necrotic core to increases the thrombogenic potential of the 
plaque (Takahashi et al., 2002; Linton and Fazio, 2003). In addition, the proteolytic 
enzymes, including matrix metalloproteinases (e.g. MMP-2, MMP-9) produced by 
macrophages, act to weaken the fibrous cap and so lead to the eventual plaque rupture 
(Newby, 2008).
1.4.2.7 Cytokines in atherosclerosis
It is now well accepted that atherosclerosis is a chronic disease of the arterial wall 
where both innate and adaptive immuno-inflammatory mechanisms are involved. Cell 
types within the atheroma include monocytes/macrophages, endothelial cells, SMCs, 
and T-lymphocytes as well as lower numbers of dendritic cells (DCs), mast cells, a 
few B cells and probably natural killer T (NKT) cells. Cytokines secreted by these 
cells play central roles during atherosclerotic lesion development. Cytokines regulate 
the recruitment o f inflammatory cells to the lesion through: chemotaxis; modulation 
of expresson of cell adhesion molecules by endothelial cells, SMCs and macrophages; 
and the regulation of cell proliferation and migration in the atheroma. 
Cytokine-induced expression of some genes, such as scavenger receptor (SR)-A and 
CD36, are involed in the uptake of modified lipoprotein (e.g. oxLDL), resulting in the 
cytoplasmic vacuoles of lipids that are the hallmark of foam cells. After proteolytic 
processing, fragments of the protein component of LDL bind major histocompatibility 
complex molecules (MHC) class II molecules and traffic to the cell surface. The 
specific molecular epitopes presented on professional antigen-presenting cells (APCs) 
(e.g. macrophages) are thought to be recognised by antigen receptors on T cells (TCR) 
and activate T lymphocytes and hence trigger the adaptive T cell immunity, [see 
(Grainger, 2004; Mehra et al., 2005; Hansson and Libby, 2006; Tedgui and Mallat, 
2006; Kleemann et al., 2008; Loppnow et al., 2008; Weber et al., 2008) for reviews]. 
Most ox-LDL reactive CD4+T cells of murine and human atherosclerotic plaques are 
of the Thl phenotype producing Thl cytokines, such as IL-2, IFN-y and TNF-a. 
Several consistent experimental studies have clearly shown a critical 
pro-inflammatory and pro-atherogenic role for these cytokines. On the other hand, 
Th2 cells, which are less abundant, compared to Thl cells in the atheroma, produce 
cytokine such as IL-10, which is thought to be athero-protective due to its
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anti-inflammatory properties. Indeed, the chronic vascular inflammation during 
atherosclerotic lesion development is thought to be probably the result of 
pro-inflammatory and pro-atherogenic cytokines (e.g. TNF-a, IFN-y and chemokines) 
overweighing the anti-inflammatory signals (e.g. TGF-p and IL-10). Cytokines also 
modulate plaque stability by regulating the expression of effectors of ECM turnover, 
and to thrombosis through the regulation of genes involved in coagulation cascades 
[see (Daugherty et al., 2005; Mehra et al., 2005; Tedgui and Mallat, 2006) for 
reviews]. Among these cytokines, some of key players exert their crucial roles at all 
stages of the lesion development, such as IFN-y.
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1.5 The roles of IFN-y in atherosclerosis
IFN-y plays a central role in the pathogenesis of atherosclerosis. The cytokine 
stimulates a wide range of immune cellular responses, including the regulation of 
antigen presentation, control of Thl/Th2 adaptive immune response, immune cell 
activation and cytokine secretion (Mallat and Tedgui, 2004; Gattoni et al., 2006; 
Schoenbom et al., 2007). These responses, together with the IFN-y-mediated 
regulation of other cellular activities, such as proliferation, differentiation and 
apoptosis (Stark et al., 1998), all participate in the complex nature of atherosclerosis. 
Although this cytokine can display anti-inflammatory properties (Muhl and 
Pfeilschifter, 2003), IFN-y predominantly exerts pro-inflammatory and 
pro-atherogenic roles throughout disesae development, ranging from early lesion 
formation (foam cell), to the more mature and advanced lesion progression (atheroma), 
to clinical complication of atherosclerotic plaques (destablisation and thrombosis) and 
these actions are discussed in detail below.
1.5.1 Foam cell formation
The formation of macrophage- and SMC-originating foam cells is the pathological 
hallmark of the early stage of atherosclerotic lesion. Monocytes are recruited into the 
subendothelial layer of the intima where they differentiate into macrophages and 
transform into foam cells (Ross, 1993, 1995; Bobryshev, 2006), due to excessive 
accumulation of cholesterol as a result of an imbalance in the uptake of modified LDL 
into the cell and efflux of cholesterol out of it (Pennings et al., 2006). IFN-y is known 
to stimulate foam cell formation by promoting immune cell recruitment to the lesion 
and disturbing cellular cholesterol homeostasis.
1.5.1.1 Recruitment of immune cells to the lesion
Development of atherosclerotic plaque is achieved largely through persistent 
recruitment of monocyte/macrophages, SMCs and T lymphocytes to the lesion sites. 
As discussed in section 1.4.2.3-4, a large group of chemokines and adhesion 
molecules orchestrate the recruitment of immune cells. IFN-y up-regulates such 
recruitment by inducing the expression of these molecules. For instance, IFN-y has 
been reported to induce the expression of a range of key chemokines, including 
MCP-1, M IP-la and P, monokine induced by IFN-y (MIG), IFN-inducible T cell 
alpha chemoattractant (I-TAC) and CXC-chemokine ligand 16 (CXCL16) (Valente et
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al., 1998; Boisvert, 2004; Charo and Taubman, 2004; Wuttge et al., 2004). This 
cytokine also acts as an important mediator in stimulating the expression of ICAM-1 
and VCAM-1 on endothelial cells, SMCs and within the atheroma (Cybulsky et al., 
1993; Chung et al., 2002).
The majority of macrophages and T cells in the atherosclerotic lesion are in an 
activated state, which involes increased secretion of pro-inflammatory cytokines and 
chemokines so contributing to the inflammation and growth of the plaque. IFN-y has 
been shown to stimulate the differentiation and activation of macrophages (Nathan et 
al., 1983). T lymphocytes are activated by recognising the fragment of LDL, as a 
result of intracellular processing, associated with MHC class II molecules presented 
on the surface of APCs. IFN-y mediates the activation of CD4+ T-cells (Thl) through 
increased expression of MHC Class II molecules on the surface of a variety of cell 
types including ECs, macrophages and SMCs (Jonasson et al., 1985; Mach et al., 
1996).
1.5.1.2 Increased cholesterol accumulation in cells
The uptake of modified LDL principally involves a family of scavenger receptors, 
such as SR-A and CD36 (Greaves et al., 1998). Although a few early studies showed 
that IFN-y inhibits the expression of these genes and foam cell formation in vitro 
(Geng and Hansson, 1992; Nakagawa et al., 1998), an increasing volume of evidence 
indicates that the cytokine increases, rather than decreases, the uptake of modified 
LDL and the expression of scavenger receptor genes, such as SR-A and CXCL16. 
IFN-y has been shown to increase the uptake of acetylated or oxidised LDL by THP-1 
macrophages (Reiss et al., 2004; Wuttge et al., 2004), a widely employed cell line for 
the study of macrophages in relation to atherosclerosis (see Table 3.1 for a list of 
publications using THP-1 for investigations on atherosclerosis). Expresison of 
chemokine/scavenger receptor CXCL16/SR-PSOX was also found to be increased by 
IFN-y in human primary monocytes, THP-1 macrophages, human aortic SMCs, as 
well as in murine atherosclerotic lesion (Wagsater et al., 2004; Wuttge et al., 2004). 
The IFN-y-induced expression of the scavenger receptor SR-A has also been reported 
in early differentiated THP-1 macrophages and vascular SMCs (Li et al., 1995; 
Grewal et al., 2001).
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As discussed in section 1.4.2.5, the cholesterol efflux pathway involves the reverse 
transport of cholesterol out of the cells by ABC transporter family, such as ABCA1, 
facilitated by apoE or apoAl serving as cholesterol acceptors. IFN-y decreases the 
cholesterol efflux from macrophages by inhibiting the expression of ABCA1 and 
apoE (Brand et al., 1993; Gamer et al., 1997; Panousis and Zuckerman, 2000). 
Moreover, IFN-y has also been shown to reduce the expression of 27-hydroxylase, 
which assists in the removal of cholesterol from foam cells (Reiss et al., 2001).
All these pieces of evidence indicate a role for IFN-y in promoting foam cell 
formation by increasing cholesterol uptake into the cells and preventing macrophage 
cholesterol efflux.
1.5.2 Advanced plaque formation
As the disease progresses, the atherosclerotic lesion becomes increasingly complex 
and the advanced plaque includes specific features such as cellular debris, a lipid-rich 
necrotic core and calcification (Lusis et al., 2004). IFN-y promotes apoptosis of 
macrophage foam cells by inducing the expression of several genes including TRAIL, 
Fas and caspase 4 and 8 (Tamura et al., 1996; Inagaki et al., 2002). IFN-y can also 
prime vascular SMCs to Fas-induced apoptosis, in part by trafficking of Fas to the cell 
surface (Rosner et al., 2006). Accelerated apoptosis of these cells has been suggested 
to contribute to the accummulation of necrotic debris and plaque instability in 
advanced lesions (Inagaki et al., 2002). IFN-y may contribute to calcification by 
up-regulating the expression of 1-a-hydroxylase, which catalyses the convertion of 
25-hydroxyvitamin D to 1-a, 25-dihydroxyvitamin D metabolite (Esteban et al., 
2004).
1.5.3 Plaque destabilisation
The high risk of plaque rupture and thrombosis seems to be highly associated with 
increased foam cell content and a thin fibrous cap (Davies, 2000). IFN-y is thought to 
promote plaque destabilisation by increasing the plaque cellularity and weakening the 
protective cap. IFN-y weakens the fibrous cap by inhibiting the expression of collagen 
genes, SMC proliferation and matrix synthesis, and meanwhile increasing the 
population of matrix metalloproteinases (e.g. MMP-1,2,3,9) that are thought to break 
down the ECMs and thereby destabilise the plaque [see (Harvey and Ramji, 2005) for
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review]. In addition, the activity of tissue factor, which stimulates thrombosis 
following plaque rupture, is enhanced by IFN-y (Nakagomi et al., 2000). IFN-y 
therefore increases the likelihood of clinical complication of atherosclerotic lesion.
1.5.4 Lessons from murine atherosclerotic models
Important insight into the roles of IFN-y in atherogenesis has been largely gained 
from studies using mouse models. Wild-type mouse strains are resistant to 
atherosclerosis as the circulating cholesterol is transported principally by high-density 
lipoproteins (HDL) that participate in the reverse cholesterol transportation pathway, 
towards the liver. In order to develop a mouse model with atherosclerotic lesion 
similar to those in humans, researchers have created knockout mice, which have 
pathological disturbance in lipid metabolism. The knockout mice most often used 
today are deficient in genes for apoE and for LDLR. These mice develop 
atherosclerosis spontaneously (apoE-/-) or following a high-cholesterol diet (LDLR-/-) 
[see (Hofker MH, 1998; Jawien et al., 2004) for reviews]. Table 1.3 summarises the 
findings from studies into the roles of IFN-y on atherosclerotic lesion formation using 
these mouse models.
IFN-y or IFN-y receptor (IFN-yR)-deficient atherosclerotic-prone mice exhibit 
significant reduction in diet-induced atherosclerosis compared with apoE-/- or 
LDLR-/- control mice (Gupta et al., 1997; Whitman et al., 2002a; Buono et al., 2003). 
More recently, Koga et al. (2007) investigated the effect of blocking of IFN-y function 
by overexpressing a soluble mutant IFN-y receptor (sIFNyR) in apoE-/- mice and 
found a reduced luminal plaque area. Furthermore, administration of exogenous IFN-y 
enhances atherosclerosis in apoE-deficient mice (Whitman et al., 2000). These results 
consistently suggest an important pro-atherogenic role for IFN-y. IL-18 has also been 
shown to increase atherosclerosis in apoE-deficient mice through the release of IFN-y 
(Whitman et al., 2002b).
In addition, knocking-out of IFN-y and IFN-yR in apoE-/- mice and deficiency of 
IFN-yR in LDLR-/- mice resulted in reduction in cellularity, amount of T lymphocytes 
and MHC Class II-positive cells within the lesion (Gupta et al., 1997; Whitman et al., 
2002a; Buono et al., 2003), thereby suggesting an important role for IFN-y in immune 
cell recruitment, cellular proliferation and activation of the adaptive immune response
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in atherosclerosis in vivo. Consistent with these findings, administration of exogenous 
IFN-y into the apoE-null mice led to the development of lesions with increased T 
lymphocytes and MHC Class II-positive cells (Whitman et al., 2000). Koga et al. 
(2007) have suggested that blocking of IFN-y could benefit atherosclerosis by 
reducing local inflammatory responses and increasing plaque stability, and therefore 
provide a useful therapeutic target to combat this disease and reduce the likelihood of 
clinical complications. The potential merits of IFN-y-deficiency in plaque stabilisation 
have also been proposed by an earlier study (Gupta et al., 1997).
Despite these pieces of compelling evidence supporting pro-atherogenic roles of 
IFN-y, Niwa et al. (2004) showed that IFN-y-deficient bone marrow transplanted 
(BMT) LDLR-/- mice develop larger atherosclerotic lesion area than LDLR-/- mice, 
thus suggesting an anti-atherogenic role for this cytokine produced by bone marrow 
(BM)-derived cells. However, the differences in lesion size in aortic arch and 
abdominal aorta only occurred after 6 weeks of high-fat diet (HFD) feeding, but 
disappeared after 12 weeks of HFD feeding. These results suggest that the IFN-y 
produced by BM-derived cells is only involved in the early phase of lesion 
development. Interestingly, consistent with some other studies (Gupta et al., 1997; 
Koga et al., 2007), these authors indicated that the enlarged atherosclerotic lesions in 
IFN-y -/- (BMT) mice, which contained increased collagen deposition and decreased 
cellularity, were probably more stable than the lesion in IFN-y +/+ mice. It is also 
worth noting that the authors agreed some limitations in their study. During BMT, the 
mice undergo lethal total body y-irradiation followed by bone marrow reconstitution 
from donors with transgenic alterations. Schiller et al. (2001) have indicated that 
BMT itself can accelerate atherosclerosis and IFN-y can be up-regulated by 
y-irradiation at BMT. This could be one of the explanations why IFN-y-/- (BMT) mice 
develop larger atherosclerotic lesion than IFN-y+/+ mice. Therefore, more work will 
be required to elucidate the precise reason why the IFN-y produced by BM-derived 
cells appeared to play a different role in atherosclerosis from the IFN-y produced by 
other cells.
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Table 1.3 Effects of IFN-y on atherosclerotic lesion formation in mice
Gene deficient Effect on atherosclerotic lesion Roles of IFN-y in atherosclerosis Diet
Treatment/
Procedure References
IFN-yR/apoE
Decreased lesion size;
Decreased lipid accumulation;
Decreased cellularity;
Increased collagen content;
Increased ApoAIV rich particles in plasma
Pro-atherogenic High fat (Gupta et al., 1997)
IFN-yR/LDLR
Decreased lesion size;
Decreased cellularity at 8 weeks; 
Decreased MHC Class II-positive cells 
No changes in serum cholesterol
Pro-atherogenic High fat (Buono et al., 2003)
IFN-y/apoE Absence of IL-18-induced atherogenesis in IFN-y-deficient mice Pro-atherogenic
Daily
injection of 
IL-18
(Whitman et al., 
2002b)
IFN-y/apoE
Decresed lesion size in males only; 
Decreased T lymphocytes and MHC Class 
II-positive cells in males only
Pro-atherogenic in male 
only
Normal/ 
High fat
(Whitman et al., 
2002a)
u n a p ic r i;  u cn era i im roaucuun
IFN-y
(BMT)/LDLR
Increased lesion size; 
Decreased cellularity; 
Increased collagen content
IFN-y produced by 
BM-derived cells 
anti-atherogenic, but 
may decrease plaque 
stability
High fat
Bone
marrow
transplant
(Niwa et al., 
2004)
ApoE
Increased lesion size;
Increased T lymphocytes;
Increased MHC Class II-positive cells; 
Decreased serum cholesterol
Pro-atherogenic
Daily
injection of 
IFN-y
(Whitman et al., 
2000)
ApoE
Decreased lesion size;
Decreased lipid core;
Decreased macrophages;
Increased SMC and fibrotic area;
Decreased expression of pro-inflammatory 
cytokines, chemokines, VCAM-1 and MMPs, 
but increased expression of pro-collagen type 
I in aorta;
No changes in serum cholesterol
Pro-atherogenic High fat
Gene
transfer of 
sIFNyR by 
injection 
every 2 
weeks
(Koga et al., 
2007)
Abbreviations: IFN, interferon; IFN-yR, interferon-y receptor; BMT, bone marrow transplant; apoE, apolipoprotein E; LDLR, low density lipoprotein receptor; 
MHC, major histocomatibility complex; IL, interleukin;
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1.6 JAK-STAT pathway in IFN-y signalling
Cytokines mediate signalling through binding to specific receptors resident at the cell 
surface. The association of the cytokine with its receptor generally results in the 
alterations in receptor conformation and initiates a specific signalling cascade leading 
to changes in gene transcription, translation or post-translational modifications. Janus 
kinase (JAK)/signal transducer and activator of transcription (STAT) signalling 
pathway is one of the best understood mechanisms by which cytokines transduce 
signals that elicit specific responses in target cells (Abbas and Lichtman, 2003). This 
pathway has been reported to be employed by over 50 cytokines to affect gene 
regulation and the IFN family is included in them (Schroder et al., 2004).
1.6.1 JAK-STAT Signalling in the IFN-y response
IFN-y-mediated cellular signalling requires the binding of the cytokine homodimer to 
the IFN-y receptor complex. The receptor complex consists of two ligand binding 
chains (IFNGR1) associated with two non-ligand binding, signal transducing chains 
(IFNGR2) (Tau and Rothman, 1999). The receptor complex is pre-assembled on the 
cell surface without requiring ligand binding (Krause et al., 2006). None of the 
receptor chains have intrinsic kinase activity and the intracellular domain of IFNGR1 
and IFNGR2 chains constitutively associate with JAK1 and JAK2 respectively 
(Aaronson and Horvath, 2002; Leon and Zuckerman, 2005). The interaction of STAT1 
with IFNGR1 results in a conformational change of IFNGR1 and although only JAK1 
is required for the two receptor chains to interact, the presence of both JAK1 and 
JAK2 is necessary for any ligand-dependant conformational change (Krause et al., 
2006).
Figure 1.2 illustrates the JAK-STAT signalling mechanism in the IFN-y response. 
Following the binding of IFN-y to the receptors, JAK2 undergoes 
auto-phosphorylation and the activated JAK2 in turn phosphorylates JAK1. 
Phosphorylated JAK1 is then able to phosphorylate a critical tyrosine residue 440 on 
IFNGR1, which then provides two adjacent docking sites for Src homology (SH)2 
domain of latent STATl. The receptor-associated STATl dimer is phosphorylated on 
tyrosine residue 701 (Y701), likely through phosphorylated JAK2. Phosphorylated 
STATl homodimer dissociates from the receptor and migrates to nucleus where it 
binds to IFN-y-activated site (GAS) elements (consensus sequence: TTNCNNNAA)
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present in the promoter of target genes to govern the transcription of IFN-y-regulated 
genes [see (Platanias and Fish, 1999; Schroder et al., 2004) for reviews]. Although 
IFN-y primarily signals through the STATl homodimer, the other complexes such as 
STAT heterodimer (e.g. STATl :STAT2) have also been found to activate transcription 
(Darnell et al., 1994).
Many of the genes induced during the first wave of IFN-y-regulated transcription are 
transcription factors themselves, most notably interferon regulatory factor-1 (IRF-1), 
which is able to further drive the regulation of the next wave of transcription. IRF-1 
belongs to the IRF gene family, of which IRF-1, -2 and -9 all participate in IFN-y 
signalling. Heterotrimers (e.g. STATl .STATl :IRF-9, STATl :STAT2:IRF-9 (known as 
ISGF3)) as well as IRF-1 are able to bind to IFN-stimulated response element (ISRE) 
to control the transcription of a spectrum of IFN-regulated genes (Platanias and Fish, 
1999; Schroder et al., 2004; Leon and Zuckerman, 2005; Platanias, 2005). 
Additionally, IRF-1 can also bind to an unusual IRF-F site, which has overlapping 
sequence with ISRE consensus site. The expression of STATl can be induced through 
this pathway (Taniguchi et al., 2001). IFN-y therefore regulates its signalling pathway 
via a positive feedback loop involving transcriptional activation of STATl.
1.6.2 Activation of STAT 1
Earlier studies revealed that phosphorylation at Tyr701 of STATl by JAKs is a crucial 
step for STATl activation as it is required for the formation of STAT complex, nuclear 
translocation and DNA binding (Darnell et al., 1994). It has now been well established 
that in addition to Tyr701 phosphorylation, the full activation of STATl-dependent 
transcription involves multiple mechanisms, including STATl serine phosphorylation 
and interaction with other proteins.
1.6.2.1 STAT serine phosphorylation
It has long been recognised that phosphorylation of STATl at serine residue (Ser727), 
localised in its carboxyl-terminus is essential for full IFN-y-dependent transcriptional 
activation (Wen et al., 1995). The biological significance of STATl Ser727 
phosphorylation has been confirmed in vivo by the use of mice expressing a 
serine727-alanine mutant of STATl (STAT1S727A), which have increased mortality 
after infection along with an impaired innate immune response. In addition, the
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expression of IFN-y-induced genes was strongly reduced in macrophages expressing 
STATlS727A (Varinou et al., 2003).
Despite the firmly established significance of STATl Ser727 phosphorylation in 
IFN-y signalling, the underlying mechanisms involved in the phosphorylation at this 
site is yet to be fully identified. It has been shown that STATl serine phosphorylation 
occurs independently of tyrosine phosphorylation and requires JAK1/2 and tyrosine 
440 STATl docking residue of IFNGR1 (Zhu et al., 1997; Nguyen et al., 2001). 
Recently, several studies have suggested a number of mechanisms involved in the 
IFN-y-induced STATl Ser727 phosphorylation and these mechanisms appear to 
operate in a cell type-specific manner. Involvement of extracellular signal-regulated 
kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase (p38 MAPK) has been 
reported in human monocytic THP-1 cell line and human keratinocytes respectively 
(Overbergh et al., 2006). Contradictory results, however, also exist in different cell 
types (see Table 1.4 for a list of studies focusing on the roles of MAPK on STAT 
serine phosphorylation). Nguyen et al. (2001) showed that IFN-y regulates STATl 
serine phosphorylation via phosphoinositide 3-kinase (PI3K)/Akt signalling in tumour 
cells and fibroblasts. A study carried out by Deb et al. (2003) demonstrated that PKC8 
is activated in an IFN-y-dependent manner and kinase activity of PKC5 mediates 
phosphorylation of Ser727 on STATl in human acute promyelocytic leukemia NB-4 
cell line. Interestingly, these authors also showed that the engagement of PKC8 in 
IFN-y signalling occurs downstream of PI3K and proposed a JAK—PI3K—PKC5 
signalling cascade. Work in our laboratory recently revealed that casein kinase 2 (CK2) 
and PI3K mediate the IFN-y-regulated expression of several key genes implicated in 
atherosclerosis, at least in part by, modulating STATl serine phosphorylation, in 
murine macrophages (Harvey et al., 2007).
1.6.2.2 Interaction with other transcription factors and cellular proteins
The transcriptional regulation of eukaryotic genes involves the specific and ordered 
interaction of a large number of proteins including transcription factors, chromosomal 
remodelling complexes and components of the basal transcriptional machinery. 
Indeed, the ability of STAT-dependent transcription is largely dependent on their 
interaction with other transcriptional regulators. STATl was shown to interact with 
NFkB, Spl, USF-1, PU.l and the glucocorticoid receptor (Brierley and Fish, 2005).
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Other studies have demonstrated the association between STATs and proteins that 
facilitate transcription through chromatin modification. p300/CBP 
(cAMP-response-element binding protein (CREB)-binding protein) is one of them and 
it belongs to a class of co-activators, namely histone acetyltransferases (HAT). These 
acetylate core histones leading to changes in chromatin structure and thus improved 
accessibility o f DNA to basal transcriptional machinery (Zhang et al., 1996). 
IFN-activated STAT has also been reported to interact with other proteins, including 
general control non-depressible 5 (GCN5), brahma-related gene-1 (BRG-1) and 
nMYC (Brierley and Fish, 2005; Platanias, 2005). STATl can also associate with 
minichromosome maintenance 5 (MCM5) and MCM3 which interact with RNA 
polymerase II and function as DNA helicases (Zhang et al., 1998).
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Figure 1.2 The paradigm of IFN-y-induced JAK-STAT signalling pathway.
Inactive JAK1 and JAK2 constantly associate with IFNGR1 and IFNGR2 
respectively. IFN-y binding causes a conformation change in IFNGR, such that the 
inactive JAK2 undergoes auto-phosphorylation, which in turn allows JAK1 
transphosphorylation by JAK2. The activated JAK1 phosphorylates tyrosine residue 
440 on each IFNGR 1 chain to provide docking sites for the Src homology (SH)2 
domains o f STATl. Recruited STATl pair is phosphorylated at tyrosine residue 701. 
The phosphorylated STATl dimer dissociates from the receptor, and migrates to the 
nucleus where it binds to promoter IFN-y-activation site (GAS) elements to 
modulate transcription of IFN-y-regulated genes [adapted from (Schroder et al., 
2004)].
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1.7 Roles of mitogen-activated protein kinase (MAPK) 
pathways in IFN-y signalling
1.7.1 Overview of MAPK pathways
Proper regulation of gene expression in all forms of cellular life is dependent on 
intracellular regulatory circuits or signal transduction pathways. Mitogen-activated 
protein kinase (MAPK) pathway is a key cellular signal transduction pathway that 
governs cellular activities ranging from gene expression, mitosis, movement, 
metabolism and apoptosis (Roux and Blenis, 2004) and hence has come to be 
appreciated as one of the most attractive targets for drug development (Hommes et al., 
2003; Kaminska, 2005; O'Neill, 2006).
To date, five distinct groups of MAPKs have been characterised in mammals: 
extracellular signal-regulated kinases 1/2 (ERK1/2); c-Jun N-terminal kinases 
(JNK)/stress-activated protein kinases (SAPK) 1, 2 and 3; p38 isoforms a, (3, y and 6; 
ERK-3 and -4; and ERK5. The best known groups of vertebrate MAPKs are the 
ERK1/2, JNK/SAPK and p38 MAPK (Robinson and Cobb, 1997; Chang and Karin, 
2001; Chen et al., 2001; Johnson and Lapadat, 2002). MAPKs are a three-tiered 
phospho-relay system composed of 3 sequentially activated kinases, a MAP kinase 
(MAPK), MAPK kinase (MAPKK, MKK or MEK) and a MAPKK kinase or MEK 
kinase (MAPKKK or MEKK). Extracellular stimuli, such as growth factors, cytokines, 
physical and/or chemical stress, initiate signal transduction from the cellular 
membrane mediated by sequential phosphorylation and activation of specific 
components of MAPK cascades—MAPKKK. MAPKKK-catalysed phosphorylation 
activates the MAPKK and induces its activity for catalysing the phosphorylation of its 
own substrates—MAPK (Figure 1.3). Activation of MAPK results in the 
phosphorylation and the subsequent activation of transcription factors, producing 
expression of target genes in response to particular biological stimuli. MAPKs can 
also catalyze the phosphorylation of several protein kinases, named MAPK-activated 
protein kinases (MKs) which further extend the enzymatic and amplification steps in 
MAPK signalling cascades [see (Chang and Karin, 2001; Pearson et al., 2001) for 
reviews].
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MAP kinase signal transduction pathway
MAPKK
MAPK
Targets
Growth Factor, 
Mitogens
Cytokines, 
chemical and 
radiant stresses
Elk-1 ATF-2
Elk-1
MEK4, MEK7MEK1, MEK2
JNKERK1, ERK2 p38 MAPK
ATF-1
c-Jun
Elk-1
Figure 13  Three best known vertebrate MAP kinase pathways [adapted from 
(Hommes et al., 2003; Kaminska, 2005)]
The best known groups of vertebrate MAPKs are the ERK1/2, JNK/SAPK and p38. 
MEK1/2-ERK1/2 pathway is known to be mainly activated by growth factors and 
mitogens, while MEK3/6-p38 and MEK4/7-JNK/SAPK pathways are stimulated by 
cytokines and cellular stresses. In addition to JNK/SAPK, MEK4/7 can also act as 
upstream kinase of p38. Activated MAPK phosphorylate a range of transcription 
factors (e.g. Elk-1, ATF-2 and c-Jun), which result in the expression of target genes in 
response to particular biological stimuli.
Abbreviation: ATF-2: activating transcription factor-2; ERK, extracellular signal regulated 
kinase; JNK, c-jun-N-terminal kinase
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1.7.2 Physiological and pathological roles of MAPK pathways
Collectively, numerous studies have revealed a wide range of physiological roles of 
MAPK pathways and different cascades are known to play distinct roles. In particular, 
gene targeting technology has largely contributed to our knowledge of their normal- 
and patho-physiological functions in vivo. The following sections will focus on the 
biological properties and functions of the best known MAPK signalling in human 
(ERK1/2, JNK 1/2/3 and p38).
1.7.2.1 Extracellular signal-regulated kinases 1/2 (ERK1/2)
ERK signalling is known to be a vital mediator of a number of cellular fates including 
growth, proliferation, differentiation, survival and immune cell activation. Results 
from gene knockout experiments have illustrated the physiological and pathological 
importance of the ERK 1/2 pathway. ERK2 and MEK 1-knockout mice have 
embryonic lethality due to defective mesoderm differentiation and placenta 
vascularisation respectively (Giroux et al., 1999; Hatano et al., 2003). These results 
illustrate indispensable roles of ERK2 and MEK1 in embryonic development. In 
addition, ERK1 knockout mice are viable but show defective thymocyte maturation 
and reduced expression of a and P chains of the T cell receptor, and exhibit reduced 
activation by anti-CD3 antibody, illustrating that ERK1 is involved in T cell activation 
and inflammatory processes (Pag et al., 1999). Addition of the ERK inhibitor 
PD98059 has been found to block Th2 cell differentiation in vitro, thereby suggested 
that activation of the ERK pathway might play a significant role in such 
differentiation (Yamashita et al., 1999).
Studies via various approaches, such as pharmacological modulation, use of 
genetically modified animals, and expression of constitutive or dominant-negative 
forms of enzymes have revealed key roles of ERK activation in cardiac pathology, 
such as myocardial hypertrophy and ischemia/reperfusion injury, as well as in the 
mechanisms of cardio-protection such as ischaemic preconditioning [see 
(Ravingerova et al., 2003) for a review].
1.7.2.2 c-Jun N-terminal kinases (JNK)/stress-activatedprotein kinases (SAPK)
JNKs include JNK1 and JNK2 which are ubiquitously expressed, and JNK3, which is 
present primarily in the heart, brain and testis (Chang and Karin, 2001). Although 
individual JNK isoform-knockout mice are viable, the combined genetic disruption of
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JNK1 and 2 proved embryonic lethal due to altered apoptosis program in the lateral 
edge of the hindbrain prior to neural tube closure, suggesting that JNK1 and JNK2 
may have redundant or at least overlapping roles (Kuan et al., 1999). Moreover, as the 
phenotypes of these JNK-deficient animals have been further examined, it has become 
clear that JNK1 and JNK2 proteins in many tissues perform different cellular 
functions. Some of the primary evidence for the different roles for JNK1 and JNK2 
came from studies for JNKs in the immune response (Dong et al., 2002). Studies on T 
cells in JNK1-/- and JNK2-/- mice revealed that JNK2 plays a critical role in Th cell 
differentiation towards Thl and is involved directly in the production of signature 
cytokines of Thl cells, such as IFN-y, whereas JNK1 promotes Thl differentiation via 
negatively regulating Th2 differentiation (Dong et al., 1998; Sabapathy et al., 1999).
Isoform-specific targeting of individual JNKs has revealed many pathological roles 
played by these kinases. JNK1-/- mice are protected against the following diseases: 
arthritis; obesity; type 2 diabetes; cardiac cell death; and non-alcoholic liver disease. 
Similarly, JNK2-/- mice are also protected against a broad range of pathologies: 
arthritis; typel diabetes; atherosclerosis; abdominal aortic aneurysm; cardiac cell 
death, and TNF-induced liver damage and tumour growth (Bogoyevitch et al., 2004; 
Waetzig and Herdegen, 2005; Marie, 2006). In particular, knockout of the JNK2 gene 
in apoE-/- mice fed with high cholesterol resulted in a significant reduction in 
numbers of atherosclerotic plaques possibly via decrease in foam cell formation, 
whereas the absence of JNK1 had no effects (Ricci et al., 2004). Although the actual 
mechanism of JNK2 in foam cell formation remains unclear, it has been suggested 
that JNK2 may act through scavenger receptor A to induce apoptosis in 
free-cholesterol-loaded macrophages (DeVries-Seimon et al., 2005).
The expression of JNK3 is restricted in certain tissues, thereby suggesting that it plays 
unique physiological roles different from JNK1 and 2. In particular, studies on 
phenotypes of JNK3 knockout mice have revealed the significant function of JNK3 in 
a range of neuronal pathologies (Brecht et al., 2005). In particular, deletion of JNK3 
gene has been shown to attenuate the pathological features of Parkinson’s disease and 
Alzheimer’s disease (Hunot et al., 2004).
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1.7.2.3 p38MAPK
Mammalian p38 MAPK pathway is associated with cell growth, differentiation and 
stress-induced apoptosis (Chang and Karin, 2001; Hommes et al., 2003). There are 
four p38 isoforms: p38a, p38p, p38y, and p385, with p38a being the major isoform 
that is activated in most inflammatory cells (Dong et al., 2002). p38 MAPK has been 
shown to positively regulate the expression of genes coding for a range of 
pro-inflammatory cytokines, such as IFN-y, TNF-a, IL-lp and IL-6 (Kaminska, 2005). 
In addition, p38 regulates the TNF-a-induced expression of vascular cell adhesion 
molecule-1 (VCAM-1) in endothelial cells, and chemoattractants such as TGF-p can 
induce neutrophil chemotaxis through p38 activation (Pietersma et al., 1997; 
Hannigan et al., 1998). Pharmacological inhibition of p38 MAPK also suggests the 
involvement of this kinase cascade in the immune and inflammatory responses. Fijen 
et al. (2001) demonstrated that inhibition of p38-MAPK by pyridinyl imidazole 
RWJ-67657 might be a tool to intervene in the deranged immune response in sepsis 
and other inflammatory diseases. Inhibition of p38-MAPK activity by SB203580 also 
reduced myocyte secretion of TNF-a, and prevented bum-mediated cardiac 
dysfunction (Ballard-Croft et al., 2001).
These observations illustrate a central role for p3 8 in the regulation of a wide range of 
immunological responses and hence, this signalling has been recognised by 
pharmaceutical companies as a therapeutic target for anti-inflammatory drug 
development (Kaminska, 2005). To date, two pharmacological inhibitors have been 
taken into Phase II clinical trials. SCIO-469 is in Phase II trials for pain, multiple 
myeloma and rheumatoid arthritis (Nikas and Drosos, 2004) whereas VX-702 has 
been reported to meet its primary objectives in 12-week Phase II trial in 315 patients 
with rheumatoid arthritis (Vertex, 2006).
1.7.3 MAPK pathways in STAT serine phosphorylation
In addition to IFN-y as discussed in section 1.5, the significance of STAT has been 
well established in various signal transduction pathways induced by diverse stimuli 
(Decker and Kovarik, 2000). Distinct STAT isoforms are known to be employed in 
various stimuli-induced signalling. By and large, STAT1 is relatively specific to IFNs, 
STAT3 is activated by IL-6 and related cytokines, STAT4 is activated by IL-12 and 
IFN-a, and STAT6 is specifically activated by IL-4 and IL-13. STAT5 is activated by
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various cytokines including IL-2, IL-3, erythropoietin and growth hormone (Decker 
and Kovarik, 2000; Yoshimura, 2006). In addition, serine phosphorylation of different 
STATs can be mediated through distinct signalling pathways. Three major signal 
transducers in MAPK pathway (i.e. ERK, JNK and p38) have all been reported to be 
vital in serine phosphorylation of different STAT isoforms modulated by different 
signals. O f note, STAT la  Ser727 is known to locate in the carboxy terminus (STATlp 
lacks the region including Ser727 site) in the sequence of PMS727P, which fits MAPK 
consensus recognition sequence [PXn(S/T)P (P, proline; SAT, serine/theronine; X, any 
amino acid; n=l or 2)], further supporting an involvement of MAPK in STAT1 
activation (Wen et al., 1995). On the other hand, there are also studies showing that 
the MAPK pathways are not required for STAT serine phosphorylation (see Table 1.4 
for a full list of publications).
L 7.3.1 ERK
PD98059 and U0126 are both highly specific inhibitors of MEK1-ERK1/2 and 
MEK5-ERK5 (Davies et al., 2000), although a much higher concentration is required 
for inhibiting MEK5-ERK5 (Mody et al., 2001). Inhibition of phosphorylation by 
these inhibitors is thus thought to be a considerably specific criterion for an 
involvement o f the ERK pathway in STAT1 and STAT3 activation in response to 
diverse stimuli including prolactin, IFN-y, UV, erythropoietin and 
hematopoietic-specific Gaj6 protein (Haq et al., 2002; Lo et al., 2003; Wierenga et al., 
2003; Zhang et al., 2004; Zykova et al., 2005; Kanda and Watanabe, 2007) (see Table 
1.4 for the full list of studies). In addition to using pharmacological inhibitors, 
involvement o f ERK-1 and -2 has also been demonstrated in cells where 
phosphorylation was shown to be either attenuated or enhanced by over-expression of 
dominant negative or constitutive active ERK protein respectively (Lo et al., 2003; 
Zykova et al., 2005). ERK2 and STAT3 have also been found to be 
co-immunoprecipitated from cells (Jain et al., 1998).
While these data support a role for ERKs as STAT serine kinases, several lines of 
evidence argue against a general validity of this concept. First, insensitivity of 
induced serine phosphorylation by PD98059 and U0126 in some cell lines suggests 
that the involvement of ERKs in the modulation of STATs serine phosphorylation is 
cellular- and stimuli- dependent (Gollob et al., 1999; Lim and Cao, 1999; Burysek et
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al., 2002; Huang et al., 2004) (see Table 1.4 for a full list of studies). In the case of 
IFN-y, only a weak and transient activation of ERK2 was observed in IFN-y-treated 
mouse embryonic fibroblasts and this low level of activation did not correspond to the 
time course of STAT1 serine phosphorylation induced by IFN-y (Zhu et al., 1997).
1.7.3.2 JNK/SAPK
As the ERK pathway, roles for the JNK pathway in STAT1 and STAT3 serine 
phosphorylation induced by various stress such as UV, anisomycin, sodium arsenite, 
Src oncoprotein and growth factors, such as epidermal growth factor (EGF) and 
platelet derived growth factor (PDGF), have also been demonstrated by using specific 
pharmacological inhibitors (e.g. SP600125) and over-expression of dominant negative 
JNK proteins (Lim and Cao, 1999; Zykova et al., 2005). Absence of the response in 
serine phosphorylation of STAT1 and STAT3 to various signals observed in JNK1-/- 
and JNK2-/- cells also demonstrates the essential roles of JNK-1 and -2 in the 
induction of such phosphorylation (Zhang et al., 2004; Zykova et al., 2005).
Active and inactive forms of MEKK1 that phosphorylate JNK1 through JNK 
upstream kinase SAPK/ERK kinase 1 respectively, enhance and reduce EGF-induced 
STAT3 serine phosphorylation and in turn its DNA binding and transcriptional 
activities (Lim and Cao, 2001). The same research group has also identified that JNK1 
negatively regulated the tyrosine phosphorylation and DNA binding and 
transcriptional activities of STAT3 stimulated by EGF (Lim and Cao, 1999). The 
authors thus proposed that JNK may have dual effects on STAT3 transcriptional 
activity, i.e. induction via Ser727 phosphorylation and inhibition in a 
Ser727-independent manner (Lim and Cao, 1999, 2001). These results indicate a 
critical and complex role of the MAPK pathway in the regulation of STATs.
1.7.3.3 p38 MAPK
As with investigation of the roles of ERK and JNK in STAT serine phosphorylation, 
specific pharmacological inhibitors, such as SB203580 and SB202190, and dominant 
negative plasmids have been employed in studies on the involvement of p38 MAPK 
in such phosphorylation. Induction of STAT1 serine phosphorylation by diverse 
stimuli, including UV, erythropoietin, IFNs, anisomycin and serine protease plasmin 
in various cell lines has been found to be sensitive to either SB203580 or SB202190 
(Goh et al., 1999; Burysek et al., 2002; Haq et al., 2002; Ramsauer et al., 2002; Zhang
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et al., 2004; Zykova et al., 2005; Kanda and Watanabe, 2007) (see Table 1.4 for a full 
list of publications). In addition, cells expressing an SB203580-resistant p38 display 
SB203580-insensitive, UV-induced STAT Ser727 phosphorylation, which positions 
p38 upstream of STAT1 in response to stress like UV (Kovarik et al., 1999).
Both STAT1 and STAT3 serine phosphorylation can be enhanced by synergistic 
actions such as those between IL-12 and IL-2 and such enhancement is also reduced 
by treatment of the cells with SB203580 (Gollob et al., 1999). p38 inhibitors have also 
been shown to attenuate STAT3 serine phosphorylation by serine protease plasmin 
(Burysek et al., 2002) and UVA (Zhang et al., 2004). p38 is also constitutively 
induced in src-transformed fibroblasts and functions as STAT3 kinase for serine 727 
phosphorylation (Turkson et al., 1999). STAT4 is phosphorylated on serine 721 in 
cells transfected with a constitutively active MKK6 and p38, suggesting it too can be 
a target of the p38 pathway. p38 also can be activated by IL-12 and in turn 
phosphorylates STAT4 (Visconti et al., 2000).
Although compelling evidence for the involvement of p38 in STAT serine 
phosphorylation has been provided, there is controversy regarding a role of p38 in 
such phosphorylation in response to some stimuli, including IFN-y. No effects of 
SB203580 was observed on serine phosphorylation induced by IFN-y in macrophages 
(Kovarik et al., 1999) and similar level of phosphorylation was induced by IFN-y in 
p38a-deficient and wild type fibroblasts (Ramsauer et al., 2002).
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Table 1.4 Dependence or independence of STAT serine phosphorylation on MAPK pathways in response to various stimuli
STAT protein Stimuli MAPK- 
dcpcndcnt or 
independent
Cell or animal used Evidence Reference
STAT1 Prolactin ERK Human neonatal foreskin keratinocytes Sensitive to U0126
(Kanda and 
Watanabe, 2007)
STAT1 IFN-y ERK Monocytic THP-1 Sensitive to PD98059 (Overbergh et al., 2006)
STAT1 IFN-y p38 Human neonatal foreskin keranocytes Sensitive to SB203580
(Kanda and 
Watanabe, 2007)
STAT1 Anisomycin p38 3T3 fibroblast from STAT1-/- mice
No phosphorylation induced by 
aninomycin in p38-/- cells; 
Reduction of phosphorylation in 
wild type cells by SB203580
(Ramsauer et al., 
2002)
STAT1 IFN-a and -y p38 HeLa S3 Cells
Activation of p38 by IFN-a and 
-y; Sensitive to SB203580 and 
dominant negative form of p38
(G ohetal., 1999)
STAT1 Synergy between LPS and IFN-y
p38 dependent; 
ERK independent Murine endothelial cells
Sensitive to SB202190; 
Resistant to PD98059 (Huang et al., 2004)
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STAT1 Hyperosmolarity p38 independents African green monkey kidney fibroblasts COS-7
No effects of either 
over-expression of wild type or 
kinase deficient form of p38 and 
MKK6
(Bode et al., 1999)
STAT1 IFN-y p38 independent
3T3 fibroblasts from 
STAT1-/- mice and 
STAT1-Ser727 mutant 
mice; p38a-/- mouse 
embryonic fibroblasts
Similar level of phosphorylation 
observed in p38a deficient and 
wild type cells
(Ramsauer et al., 
2002)
STAT1 UVB ERK, JNK and p38
Mouse epidermal JB6 
C141 cells; JNKl-/-and 
JNK2-/- cells
Sensitive to PD98059, U0126, 
SB203580 and SP600125; 
Inhibition by dominant negative 
forms of ERK2, JNK1 and p38; 
Response absent in JNK1-/- and 
JNK2-/- cells
(Zykova et al., 2005)
STAT1 UVA ERK, JNK, p38 Mouse epidermal JB6 C141 cells
Sensitive to PD98059, U0126, 
SB202190 and PD169316; 
Phosphorylation blocked by 
dominant negative forms of p38a 
and JNK1;
Phosphorylation blocked in 
JNK 1/2-/- cells
(Zhang et al., 2004)
STAT1 Erythropoietin ERK, p38 Ba/F3 cells with erythropoietin receptors
Sensitive to PD98059, U0126 and 
SB202190 (Haq et al., 2002)
38
STAT1 IFN-y MAPKindependent
Mouse embryonic 
fibroblast cell line NIH 
3T3
No activation of ERK, JNK or p38 
by treatment with IFN-y;
No effects on STAT1 
phosphorylation by dominant 
negative Ras;
Absence of response to activated 
form of Ras
(Zhu et al., 1997)
STAT 1/3 Serine protease plasmin
p38 dependent; 
ERK independent
Human primary 
monocytes
Sensitive to SB203580; 
Resistant to U0216
(Burysek et al., 
2002)
STAT 1/3 Synergy between IL-2 and IL-12
p38 dependent; 
ERK independent Human primary T cells
Sensitive to SB203580; 
Resistant to PD98059 (Gollob et al., 1999)
STAT3 Erythropoietin ERK Ba/F3 cells with erythropoietin receptor Sensitive to PD98059 and U0126 (Haq et al., 2002)
STAT3 Hematopoietic-spe cific Gal 6 protein ERK
Human embryonic 
kidney 293 cell line
Enhancement by over-expression 
of active ERK1;
Sensitive to U0126;
Inhibition by co-expression of 
dominant negative Ras and Rac-1
(Lo et al., 2003)
STAT3 UV
JNK dependent;
ERK and 
p38 independent
African green monkey 
kidney fibroblast COS-1 
cell line
Resistant to PD98059 and 
SB203580; phosphorylation by 
MEKK1 activated JNK1 in vitro; 
Phosphorylation by JNK and 
MEKK1 expression plasmids in 
vivo
(Lim and Cao, 1999)
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STAT3
Epidermal growth 
factor/platelet 
derived growth 
factor
JNK
African green monkey 
kidney fibroblast COS-1 
cel lline; Hela S3 cell line
Inhibition by kinase-inactive 
MEKK1; induced by active 
MEKK1
(Lim and Cao, 2001)
STAT3 Src JNK, p38 3T3 fibroblasts Phosphorylation by active JNK and p38
(Turkson et al., 
1999)
STAT3 UVA ERK, JNK, p38 Mouse epidermal JB6 C141 cells
Sensitive to PD98059 and 
SB202190; inhibition by dominant 
negative ERK2, JNK1 and p38; 
absence of phosphorylation in 
JNK1 -/- and JNK2-/- mice
(Zhang et al., 2004)
STAT3 Erythropoietin ERK Erythroid cell line ASE2 Sensitive to PD98059 and U0126 (Wierenga et al., 2003)
STAT4 IL-12 p38 Human primary lymphocytes
Activation of p38 by IL-12; 
phosphorylation by active p38a 
and MKK6
(Visconti et al., 
2000)
Abbreviations: ERK, extracellular signal-regulated kinase; IL, interleukin; IFN, interferon; JNK, c-Jun N-terminal kinases
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1.8 Peroxisome proliferator-activated receptors (PPAR) and 
liver X receptors (LXR) agonists target inflammation
Perioxisome proliferators-activated receptors (PPARs) and liver X receptors (LXRs) 
belong to class of nuclear receptors (NRs), so called ‘adopted orphan nuclear 
receptors’. This class of NRs is a superfamily of ligand-activated transcription factors 
that regulate diverse aspects of development, immunity, homeostasis and metabolic 
processes (Tobin and Freedman, 2006). The most striking property of this class is its 
ability to form heterodimers with retinoid X receptor (RXR) to bind to DNA (Giguere, 
1999). PPARs and LXRs are emerging as key regulators of inflammation, and 
potentially the major targets for therapeutic intervention of atherosclerosis (Marx et 
al., 2004; Barish, 2006; Li and Palinski, 2006; Rizzo and Fiorucci, 2006). However, 
the molecular mechanisms underlying the anti-inflammatory actions of PPARs and 
LXRs remain poorly understood (Kota, 2005). Thus, understanding the mechanisms 
involved in inflammatory responses could potentially benefit the development of new 
therapeutic approaches for intervention of atherosclerosis.
1.8.1 PPARs 
1,8,L1 Biology of PPARs
The PPAR family is composed of 3 receptor isoforms, PPARa, PPARy and PPARS 
(also known as PPAR{3). All of them can form heterodimer with RXR and activate 
transcription by binding to a specific DNA element termed the PPAR response 
element (PPRE). In the absence of ligands, PPAR-RXR heterodimers can recruit 
corepressor complex to actively repress transcription. Upon activation by ligands, the 
heterodimer complex undergoes conformational changes, resulting in the release of 
the corepressor complex, the association of coactivators and activation of transcription 
of target genes (Kota, 2005). This activity enables PPARs to positively regulate gene 
networks involved in the control of lipid metabolism and glucose homeostasis in 
several tissues including adipose tissue, muscle and liver, ultimately influencing 
circulating lipid and glucose levels (Delerive et al., 2001; Kersten, 2002). In addition, 
PPARs also act negatively to regulate the expression of pro-inflammatory genes in a 
ligand-dependent manner and several distinct mechanisms have been proposed to date 
(Ricote and Glass, 2007). The details of these mechanisms are discussed below.
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There are a variety of potential endogenous ligands for the PPARs (Table 1.5), 
including unsaturated fatty acids and naturally occurring fatty acids derivatives. 
Synthetic, high-affinity, selective ligands for each type of PPARs are also available, 
such as fibrates (PPARa agonist used to treat hypertriacylglycerolaemia) and 
thiazolidinediones (TZD, also known as glitazones, PPARy agonist used to treat type 
2 diabetes mellitus) (Straus and Glass, 2007).
Table 1.5 Endogenous and synthetic ligands for PPAR isoforms [adapted from 
(Bensinger and Tontonoz, 2008)]
PPAR isoform Endogenous ligands Synthetic ligands
PPARa Unsaturated fatty acids 
Saturated fatty acids 
Leukotriene B4 
8-HETE
Fibrates:
Fenofibrate 
Clofibrate 
Gemfibrozil 
GW7647 
Wy 14643
PPARS Unsaturated fatty acids 
Saturated fatty acids 
Carbaprostacyclin
GW501516 
L-165041
PPARy Unsaturated fatty acids 
15-deoxy-A12,14-PGJ2 
15-HETE 
9- and 13-HODE
TZD (glitazones):
Rosiglitazone (BRL49653)
Pioglitazone
Troglitazone
Ciglitazone
Tyrosine derivatives:
Farglitazar
GW7845
1.8.1.2 PPARs in inflammation and atherosclerosis
Substantial evidence suggests that PPARs are important regulators of the immune 
system and numerous studies have shown that PPAR ligands can exert 
anti-inflammatory roles in a range of tissues, such as lungs, joints, nervous systems 
and gastrointestinal tract (Bensinger and Tontonoz, 2008). The expression of all three 
PPAR isoforms has been observed in vascular wall cells, immune cells and 
atherosclerotic lesions (Neve et al., 2000; Fernandez, 2008). A growing body of 
evidence suggests the atheroprotective effect o f PPARs and the most compelling
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evidence arises from studies on transgenic mice (Table 1.6) and clinical trails. Two 
research groups have shown that administration of PPARa agonists fenofibrate (Duez 
et al., 2002) and GW7647 (Li et al., 2004) could ameliorate atherosclerotic lesion 
progression in LDLR- and apoE-deficient mice respectively. In addition, a number of 
PPARy agonists, such as rosiglitazone (Li et al., 2004), troglitazone (Collins et al., 
2001; Chen et al., 2001b), as well as PPAR-a and -y agonist LY465608 (Zuckerman et 
al., 2002) have been shown to reduce the atherosclerotic lesion size in LDLR- and 
apoE-deficient mice. These results clearly demonstrate the anti-atherogenic effects of 
PPAR-a and -y in transgenic atherosclerosis-prone mice, thereby suggesting the 
therapeutic potential of PPAR-a and -y agonists in the treatment of atherosclerosis. To 
date, a number of clinical trails have produced promising results on the potential 
therapeutic benefits of PPAR-a and -y agonists for the treatment of atherosclerosis. 
Fibrates have been shown to reduce the progression of coronary atherosclerosis in a 
number of independent clinical trails (Ericsson et al., 1997; Frick et al., 1997; 
Diabetes Atherosclerosis Intervention Study Investigators 2001). In addition, various 
studies have demonstrated potential therapeutic benefits of PPARy agonists in 
restoring cardiovascular function by focusing on surrogate markers of atherosclerosis. 
For example, treatment of patients with coronary artery disease and type 2 diabetes 
mellitus with glitazones demonstrated a significant reduction in the circulating level 
of serum amyloid A, TNF-a and MMP9 (Marx et al., 2003a; Marx et al., 2003b). 
Serum amyloid A, TNF-a and MMP9 are all known to predict the risk for the 
development of atherosclerosis (Libby et al., 2002). Moreover, in a clinical study of 
135 Japanese patients with diabetes, troglitazone treatment reduced intimal and 
medial complex thickening in carotid arteries, suggesting that the drug influences 
structural changes in arteriosclerosis (Minamikawa et al., 1998).
In contrast to the compelling evidence on the anti-inflammatory and atheroprotective 
effects of PPAR-a and -y agonists, the role of PPAR5 in the modulation of 
inflammation is less understood (Bensinger and Tontonoz, 2008) and studies on 
mouse models of atherosclerosis have yielded conflicting results. In LDLR-null male 
mice, the PPAR5 agonist GW0742 reduced the expression of inflammatory genes but 
failed to inhibit lesion formation (Li et al., 2004). However, another group has shown 
that the same ligand at a similar concentration has a potent anti-atherogenic effect in 
LDLR-/- female mice (Graham et al., 2005). Additional study in LDLR-/- mice
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transplanted with PPAR8-deficient bone marrow has suggested a pro-atherogenic 
effect of PPARS (Lee et al., 2003). The authors proposed that in the absence of the 
ligand, PPAR8 binds and sequesters Bcl-6, a repressor of atherogenic inflammation 
and by knocking out of PPAR5, Bcl-6 is released and represses inflammation.
These studies (Table 1.6) in mouse models of atherosclerosis have also revealed that 
the atheroprotective effect of PPAR ligands are significantly attributed to their 
anti-inflammatory actions in atherosclerotic lesion cells, most importantly, 
macrophages. Expression of pro-inflammatory molecules, including IFN-y, TNF-a 
and chemokines (e.g. MCP-1, RANTES), have been shown to be inhibited by agonists 
of all three PPAR isoforms in lesions (Li et al., 2004; Graham et al., 2005; Takata et 
al., 2008). In addition, inhibited expression of ICAM-1 and VCAM-1 suggests that 
these ligands negatively regulate atherosclerotic progression, possibly at least in part, 
through inhibition of leukocytes adhesion to vascular endothelial cells (Li et al., 2004; 
Graham et al., 2005). This notion has been confirmed by a number of studies in vitro 
(Marx et al., 1999; Collins et al., 2001; Barish et al., 2008).
Therefore, investigating the molecular mechanisms of PPAR agonists in 
atherosclerotic lesion cells not only could improve our understanding of roles of these 
nuclear receptors in the development of atherosclerosis, but might also facilitate our 
search for novel therapies to combat this disease.
44
Chapter 1: General Introduction
Table 1.6 Roles of PPARs on atherosclerotic lesion formation in mice
Nuclear
receptor
Ligands (dose) or 
other treatment
Effects on atherosclerotic lesion Role of PPAR in 
atherosclerosis
References Animal Diet
PPARa GW7647
(2.5mg/kg/day)
Decreased lesion area;
Decreased expression of IFN-y,TNF-a, MCP-1, 
ICAM-1 and VCAM-1 in lesion;
Decreased lipid accumulation in peritoneal 
macrophages
anti-atherogenic (Li et al., 2004) LDLR-/- 
male mice
high fat
PPARa fenofibrate
(lOOmg/kg/day)
Decreased lesion area in human apoA I 
transgenic mice;
Decreased expression of MCP-1 mRNA in aorta
anti-atherogenic (Duez et al., 
2002)
apoE-/-
mice
high fat
PPARy rosiglitazone
(lOmg/kg/day)
Decreased expression of IFN-y, TNF-a, MCP-1, 
ICAM-1 and VCAM-1 in lesion;
Decreased lipid accumulation in peritoneal 
macrophages;
anti-atherogenic in 
male mice
(Li et al., 2004) LDLR-/- 
male mice
high fat
PPARy troglitazone
(4g/kg/day)
Decreased lesion size;
Decreased macrophage accumulation in intimal 
xanthomas;
anti-atherogenic (Collins et al., 
2001)
LDLR -/- 
Mice
high fat 
or
high
fructose
PPARy troglitazone 
(0.1% of food w/w)
Decreased lesion area;
Increased HDL cholesterol level
anti-atherogenic (Chen et al., 
2001b)
apoE-/-
mice
high fat
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PPARy rosiglitazone
GW7845
(20mg/kg/day)
Decreased lesion size in male mice;
Decreased expression of TNF-a and gelatinase B 
in aortic root;
No change in lesion size in female mice;
anti-atherogenic in 
male mice
(Li et al., 2000) LDLR-/-
mice
high fat
PPARa, y LY465608
(lOmg/kg/day)
Decreased lesion size anti-atherogenic (Zuckerman et 
al., 2002)
apoE -/- 
mice
/
PPARS GW0742
(5mg/kg/day)
Decreased expression of IFN-y, TNF-a, MCP-1, 
ICAM-1 and VCAM-1 in lesion;
No change in lesion size;
No change in weight and insulin level;
No change in lipid accumulation in peritoneal 
macrophages
anti-inflammatory in 
male mice
(Li et al., 2004) LDLR-/- 
male mice
high fat
PPARS GW0742
(6 and 60mg/kg/day)
Decreased lesion area;
Decreased expression of MCP-1 and ICAM-1 
(lesion), TNF-a (macrophages and adipose 
tissue), MCP-1, RANTES, IL-12 and sTNFRl 
(serum)
anti-atherogenic in 
female mice
(Graham et al., 
2005)
LDLR-/-
female
mice
high fat
PPARS GW501516
(2mg/kg/day)
Decreased lesion area;
Increased HDL cholsterol level;
Decreased monocyte transmigration through an 
endothelial cell monolayer mediated by MCP-1 
gradient
anti-atherogenic in 
male mice
(Barish et al., 
2008)
apoE-/- 
male mice
high fat
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PPARS GW0742
(1 and lOmg/kg/day)
Decreased lesion area;
Decreased macrophage content in lesion; 
Decreased vascular expression of TNF-a, IL-6, 
MCP-1, CCR2, VCAM-1 and osteopontin; 
Increased expression of angiotensin II-inhibited 
Bcl-6 in aorta and peritoneal macrophages; 
abolished angiotensin II-stimulated 
phosphorylation of ERK1/2 and p38 in 
peritoneal macrophages
anti-atherogenic (Takata et al., 
2008)
LDLR-/-
mice
stimulated
with
angiotensin
II
high fat
PPARS bone marrow 
transplant from 
PPARS-/- mice
Decreased lesion size pro-atherogenic (Lee et al., 
2003)
LDLR-/-
Mice
high fat
Abbreviations: PPAR, perixisome proliferators-activated receptors; IFN, interferon; TNF, tumor necrosis factor; MCP, Monocyte chemoattractant protein; 
ICAM, Inter cellular adhesion molecule 1; VCAM, Vascular cell adhesion molecule; IL, interleukin; CCR, CC chemokine receptor; ERK, extracellular 
signal-regulated kinase; HDL, high density lipoprotein
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1.8.1.3 Anti-inflammatory actions of PPAR ligands in cells associated with 
atherosclerosis
PPARs have been demonstrated to be expressed in cells within human and murine 
atherosclerotic lesions, co-localising with macrophages, endothelial cells and SMCs 
(Marx et al., 1998; Ricote et al., 1998; Chinetti et al., 2000a; Chinetti et al., 2000b). 
Several studies have indicated that PPAR ligands may exert their anti-inflammatory 
and protective roles in atherosclerotic lesion development by modulating immune and 
inflammatory responses in these cells (Figure 1.4).
Early atherogenesis is characterised by the recruitment and the subsequent entry of 
monocytes/macrophages to an activated endothelium and ultimately their 
trans-migration into the intima. This process is largely mediated by interactions 
between different molecules, including pro-inflammatory cytokines (e.g. IFN-y, 
TNF-a), chemokines (e.g. MCP-1, IP-10), adhesion molecules (e.g. ICAM-1, 
VCAM-1), selectins (e.g. E-selectin) and intergrin [see (Quehenberger, 2005) for 
review]. Expression of chemokines is induced by various pro-inflammatory stimuli, 
such as IFN-y and LPS, and PPAR-a, -y and -5 ligands have been shown to repress the 
expression of these molecules in macrophages and endothelial cells (Marx et al., 2000; 
Pasceri et al., 2001; Lee et al., 2003; Welch et al., 2003; Kim and Kim, 2006; Barish 
et al., 2008; Kitajima et al., 2009). In addition, several studies have demonstrated that 
the expression of VCAM-1 in endothelial cells induced by TNF-a is inhibited by 
agonists of PPAR-y (MCC-555) and -a agonists (fenofibrate and WY14643) (Marx et 
al., 1999; Xu et al., 2001; Kurebayashi et al., 2005). The anti-inflammatory effect of 
PPAR ligands is further confirmed by the findings that the expression of key 
pro-inflammatory cytokines, such as TNF-a, IFN-y, IL-1 and -8, as well as the 
cytokines involved in immuo-modulation such as IL-2 and -4 is suppressed by various 
types of ligands for all three PPAR isoforms in macrophages and SMCs (Jiang et al., 
1998; Takano et al., 2000; Ryoo et al., 2004; Ding et al., 2006; Piraino et al., 2006). 
Repression of IFN-y expression by fenofibrate has also been confirmed in 
IL-10-deficient mice (Lee et al., 2007a).
T lymphocytes and SMCs are recognised as crucial players in atherosclerotic lesion 
formation and complication (Hansson, 2001). After the recruitment into the vessel 
wall, T cells undergo differentiation into CD4+ Thl cells after stimulation by antigens 
such as oxLDL. Thl cell predominantly secrete pro-inflammatory cytokines such as
48
Chapter 1: General Introduction
IFN-y, TNF-a and IL-12, which can in turn activate other cellular participants in 
atherosclerosis (Binder et al., 2002). PPAR-a and -y activation reduces the T cell 
production of IFN-y, TNF-a, IL-2 and IL-4, thus possibly modulating multiple levels 
of distal responses to these cytokines during atherogenesis (Jones et al., 2002; Marx et 
al., 2002). In SMCs, PPARa agonists reduce IL-1- or PMA-induced cyclooxygenase 2 
(COX2) expression (Staels et al., 1998). Cytokine induced COX2 expression in 
macrophages is also repressed by ligands for PPAR-y (Castrillo et al., 2000; Inoue et 
al., 2000; Straus et al., 2000) and -8 (Welch et al., 2003). At sites of inflammation, 
COX promotes increased production of various inflammatory mediators (Linton and 
Fazio, 2002; Burleigh et al., 2005) and has been shown to promote early 
atherosclerotic lesion formation in apoE-null mice (Burleigh et al., 2005).
In summary, PPAR ligands exert their atheroprotective roles, at least in part by 
antagonising inflammatory responses within key cells involved in atherogenesis. Such 
anti-inflammatory effects of these ligands are mediated by inhibition of expression of 
inflammatory molecules, such as pro-inflammatory cytokines, chemokines and 
adhesion molecules. The exact molecular mechanisms underlying such repression are 
yet to be fully understood although a number of models have been proposed (details 
discussed in section below).
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Figure 1.4 Cellular targets for the anti-inflammatory actions of PPARs.
PPAR are activated by various ligands and down-regulate diverse components of 
inflammatory responses such as cytokine and chemokine secretion within key 
atherosclerotic lesion cells
Abbreviations: PPAR, peroxisome proliferators-activated receptors; iNOS, inducible nitric 
oxide synthase; COX, cyclooxygenerase; IL, interleukin
I
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1.8.1.4 Transrepression of IFN-y signalling by PPARs
Ligand-dependent inhibition of inflammatory gene expression represents one of the 
key repressive functions of PPARs. This process is termed transrepression, in which 
PPARs interfere with signal-dependent activation of inflammatory response genes 
through protein-protein interactions with co-regulatory proteins and promoter-bound 
transcription factors, rather than direct, sequence-specific interaction with DNA 
(Pascual and Glass, 2006). IFN-y is one of the key pro-inflammatory cytokines 
involved in inflammatory regulation and the pathogenesis of atherosclerosis (see 
section 1.5). An ever growing volume of evidence indicates that the potent 
anti-inflammatory and atheroprotective actions of PPAR ligands are mediated in part 
through the inhibition of the deleterious actions of IFN-y (see Table 1.7 for a full list 
of publications). Of particular importance, various types of PPARy activators inhibit 
the IFN-y-induced expression of inflammatory cytokines and chemokines in a large 
range of cell types, such as macrophages and endothelial cells (Maggi et al., 2000; 
Marx et al., 2000; Park et al., 2003; Welch et al., 2003; Giri et al., 2004; Antonelli et 
al., 2006; Barish et al., 2008; Panzer et al., 2008).
A number of distinct molecular mechanisms underlying transrepression by PPAR 
ligands in IFN-y signalling have been proposed and all of mechanisms discovered to 
date operate at the transcriptional activation of target genes (Ricote and Glass, 2007). 
First, the endogenous PPARy ligand 15-deoxy-A12,14-PGJ2 (15d-PGJ2) antagonises the 
IFN-y-induced expression of chemokines (e.g. IP-10 and MIG) and iNOS by targeting 
the JAK-STAT pathway (Chen et al., 2003; Weber et al., 2003, 2004; Panzer et al.,
2008). Chen et al. (2003) demonstrated that 15d-PGJ2 inhibited the IFN-y-induced 
expression of iNOS in the mouse macrophage RAW264.7 cell line by attenuating the 
phosphorylation of JAK2 and STAT1 (tyrosine 701), as well as STAT1 DNA binding 
activity. This agonist has also been demonstrated to inhibit the IFN-y-mediated 
expression of genes, such as chemokines (e.g. IP-10, Mig and I-TAC) by similar 
mechanisms in mouse mesangial and insulinoma cells (Weber et al., 2003; Panzer et 
al., 2008). In addition, these authors indicated that 15d-PGJ2 could mediate the 
inhibition via targeting the IFN-y-induced STAT1 nuclear translocation. These results 
together suggest that the JAK-STAT pathway may be a general target for 15d-PGJ2 in 
attenuating the IFN-y-mediated gene expression. Interestingly, these research groups 
independently reported that 15d-PGJ2 targets IFN-y signalling in a
51
Chapter 1: General Introduction
PPARy-independent manner as the PPARy inhibitor (GW9662 or BADGE) failed to 
influence the effect of 15d-PGJ2 in IFN-y-mediated signalling (Chen et al., 2003; 
Weber et al., 2004; Panzer et al., 2008). In addition to the endogenous PPARy ligand, 
various types of the synthetic agonists (glitazone) have been shown to attenuate the 
IFN-y-induced STAT1 transactivation in mouse macrophages (Ricote et al., 1998; 
Chen et al., 2003). However, Panzer et al. (2008) have shown that the PPARy agonists, 
ciglitazone and GW9662 do not target IFN-y-dependent JAK-STAT pathway and 
downstream genes in mouse mesangial cells. This suggests that the mechanism may 
operate in a cell type- and ligand-specific manner.
In contrast to the mechanisms detailed above, Park et al. (2003) have suggested that 
15d-PGJ2and rosiglitazone inhibit the IFN-y-mediated expression of MCP-1, IP-10, 
TNF-a, IL-1 p and IRF-1 by increasing the expression of suppressor of cytokine 
signalling (SOCS)-l and -3, which are thought to suppress the JAK-STAT pathway 
via a negative feedback loop (Krebs and Hilton, 2001).
Another important mechanism by which PPAR ligands repress the cytokine-mediated 
expression of inflammatory response genes is to target the nuclear factor-xB (NFkB) 
pathway (Ricote et al., 1998; Straus et al., 2000; Takano et al., 2000; Xu et al., 2001; 
Ding et al., 2006; Piraino et al., 2006). NF-kB is a dimer composed of various 
subunits that are members of the Rel family of proteins [pi05/50, p i00/52, p65 
(RelA), RelB and c-Rel]. In resting cells, NF-kB proteins reside in the cytoplasm 
where they are sequestered by a family of inhibitors of kB (IkB) proteins. Upon 
stimulation with pro-inflammatory mediators including cytokines, the activated 
NF-kB complex translocate to the nucleus. This activation of NFkB requires 
phosphorylation by IkB kinase (IKK) of IkB protein at specific serine residues, which 
target these proteins for ubiquitin conjugation and degradation by the 26S proteasome. 
Activation of IKK is mediated by phosphorylation through various upstream kinases, 
such as NFKB-inducing kinases, Akt and PKC£ [see (Ghosh and Karin, 2002) for 
review]. 15d-PGJ2 has been shown to suppress the IFN-y/LPS-synergistically 
mediated gene expression, including pro-inflammatory cytokines and COX2, by 
inhibiting the activity of IKK, resulting in impaired degradation of IkB (Castrillo et al., 
2000), and this further leads to the inhibition of p65 (NFkB) nuclear translocation and 
recruitment of the transcriptional co-activator p300 by p65 (Giri et al., 2004). Giri et
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al. (2004) also indicated that 15d-PGJ2 down-regulates the IFN-y/LPS-mediated 
PI3K-Akt pathway. In addition to 15d-PGJ2, synthetic PPARy agonists, such as 
rosiglitazone and troglitazone also attenuate the IFN-y-induced gene expression (e.g. 
chemokines and iNOS) by down-regulating NFkB DNA binding activity (Marx et al., 
2000) and transcriptional activity (Ricote et al., 1998).
Overall, these studies suggest that PPAR ligands down-regulate IFN-y-mediated 
inflammatory gene expression mainly through attenuation of the JAK-STAT and 
NFkB pathways. These mechanisms probably act in a ligand- and cell type-specific 
manner.
1.8.1.5 Transrepression models of PPARs
Studies in the last decade have proposed a number of models that account for the 
transrepression effect by PPARs. First, co-activator molecules, such as CREB binding 
protein (CBP) and p300 are shared by NRs and inflammatory transcription factors, 
such as NFkB, AP-1 and STAT1 (Gerritsen et al., 1997; Liu et al., 2004a; Bouhet et al., 
2009). It has thus been suggested that competition for limiting amounts of these 
proteins represents a mechanism for transrepression by PPARy and other NRs (Kamei 
et al., 1996; Li et al., 2000b), and such a mechanism is so-called cco-activators 
competition model’ (Gerry and Pascual, 2008) (see section 6.1.2 for details).
Additionally, several reports have suggested that PPARs inhibit the expression of 
inflammatory gene expression by direct interaction with proteins involved in the 
signal-dependent activation of STAT1, N FkB, AP-1 and C/EBP. Such protein-protein 
interactions prevent the binding of these transcription factors to their response 
elements (Pascual and Glass, 2006; Ricote and Glass, 2007; Gerry and Pascual, 2008). 
For example, Delerive et al. (1999a) showed that in human aortic SMCs, 
ligand-activated PPARa interferes with AP-1 and NFkB DNA binding acitivity by 
direct protein interaction with p65 (subunit of NFkB ) and c-Jun (subunit of AP-1). 
The same research group also demonstrated that in human vascular endotheial cells, 
ligand-activated PPAR-a and -y alter c-Jun binding to the human endothelin-1 
promoter (Delerive et al., 1999).
Recent studies have suggested co-repressor-dependent transrepression models by 
PPARs. In the case of PPAR5, Lee et al. (2003) proposed a model in which PPAR5
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controls the inflammatory status of macrophages based on its association with the 
transcriptional repressor Bcl-6. In the absence of the ligand, PPARS sequesters Bcl-6 
from inflammatory response genes, such as MCP-1 and IL-ip, resulting in increased 
gene expression. Once bound to the ligand, PPARS releases Bcl-6, which in turn 
exerts anti-inflammatory effects by repressing expression of these genes.
Pascual et al. (2005) suggested that in mouse primary macrophages, PPARy mediates 
transrepression of a subset of inflammatory response genes (MIP-1, IP-10, MCP-3 
and iNOS) by preventing the signal-specific removal of co-repessor complexes on 
inflammatory gene promoters downstream of LPS signalling. Ligand activation of 
PPARy results in a conformation change allowing the SUMOylation of PPARy, 
mediated by the E2 ligase Ubc9 and the E3 ligase, protein inhibitor of activated 
STAT1 (PIASI). SUMOylated PPARy binds to the NR corepressor (NCoR)-histone 
deacetylase-3(HDAC3)-containing co-repressor complex on inflammatory gene 
promoters, and blocks its degradation by ubiquitylation/19S proteasome pathway, 
thereby preseving the repressed state. This mechanism has recently been confirmed in 
mouse peritoneal macrophages by Ghisletti et al. (2007). It will be very interesting to 
define the extent to which this mechanism is used by other PPAR isoforms and other 
stimulators. Interestingly, Ghisletti et al. (2007) demonstrated that LXR also uses a 
SUMOylation and NCoR-dependent pathway to transrepress LPS-mediated 
inflammatory target gene expression, although the proteins involved in the 
modification differ. These results suggest that this mechainism may be a general 
strategy for transrepression by PPARs and LXRs (Ricote and Glass, 2007).
54
Table 1.7 Transrepression effects of PPARs on IFN-y-mediated expression of inflammatory response genes
Cell Types Agonist(s) PPAR
Genes or 
proteins 
analysed
Stimulus
PPAR- 
dependent or 
independent
Potential prospective 
mechanism(s) References
Mouse RAW264.7 
macrophages 15d-PGJ2 y iNOS IFN-y independent
inhibition of tyrosine 
phosphorylation of JAK2, STAT1, 
DNA binding and transcriptional 
activity of STAT 1
(Chen et al., 
2003)
Embryonic stem 
cell-derived 
macrophages
15d-PGJ2,
BRL49653
ciglitazone
troglitazone
y iNOS, COX2 IFN-y independent
(Chawla et 
al., 2001)
Peritoneal
macrophages rosiglitazone y
iNOS, IP-10, 
Mig IFN-y
partially
dependent
(Welch et 
al., 2003)
Human saphenous 
vein endothelial 
cells
15d-PGJ2 
troglitazone, 
BRL49653
y
IP-10, Mig, 
I-TAC IFN-y /
inhibition of NFkB DNA binding 
activity
(Marx et al., 
2000)
Mouse mesangial 
cells 15d-PGJ2 y
IP-10, Mig, 
I-TAC IFN-y independent
inhibition of tyrosine 
phosphorylation of JAK1,2 and 
STAT1, and nuclear translocation 
and DNA binding of STAT1
(Panzer et 
al., 2008)
Mouse astrocytes 15d-PGJ2rosiglitazone y
MCP-1, 
IP-10, 
TNF-a, 
IL-13, IRF-1
IFN-y independent induction of SOCS-1 and SOCS-3
(Park et al., 
2003)
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Rat insulinoma 
RINm5F
15d-PGJ2 y IFN-y independent
inhibition of STAT1 
phosphorylation
(Weber et 
al., 2004)
Rat insulinoma 
RINm5F and 
islets
15d-PGJ2 y IFN-y /
inhibition of IFN-y-induced 
STAT1 phosphorylation, nuclear 
localisation and DNA binding
(Weber et 
al., 2003)
Mouse 
bone-marrow-deri 
ved macrophages 
and primary 
peritoneal 
macrophages
15d-PGJ2
troglitazone,
rosiglitazone,
GW9020
y iNOS
IFN-y,
LPS dependent
inhibition of transcriptional 
activity of AP-1, STAT1 and 
NFkB
(Ricote et 
al., 1998)
Mouse
macrophages 15d-PGJ2 y
NOS2,
COX2 IFN-y+LPS independent
inhibition of activity of IkB kinase 
resulting in impaird 
phosphorylation and degradation 
of hcBa
(Castrillo et 
al., 2000)
RAW264.7 mouse 
macrophages 15d-PGJ2 y
iNOS, IL-1, 
COX2 IFN-y+LPS /
(Maggi et 
al., 2000)
Mouse mesangial 
cell C57BL6 and 
RAW 264.7 
macrophages
GW347845x
GW7845
pioglitazone
rosiglitazone
y iNOS IFN-y+LPS independent
(Crosby et 
al., 2005)
Mouse astrocytes 15d-PGJ2 y
TNF-a, 
IL-1 p, IL-6, 
iNOS
IFN-y+LPS independent
inhibition of IkB kinase activity 
leading to the inhibition of 
degradation of IkB and nuclear 
translocation of NFkB 
(p65);inhibition of PI3K-Akt 
pathway and recruitment of p300 
by NFkB (p65)
(Giri et al., 
2004)
56
C hapterl: G eneral Introduction
Thyrocyte,
retrobulbar
fibroblasts,
retrobulbar
preadipocytes
rosiglitazone y IP-10
IFN-y
+TNF-a /
(Antonelli et 
al., 2006)
Peritoneal
macrophages GW501516 5 MCP-1,3,5
IFN-y,
LPS dependent
(Barish et 
al., 2008)
Abbreviations: IFN, interferon; TNF, tumour necrosis factor; LPS, lipopolysaccharide; IL, interleukin; iNOS, inducible nitric oxide synthase; MMP, matrix 
metalloproteinase; MCP, monocyte chemotactic protein; NFkB, nuclear factor kB; MIP, macrophage inflammatory protein; COX, cyclooxygenase; IP, 
interferon-gamma inducible protein; Mig, monokine induced by IFN-gamma; I-TAC, interferon-inducible T-cell alpha chemoattractant; STAT, signal 
transducer and activator of transcription; IkB, Inhibitor of kB
57
Chapter 1: General Introduction
1.8.2 LXRs
1.8.2.1 Biology of LXRs
Two isoforms of LXR exist (LXRa and p), and they function as cholesterol sensor 
that regulates both cellular and systemic cholesterol homeostasis (Bensinger and 
Tontonoz, 2008). The natural ligands for LXRs are sterol metabolites, such as 22(R)-, 
20(S)-, 24(S)-hydroxycholesterol and 24(S), 25-epoxy cholesterol (Janowski et al., 
1996; Janowski et al., 1999). In addition to the endogenous ligands, a number of 
synthetic pharmacological LXR agonists (i.e. TO901317, GW3965 and acetyl 
podocarpic) have been reported, which are structurally unrelated to oxysterols 
(Collins et al., 2002; Sparrow et al., 2002). LXR-a and -P have considerable sequence 
homology (77% identity in DNA sequence), and seem to respond to the same 
endogenous ligands, and have almost identical target genes (Bensinger and Tontonoz, 
2008; Rigamonti et al., 2008). The mechanisms that regulate LXR gene expression are 
currently poorly understood. It is, however, interesting to note that human LXRa can 
autoregulate itself whereas LXRp cannot. The autoregulation occurs via LXR 
response elements (LXREs) present in the human LXRa promoter (Laffitte et al., 
2001; Whitney et al., 2001). Interestingly, LXRa auto-regulation appears to be limited 
to human cell types such as macrophages and hepatoma cells and does not occur in 
murine cells such as primary murine macrophages (Rigamonti et al., 2008). Indeed, 
important differences have been reported to exist between human and mouse in term 
of gene regulation by LXRs (Rigamonti et al., 2008 and references therein). As an 
example, in human macrophages, LXR activation potentiates LPS responses, while no 
such effect is observed in murine macrophages (Fontaine et al., 2007). Such 
species-specific action of LXRs indicates that development of a humanised model, 
such as a murine model that expresses human forms of NRs, represents an attractive 
strategy for studying LXR biology.
1.8.2.2 LXRs in atherosclerosis
LXRs have the unique ability to promote cholesterol efflux from lipid-laden 
macrophages, reverse-cholesterol-transport (RCT) to the liver and cholesterol 
excretion via the bile system [see (Repa et al., 2000; Tobin and Freedman, 2006; 
Rigamonti et al., 2008) for reviews]. Recently, LXRs have emerged as an important 
regulator of inflammatory gene expression and immunity. An increasing number of 
studies clearly demonstrate the potent anti-inflammatory effect of ligand-activated
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LXRs in macrophages, the key cells central to lipid homeostasis and inflammatory 
responses within atherosclerotic lesion formation [(Rigamonti et al., 2008) and 
references therein]. Indeed, a number of studies on mouse models of atherosclerosis 
have indicated that LXR activation prevents atherosclerotic development in vivo. 
Joseph et al. (2002) demonstrated that LXR ligands prevent diet-induced 
atherosclerosis in apoE-/- and LDLR-/- mice. Such athero-protective effect of LXR in 
LDLR-null mice has been confirmed by Terasaka et al. (2003). Additional 
investigations have focused on macrophages as the key cellular target for the efficacy 
of LXR ligands to prevent atherosclerosis. Transplantation of bone marrow from 
LXR-/- mice into either apoE-/- or LDLR-/- mice increased atherosclerosis, thereby 
suggesting a protective role of macrophage LXRs in atherosclerotic development 
(Tangirala et al., 2002). Consistent with this, Levin et al. (2005) further demonstrated 
that macrophage LXR expression is required for the athero-protective action of LXR 
agonists using the bone marrow transplantation approach.
Despite the overwhelming evidence supporting the potential benefits of LXR agonists 
for the treatment of atherosclerosis, the development of an effective and safe LXR 
agonist-related therapeutic agent is currently facing a major challenge from its role in 
hepatic lipogenesis. The lipogenic activity of LXR results because of the induced 
expression of the major regulator of hepatic lipogenesis, SREBP-lc (Repa and 
Mangelsdorf, 2002) and thereby its downstream targets such as fatty acid synthase 
(FAS), steroyl CoA desaturase I (SCD-1) and acyl CoA carboxylase (ACC) (Tontonoz 
and Mangelsdorf, 2003). Thus, pharmacological activation of LXR causes high 
plasma triglyceride level (Grefhorst et al., 2002), which is clearly a major limitation 
of using LXR agonists in the treatment of atherosclerosis.
It has become increasingly clear that in addition to its role in regulating cholesterol 
homeostasis, the athero-protective effect of LXR is also largely dependent on its 
anti-inflammatory action [see (Bensinger and Tontonoz, 2008; Nomiyama and 
Bruemmer, 2008) for reviews]. Therefore, understanding the roles of LXRs in 
inflammatory and immune responses could greatly facilitate our search for the next 
generation of LXR ligands, which would preferentially exert their protective roles in 
RCT and inflammation, but exibiting minimal effect on harmful lipogenesis genes.
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1.8.2.3 LXRs in inflammation and transrepression
An ever increasing body of evidence suggests that LXRs are an important regulator of 
inflammatory responses, especially in monocytes/macrophages. Ligand-dependent 
LXR activation transrepresses the expression of a large range of inflammatory 
response genes, induced by pro-inflammatory mediators such as LPS, IFN-y, TNF-a 
and IL-lp. These genes include chemokines (i.e. MCP-1 and -3, MIP-1(3 and IP-10), 
pro-inflammatory cytokines (i.e. IFN-y, TNF-a, IL-6 and -8), genes important for 
inflammation response (i.e. COX2 and iNOS), adhesion molecules (VCAM-1) and the 
genes involved in atheroscleotic plaque rupture and thrombosis (MMP9 and tissue 
factor) (Castrillo et al., 2003; Joseph et al., 2003; Ogawa et al., 2005; Terasaka et al., 
2005; Piraino et al., 2006; Walcher et al., 2006; Birrell et al., 2007; Ghisletti et al., 
2007; Myhre et al., 2008) (see Table 1.8 for a full list of publications).
The mechanism underlying the transrepression of inflammatory genes by LXRs is 
poorly understood. LXRE has not been identified in the proximal promoter of 
repressed genes at present, thereby suggesting a mechanism distinct from 
transactivation that is involved in transrepression (Rigamonti et al., 2008). Several 
lines of evidence indicates that the repression of the NFkB pathway is involved, but 
maybe via mechanisms independent of inhibition of NFkB nuclear translocation, 
DNA binding activity or degradation of IkB (Castrillo et al., 2003; Joseph et al., 2003; 
Terasaka et al., 2005; Piraino et al., 2006; Birrell et al., 2007) (Table 1.8). Although 
several studies suggested that LXR ligands do not affect the DNA binding and 
transcriptional activity of AP-1 in mouse peritoneal and human lung tissue 
macrophages (Castrillo et al., 2003; Joseph et al., 2003; Terasaka et al., 2005; Birrell 
et al., 2007), Ogawa et al. (2005) showed that in human monocytic THP-1 cell line 
and RAW264.7 mouse macrophage cell line, LXR ligands inhibit pro-inflammatory 
cytokine-induced expression of osteopontin by repressing the binding of c-Jun and 
c-Fos to their AP-1 site in target gene promoters, as well as reducing the expression of 
c-Jun and c-Fos. Osteopontin is a pro-inflammatory cytokine and adhesion molecule 
implicated in the chemoattraction of monocytes (Denhardt et al., 2001).
As discussed earlier, SUMOylated PPARy prevents the LPS-dependent clearance of 
co-repressors and thus maintains the repressed state of the iNOS promoter (Pascual et 
al., 2005). A similar but not identical mechanism has also been elucidated for the
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transrepression function of LXR. Ghisletti et al. (2007) showed that ligand binding to 
LXRs results in its SUMOylation by SUMO-2 or -3 and E3 ligase HDAC4 (rather 
than on SUMOl and PIAS1 as in the case for PPARy) for the prevention of clearance 
of the co-repressor complexes in promoters of inflammatory genes, such as 
chemokines, iNOS and VCAM-1.
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Table 1.8 Transrepression effects of LXRs in inflammatory stimuli-mcdiated expression of inflammatory response genes
Cell types Ligands Genes or proteins analysed
Pro-
inflammatory
stimuli
Potential prospective mechanisms References
Human
monocytes;
human THP-1
cells;
mouse
RAW264.7
macrophages
GW3965
TO901317 osteopontin
IFN-y,
TNF-a,
IL-ip
LPS
inhibition of expression of c-Fos and 
c-Jun;
inhibition of binding of c-Fos and c-Jun 
to AP-1 site of osteopotin promoter
(Ogawa et al., 
2005)
J774.2
macrophages
TO901317, 
22(R) hydroxy- 
Cholesterol iNOS, TNF-a LPS inhibition of NFkB activity
(Piraino et al., 
2006)
Mouse peritoneal 
macrophages
GW3965,
22(R)-hydroxy-
cholesterol
iNOS, IL-6, MIP-ip, 
MCP-1 and-3, COX-2, 
IP-10, IL-lp, SOCS-1 
and -3, MMP-9 LPS
inhibition of transcriptional activity of 
NFkB without affecting that of AP-1
(Joseph et al., 
2003)
Human
monocytes GW3965
IL-ip, IL-6, IL-8, 
TNF-a, M IP-la, 
MIP-ip, MCP-1 LPS
(Myhre et al., 
2008)
Mouse peritoneal 
macrophages
GW3965
TO901317 TF LPS
inhibition of NFkB signalling pathway, 
without affecting AP-1 transcriptional 
activity
(Terasaka et al., 
2005)
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Human lung 
tissue
macrophages; 
human THP-1 
cells
GW3965
TO901317
IL-6, IL-8, MIP-la, 
TNF-a LPS
independent of inhibition of NFkB or 
AP-1 DNA binding
(Birrell et al., 
2007)
Mouse peritoneal 
macrophages GW3965
iNOS, MIP-ip, MCP-1, 
VCAM-1,IL-15 LPS
SUMO-LXR inhibit corepressor NCoR 
clearance required for gene 
transcription
(Ghisletti et al, 
2007)
Mouse peritoneal 
macrophages
GW3965
TO901317 MMP9
LPS
IL-ip
TNF-a
antagonism of NFkB pathway without 
affecting NFkB nuclear translocation, 
IkB degradation or DNA binding 
activity of NFkB or AP-1
(Castrillo et al., 
2003)
Human
CD4-positive T 
cells TO901317 IFN-y, TNF-a, IL-2 PMA
(Walcher et al., 
2006)
Abbreviations: IFN, interferon; LPS, lipopolysaccharide; IL, interleukin; TNF, tumour necrosis factor; PMA, phorbol 12-myristate 13-acetate; MMP, matrix 
metalloproteinases; MIP, macrophage inflammatory protein; MCP, monocyte chemoattractant protein; iNOS, inducible nitric oxide synthase; AP-1, activator 
protein-1; VC AM, vascular cell adhesion molecule; SUMO, small ubiquitin-related modifier; NcoR, nuclear receptor corepressor; NFkB, Nuclear factor kB; 
TF, tissue factor
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1.9 3-hydroxy-3-methylglutaryl coenzyme A (HMG-coA) 
reductase inhibitors (Statins) target inflammation
3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors, so-called 
statins, can largely lower plasma LDL cholesterol levels and are regarded as the most 
effective cholesterol lowering drugs available. To date, there are many types of statin 
available including atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, 
pravastatin, rosuvastatin, and simvastatin. A large number of clinical trials have 
demonstrated the therapeutic beneficial effects of statins in the prevention of 
cardiovascular disease, such as atherosclerosis. Although such clinically beneficial 
effect of statins was initially thought to associate with its cholesterol-lowering effect, 
a growing body of animal and clinical studies (Davignon and Leiter, 2005; Athyros et 
al., 2009) have recently provided compelling evidence that statins could exert their 
athero-protective via actions beyond their effects on serum cholesterol levels [see(Jain 
and Ridker, 2005; James, 2005; Jasinska et al., 2007; Paumelle and Staels, 2008) for 
reviews)]. For instance, two groups have independently shown that simvastatin 
treatment can preserve coronary endothelial function and subsequently moderate 
atherosclerotic progression independent of lipid lowering actions (Wilson et al., 2001; 
Bonetti et al., 2002). Such cholesterol-independent effects, so-called ‘pleiotropic 
effects’ involves restoration of endothelial function, decrease in oxidative stress, 
inhibition of vascular inflammation and increase in stability of atherosclerotic plaques 
[see (Takemoto and Liao, 2001; Lahera et al., 2007; Paumelle and Staels, 2007) for 
reviews].
1.9.1 An overview of the effects of statins on endothelial dysfunction 
and inflammation
With regard to the benefits of statin therapy on endothelial function, the pleiotropic 
actions of statins seem to be directly associated with induced synthesis and activity of 
eNOS—an enzyme involved in the generation of NO within the vascular wall (Walter 
et al., 2004; Sugawara et al., 2008; Wang et al., 2008) (Table 1.9). NO confers many 
beneficial effects such as vascular relaxation and inhibition of leukocyte-endothelial 
interactions (Jain and Ridker, 2005). In addition, it has been reported that statins 
inhibit the recruitment of immune cells to the vascular wall through inhibition of 
pro-inflammatory stimuli-induced expression of adhesion molecules (e.g. VCAM-1 
and ICAM-1) (Chung et al., 2002; Takahashi et al., 2005; Montecucco et al., 2009)
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and chemokines (e.g. MCP-1 and MIP-la and -P) (Han et al., 2005; Bruegel et al., 
2006; Veillard et al., 2006; Yano et al., 2007; Montecucco et al., 2009) (Table 1.9). 
The reduction in the expression of adhesion molecules and chemokines, and 
consequently the cellularity within atherosclerotic lesion have been observed in 
animal models and human tissues (Aikawa et al., 2001; Crisby et al., 2001; Fukumoto 
et al., 2001; Kim et al., 2007a; Monetti et al., 2007; Rallidis et al., 2008).
Statins also show immunomodulatory effects [see (Tristano and Fuller, 2006; Kuipers 
and van den Elsen, 2007) for reviews]. The drugs were identified to directly reduce 
the IFN-y-induced major histocompatibility complex class II (MHC-II) and thus 
repress MHC-II-mediated T-cell activation. Such inhibition was believed to be 
attributable, at least in part, to statins-mediated blockage of expression of major 
histocompatibility class II transactivator (CIITA) (Kwak et al., 2001; Sadeghi et al., 
2001; Mach, 2002a; Buttice et al., 2006; Zeinstra et al., 2006; Lee et al., 2008). 
Additionally, statins suppress the expression of CD40, which plays critical roles in 
immunological responses, including antigen presentation to T cells, and hence are 
associated with the adaptive immune response and atherothrombotic complication 
(Youssef et al., 2002; Mulhaupt et al., 2003; Takahashi et al., 2005; Lee et al., 2007b). 
Several studies have demonstrated that statins can suppress T cell activation and 
inflammatory responses by inhibiting the production of pro-inflammatory cytokines, 
such as IFN-y, TNF-a, IL-2, IL-12 and IL-6 (Youssef et al., 2002; Takahashi et al., 
2005). By contrast, treatment of statins has been shown to increase the production of 
Th2 cytokines, such as IL-4, -5 and -10 (Youssef et al., 2002; Aktas et al., 2003). 
These results suggest that statins may suppress inflammatory responses at least in part, 
by promoting a bias from a Thl response to that of Th2 (see Table 1.9 for a full list of 
publications).
In addition to its anti-inflammatory and immunomodulatory effects, statins may also 
benefit atherosclerosis by increasing plaque stability through different mechanisms, 
such as decreasing macrophage accumulation in atherosclerotic lesions as discussed 
above, and inhibiting the secretion of MMPs that degrade plaque matrix and, thereby, 
weaken the fibrous cap (Luan et al., 2003).
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Table 1.9 Effect of statins on inflammatory gene expression in vascular cells and atherosclerosis development
Statins Pathological process Statin effect Target genes Target cells References
paravastatin,
fluvastatin,
simvastatin,
atorvastatin,
lovastatin EC dysfunction |  adhesion
IVCAM-1, 
flC  AM-1
peripheral blood 
mononuclear cell, 
EC, SMC
(Chung et al., 2002); 
(Takahashi et al., 2005); 
(Montecucco et al., 2009)
pitavasatin,
simvastatin EC dysfunction fvasoreactivity TeNOS EC
(Walter et al., 2004); 
(Sugawara et al., 2008); 
(Wang et al., 2008)
pitavasatin,
simvastatin,
atorvastatin
inflammatory cell 
infiltration
I macrophages/
T cells recruitment
1 MCP-1, 
IM IPl-a and -0, 
1CCR1,2,4,5
monocytes/macrophages/ 
T lymphocytes
(Yano et al., 2007); 
(Montecucco et al., 2009); 
(Veillard et al., 2006); 
(Han et al., 2005); 
(Bruegel et al., 2006)
pitavasatin,
simvastatin,
atorvastatin,
fluvastatin,
lovastatin
inflammatory
responses
jpro-inflammatory 
cytokines, 
i chemokines, 
t  anti-inflammatory 
cytokines
TCD40, IL-12, 
TIL-ip, IL-6, 
TIFN-y, TNF-a, 
1IL-4,5,10
monocytes/macrophages/ 
T lymphocytes, SMC,
EC
(Wagner et al., 2002); 
(Paumelle et al., 2006); 
(Takahashi et al., 2005); 
(Yano et al., 2007); 
(Townsend et al., 2004); 
(Lee et al., 2007b)
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(Kwak et al., 2001);
(Sadeghi et al., 2001);
simvastatin, (Lee et al., 2008);
lovastatin, (Mach, 2002a);
atorvastatin, i  immunemodulatory (Zeinstra et al., 2006);
paravastatin immune response molecules 1MHCII, CIITA EC, macrophages, SMC (Buttice et al., 2006)
Abbreviations: EC, endothelial cells; SMC, smooth muscle cells; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; CCR, CC 
chemokine receptor; IL, interleukin; IFN, interferon; TNF, tumour necrotic factor; NOS, nitric-oxide synthase 
| ,  decreased expression; f, increased expression
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1.9.2 Pleiotropic effects of statins mediated via PPARs
Despite compelling evidence for the pleiotropic effects of statins, the molecular 
mechanisms underlying their actions remain less understood. Some recent studies 
have suggested that statins may exert their anti-inflammatory effects via PPARs. 
Paumelle et al. (2006) demonstrated that in mouse macrophages, statins inhibit the 
LPS-induced expression of iNOS and IL-6 by enhancing the PPARa transrepression 
activity on the NFkB pathway. More recently, Yano et al. (2007) showed that statins 
may exert anti-inflammatory properties via PPARs by generating the ligand, 15d-PGJ2. 
In this model, statins induce PPAR-a and -y activity by increasing the expression of 
COX2, which converts arachidonic acid into varioius bioactive lipids, such as 
15d-PGJ2. These authors additionally showed that statins induce the expression of 
COX2 by activation of ERK and p38 MAPK pathways. Such MAPK-dependent 
inhibition of inflammatory gene expression by statins has also been shown by other 
research groups (Chung et al., 2002; Menschikowski et al., 2005; Montecucco et al.,
2009). As discussed earlier, ligand-dependent PPARs suppress the expression of 
inflammatory genes, at least in part, by antagonising the activity of NFkB and STAT1 
(section 1.8.1). Thus the potential statins—MAPK—COX2— 15d-PGJ2—PPAR 
signalling pathway probably provides one of the explanations for the repressive 
effects of statins on the transcriptional activity of NFkB and STAT1 (Chung et al., 
2002; Townsend et al., 2004; Kim et al., 2007b) (Figure 1.5). In addition, the PPARa 
transrepression properties have been shown to be negatively modulated by PKC 
signalling in hepatocytes (Blanquart et al., 2004) and the anti-inflammatory effect of 
simvastatin was suggested to occur via PPARa by a mechanism involving inhibition 
of the PKC pathway (Paumelle et al., 2006).
Several studies have also suggested that statins might further enhance the mechanisms 
detailed above by inducing PPAR mRNA expression (Inoue et al., 2002; Roglans et al., 
2002; Landrier et al., 2004). Interestingly, a synergistic action of statins and PPARa 
has been reported on a number of target genes in both macrophages and hepatocytes 
(Inoue et al., 2002; Landrier et al., 2004; Paumelle et al., 2006). Together, these data 
support the existence of cross-talk between statins and PPAR signalling pathways 
(Figure 1.5). The results provide a molecular basis and scientific rationale for the 
therapeutic association of these drug classes.
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Figure 1.5 Cross-talk of statins and PPARs: anti-inflammatory roles of statins 
[adapted from (Paumelle and Staels, 2008)]
Statins are competitive inhibitors of the HMG-CoA reductase, the rate-limiting 
enzyme in cholesterol synthesis. Statins exert their pleiotropic effects via 
transrepression properties of PPARs, potentially via two mechanisms. Statins induce 
the expression of COX2 through MAPK pathways. The induced COX2 in turn 
promotes the generation of PPAR ligands (i.e. 15d-PGJ2), which then activates 
PPARy. Alternatively, statins also mediate the inhibition of the PKC pathway, which 
results in the enhancement of the PPARa transrepession activity. The activated PPARs 
transrepress the inflammatory response genes (e.g. MCP-1 and iNOS).
Abbreviations: iNOS, inducible nitric oxide synthase; PKC, protein kinase C; PPAR, 
peroxisome proliferator-activated receptors; IL, interleukin; MAPK, mitogen-activated 
protein kinase; COX, cyclooxygenase; 15d-PGJ2, 15-deoxy-A12,14-PGJ2; MCP, monocyte 
chemoattractant protein; TNF, tumor necrosis factor
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1.10 Aims of the study
Atherosclerosis is recognised as a chronic inflammatory disorder, representing the 
major cause of mortality in the Western society. Cytokines play crucial roles in the 
regulation of inflammatory responses during atherosclerosis development, largely 
through the modulation of gene expression associated with this disease. The study of 
signalling mechanisms involved in the cytokine-mediated regulation of gene 
expression implicated in the progression of this disease is vital for the identification of 
new targets for therapeutic intervention. IFN-y, an important pro-inflammatory 
cytokine, acts as a key mediator in atherosclerotic lesion development. The classical 
JAK-STAT pathway plays a pivotal role in IFN-y signalling, and of importance, 
STAT1 Ser727 phosphorylation is known to be essential for its full transcriptional 
activity. In particular, Ser727 phosphorylation of STAT1 has recently been shown to 
be important for the IFN-y-mediated regulation of expression of several key genes 
implicated in atherosclerosis (Harvey et al., 2007). However, the molecular 
mechanisms underlying such phosphorylation are yet to be fully elucidated. Thus, the 
mechanisms underlying STAT1 transcriptional activity, particularly via STAT1 Ser727 
phosphorylation stimulated by IFN-y, is an important area for scientific research.
Recently, a growing body of evidence suggests that ligand-activated NRs (i.e. PPARs 
and LXRs) and cholesterol-lowering drugs, statins exert atheroprotecctive effects via 
their crucial anti-inflammtory properties. Despite their well established significance in 
inflammatory and immune responses, the molecular mechanisms involed in their 
atheroprotective effects remain largely unknown, particularly in relation to IFN-y 
responses, due to limited research on this aspect.
The initial aims of the work presented in this thesis were therefore to:
• Identify the key kinases responsible for the IFN-y-induced STAT1 
phosphorylation, particularly at serine 727 (Chapter 4)
Investigate the effect of the potential therapeutic agents (i.e. agonists for 
PPARs and LXRs, along with statins) on the IFN-y-mediated regulation of 
gene expression, STAT1 phosphorylation and cellular responses (Chapter 5).
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This was to be achieved through the use of RT-PCR and Western blotting, to analyse 
changes in mRNA and protein levels respectively, combined with the use of specific 
pharmacological inhibitors, agonists for PPARs and LXRs, and statins. Transient 
transfection assays and monocyte-endothelium adhesion assays were employed to 
confirm further the effect of these drugs along with statins on IFN-y responses.
Initial investigations led to the identification of key roles for protein kinases ERK and 
JNK in the IFN-y-mediated STAT1 serine phosphorylation and repressive effects of 
potential therapeutic agents on IFN-y-mediated responses. The aims were then 
extended to include:
• Detailed analysis on the roles of ERK and JNK in the IFN-y-mediated 
regulation of gene expression and cellular responses associated with 
atheroslerosis (Chapter 4)
Investigate the molecular mechainisms underlying the repressive effects of 
these therapeutic agents on IFN-y signalling (Chapter 6)
The roles of ERK and JNK in the IFN-y signalling pathway were analysed with the 
use of pharmacological inhibitors and dominant negative mutants. This was achieved 
by monitoring changes in gene expression, promoter activation, kinase activity and 
monocyte-endothelium adhesion in response to IFN-y following treatment of the cells 
with inhibitors or dominant negative mutants. Moreover, the molecular mechanisms 
by which the therapeutic agents repress IFN-y signalling were investigated with the 
continued use of agonists for PPARs and LXRs, along with statins, by analysing 
changes in the IFN-y-induced nuclear accumulation of activated STAT1, STAT1 DNA 
binding activity and transactivaiton by this transcription factor.
Overall, it was hoped that these studies will significantly contribute to the 
understanding of the signal transduction pathways activated by IFN-y and the 
molecular mechanisms underlying the anti-inflammatory effects of agonists for 
PPARs and LXRs, along with statins, in relation to IFN-y responses. Such studies will 
hopefully contribute to the eventual development of novel therapies to combat 
atherosclerosis and CAD.
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Chapter 2: Materials and methods
2.1 Materials
The materials used throughout the course o f this study and the suppliers from which 
they were purchased are listed in Table 2.1.
Table 2.1 A list of materials and chemicals used in this study with their 
suppliers.
Materials Supplies
1-Butanol Acros, New Jersey, USA
ECL Western Blotting Detection Reagent 
Rainbow Protein Size Markers 
Random Hexamers (PdN6)
GE Healthcare, 
Buckinghamshire, UK
Acrylamide: Bisacrylamide (37.5:1) Anachem, Luton, UK
10X NH4 Reaction Buffer 
Agarose
PCR grade Magnesium Chloride 
Taq Polymerase
Bioline, London, UK
15-Deoxy-A12,14-Prostaglandin J2 BIOMOL International, Exeter, UK,
Apigenin
Bisindolylmaleimide
KN-93
LY294002
PD98059
SB203580
SP600125
Simvastatin (carboxylate form) 
TO901317
MERCK (Calbiochem), 
Nottingham,UK
Rosiglitazone (BRL49653) 
GW7647
Cayman Chemical, Michigan, USA
Falcon 15ml and 50ml Polypropylene 
Tubes
Coming Costar, Schiphol-Rijk, 
Netherlands
LB Agar Capsules 
LB Medium Capsules
DIFCO Laboratories, Surrey, UK
Cell Lines (T H Pl,H ep3B ) European Collection o f Animal Cell 
Culture (ECACC), Salisbury, UK
72
Chapter 2: Materials and Methods
EDTA
Ethanol
Hydrochloric Acid
Industrial Methylated Spirits
Isopropanol
Methanol
Sodium Chloride
Sodium Hydroxide
Tris-Base
Other General Chemicals
Fisher Scientific, Loughborough, UK
Kodak X-ray Film Genetic Research Instrumentation, Essex, 
UK
D-MEM Tissue Culture Medium with 
GlutaMAX™
Fetal Calf Serum
R.P.M.I 1640 Tissue Culture Medium 
0.25% Trypsin-EDTA 
(3-Mercaptoethanol
Gibco BRL, Paisley, UK
1ml Cryo-vials 
96 Well Plates
Falcon 15ml and 50ml Polypropylene 
Tubes
Tissue Culture Flasks
Greiner, Gloucestershire, UK
Cell Scrapers Helena Biosciences, Sunderland, UK
1Kb DNA Ladder Invitrogen, Paisley, UK
HUVEC 
EGM2 bulletkit
Lonza, Birkshire, UK
High Purity Plasmid Maxi Prep System Marligen Biosciences, High Wycombe, 
UK
PVDF Membrane Millipore Ltd., Gloucestershire, UK
Anti-p38 Antibody 
Anti-p44/42 Antibody 
Anti-STATl Ser705 Antibody 
Anti-STATl Tyr701 Antibody 
U0126
New England Biolabs, Hertfordshire, UK
Phosphate-Buffered Saline Tablets Oxoid Ltd, Hampshire, UK
dNTPs Promega, Southampton, UK
MMLV 10X Buffer
MMLV Reverse Transcriptase
RNasin Ribonuclease Inhibitor
SuperFECT™ 
RNeasy MicroKit 
RNeasy MiniKit
Qiagen, West Sussex, UK
Anti-STATl Antibody Santa-Cruz Biotech Inc., California, USA
Tissue Culture Filters (0.2pM) Schleicher and Schuell, London, UK
PCR Primers Sigma Genosys, Cambridgeshire, UK
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9-czs-retinoic acid Sigma, Poole, UK
10X TBE Buffer
22(R) hydroxycholesterol
22(S) hydroxycholesterol
Ampicillin
Anti-P-Actin
Benzamidine
Bovine Serum Albumin
Bromophenol Blue
Dimethyl Sulfoxide
Molecular Biology Grade DMSO
Ethidium Bromide
Glycerol
Leupeptin
Lovastatin (active form)
Mineral Oil
Penicillin/Streptomycin
PMA
PMSF
Sodium Dodecyl Sulphate
Sodium Fluoride
Sodium Orthovanadate
Sodium Pyrophosphate
TBE (xlO)
Tissue Culture Grade DMSO
Trypan Blue Solution
Interferon-y Totam Biologicals (Tebu Bio), 
Cambridgeshire, UK
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2.2 Preparation of solutions, glass-and plastic-ware
Solutions, glass- and plastic-ware used for RNA/DNA and tissue culture related 
work were autoclaved at 121 °C (975kPa) for 20-3Omin.
2.3 Cell culture techniques
2.3.1 Cell lines
The cell lines utilised for the work detailed in this study were human monocytic 
leukemia cell line, THP-1 and human hepatoma cell line, Hep3B. THP-1 cells are 
undifferentiated monocytes grown in suspension (derived from a human monocytic 
leukaemia) (Tsuchiya et al., 1980). This cell line provides a valuable model for 
studying the physiological and biochemical properties displayed by macrophages 
along with the regulation of gene expression in these cells because following 
differentiation with phorbol esters, such as phorbol 12-myristate 13-acetate (PMA), 
they mimic native monocyte-derived macrophages in several aspects (Tsuchiya et al., 
1982; Auwerx, 1991). Hep3B cells are fully adherent hepatocytes derived from a 
human carcinoma (Aden et al., 1979).
2.3.2 Maintenance of cell lines in culture
THP-1 cells were grown in R.P.M.I-1640, and Hep3B cells were grown in DMEM. 
All media were supplemented with 10% (v/v) heat-inactivated (3Omin, 56°C) fetal 
calf serum (HI-FCS) in the presence of penicillin (pen, lOOU/ml) and streptomycin 
(strep, lOOpg/ml). Penicillin, streptomycin and HI-FCS were filter-sterilised by 
passing through 0.2pm sterile filters prior to use.
2.3.3 Subculturing of cell lines
2,3,3.1 THP-1 cells
The suspension cells were subcultured when they reached approximately 60% 
confluence. The cells were transferred into polypropylene tube (Falcon) and
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centrifuged at 1 lOg for 5min. Following the aspiration of the medium from the cells, 
the pellet was re-suspended in fresh R.P.M.I-1640 medium with 10% (v/v) HI-FCS 
at a ratio of 1:6 (i.e. cells from one tissue culture flask were subcultured into 6 new 
flasks). The cells were then grown up at 37°C in a humid incubator with an air 
mixture containing 5% (v/v) CO2 in air.
2.3.3.2 Hep3B cells
Adherent Hep3B cells were subcultured when they reached approximately 70% 
confluence. The cells were first washed once with antibiotic-and HI-FCS-free 
DMEM medium. Cells were then treated with appropriate volume of 0.25% trypsin- 
EDTA solution (2, 5 and 10 ml for 25, 75, 125mm2 flasks, respectively) and 
incubated at 37°C (5% (v/v) CO2) for approximately 2-5min until the cells were 
visibly detached from the substratum. Cells were then re-suspended in an 
appropriate volume of complete medium (10% (v/v) HI-FCS) and centrifuged at 
llOg for 5min (FCS contains proteins that neutralize trypsin). The cell pellet was 
then re-suspended in an appropriate volume of complete medium (10% (v/v) HI- 
FCS) and seeded into tissue culture flasks at a ratio of 1:4-1:6 (i.e. cells from one 
tissue culture flask were subcultured into 4-6 new flasks).
2.3.4 Counting cells
A haemocytometer (Neubauer Chamber, GMBH & Co., Wertheim, Germany) was 
used to count the cells. The haemocytometer was covered with a precision ground 
coverslip and 8pi of cell suspension was placed at the edge of the coverslip. The 
cells within the large square were then counted (total number of cells/ml=cells in the 
large counting square x 104).
2.3.5 Preservation and storage of cell lines
Only cells of an early passage (normally less than 2) were preserved. Adherent cells 
were first trypsinised using trypsin-EDTA. Following centrifugation of trypsinized
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Hep3B cells and THP-1 suspension cells at llOg for 5min, cell pellets were re­
suspended at a density of approximately 5xl06 cells/ml in HI-FCS with 10% (v/v) of 
either filter-sterilised glycerol (for THP-1) or DMSO (for Hep3B). The cell 
suspension was aliquoted into 1ml cryo-ampoules, which were frozen down slowly 
at -80°C in an insulated box overnight. The cells were then transferred into a liquid 
nitrogen container.
2.3.6 Thawing of frozen cell lines
Frozen cells were thawed in a 37°C water-bath and then transferred to a centrifuge 
tube containing 15ml of appropriate medium supplemented with 10% (v/v) HI-FCS. 
Following centrifugation at llOg for 5min, the cell pellets were resuspended in 15- 
20ml of appropriate medium supplemented with 20% (v/v) HI-FCS. The suspension 
was then transferred into tissue culture flasks and cultured as normal.
2.3.7 Treatment of THP-1 cells with PMA
THP-1 cells were prepared and cultured in tissue culture flasks or multiple-well 
plates for 4h (sections 2.3.2-3). The suspension monocytes were then differentiated 
into macrophages by addition of 0.16pM PMA followed by incubation for 24h.
2.3.8 Treatment of cells with inhibitors or therapeutic drugs and IFN-y
PMA-differentiated THP-1 macrophages were cultured as normal. When Hep3B 
cells reached approximately 70% confluence, the cells were washed with fresh 
DMEM 4h before treatment with the effectors. Inhibitors or therapeutic drugs were 
added to the cell culture medium for appropriate period of time prior to the addition 
of IFN-y at lOOOU/ml for THP-1 macrophages and lOOU/ml for Hep3B cells. 
Control cells were treated with an appropriate volume of a vehicle, typically DMSO. 
The cells were incubated with IFN-y for the appropriate period of time after which 
RNA or protein extraction was carried out. Table 2.2 lists the pharmacological 
inhibitors used and their mechanisms of action.
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Table 2.2 Pharmacological inhibitors with concentrations used in this study and their mechanisms of actions
Inhibitors Chemical name Target Mechanism of action jj:;
.....................  ...... ‘ . >....:....’..... ■ ......
Cone, 
Us*d (|iM) References
KN-93
2-[N-(2-hydroxyethyl)-N-(4-
methoxybenzenesulfonyl)]
amino-N-(4-chlorocinnamyl)-N-
methylbenzylamine
CaMKII
Competitive binding to calmodulin binding 
sites of the enzyme and preventing the 
association of calmodulin with CaMK II; 
also affects calcium channels in a CaMKII- 
independent manner
5,10,20 (Sumi et al., 1991)
Apigenin 4',5,7-Trihydroxyflavone CK2 Reversible ATP/GTP-competitive inhibitor of CK2 5,10,20
(Critchfield 
et al., 1997)
U0126
1,4-diamino-2,3-dicyano-1,4- 
bis [2-aminopheny lthio] 
butadiene
ERK 1/2/5
Reversible allosteric inhibitor of inactive 
forms of MEK1/2/5 and hence prevents the 
activation of downstream kinases, ie. 
ERK 1/2/5
5,10,20 (Favata et al., 1998)
PD98059 2-(2'-amino-3 '-methoxypheny 1)- oxanaphthalen-4-one ERK 1/2/5
Reversible allosteric inhibitor of inactive 
forms of MEK 1/2/5 and hence prevents the 
activation of downstream kinases, ie. 
ERK 1/2/5
5,30,50 (English and Cobb, 2002)
SP600125 1,9-Pyrazoloanthrone JNK/SAPK Reversible ATP-competitive inhibitor of JNK 1,2,3 isoforms with similar potency 10,15,30
(Bennett et 
al., 2001)
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SB203580
4-(4-fluorophenyl)-2-(4- 
methylsulfinylpheny)-5-(4- 
pyridy 1) 1 H-imidazole
p38
Reversible ATP-competitive inhibitor to 
active form of p38 MAPK; 
Non-ATP-competitive inhibitor to inactive 
form of p38 kinase by preventing the 
binding of the enzyme to ATP and hence 
inhibiting kinase activation in vivo.
5,10,30 (Frantz et al., 1998)
LY294002 2-(4-Morpholinyl)-8-phenyl- 4H-1 -benzopyran-4-one PI3K
Reversible ATP-competitive inhibitor of 
PI3K 10,20,30
(Vlahos et 
al., 1994)
Rottlerin
5,7-dihydroxy-2,2-dimethy-6- 
(2,4,6-trihydroxy-3-methyl-5- 
acetylbenzyl)-8-cinnamoyl-l ,2- 
chromene
PKC5 Reversible ATP-competitive inhibitor of PKC8 at low concentrations (ICso=3-6pM) 3,6,10
(Gschwendt 
et al., 1994)
Abbreviation: CamK II, calcium camodulin-dependent protein kinase II; CK2, casein kinase 2; ERK, extracellular-regulated kinase; JNK/SAPK, 
c-Jun N-terminal kinase/stress-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; Cone. Concentrations
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2.3.9 Delipidation of HI-FCS
In order to prevent the potential interference of responses studied by fatty acids and 
other lipids that might exist in FCS (activation of LXRs and PPARs), HI-FCS was 
further delipidated for the studies on NRs by the method of Cham and Knowles 
(1976). Thus, HI-FCS (10ml) was mixed with 8ml of 1-butanol and 12ml of 
diisopropyl ether (DIPE) by rotation for 60min at room temperature. The serum 
phase (aqueous phase at the bottom of the centrifuge tube) was separated from lipids 
and the organic solvent by centrifugation at 2300g for lOmin at room temperature, 
and then transferred into a fresh Universal tube using a syringe with needle. The 
residual solvent in serum was removed by blowing nitrogen bubbles through it for 5- 
6h until the solvent’s odour had disappeared. The delipidated FCS was filter- 
sterilised by passing through a 0.2pm sterile filter and stored at -20°C until required.
2.3.10 Primary culture of Human Umbilical Vein Endothelial Cells 
(HUVEC)
The primary endothelial cells utilised for leukocyte-endothelium adhesion assay 
(section 2.8) were HUVEC (pooled, cryopreserved cells obtained from Lonza, 
(Berkshire, UK). The cells were cultured in EGM medium (Bulletkits) and prepared 
for experiments according to the instructions detailed by the provider, with minor 
modifications. Thus, 15ml of EGM medium was pre-warmed in a 75cm flask in a 
37°C, 5% CO2 humidified incubator for at least 30min. Frozen cells were defrosted 
in a 37°C water bath straight after being taken out from liquid nitrogen and quickly 
dispensed into this culture vessel. The growth medium was changed everyday after 
seeding and more volume of medium was added as the cells became more confluent: 
lml per 5cm2 at -25%  confluency, 1.5ml per 5cm2 at between 25-45% confluency 
and 2ml per 5cm2 for over 45% confluency.
The cells were then prepared for experiments (section 2.8) or sub-cultured when 
they were 70-80% confluent. For each 25cm2 of cells to be cultured, they were first
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washed once with 10ml pre-warmed HEPES (4-(2-hydroxyethyl)-l- 
piperazineethanesulfonic acid)-buffered saline solution (HEPES-BSS), and 
subsequently treated with 2ml pre-warmed trypsin-EDTA solution and incubated at 
37°C for approximately 10-15sec until the cells were visibly detached from the 
substratum. Cells were then re-suspended in 4ml of pre-warmed trypsin neutralising 
solution and centrifuged at 1 lOg for 5min. The cell pellet was then re-suspended in 
3ml of EGM and cells counts and viability were determined (section 2.3.12). An 
appropriate volume of fresh EGM was then added to the suspension to make the 
seeding density of 2000-3000 cells/cm2 (1ml of growth medium for every 5cm2 
surface area of the flask).
2.3.11 Human primary monocyte-derived macrophages
Human blood buffy coats were obtained from the National Blood Service Wales. 
The buffy coat was underlayered with Lymphoprep (Nycomed Pharma) (2:1 (v/v) 
buffy coats:Lymphoprep), which contains dextran and sodium diatrizoate to cause 
erythrocyte aggregation, and subjected to centrifugation (800g, 3Omin) to allow 
sedimination of erythrocytes. The resulting interface was collected and washed with 
an equal volume of phosphate buffered saline (PBS)-0.4% (w/v) tri-sodium citrate. 
Cells were pelleted by centrifugation (800g, 5min), resuspended in 0.2% (w/v) 
saline (sodium chloride) solution and incubated on ice (30sec). An equal volume of 
1.6% (w/v) saline (sodium chloride) solution was added and the cells pelleted 
immediately by centrifugation (800g, 5min). The pellet was then washed 6-8 times 
with PBS-0.4% (w/v) tri-sodium citrate to remove contaminating platelets. The 
remaining cells were plated in R.P.M.I 1640 (5% HI-FCS and 1% (v/v) pen/strep) 
and incubated overnight at 37°C, 5% (v/v) CO2 in order to allow the adherence of 
monocytes. After this time, half of the medium was replaced with fresh complete 
medium. Culture medium was replaced every 4 days for 7-10 days, over which time 
the cells differentiated from monocytes to macrophages.
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2.3.12 Cell viability assays
2.3.12.1 Trypan blue exclusion assay
The procedure was adapted from that by Lecaroz et al. (2006). Cells were counted, 
cultured and differentiated as normal in 8cm2 cell culture dishes (sections 2.3.2-4). 
The incubation medium was removed from the cells, which were then washed with 
antibiotic- and HI-FCS-free R.P.M.I-1640 and detached with typsin-EDTA. Trypan 
blue solution (0.4% (w/v)) was added to the cell solution at a ratio of 1:1 (v/v) and 
incubated for l-2min. The number of stained and total cells was counted using a 
hemocytometer as detailed in section 2.3.4. The calculated percentage of unstained 
cells represents the percentage of viable cells.
2.3.12.2 ViaLight® plus assay
The assay was performed according to manufacturer’s instruction of the kit (Lonza). 
All the reagents in the kit [i.e. cell lysis reagent, ATP monitoring reagent plus (AMR 
PLUS), assay buffer)] were gently allowed to reach room temperature. The tissue 
culture plates were removed from the incubator and left to cool down to room 
temperature for 5min. Cells were then lysed with 50pl of cell lysis buffer for lOmin 
and lOOpl AMR PLUS assay buffer was then added to each well of the plates. After 
incubation for 2min, living cells was quantified by measuring luminescence using 
FluoStar Optima (BMG LABTECH, Aylesbury, UK) with 1 sec integrate period.
2.3.12.3 MTT-based toxicology assay
The assay was performed according to instructions by the manufacturers (Sigma). 
Thus, MTT solution (10% (v/v) of the culture medium volume) was added directly 
to the cells with medium, and then incubated as normal for 2h. Following the 
incubation period, the plates were removed from the incubator and the resulting 
formazan crystals were dissolved in MTT solubilisation solution using an amount 
that was equivalent to the original culture medium volume. The absorbance of the 
resulting solution was measured spectrophotometrically at a wavelength of 570nm.
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2.4 RNA/DNA-related techniques
2.4.1 RNA isolation
Total RNA was isolated from cells using the RNeasy kit (Qiagen). Adherent cells 
were detached by using a cell scraper, and the mixture was then transferred into a 
polypropylene tube (Falcon) and centrifuged at llOg for 5min. The pellets were 
lysed by the addition of RLT buffer (provided in the kit) supplemented with 10pl/ml 
of p-mercaptoethanol, and the suspension was homogenised by passing several 
times through a 0.9mm needle. The rest of the steps were carried out according to 
the manufacturer’s instructions.
The concentration and purity of RNA was determined using U-1500 Hitachi 
spectrophometer by measuring the absorption at 260nm and 280nm (O.D. 260 and
0.D . 280, respectively). The quality of RNA (lpg) was also analyzed by 
electrophoresis on a 1% (w/v) agarose gel (section 2.4.3).
2.4.2 Reverse Transcriptase PCR (RT-PCR)
RT-PCR consisted of two steps:
1. cDNA was synthesised from isolated RNA using reverse transcriptase (section 
2.4.2.1)
2. Standard PCR reaction was performed using gene-specific primers to obtain a 
specific product (section 2.4.2.2)
2.4.2.1 Reverse Transcription
RNA (typically lpg) was incubated with random hexamers (PdN6, 200pmol) in a 
volume of 13.5pl (made up with sterile water) at 72°C for 5min and then cooled 
immediately on ice. Subsequently, the following reagents were added into the 
reaction mixture:
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lpi o f dNTP mixture (lOmM each of dATP, dGTP, dCTP and dTTP);
1 pi of 200U of M-MLV (Molony Murine Leukemia Virus) reverse transcriptase;
0.5 pi o f 40U/ml recombinant RNase inhibitor;
4pl o f 5X reverse transcriptase buffer
The total mixture (20pl) was then incubated at 37°C for lh  and the reaction was 
terminated by incubation at 94°C for 2min. The resultant cDNA was then diluted 5- 
fold by adding 80pl nuclease-free water and stored at -20°C.
2.4.2.2PCR
The primer sets used in the PCR reactions are shown in Table 2.3. PCR reactions 
contained lx  buffer (Bioline), dNTPs (lOOpM), Taq polymerase (1U) and forward 
and reverse primers (lpM ). The concentration of magnesium chloride (MgCb) and 
cDNA was varied according to initial optimisation experiments, and DMSO was 
used for some primer sets (Table 2.4). Molecular grade water was added to bring the 
final volume of the reaction to 50pl.
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T a b le  2 .3  S e q u e n c e s  o f  f o r w a r d  a n d  re v e r s e  p r im e r s  u se d  in  P C R  a n d  th e i r  p r o d u c t  s izes  in b a se  p a i r s  (b p )
Primer names Forward primer Reverse Primer Product
size
References
28S rRNA 5'-TTAGACCGTCGTGAGACAGG-3' 5f-TTC A AT AGATCGC AGCGAGG-3' 510
(Gibbs et al., 
2002)
p-actin 5 ’ - ATG AT ATCGCCGCGCTCG-3 ’ 5’-CGCTCGGTGAGGATCTTCA-3’ 580 /
CIITA pill 5’-GCCCTGCTGGGTCCTACCTG-3’ 5 ’ -G A ACTGGTCGC AGTTG ATG-3 ’ 215
(Piskurich et 
al., 2006)
CIITA pIV 5 ’-AGGG AGAGGCC ACC AGC AG-3 ’ 5 ’ -G A ACTGGTCGC AGTTG ATG-3 ’ 227
(Zhao et al., 
2007)
GAPDH 5 ’-CCCTTC ATTG ACCTC A ACT AC ATGG-3 ’ 5 ’ -AGTCTTCTGGGTGGC AGTG ATGG-3 ’ 455
(Sabatakos 
et al., 1998)
ICAM-1 5’-AATGCCCAGACATCTGTGTC-3’ 5 ’ -C AGTT C AGT GCGGC ACG AG A AAT 521 /
ICER I/II 5 ’ -CTG ATG AGG A AACTG A ACTTG-3 ’ 5 ’ -TCGGCTCTCC AGAC ATTTTAC-3 ’ 657/257
(Peri et al., 
2001)
IP-10 5 '-CC ACGTGTTG AG ATC ATTGC-3' 5 '-AC AT AGC ACCTC AGT AG AGC-3' 383
(Berg et al., 
2006)
MCP-1 5-CTTCTGTGCCTGCTGCTCATAGCA-3' 5'-CTTGGGGTCAGCACAGATCTCCTT-3' 219 /
MIP-ip 5 ’ -GG A AGCTTCCTCGC AACTTTG-3 ’ 5 ’ -GCTC AGGTG ACCTTCCCTG A A-3 ’ 200
(Chiba et al., 
2004)
SOCS-1 5-AGACCCCTTCTCACCTCTTG-3' 5'-CTGCACAGCAGAAAAATAAAGC-3' 202 /
Table 2.4 Reaction conditions for the amplification of various PCR products
Genes
dNTPs
(lOmM)
MgCh 
(50 m M) 
pi
DMSO
Pi
cDNA
pl
Initial
melting Annealing
Extension Melting
Final long 
extension
No. of 
cycles
28S rRNA 1 2 5 10 94°C2min
62 °C 
30sec
72 °C 
lmin
94 °C 
30sec
72 °C 
lOmin 12
P-actin 1 1.5 2.5 10 95 °C 5min
57 °C 
lmin
72 °C 
2min
93 °C 
30sec
72 °C 
lOmin 16
CIITA p ill 1 1 2.5 10 96 °C 5min
60 °C 
lmin
72 °C 
lmin
96 °C 
lmin
72 °C 
lOmin 25
CIITA pIV 1 1 - 10 96 °C 5min
60 °C 
lmin
72 °C 
lmin
96 °C 
lmin
72 °C 
lOmin 31
GAPDH 0.5 2 - 10 96 °C 5min
60 °C 
lmin
72 °C 
2min
93 °C 
30sec
72 °C 
lOmin 18
ICAM-1 0.5 2 - 5 96 °C 5min
64 °C 
30sec
72 °C 
1.5min
96 °C 
40sec
72 °C 
lOmin 25
ICERI/II 1 1.5 - 5 95 °C 2min
56 °C 
lmin
72 °C 
2mim
95 °C 
30sec
72 °C 
5min 27
IP-10 1 1 - 10 95 °C 15min
56 °C 
45sec
72 °C 
lmin
94 °C 
45sec
72 °C 
lOmin 16
MCP-1 0.5 1.5 - 10 92 °C 2min
60 °C 
lmin
72 °C 
2min
95 °C 
30sec
72 °C 
lOmin 17
M IP-lp 1 1 5 10 50 °C 2min; 95 °C 15min
60 °C 
30sec
72 °C 
lmin
95 °C 
15 sec
72 °C 
lOmin 34
SOCS-1 1 1.5 2.5 5 94 °C 5min
58 °C 
lmin
72 °C 
lmin
94 °C 
lmin
72 °C 
lOmin 27
Abbreviations: CIITA: MHC class II transactivator; GAPDH: Glyceraldehye-3-phosphate dehydrogenase; ICAM: intercellular adhesion 
molecule 1; ICER: inducible cAMP early repressor; IP-10: interferon-gamma inducible protein-1; MCP: monocyte chemotactic protein; MIP: 
macrophage inflammatory protein; SOCS: suppressor of cytokine signaling
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2.4.3 Agarose gel electrophoresis of RNA/DNA
Size fractionation of PCR products and RNA was carried out by agarose gel 
electrophoresis. Gels were made from agarose dissolved in lx TBE buffer 
containing 0.5pg/ml o f ethidium bromide. The following stock solutions were used 
for electrophoresis:
1 Ox TBE;
5x DNA loading dye (lx  TBE, 50% (v/v) glycerol and 2.25% (w/v) bromophenol 
blue);
RNA loading dye stock (1M EDTA, 50% (v/v) glycerol and 2.25% (w/v) 
bromophenol blue)
*
2*43.1 Resolving RNA on agarose gels
RNA (lpg) was resolved on 1% (w/v) agarose gels to assess its integrity. RNA 
samples were prepared with 3 pi of sterile RNA loading dye and made up to a final 
volume o f 18pl with RNase free water (Qiagen). Electrophoresis was carried out in 
lx TBE buffer using a Fisherbrand Horizonal Gel Unit at 100V for approximately 
10-15min
2.43.2 Resolving PCR products and plasmid DNA on agarose gels
Agarose gels (1.0-2.0% (w/v)) were prepared depending on the size of the PCR 
products (the larger the size of DNA, the lower the concentration of agarose used). 
The size of PCR products were determined by comparison with standard DNA 
molecular markers (see Appendix I). Routinely, DNA samples were prepared with 
10)xl of 5x DNA loading dye to achieve a final lx  DNA loading dye concentration. 
Electrophoresis was carried out on a Fisherbrand Horizontal Gel Unit at 100-200V 
for 30-60min in lx  TBE buffer.
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2.4.3.3 Densitometric analysis
Following electrophoresis, RNA/DNA was visualized under UV light using a 
Syngene Gel Documentation System. The signals were quantified using Quantiscan 
computer package (Biosoft, Cambridge, UK).
2.4.4 Bacterial strains and vectors
All bacterial culture media (LB-agar and LB-liquid media) were prepared according 
to the manufacturer's instructions (DIFCO Laboratories). Table 2.5 indicates the 
genoty pe o f the Escherichia Coli {E. Coli) strains used in this work. Plasmid vector 
maps can be found in Appendix II.
Table 2.5 Genotypes of E.Coli strains used in this study
Strain Genotype Reference
DH5cc supE44 AlacU 169(<|> 801acZ AM 15)hsd 17 rec A 1 endA 1 gyrA96thi-1 rel A 1 (Hanahan, 1983)
2.4.4.1 Transformation o f competent cells
Plasmid DNA (lpg ) was added to 200pl o f competent cells, which were 
subsequently incubated on ice for 30-40min. After being heat shocked at 42°C for 
90sec the cells were immediately placed for 2min on ice. LB medium (8001) (pre­
warmed to 37°C) was added to the cells and incubated at 37°C with shaking 
(300r.p.m.) for lh. Transformed bacteria (200pl) were spread onto agar plates 
containing ampicillin (lOOg/ml). The remaining cells were pelleted by 
microcentrifugation (3000g, 3min), resuspended in LB medium (200pl) and spread 
onto separate plates. Colonies o f transformed bacteria (ampicillin resistant) were 
grown overnight at 37°C.
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Z4.4.2 Preparation of plasmid DNA (maxi-prep)
LB medium (15ml) containing ampicillin (lOOg/ml) was inoculated with a single 
colony of transformed E.Coli and incubated at 37° C for 7h with constant shaking 
(300r.p.m.). Then, 1ml of this bacterial culture was inoculated into fresh LB- 
medium (500ml) containing ampicillin (lOOpg/ml) and incubated overnight at 37°C 
with shaking (300r.p.m.). Plasmid DNA was subsequently prepared using a High 
Purity Plasmid Purification Maxiprep kit according to the manufacturer’s 
instructions (Marligen Biosciences). The plasmid DNA was diluted in sterile 
molecular biology grade water following purification. The concentration and purity 
of the DNA was determined by measuring O.D.260 and O.D.280 using a U-1800 
Hitachi spectrophotometer.
Z4.4.3 Restriction endonuclease digestion o f recombinant plasmid DNA
DNA (0.5pg) was mixed with the restriction endonuclease and its appropriate buffer 
(recommended by the enzyme’s supplier New England Biolabs) in a total volume of 
20pl. The digests were typically carried out using 10U of each enzyme with the 
exception of Kpnl where 20U were used due to its low activity. BSA (lx) was added 
where required. The reaction mixture was incubated at 37°C for 2h, unless otherwise 
stated. All reactions were terminated by incubation at 65°C for lOmin. The DNA 
fragments were analysed by agarose gel electrophoresis (section 2.4.3).
2.5 Transfection of cells with DNA
2.5.1 Plasmids used for transfection-based assays 
2.5. / . /  MCP[213]Luc
The luciferase reporter construct MCP[213]Luc was donated by Dr. R. M. 
Ransohoff (Cleveland Clinic Foundation). A region of the human MCP-1 promoter 
213bp upstream of the transcriptional start site was inserted into the pGL2-Basic 
luciferase reporter vector (Promega) (Zhou et al., 1998).
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2.5.1.2 3xly6e
The construct 3xly6e was donated by Prof J E Darnell (Rockefeller University, New 
York). The promoter contains 3 tandem STAT1 consensus sites (GAS) regulating 
the expression o f a luciferase reporter gene in the pZLuc-TK vector.
2.5.1.3 DN JNK/SAPK
The DN JNK/SAPK plasmid, SAPKa-VPA, was generated by changing the 
phosphorylation site Thr-Pro-Tyr to Val-Pro-Ala (Kawasaki et al., 1996).
2.5.1.4 DNERK1 (K71R) and ERK2 (K52R)
The ERK1 and ERK2 DN plasmid constructs, K71R and K52R respectively, were a 
generous gift from Prof. M.H.Cobb (UT Southwestern Medical Center, Dallas, 
Texas, U.S.A). The constructs contain kinase inactive mutants (lysine to arginine 
change at residues 71 and 52 for ERK-1 and -2 respectively) in the plasmid vector 
pCEP4 (Invitrogen) and p3XFLAG-CMV-7.1 (Sigma) for ERK-1 and -2 
respectively (Frost et al., 1994).
ZS.l.S DNRas and Raf-1
The Ras (Asn-17) and Raf-1 (Ala-375) DN plasmid constructs were a kind gift from
I. Komuro of Tokyo University Medical School (Zou et al., 1996).
2.5.1.6 DN MEK1
Plasmids encoding dominant-negative (pCMV-MEK-2A) form of MEK1, in which 
serine-218 phosphorylation sites were modified to alanine, were kindly provided by 
Prof. J. Han (Scripps Research Institute, California, US) (Yan and Templeton, 1994).
2.5.1.7 SRC-1 and p300
pSP64-p300 and pSP64-SRC-l in the pSP64(polyA) vector were constructed by 
cloning the full-length cDNA encoding human p300 or SRC-1 respectively (Li et al.,
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2000c). They were both generously given by D M Livingston (Dana-Farber Cancer 
Institute, Boston, MA, USA).
2.5.1.8 LXR-a and -fi expression plasmids
LXR-a and LXR-(3 expression plasmids were a generous gift from Prof. Steven A. 
Kliewer (Department of Molecular Biology, University of Texas Southwestern 
Medical Center, Dallas, Texas, U.S.A). The cDNAs encoding the human LXR-a or 
LXR-p was inserted into the expression vector pSG5 (Lehmann et al., 1997).
2.5.1.9 DN LXR-a plasmid
The DN LXR-a plasmid was a generous gift from Prof. Thomas A. Kocarek 
(Institute o f Environmental Health Sciences, Wayne State University, Detroit, 
U.S.A.). The construct contained the full length sequence of the mouse LXR-a 
lacking the C-terminal 10 amino acids and the AF-2 subdomain in the pSG5 
expression vector (Kocarek et al., 2002).
2.5.2 Transfection using SuperFECT™
SuperFect Reagent consists of molecules ended with charged amino groups which 
can interact with negatively charged phosphate groups of DNA. SuperFect Reagent- 
associated DNA can then bind to the cell membrane and are taken into the cell by 
endocytosis.
To prepare the cells for transient transfection, Hep3B were split at a ratio of 1:4-l :6 
and seeded at equal numbers in 12-well plates (1ml of complete DMEM medium in 
each well). The cells were incubated until they reached approximately 70% 
confluence (section 2.3.3.2). The medium was withdrawn and replaced with new 
fresh complete medium (0.5ml for each well) prior to transfection. The transfection 
method was carried out essentially as described in the manufacturer’s protocol 
(Qiagen). The DNA/SuperFect complex was prepared by diluting DNA (l-2pg) in
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50pl DMEM (without HI-FCS and antibiotics). SuperFect solution (3.5pl/pg DNA) 
was added and the mixed DNA-SuperFect solution was incubated at room 
temperature for lOmin. The complex was then resuspended in DMEM complete 
medium (500pl/pg DNA) and added dropwise to the cells. The cells were then 
incubated for lh  prior to the further treatment with the appropriate effectors.
2.5.3 Preparation of cell extracts for measurement of luciferase 
activity
The cells were washed once with PBS. Then, 120pl of lx  passive lysis buffer 
(Promega) was added directly to the cell monolayer and left to incubate for lOmin at 
room temperature. The cells were then scraped into the buffer, transferred into a 
microcentrifuge tube, vortexed for 45sec and centrifuged at 9,600g for 3min. The 
supernatant was transferred into a fresh tube and was either stored at -80°C or used 
immediately for the measurement of luciferase activity.
2.5.4 Measurement of luciferase activity
Extracts from transfected cells (60pi) were mixed with the luciferase substrate 
(100pi) and the fluorescent intensity (counts) was determined using a Turner 
Designs 50/50 Luminometer set at a sensitivity value of 70% with a 2sec delay 
period and 20sec integrate period. The recorded number of counts was relative to the 
amount of luciferase expressed by the reporter plasmid and hence the activity of the 
promoter sequence of interest. All measurements were taken in duplicate and the 
background values using the luciferase substrate (lOOpl) alone were subtracted from 
the sample values. Counts were normalised to the concentration of the proteins 
(pg/ml) in each lysate, which were determined as described in section 2.6.5.
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2.6 Protein analysis
2.6.1 Stock solutions
Table 2.6 A list o f the stock solutions used for protein analysis
Solution Composition
Bromophenol blue solution 0.05% (w/v) bromophenol blue in H2O
Laemmli sample buffer 0.125M Tris-HCl (pH 6.8), 4% (w/v) SDS, 10% (v/v) 
glycerol, 10% (v/v) P-2-mercaptoethanol
Phosphatase-free whole cell 
extraction buffer
lOmM Tris-HCl (pH 7.05), 50mM NaCl, 50mM NaF, 1% 
(v/v) Triton X-100, 30mM sodium pyrophosphate, 5pM 
ZnCh, 100gM sodium orthovanadate, ImM DTT, 2.8pg/ml 
aprotinin, 2.5pg/ml each of leupeptin and pepstatin, 0.5mM 
benzamidine, 0.5mM PMSF
SDS-PAGE lower gel buffer 1.5M Tris-HCl (pH 8.8), 10% (w/v) SDS, pH 6.8
SDS-PAGE upper gel buffer 1M Tris-HCl (pH 6.8), 10% (w/v) SDS pH 8.8
SDS-PAGE running buffer 25mM Tris, 250mM glycine, 0.1% (w/v) SDS pH 8.3
SDS-PAGE gel loading 
buffer (reducing)
50mM Tris-HCl (pH 6.8), lOOmM DTT, 2% (w/v) SDS, 
0.1% (w/v) bromophenol blue, 10% (v/v) glycerol
Western blot transfer buffer 25mM Tris, 192mM glycine, 20% (v/v) methanol
Whole cell extraction buffer lOmM HEPES (pH 7.9), 400mM NaCl, 0.5mM DTT, 5% 
(v/v) glycerol, 0.5mM PMSF, lOpg/ml aprotinin, 0.5M 
benzamidine, O.lmM EDTA
lOx Tris-buffered saline 
(TBS)
lOmM Tris-HCl, 20mM NaCl, pH 7.4
2.6.2 Preparation of protein extracts using the Laemmli sample buffer
The cells were washed with PBS and freshly prepared Laemmli sample buffer 
(70pl/well for 6-well plate; 150pl for 40-50ml flask; 400pl for 250-300ml flask) was 
added directly to the cells, which were then scraped directly into this buffer. The 
extracts were then collected by microcentrifugation (17,000g, 3min). At this point, 
the extracts were either frozen (-80°C) for use on a later date or subjected to SDS-
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polyacrylamide gel electrophoresis (SDS-PAGE) (section 2.6.7) and western 
blotting (sections 2.6.8).
2.6.3 Preparation of phosphatase-free whole cell protein extracts
Cells were scraped into the medium, transferred to a polypropylene tube (Falcon) 
and centrifuged at lOOOg for 5min. The cell pellet was washed twice with ice-cold 
PBS containing lOmM NaF and lOOpM sodium orthovanadate (1ml), and 
microcentrifuged (17,000g, lmin) between washes. The supernatant was discarded 
and the cell pellet was resuspended in freshly prepared phosphatase-free whole cell 
extraction buffer (Table 2.6) (lOOjil for 25cm2 flask; 200pl for 75cm2 flask) by 
vigorous pipetting and vortexing (45sec). Following centrifugation (10,000g for 
lOmin at 4°C), the supernatant, containing the total cellular protein, was removed 
and stored at -80°C. The concentration of total cellular protein was determined using 
the Micro BCA protein assay reagents (Pierce) (section 2.6.5).
2.6.4 Preparation of nuclear/cytoplasmic protein extracts
Nuclear and cytoplasmic extracts were prepared using the Nuclear Extract Kit from 
Active Motif (Rixensart, Belgium) according to manufacturer’s protocol. The 
volume of reagents stated below is applicable to protein extracted from 
approximately 8 million cells. After washing once, the cells were scrapped into ice- 
cold PBS/phosphatase inhibitor and subjected to centrifugation (4°C, 800g, 5min). 
The pellet was resuspended into 500pi of lx hypotonic buffer (provided in the kit) 
and incubated on ice for 15min. Then, 25pl of detergent (provided in kit) was added 
to the mixture, which was then subjected to vortexing for lOsec followed by 
micrcentrifugation for 30sec (13,000g, 4°C). The supernatant (cytoplasmic fraction) 
was stored at -80°C until required. The nuclear pellet was resuspended in 50pl of 
complete lysis buffer [supplemented with lOmM DTT and protease inhibitor 
cocktail (provided in kit)] by vortexing for lOsec. The suspension was incubated on 
ice for 30min and then vortexed for 30sec. Following microcentrifugation (lOmin at
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13,000g, 4°C), the supernatant (nuclear fracton) was aliquoted, in order to avoid 
freeze/thaw cycles, and stored at -80°C. The concentration of protein fractions was 
determined using the Micro BCA protein assay reagents (Pierce) (section 2.6.5).
2.6.5 Determination of protein concentration
The concentration of proteins in extracts was determined using the Micro BCA 
Protein Assay Reagent Kit (Pierce) according to the manufacturer’s instructions. A 
standard curve of absorbance versus concentration was produced for each assay 
using dilutions of a 2mg/ml bovine serum albumin (BSA) solution in order to give 
concentrations o f 5pg/ml, lOpg/ml, 15pg/ml, 20pg/ml and 25 jig/ml in a final 
volume of lOOpl. Each sample was then diluted to 1/100 and 1/200 (v/v) using PBS. 
Then, 100pi o f the diluted sample was placed in a well of a 96-well micro-titre plate 
(Greiner). Each analysis was carried out in duplicate and lOOpl of protein assay 
reagent was added to each well. The plate was incubated at 37°C for 2h to allow the 
reaction to occur. The absorbance of each sample was read at 595nm using a Dynex 
Technologies MRX microplate reader. The protein concentration of each sample 
was then calculated from the standard curve.
2.6.6 p44/42 MAPK (ERK) and SAPK/JNK Activity Assays
The p44/42 MAPK and SAPK/JNK assays were carried out using the appropriate 
non-radioactive kinase assay kits according to the protocol provided by the 
manufacturer (Cell Signalling Technology). Thus, the cells were washed with ice- 
cold PBS and ice-cold cell lysis buffer (IX) (provided in kit), supplemented with 
ImM PMSF, was directly added to the cells (500pl for 250-300cm flask). Following 
5min incubation on ice, the cells were scraped into the buffer. The cell extract was 
then sonicated for 20sec in ice and micro-centrifuged (lOmin at 10,000g) at 4°C. The 
supernatant was stored as cell lysate at -80°C.
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To 200|il of cell lysate, 15|xl of immobilised phospho-p42/44 MAPK 
(Thr202/Tyr204) antibody beads or 20pl of c-Jun fusion protein beads (provided in 
the kit) were added, and the sample was left to incubate overnight at 4°C with gentle 
rocking. The sample was then micro-centrifuged at 17,000g for lmin, and the 
resultant pellet was washed three times with 500pl o f IX cell lysis buffer, with 
micro-centrifugation at 17,000g for lmin between washes. The pellet was then 
washed three times with 500pl of IX kinase buffer with micro-centrifugation at 
17,000g for lmin between washes. Following the final wash, the pellet was 
resuspended in 50pl o f IX kinase buffer supplemented with lOOpM of ATP (Elk-1 
fusion protein was also added into the pellet for the p42/44 MAP kinase assay). The 
kinase mix was incubated at 30°C for 30min and the reaction terminated by the 
addition of 25pi of SDS-PAGE reducing gel loading buffer (Table 2.6). The sample 
was then boiled for 5min and loaded immediately onto a SDS-PAGE gel. SDS- 
PAGE and western blotting were carried out as described in sections 2.6.7 and 2.6.8 
respectively. An antibody specific to the assay [anti-phospho-Elkl (Ser383) for 
p44/p42 MAP kinase and anti-phospho-c-Jun (Ser63) for SAPK/JNK] was used for 
the immunodetection of the proteins (section 2.6.9, also see Table 2.8).
2.6.7 SDS-PAGE
SDS-PAGE was performed under reducing conditions following the method by 
Laemmli (1970), where separating gels and stacking gels were used. The gels were 
prepared from stock solutions (Table 2.6) as shown below in Table 2.7. 
Electrophoresis was carried out using the Mini-PROTEAN II slab electrophoresis 
cell from Bio-Rad Laboratories with the gel apparatus being assembled as described 
by the manufacturer (Bio-Rad Laboratories).
The separating gel was poured to within 3cm of the upper edge of the inner glass
plate. Isopropanol was layered on top of the gel solution to exclude any air bubbles
and the gel was allowed to polymerise. Once the gel had set, the isopropanol was
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washed off with ddFLO and the upper surface dried with Whatman 3 MM paper. The 
stacking gel was then poured on top and the well-forming comb inserted. Following 
polymerisation o f the stacking gel, the comb was removed and the wells were 
washed with ddFLO. The gels were then placed in the electrophoresis tank and the 
upper and lower chambers were filled with running buffer containing 0.1% (w/v) 
SDS (Table 2.6).
Equal volume o f protein samples prepared using the Laemmli sample buffer were 
mixed with an appropriate volume of bromophenol blue solution (Table 2.6), and 
then heated to 100°C for 7min before being loaded onto the gel. Equal amount o f all 
the other protein samples were mixed with an appropriate volume of reducing gel 
loading buffer (Table 2.6) and then heated to 100°C for 3-5min. The samples were 
then cooled and loaded onto the gel. Rainbow protein size markers (lOpl) (GE 
healthcare) were loaded into each gel (see Appendix I). The gel was subjected to 
electrophoresis at a constant voltage o f 200V for 30-60min according to the size of 
protein. Gels were then used for western blotting (section 2.6.8).
Table 2.7 Composition of separating and stacking gels used for SDS-PAGE
Gel component 7.5% (w/v) Separating Gel
10% (w/v) 
Separating Gel
12.5% (w/v)
Separating
Gel
5% (w/v) 
Stacking 
Gel
Upper buffer - - - 2.5ml
Lower buffer 2.5ml 2.5ml 2.5ml -
Acrylamide:
bisacrylamide
(37.5:1)
1.875ml 2.5ml 3.125ml 1.25ml
ddH 20 5.625ml 5ml 4.26ml 6.25ml
10% (w/v) APS lOOpl lOOpl lOOpl lOOpl
TEMED lOpl lOpl lOpl lOpl
Abbreviations: APS, Ammonium persulphate; TEMED, N, N, N, N - tetra methyl ethylene 
diamine
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2.6.8 Western blotting
Electrophoretic transfer of proteins was carried out using a Bio-Rad Trans Blot 
Electrophoretic transfer cell (Bio-Rad Laboratories). The transfer of proteins to 
PVDF membranes (Millipore) was carried out as described by the manufacturer. 
Briefly, the gel was removed from the glass plates and the stacking gel was cut away. 
The gel was then equilibrated by incubation in transfer buffer (Table 2.6) for 15min 
at room temperature. Whatman 3MM paper, activated PVDF membrane (soaked in 
methanol for 15sec) (both cut to the same size as the gel) and the sponge pads of the 
transfer apparatus were also pre-soaked in transfer buffer. The activated PVDF 
membrane was then placed on the gel and sandwiched between the Whatman 3MM 
paper and the sponge pads before being placed into the blotting cassette. The 
cassette was then subjected to electro-blotting in a tank containing transfer buffer at 
4°C at a constant voltage of 15V overnight or at 150V for lh. The proteins in the 
membrane were then subjected to immunodetection.
2.6.9 Immunodectection of proteins
The membrane was incubated in 20ml of blocking solution [lx  TBS containing 5% 
(w/v) skimmed milk powder and 0.1% (v/v) Tween-20] for lh. The blocking 
solution was removed and the membrane washed three times (lOmin for each wash) 
in wash solution [lx  TBS containing 0.1% (v/v) Tween-20]. The membrane was 
then incubated with the primary antibody, which was diluted in lx TBS, containing 
5% (w/v) skimmed milk or BSA and 0.1% (v/v) Tween-20, for lh at room 
temperature or overnight at 4°C (Table 2.8). The primary antibody was removed and 
the membrane was washed as described above, and then immersed (10-20ml) in the 
appropriate secondary antibody diluted 1:10,000 (anti-STATl, anti-p-actin and anti- 
nucleolin) or 1:2000 (anti-phospho-STATl, anti-p44/42 MAP kinase, anti-phospho- 
p44/42 MAP kinase, anti-phospho-Elkl and anti-phospho-c-Jun) in lx TBS 
containing 5% (w/v) skimmed milk and 0.1% (v/v) Tween-20. Following incubation
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for lh  at room temperature and series o f washes detailed above, the detection of 
membrane bound reactive protein was carried out as described in the instructions 
supplied with the ECL detection kit (GE healthcare).
Table 2.8 Primary’ antibodies used for the immunodetection of the proteins
Primary antibody
Dilution in 
lxTBS  
0.1% (v/v) 
Tween 20
% (w/v) 
skimmed  
milk or 
BSA 1
Incubation
period2 Size(kDa)
Anti-STATl 1:2000 5, skimmed milk
Overnight or 
lh 84,91
Anti-phospho-ST AT 1 
(Tyr701) 1:1000 5, BSA Overnight 84,91
Anti-phospho-ST AT 1 a 
(Ser727) 1:1000 5, BSA Overnight 91
Anti-P-actin 1:10,000 5, skimmed milk
Overnight or 
lh 42
Anti-phospho-Elk-1 
(Ser383) 1:1000 5, BSA Overnight
41*
Anti-phospho-c-Jun (Ser63) 1:1000 5, BSA Overnight 35*
Nucleolin 1:5000 5, BSA Overnight 110
1; BSA denotes bovine serum albumin.
2; Overnight and lh  incubations were carried out at 4°C and room temperature, 
respectively.
*; The size o f the protein indicated in the table is the size o f the product detected in 
kinase activity assay (according to Cell Signalling Technology), which are different 
from the endogenous protein.
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2.7 Electrophoretic mobility shift a s s a y s  (EMSA)
2.7.1 Stock solutions
Table 2.9 Stock solutions used in EMSA analysis
Solution Composition
5x Binding buffer 50mM Tris-HCl (pH 8); 750mM KC1; 2.5mM EDTA; 0.5% (v/v) Triton X100; 62.5% (v/v) glycerol; ImM DTT
2.7.2 Preparation of radiolabelled oligonucleotide probe
2.7.2.1 Annealing o f oligonucleotides
The sequences o f the oligonucleotides used for EMSA analysis are shown in Table 
2.10. The forward and reverse sequences were designed to leave 5’ overhangs, 
containing at least one G residue, following annealing to allow for complementary 
binding of [a32P]-dCTP during radiolabelling.
The forward and reverse oligonucleotides (200ng of each) were incubated together 
at 100°C (lOmin) in the presence of a medium salt buffer ( lx  NEB Buffer 3) in a 
final volume o f lOOgl. The mixture was then allowed to cool to room temperature. 
Double stranded oligonucleotides prepared in this way were either radiolabelled 
immediately or stored at -20°C.
Table 2.10 Seqences o f oligonucleotide probes for EMSA analysis
Probe Annealed Oligonucleotide Reference
MCP-
GAS 5’ GATCG CTT CCC TTT CCT ACT TCC TGG AAA 3’3’GAAGGGAAAGGATGA AGGACC TTT AGGT 5’
(Matikainen 
et al., 2000)
STAT1
consensus
sequence
5’ CAT GTT ATG CAT ATT CCT GTA AGT G 3’ 
3’ GTA CAA TAC GTA TAA GGACAT TCA C 5’
/
NFkB
consensus
sequence
5’ GGA GTT GAG GGG ACT TTC CCA 3’
3’ AA CTC CCC TGA AAGGGT CCG G 5’
/
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2.7.2.2 Radiolabelling o f  double-stranded oligonucleotides
Radiolabelling was carried out using the reagents supplied in the Megaprime™ 
Labelling Kit (GE Healthcare) according to the manufacturer’s protocol. The 
annealed double-stranded oligonucleotides (lOul) were incubated for 20min with lx  
Labelling buffer, [a32P]-dCTP (3 pi) and Klenow DNA polymerase (2pl) in a fined 
volume o f 50pl at 37°C. Separation of the radiolabelled probe from unincorporated 
nucleotides was carried out using a Sephadex G50 nick column. The column was 
equilibrated with lxTE buffer [lOmM Tris-HCl (pH 7.5), ImM EDTA] (9ml) and 
the reaction mix (50pl) loaded onto the column and eluted with lx  TE buffer (350pl), 
which was then discarded. The column was then further eluted with lx  TE (400pl) 
and the eluate collected and stored at -20°C.
2.7.3 DNA-protein binding reactions
The following components were added in order into the reaction:
Xpl o f water to bring up the total volume of the mixture to lOpl;
2pi of poly-(dI-dC).poly-(dI-dC) (lpg/pl);
2pi 5X binding buffer (Table 2.9);
5pg nuclear extract;
3 pi radiolabelled probe
The mixture was centrifuged briefly and incubated for 30min at room temperature, 
and then subjected to electrophoresis (section 2.7.5).
2.7.4 Antibody interference/supershift and competition binding studies
For antibody interference/supershift experiments, the antibody (2pg) was added to 
the nuclear extract and incubated on ice for 20min prior to the addition of the 
radiolabelled probe. In competition binding studies, the binding reaction mixture 
was incubated on ice for 20min with a 200-fold molar excess of unlabelled probe 
prior to the addition o f the radiolabelled probe.
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2.7.5 Electrophoresis of DNA-protein complexes
DNA-protein complexes were resolved by electrophoresis on 4-6% (w/v) non­
denaturing polyacrylamide gels (Table 2.11). Electrophoresis was carried out for 3- 
4h at 150V or 12-18h at 35V (both at 4°C) using vertical gel apparatus (Scotlab) 
with 0.25x TBE as running buffer. Following electrophoresis, the gel was 
transferred to Whatmann 3 MM paper and dried under vacuum using a Gel Dryer 
(Model 583, Bio-Rad) at 80°C for lh. The dried gel was exposed to Kodak X-ray 
film in a light proof cassette (Genetic Research Instrumentation) at -80° C for 
varying exposure periods (12-72h). The X-ray films were developed using a 
Gevamatic 60 automatic developer (Agfa-Gevaert).
Table 2.11 Composition of non-denaturing polyacrylamide gels for EMSA 
analysis
Component 4% (w/v) Acrylamide 6% (w/v) Acry lamide
Acrylamide: Bisacrylamide (29:1) 5 ml 7.5ml
lOx TBE 2.5ml 2.5ml
ddH20 42.5ml 40ml
10% (w/v) APS 500pl 500pl
TEMED 50pl 50pl
2.7.6 Autoradiogaphy
The dried gel was placed in contact with Kodak X -ray film in a Hi-speed-X light 
proof cassette with an intensifying screen (Genetic Research Instrumentation) and 
stored at -80°C for varying exposure times (6~72h), depending on the strength of the 
signal. The film was developed in a Gevamatic 60 automatic developer (Agfa- 
Gevaert).
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2.8 Leukocyte-endothelium adhesion assay
The CytoSelect Leukocyte-endothelium adhesion assay kit was provided by Cell 
BioLabs Inc. (San Diego, U.S.A.). The assay was performed according to the 
protocol of the manufacturer. Thus, 50,000 HUVEC cells/well were seeded in the 
Gelatin-coated 96-well plates and cultured until the endothelial cells formed a 
monolayer. The cells were then treated with effectors for an appropriate period of 
time. Monocytes (THP-1 or U937 cell line) were prepared in cell suspension at 
lxlO6 cells/ml in serum free media (SFM) and then incubated with LeukoTracker 
(lx) (provided in kit) for 60min at 37°C in a cell culture incubator. Following 
incubation, the cells were washed twice with SFM and finally resuspend in SFM at 
0.5x106cells/ml. Then, 200pl of LeukoTracker-labelled monocytes were added into 
each well and allowed to attach to HUVEC monolayer for lh. After washing 3 times, 
the adherent cells were lysed with lx  lysis buffer (provided in kit) and quantified by 
fluorescence measurement which was performed on FluoStar Optima (BMG 
LABTECH, Aylesbury, UK) at 485nm/520nm. The background values using the lx 
lysis buffer (lOOpl) alone were subtracted from the sample values.
2.9 Densitometric analysis of the data
The intensity of bands from agarose gel images and immunoblots were analysed 
using GeneTools™ (Syngene) software as described by Harvey et al (2007).
2.10Statistical analysis of the data
To assess data for statistical significance a standard student’s t test was carried out, 
the details of which are given in the Appendix III.
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Chapter 3: Regulation of gene expression and STAT1 
phosphorylation by IFN-y in human macrophages
3.1 Introduction
As described in General Introduction, IFN-y is known to regulate the expression of 
numerous genes in macrophages, many of which play significant roles in the 
progression of atherosclerosis (section 1.5). Studying the signalling mechanism 
underlying the IFN-y-regulated expression of such genes could potentially identify 
novel therapeutic targets for the treatment o f this disease. The JAK-STAT pathway 
is known as a key signalling cascade mediating IFN-y-regulated gene transcription. 
In particular, STAT1 phosphorylation at tyrosine 701 and serine 727 plays critical 
roles in the regulation of gene expression and cellular function by IFN-y (section 
1.6).
3.1.1 Specific aims
Previous work in our laboratory, most of which was carried out in the mouse 
macrophage J774.2 cell line, has led to great successes in unravelling the 
mechanisms underlying the IFN-y-regulated transcription of key genes implicated in 
inflammation and atherosclerosis. The studies have identified potentially key roles 
for CK2 and the PI3K pathways (Hughes et al., 2002; Mead et al., 2003; Harvey et 
al., 2007; Harris et al., 2008). In the light of these findings, we decided to further 
explore the pathways by which IFN-y regulates gene expression in human 
macrophages. In order to achieve this, it was first decided to validate the use of a 
human macrophage cell line as a model system for future work.
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3.1.2 Experimental strategy
The human monocytic cell line THP-1 was selected as a model system because it 
has been employed extensively to investigate the cytokine-mediated regulation of 
gene expression relevant to the pathogenesis of atherosclerosis (Hsu et al., 1996; 
Kang et al., 2006; Singh and Ramji, 2006; Imaizumi et al., 2007). In many of these 
studies, THP-1 cells were stimulated with phorbol esters to initiate their 
differentiation into macrophage-like cells, which mimic native monocyte-derived 
macrophages (Kosaka et al., 2001; Imaizumi et al., 2007; Kang et al., 2007). It has 
been claimed that compared to other human myeloid cell lines, such as HL-60 and 
U937, differentiated THP-1 cells behave more like native monocyte-derived 
macrophages (Auwerx, 1991). Indeed, numerous responses and underlying 
mechanisms of actions in this cell line have been found to be conserved with 
primary cultures (Shiratsuchi and Basson, 2005; Singh and Ramji, 2006; Stephenson 
et al., 2006; Harvey et al., 2007). In contrast to human primary monocyte-derived 
macrophages with potential donor-specific variations, the THP-1 cell line provides a 
more homogeneous system and also allows the extraction of a greater amount of 
RNA or protein. The PMA-differentiated THP-1 cell line has been used successfully 
to model macrophage responses to various mediators in our laboratory, producing 
data that has subsequently been replicated in primary cells and other macrophage 
cell lines (Hughes et al., 2002; Mead et al., 2003; Greenow, 2004; Singh and Ramji, 
2006; Harvey et al., 2007; Huwait, 2008).
In order to establish the routine use of THP-1 cells for future studies, it was decided 
initially to analyse the effect of IFN-y on the expression of several model genes that 
have previously been employed in our laboratory to investigate the action of this 
cytokine in other macrophage cell lines and primary cultures (Harvey et al., 2007; 
Harris et al., 2008). The genes are discussed below in detail. It was hoped that such 
studies would validate previous findings and identify the optimal concentration and
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time point for cytokine treatment for each gene studied. Once this had been 
established, the next step was to expand the previous findings on the potentially 
important roles for CK2 and PI3K in IFN-y signalling identified using the mouse 
system to human macrophages. This would involve analysis of the effect of 
pharmacological inhibitors of these pathways on the induction of MCP-1 expression 
by IFN-y. Finally, it was decided to investigate the effect of IFN-y on STAT1 
phosphorylation at serine 727 and tyrosine 701 in THP-1 macrophages given that 
this is involved in the activation of this transcription factor, and thereby the 
regulation of numerous downstream genes (section 1.6). The information gained 
from these experiments would then be used for future investigation of the 
mechanisms underlying the STAT1-mediated IFN-y signalling in human 
macrophages. The overall experimental strategy employed for the studies described 
in this chapter is outlined in the flow chart shown in Figure 3.1.
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Figure 3.1 Experimental strategy
The aims of the studies presented in this chapter were to establish the use of THP-1 as 
a model cellular system for future studies. Part 1 of the experimental strategy was to 
analyse the effect of IFN-y on the expression of each model gene. This would lead to 
the identification of the optimal concentration and time point for cytokine treatment 
for each gene studied. The aim of part 2 was to confirm and to expand on the previous 
finding of crucial roles for CK2 and PI3K in the IFN-y-regulated expression of 
MCP-1 to THP-1 macrophages using pharmacological inhibitors. Finally, part 3 of the 
experimental strategy was to establish the use of THP-1 in investigating the regulation 
of STAT1 phosphorylation by IFN-y using western blot analysis.
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3.1.3 CK2
CK2 is a ubiquitous, constitutively active protein kinase, typically present as a 
tetrameric holoenzyme complex of two catalytic subunits (a and/or a ’) and two 
regulatory p subunits (Litchfield, 2003; Singh and Ramji, 2008). A third catalytic 
subunit, a ”  has also been discovered in hepatocytes (Shi et al., 2001). CK2 has 
traditionally been classified as a serine/threonine protein kinase. However, there are 
reports showing it as also being capable of phosphorylating tyrosine residues, 
suggesting that CK2 may be a dual-specificity kinase (Marin et al., 1999; Litchfield, 
2003). CK2 is known to catalyse the phosphorylation of a broad range of substrates, 
including signalling molecules, transcription factors and proteins implicated in RNA 
synthesis and translation (Meggio and Pinna, 2003 and references therein). In 
particular, CK2 has been recognized to modulate several key transcription factors 
[e.g. nuclear factor-icB (NF-kB), STAT1, cyclic adenosine monophosphate (cAMP) 
response element binding protein (CREB), c-Jun, c-Fos] that have been implicated 
in inflammatory responses and associated diseases (Singh and Ramji, 2008). A 
potential key role for CK2 in the IFN-y-regulated expression of several key genes 
implicated in atherosclerosis has also been identified, mainly through studies using 
the mouse macrophage J774.2 cell line (Mead et al., 2003; Harvey et al., 2007).
3.1.4 PI3Ks
PI3Ks are a family of related lipid kinases which phosphorylate 3-OH position of 
the inositol ring of phosphoinositides. They have been linked to a diverse group of 
physiological processes, including cell growth, proliferation, differentiation, and 
migration. PI3K-dependent signalling has been implicated in the pathogenesis of a 
number o f disorders, including cancer, allergy, diabetes, cardiovascular disease and 
chronic inflammation (Rameh and Cantley, 1999; Krasilnikov, 2000; Fruman, 2004). 
For example, the activation of PI3K, along with its downstream effector Akt (also 
called protein kinase B), by oxLDL and inflammatory chemokines observed in
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inflammatory cells is absent in macrophages derived from mice that are deficient in 
the PI3K pllOy catalytic subunit. In addition, the aggressive development of 
atherosclerotic plaques in apoE-/- mice was significantly reduced in the absence of 
pi 1 Oy (Chang et al., 2007). These results strongly demonstrate that the PI3K 
pathway plays a significant role in the development of atherosclerosis and thus 
provides a promising target for the treatment of this disease.
A number of studies have shown that PI3Ks play important roles in the IFN-y- 
mediated gene expression and cellular responses, and appear to exert their function 
via activation of the major downstream effector Akt (Nguyen et al., 2001; Kristof et 
al., 2003; Navarro et al., 2003; Choudhury, 2004; Hwang et al., 2004; Rosner et al., 
2006; Venkatesan et al., 2006). In addition, other studies have shown that in certain 
cellular systems, IFN-y induces STAT1 phosphorylation at Ser727 and this is 
associated with transcriptional activation in a PI3K-Akt-dependent manner (Nguyen 
et al., 2001; Kristof et al., 2003; Choudhury, 2004; Venkatesan et al., 2006). PI3K 
appears to be dispensable for Tyr701 phosphorylation as shown by most of these 
studies. However, Hwang, et al. (2004) have found that the PI3K inhibitor 
LY294002 attenuates the IFN-y-stimulated phosphorylation at this site in microglial 
cells.
Although most of the studies suggest that the PI3K pathway regulates IFN-y 
responses via modulation of STATI activation, a PI3K-dependent, but STAT1- 
independent pathway, has also been demonstrated (Navarro et al., 2003). For 
example, Nguyen et al. (2001) have observed the activation of PI3K/Akt in response 
to IFN-y in JAK1- or JAK2-deficient cells, where STAT1 phosphorylation was 
abolished. It is therefore possible that PI3K takes part in IFN-y signalling through 
both STATI -dependent and JAK-STAT-independent manner.
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3.1.5 Genes selected for study
To investigate the IFN-y signalling pathways in the regulation of macrophage gene 
expression, our laboratory has employed a range of model genes, which are all 
known to exert critical, but distinct, functions in inflammation and atherosclerosis.
3.1.5.1 MCP-1
Amongst the genes that have been previously demonstrated to be regulated by CK2 
and the PI3K pathway in response to IFN-y is the key chemokine MCP-1 (Harvey et 
al., 2007), the pro-atherogenic role of which has been detailed before (section 
1.4.2.4). Because of such an important role, investigation of the mechanisms 
underlying the regulation of this gene will not only enhance our understanding of the 
molecular basis o f atherosclerosis, but could also ultimately lead to the identification 
of potentially novel avenues for the treatment o f this disease.
The expression of MCP-1 has been reported to be induced by IFN-y at the 
transcriptional level in a variety of cell types. Such regulation by IFN-y appears to 
be controlled predominantly by the proximal promoter region (-213/+1), which 
contains a number o f putative consensus regulatory sequences, including the GAS 
site, GC-box, AP-1 binding sites (i.e. TPA-responsive element (TRE)), NF-kB 
binding site and possibly C/EBP binding sites (Figure 3.2). The interaction of 
transcription factors with these binding sites have been demonstrated in different 
cell lines and in response to various mediators that are known to regulate MCP-1 
gene transcription (Valente et al., 1998; Zhou et al., 1998; Lim and Garzino-Demo, 
2000; Ping et al., 2000; Zhou et al., 2001). For example, studies in astrocytes and 
osteoblastic cells have demonstrated the presence of a functional STATI -binding 
site (GAS site) that is responsible for the IFN-y-inducible promoter activation 
(Valente et al., 1998; Zhou et al., 1998; Zhou et al., 2001). It should, however, be 
noted that a study on gene expression in STATl-null bone marrow-derived 
macrophages (BMMs) showed the induction of MCP-1 by IFN-y in both wild type
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and STAT1-deficient cells (Gil et al., 2001; Ramana et al., 2001). The precise 
reason(s) for this is unclear but could be because o f the potential existence of 
ST ATI -independent pathways or the high expression level o f STAT3, which can 
also bind to GAS sites with lower affinity, that has been found in STAT1-deficient 
cells (Ramana et al., 2005).
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Figure 3.2 Schematic representation of the proximal cis-regulatory region of 
the MCP-1 gene promoter
The region from -212 to the ATG translation start codon is indicated with the 
putative binding sites o f key transcription factors (boxed). Box with orange colours 
represents the binding sites that have been found to be crucial for the IFN-y- 
inducible MCP-1 gene expression.
3A.5.2 SOCS-1
SOCS-1 is a member o f the SOCS protein family, which as the name suggests, act 
as negative regulators o f the JAK-STAT pathway activated by a range o f cytokines 
(Nicola and Greenhalgh, 2000; Kile and Alexander, 2001). SOCS-1 inhibits the 
JAK-STAT pathway by acting as a pseudosubstrate o f JAK2 (Giordanetto and 
Kroemer, 2003), and can also facilitate the degradation of JAKs (Valentino and 
Pierre, 2006). The expression of SOCS-1 is at low levels in unstimulated cells, but is 
induced in different cell types by many inflammatory cytokines, including IFN-y. 
SOCS-1 in turn suppresses cytokine signalling in a classical negative feedback 
pathway (Nicola and Greenhalgh, 2000; Krebs and Hilton, 2001; Alexander and
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Hilton, 2004). SOCS-1-/- mice develop a neonatal lethal phenotype due to a 
complex inflammatory disease (Alexander et al., 1999). This pathology is thought to 
be caused by excessive responses to IFN-y as SOCS-1/IFN-y double knock-out mice 
do not suffer from such condition (Alexander et al., 1999). A number of other 
transgenic animal studies have indicated that the expression of SOCS-1 can reduce 
sustained IFN-y signalling associated with chronic inflammatory diseases (Egan et 
al., 2003; Chen et al., 2004; Fujimoto et al., 2004). SOCS-1 has also been recently 
found in atherosclerotic lesions in apoE-/- mice (Tang et al., 2005) and is now 
recognised as a potential target for therapeutic intervention of this disease (Tang and 
Raines, 2005). Ramana et al. (2001) demonstrated that the expression of SOCS-1 is 
induced by IFN-y in wild type cells but not in STATl-null BMMs, thereby 
suggesting that the IFN-y-inducible expression o f SOCS-1 is STAT1 -dependent.
3.1.5.3 Lipoprotein lipase (LPL)
The LPL enzyme expressed by macrophages is known to exert a pro-atherogenic 
role. The enzyme catalyses the hydrolysis of the triacylglycerol component of 
circulating chylomicrons and very low density lipoproteins (VLDL). As 
triacylglycerols are removed by hydrolysis, chylomicrons shrink in size and become 
chylomicron remnants that are readily taken up by macrophages (Mead and Ramji, 
2002). In addition, the free fatty acids produced by the action of LPL can be re- 
esterfied by macrophages. Together, these processes lead to the increase of 
cholesteryl esters within macrophages. The hydrolysis of VLDL also produces LDL, 
the modification of which, such as oxidation by free radicals in intimal space 
increases their rate of uptake into macrophages (Mead et al., 2002). oxLDL is one of 
the major contributors to the development of atherosclerotic lesion (section 1.4.2.1). 
Moreover, because of the existence of two separate domains for binding to 
lipoproteins and the cell surface, the enzyme also possesses a non-catalytic bridging 
action that causes the accumulation of lipoproteins at the cell surface, and thereby
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their subsequent uptake by the cells (Mead et al., 2002; Mead and Ramji, 2002). 
Both the catalytic and the non-catalytic actions of LPL contribute to the 
transformation of macrophages into foam cells (Palmer et al., 2005; Bravo and 
Napolitano, 2007). In support for a pro-atherogenic role, decreased diet-induced 
atherosclerotic lesion formation was observed in chimeric mice that are deficient for 
macrophage LPL expression, thereby suggesting that LPL deficiency in 
macrophages has a protective effect against a highly atherogenic lipoprotein profile 
(Babaev et al., 1999; Babaev et al., 2000; Van Eck et al., 2000). The expression of 
LPL has been shown to be inhibited by IFN-y in human macrophages (Jonasson et 
al., 1990). Previous work in our laboratory has shown that CK2 and PI3K signalling 
pathways play important roles in the IFN-y-mediated inhibition of macrophage LPL 
gene transcription through the regulation of Spl/Sp3 binding (Hughes et al., 2002; 
Harris et al., 2008).
113
Chapter 3: Regulation of gene expression and STATI phosphorylation by IFN-y in human macrophages
3.2 Results
3.2.1 The effect of IFN-y on the expression of MCP-1, SOCS-1 and 
LPL genes
The effect of IFN-y on the expression of MCP-1, SOCS-1 and LPL genes in human 
THP-1 macrophages over a 24h time course was analysed using semi-quantitative 
RT-PCR (section 2.4.2). Following differentiation, THP-1 cells were incubated with 
or without IFN-y for periods of 1, 3, 6, 12 and 24h, after which total RNA was 
extracted. The concentration of IFN-y used here was exactly the same as that 
employed for previous studies in the J774.2 cell line (Harvey et al., 2007). The 
integrity of total RNA was determined by resolving an aliquot on a 1% agarose gel. 
As shown in Figure 3.3A, the extracted RNA was of high quality as the relative 
density of 28S rRNA band was approximately twice compared to that for 18S rRNA 
band for each sample. Such high quality RNA was consistently obtained for all 
studies carried out in this thesis and hence the data are not shown in all cases to 
avoid repetition. Semi-quantitative RT-PCR was carried out for each of the genes 
using the primers and conditions detailed in Tables 2.3 and 2.4 respectively. The 
optimal RT-PCR condition for MCP-1 and LPL has been previously determined in 
our laboratory (Harvey, 2006; Harvey et al., 2007; Huwait, 2008). The condition for 
SOCS-1 and 28S rRNA was optimised as a part of the research carried out during 
the course of this thesis (data not shown).
Figure 3.3B shows the PCR products for MCP-1, SOCS-1 and LPL as fractionated 
by agarose gel electrophoresis. The absence of PCR product in the ‘no reverse 
transcriptase’ (-RT) reaction indicates that the amplification products were not 
derived from any contamination of the samples with genomic DNA. The size of 
each amplification product was determined from DNA molecular weight markers 
(Appendix I) that were analysed alongside. The images shown in Figure 3.3B are 
representative of three independent experiments. Although the technique is semi-
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quantitative in nature, an indication of relative changes can be gauged more easily 
by densitometric analysis o f the amplification products. Densitometric analysis 
(section 2.9) was therefore carried out and the relative intensity of the bands at each 
time point was calculated in relation to the intensity of a PCR product band for a 
control gene (28S rRNA) to ensure equal cDNA input. The data was normalised to 
the lh  untreated control and expressed as a fold change relative to this (Figure 3.3C). 
Student’s t test (Appendix III) was carried out for this data and the changes in 
expression were significant to the degree indicated. It is worth noting that there was 
no significant change in constitutive expression (i.e. in the absence of IFN-y) of all 
genes analysed throughout the time course. Untreated sample at lh  was therefore 
chosen as constitutive control to allow indication of whether there was any change 
in constitutive and IFN-y treated samples.
MCP-1 mRNA was present at undetectable levels in untreated cells (Figure 3.3). 
However, the mRNA levels increased continuously after IFN-y treatment peaking at 
12h but declining at 24h treatment. The increase at all time points observed was 
statistically significant in relation to untreated lh  control. Similar to MCP-1, SOCS- 
1 had low expression without IFN-y treatment and this was induced by the cytokine 
to reach maximal levels at the 12h point. At 24h post-treatment, the expression of 
SOCS-1 decreased back to the similar level as that observed in untreated samples. 
Unlike these two genes, LPL was expressed at high levels throughout the 24h 
incubation period without IFN-y treatment. In IFN-y-treated cells, the mRNA levels 
started declining significantly at 3h and this continued throughout the 24h 
incubation period. A comparison of the mRNA levels at each of the time points for 
untreated control samples confirmed that the changes in expression were due to the 
effect o f the cytokine and not the status of the cells at each of the time point.
The constant 28S/18S rRNA levels and the expression of 28S rRNA as judged by 
RT-PCR, suggest that IFN-y does not have a global effect on cellular gene
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transcription. In addition, a trypan blue exclusion assay (section 2.3.12.1) was 
carried out and showed that there were a negligible proportion of cells dying 
throughout the time course (Table 3.1). Overall, therefore , these results suggest that 
the changes in gene expression observed for these IFN-y-regulated genes was not 
due to a toxic effect of the cytokine on the cells.
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Figure 3.3 Time-dependent effect of IFN-y on MCP-1, SOCS-1 and LPL mRNA 
expression
PMA-differentiated THP-1 macrophages were exposed to IFN-y (lOOOU/ml) or left 
untreated for the indicated period of time. Total RNA was isolated and size-fractionated 
by electrophoresis on a 1% agarose gel (A). RNA was subjected to RT-PCR using 
primers against MCP-1, SOCS-1, LPL and 28S rRNA as shown. The amplification 
products were analysed by agarose gel electrophoresis. The images shown are 
representative of three independent experiments (B). M denotes the lkb DNA ladder 
(Appendix I) and -RT denotes a reaction in which no reverse transcriptase was 
included for the cDNA synthesis step (RNA from cells incubated for lh with IFN-y 
were used and this has only been carried out for MCP-1, SOCS-1 and 28S rRNA). 
Panel C shows the fold changes (mean ±SD) in the expression of the indicated gene 
normalised to the expression of 28S rRNA as determined by densitometric analysis 
from three independent experimental series (lh  untreated control assigned as 1). Green 
and blue bars represent the untreated and IFN-y-treated samples respectively. 
Statistical comparisons were carried out using the Student’s t test between the lh  
untreated control and treated samples at each of time point (*, PO .05; ***, PO.OOl; 
N/S, not significant).
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Untreated Treated with IFN-ylh 3h 6h 12h 24h
THP-1 viability
(% ) 100 100 98 98 98 96
Table 3.1 Assessment of toxicity of IFN-y on THP-1 macrophages over a time 
course
PMA-differentiated THP-1 cells were either left untreated or exposed to IFN-y 
(lOOOU/ml) for the indicated period of time. The viability of the cells was than 
assessed using the trypan blue exclusion assay, which detects dead cells taking up 
the trypan blue stain. The average percentage viability o f cells at each time point 
from two independent experiments is shown.
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3.2.2 Concentration-dependent effect of IFN-y on the expression of 
MCP-1
The experiments shown in Figure 3.3 used only a single concentration of IFN-y 
(lOOOU/ml). Dose-response experiments were therefore carried out using MCP-1 as 
a model gene in order to determine an optimal concentration of this cytokine that is 
required to produce a maximal response. The 3h time point was chosen because it is 
the earliest time point where a marked induction of MCP-1 mRNA expression was 
observed. Thus, THP-1 macrophages were either left untreated or incubated for 3h 
with four different concentrations of IFN-y (100, 250, 500 and 1000U). Total RNA 
was then extracted for semi-quantitative RT-PCR analysis. Figure 3.4 shows that the 
expression of MCP-1 mRNA was induced maximally at a concentration of 
lOOOU/ml of IFN-y. As this concentration had negligible effect on the viability of 
THP-1 macrophages at the 3h time point, it was selected for all future studies with 
THP-1 cells presented in this thesis.
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Figure 3.4 Concentration-dependent effects of IFN-y on MCP-1 mRNA expression
PMA-differentiated THP-1 macrophages were either left untreated or exposed for 3h with 
the indicated concentration o f IFN-y. Total RNA was isolated and subjected to RT-PCR 
using primers against MCP-1 and 28S rRNA. The amplification products were analysed 
by agarose gel electrophoresis. The images shown are representative o f two independent 
experiments (A). M denotes the lkb DNA ladder (Appendix I) and -R T  denotes a 
reaction in which no reverse transcriptase was included during the cDNA synthesis step 
(RNA from cells treated with 1 OOOU/ml o f IFN-y was used). Panel B shows the average 
fold induction in the expression of MCP-1 normalised to the expression of 28s rRNA as 
determined by densitometric analysis (untreated control assigned as 1) from two 
independent experimental series.
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3.2.3 Effect of a pharmacological inhibitor of CK2 on the IFN-y- 
induced MCP-1 expression
Work in our laboratory has demonstrated novel roles for CK2 and PI3K in the IFN- 
y-mediated regulation of macrophage gene expression implicated in atherosclerosis. 
These studies were mainly carried out using the mouse macrophage J774.2 cell line. 
It was therefore decided to replicate key experiments in THP-1 macrophages. MCP- 
1 was selected as a model gene because of the marked induction in its expression by 
IFN-y at 3h (Figure 3.3). The specific pharmacological inhibitor of CK2 (apigenin) 
was used at concentration that is widely used in the published literature (Table 2.2) 
and in our laboratory (Ali, 2007; Harvey et al., 2007; Huwait, 2008).
PMA-differentiated THP-1 macrophages were pre-treated with apigenin (20pM) or 
DMSO as a vehicle control (section 2.3.8). They were then cultured in the presence 
or the absence of IFN-y for 3h. RNA was extracted and its quality was determined 
by resolving a small aliquot by agarose gel electrophoresis (Figure 3.5A). RT-PCR 
analysis was then carried out using primers against MCP-1 and GAPDH (Figure 
3.5B). GAPDH is another routinely used constitutive control gene in our laboratory 
and its optimal RT-PCR conditions have been previously determined in our 
laboratory (N. Singh, personal communication) and are detailed in Table 2.4. 
GAPDH was employed here because of unanticipated sudden problems with 28S 
rRNA RT-PCR when these experiments were carried out. As expected, IFN-y 
increased the expression of MCP-1 mRNA and this was attenuated in the presence 
of apigenin (Figure 3.5C). Thus, similar to mouse J774.2 macrophages, CK2 is also 
involved in the IFN-y-mediated regulation of MCP-1 expression in THP-1 
macrophages.
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Figure 3.5 Effect of apigenin on the regulation of MCP-1 mRNA expression by IFN-y
PMA-differentiated THP-1 macrophages were pre-treated for lh with apigenin (20pM) or 
DMSO as a vehicle control. The cells were then cultured in the presence or the absence of 
IFN-y f°r 3h. Total RNA was isolated and size-fractionated by agarose gel electrophoresis 
(A). RNA was subjected to RT-PCR using primers against MCP-1 and GAPDH. The 
amplification products were analysed by agarose gel electrophoresis and the images shown 
are representative o f two independent experiments (B). M denotes the lkb DNA ladder 
(Appendix I). -R T  denotes a reaction in which no reverse transcriptase was included for the 
cDNA synthesis step (RNA from cells incubated with DMSO and IFN-y were used). Panel 
C shows the average relative expression of M CP-1 normalised to the expression of GAPDH 
(IFN-y-treated, DMSO control assigned as 1) from two independent experiments.
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The study detailed above used only a single concentration of apigenin (20pM). It 
was therefore decided to assess whether the effect of this compound on MCP-1 
mRNA expression occurred in a concentration dependent manner. Therefore, THP-1 
macrophages were pre-treated with various concentrations of the inhibitor or DMSO 
as a vehicle control (the volume of DMSO corresponding to the highest 
concentration of apigenin (20pM) was used). The cells were then either left 
untreated or incubated with IFN-y for 3h. The expression of MCP-1 and 28S rRNA 
was determined by semi-quantitative RT-PCR.
As shown in Figure 3.6, apigenin significantly attenuated the IFN-y-mediated 
induction of MCP-1 expression in a concentration-dependent manner. In contrast, 
the expression of the constitutive control, 28S rRNA was not affected by the 
inhibitor, thereby indicating that the inhibitory effect of apigenin on the IFN-y- 
mediated induction of MCP-1 expression was not a result of global action of the 
inhibitor on cellular gene expression. In addition, a trypan blue exclusion assay 
(section 2.3.12.1) was carried out to confirm that the observed changes in expression 
were not because of a toxic effect of the inhibitor. The results showed over 86% 
cellular viability following treatment of cells with apigenin at 20pM and the 
cytokine (Table 3.2). Together, these results further support the hypothesis that CK2 
plays a potentially important role in the regulation of MCP-1 expression in response 
to IFN-y stimulation in human macrophages.
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Figure 3.6 Concentration-dependent effect of apigenin on the regulation of MCP-1 
mRNA expression by IFN-y
PMA-differentiated THP-1 macrophages were pre-treated for lh  with apigenin (5, 10 and 
20pM) or DMSO as a vehicle control. The cells were then cultured in the presence or the 
absence o f IFN-y for 3h. Total RNA was isolated and subjected to RT-PCR using primers 
against MCP-1 and 28S rRNA as shown. The amplification products were analysed by 
agarose gel electrophoresis and the images are representative o f three independent 
experiments (A). M denotes the lkb DNA ladder (Appendix I). Panel B shows the 
relative expression (mean ±SD) of MCP-1 normalised to the expression of 28S rRNA 
(IFN-y-treated, DMSO control assigned as 1) from three independent experiments. 
Statistical comparisons were carried out using the Student’s t test between the DMSO and 
IFN-y treated control and samples under treatment with apigenin and IFN-y (***, 
PO.OOl).
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DMSO DMSO apigenin LY294002
IFN-y - + + +
THP-1 viability
(% )
100 100 86 92
Table 3.2 Assessment o f toxicity of apigenin and LY294002 with IFN-y on THP- 
1 macrophages at the 3h time point
PMA-differentiated THP-1 cells were pre-treated for lh  with apigenin (20pM) or 
LY294002 (20pM). The cells were subsequently either left untreated or exposed to 
IFN-y (lOOOU/ml) for 3h. The viability o f the cells was than assessed using the 
trypan blue exclusion assay, which detects dead cells taking up the trypan blue stain. 
The data was obtained from a single experiment.
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3.2.4 Effect of the pharmacological inhibitor of PI3K on the IFN-y- 
induced MCP-1 expression
In addition to CK2, PI3K has been demonstrated to play a critical role in the 
regulation of gene expression by IFN-y in our laboratory using mainly mouse 
macrophages (Harvey et al., 2007). It was therefore decided to next investigate the 
effect of the PI3K inhibitor, LY294002, on the IFN-y-mediated regulation of MCP-1 
expression in human THP-1 macrophages. The experiment was carried out exactly 
as described in section 3.2.3, except that the cells were treated with LY294002 
instead of apigenin. Semi-quantitative RT-PCR of MCP-1 and GAPDH was carried 
out and the results are presented in Figure 3.7 and 3.8. The results show that 
LY294002 significantly attenuates the IFN-y-induced expression of MCP-1 in a 
concentration-dependent manner. In addition, the trypan blue assay shows that 
treatment of THP-1 macrophages with LY294002 at 20pM resulted in over 90% 
cellular viability (Table 3.2), thus confirming that the observed changes in 
expression was not due to toxic effect of the inhibitor, but its specific action on the 
PI3K-dependent pathway.
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Figure 3.7 Effect o f LY294002 on the regulation of MCP-1 mRNA expression by 
IFN-y
PMA-differentiated THP-1 macrophages were pre-treated for lh  with LY294002 (20pM) 
or DMSO as a vehicle control. The cells were then cultured for 3h in the presence or the 
absence of IFN-y- Total RNA was isolated and subjected to RT-PCR using primers 
against MCP-1 and GAPDH as shown. The amplification products were analysed by 
agarose gel electrophoresis and the images are representative o f two independent 
experiments (A). M denotes the lkb DNA ladder (Appendix I). Panel C shows the 
average relative expression of MCP-1 normalised to the expression GAPDH (IFN-y- 
treated, DMSO control assigned as 1) from two independent experiments.
+
LY294002
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Figure 3.8 Concentration-dependent effect of LY294002 on the regulation of MCP-1 
mRNA expression by IFN-y
PMA-differentiated THP-1 macrophages were pre-treated for lh  with LY294002 (5, 10 
and 20pM) or DMSO as a vehicle control. The cells were then cultured for 3h in the 
presence or the absence o f IFN-y. Total RNA was isolated and subjected to RT-PCR 
using primers against MCP-1 and GAPDH. The amplification products were analysed by 
agarose gel electrophoresis and the images shown are representative o f three independent 
experiments (A). M denotes the lkb DNA ladder (Appendix I). Panel B shows the 
relative expression (mean ±SD) of MCP-1 normalised to the expression of GAPDH (IFN- 
y-treated, DMSO control assigned as 1) from three independent experiments. Statistical 
comparisons were carried out using the Student’s t test between the DMSO and IFN-y 
treated control and samples under treatment with LY294002 and IFN-y (***, PO.OOl).
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3.2.5 Effect of IFN-y on STAT1 phosphorylation in THP-1 
macrophages
The effect of IFN-y on the phosphorylation of STAT1 on serine727 and tyrosine 701 
was analysed over a 3h time-course using western blot analysis. Differentiated THP- 
1 macrophages were incubated with IFN-y for periods of 30, 60 and 180min or left 
untreated and whole cell proteins were prepared using the Laemmli sample buffer 
(section 2.6.2). Western blot analysis was carried out using antibodies against 
phospho-STATl Ser727, phospho-STATl Tyr701 and total STAT1 (p84/91). 
Densitometric analysis o f the data was carried out and band intensities for phospho- 
STATl Ser727 and phospho-STATl Tyr701 were normalized to total STATI, the 
expression of which was not affected by the cytokine. The results are presented as 
mean fold induction with those at Oh being arbitrarily assigned as 1.
Figure 3.9 shows that the level of phospho-STATl Ser727 was low in untreated 
cells and was induced dramatically by IFN-y throughout the incubation period 
reaching the highest level at the 180min time point. On the other hand, phospho- 
STATl Tyr701 was present at almost undetectable levels in untreated cells, 
increased dramatically following incubation of the cells with IFN-y to reach high 
levels at 30-60min and declined at 180min. The 30min period was selected for 
future studies as this was the earliest time point where high levels of both phospho- 
STAT1 Ser727 and phospho-STATl Tyr701 were observed.
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Figure 3.9 Effect of IFN-y on the phosphory lation of STAT1 at serine 727 and 
ty rosine 701 over time
PMA-difTerentiated THP-1 macrophages were treated with IFN-y for the indicated 
period of time and whole cell protein extracts were prepared. Western blot analysis 
was carried out using antibodies specific for phospho-STATl Tyr701, phospho- 
STATl Ser727 and STAT1 p84/91 (A). Panel B shows the average fold induction in 
the phosphorylation level o f STAT1 at these sites (Ser727 and Tyr701) normalised 
to the expression o f the total ST ATI protein level as determined by densitometric 
analysis from two independent experiments. The values for the Oh control have been 
arbitrarily assigned as 1.
IFN-y (min)
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3.3 Discussion
The inflammatory cytokine IFN-y has fundamental and complex roles in the 
progression of atherosclerosis. It regulates the expression of numerous genes that 
contribute to the pathology of this disease in the major atherosclerotic cellular 
components, most importantly macrophages [see (Boehm et al., 1997; Harvey and 
Ramji, 2005; Leon and Zuckerman, 2005; Schroecksnadel et al., 2006) for reviews]. 
Studies of the mechanisms underlying such actions of IFN-y may identify 
potentially novel therapeutic targets for the treatment of atherosclerosis and other 
inflammatory diseases.
The human monocytic cell line THP-1 was selected as a model cellular system for 
these studies because of numerous potential benefits as discussed in the introduction 
of this chapter. Indeed, this cell line has been used widely by numerous laboratories 
to investigate various aspects of atherosclerosis (Table 3.3). Most of our previous 
studies on IFN-y signalling in macrophages were carried out using J774.2 
macrophages. It was therefore important that key findings were validated in THP-1 
macrophages before detailed studies were initiated. The choice of the three genes 
selected for the initial experiments (MCP-1, SOCS-1 and LPL) was based on then- 
key roles in atherosclerosis and potential regulation by different mechanisms. For 
example, MCP-1 and SOCS-1 are both recognised as being regulated by IFN-y 
through the action of STATI (Valente et al., 1998; Zhou et al., 1998; Zhou et al., 
2001; Alexander, 2002; Ramana et al., 2002). However, Gil et al. (2001) have 
shown that MCP-1 expression is up-regulated by IFN-y in both wild type and 
STAT1-deficient cells, thereby suggesting potential roles of STAT1 -independent 
pathways, whereas SOCS-1 expression was not induced by IFN-y in STATl-null 
macrophages (Ramana et al., 2002). The inhibition of LPL expression in response to 
IFN-y has been studied previously in our laboratory and has resulted in the 
identification of a potentially important role for CK2 and PI3K through the
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modulation of binding of the transcription factors Spl/Sp3 to regulatory regions of 
this gene (Hughes et al., 2002; Harris et al., 2008). CK2 and PI3Ks were also found 
to be involved in the IFN-y-mediated induction of MCP-1 and SOCS-1 expression 
through the regulation of STAT1 phosphoiylation at serine 727 (Harvey et al., 2007).
The action of IFN-y on the expression of MCP-1, SOCS-1 and LPL in THP-1 
macrophages was investigated initially by time course RT-PCR experiments. 
Consistent with previous studies in J774.2 macrophages, IFN-y induced the 
expression of MCP-1 and SOCS-1, but reduced that for LPL (Figure 3.3). The 
kinetics for IFN-y action on these genes was similar to that observed in mouse 
macrophages (Hughes et al., 2002; Harvey et al., 2007). The expression of MCP-1 
and SOCS-1 peaked at 6h, and were reduced at subsequent time points, thereby 
suggesting the existence of further signalling events that inhibit MCP-1 and SOCS-1 
expression. SOCS-1 itself is likely to be responsible for this inhibition through a 
negative feedback mechanism.
Macrophage LPL is recognised as a pro-atherogenic mediator and inhibition of its 
expression therefore represents an athero-protective role for IFN-y. Although widely 
recognized as a pro-inflammatory cytokine, IFN-y also possesses some anti­
inflammatory and anti-atherogenic properties (Harvey and Ramji, 2005; McLaren 
and Ramji, 2009), such as inhibition of macrophage LPL expression and the 
oxidation of LDL (Christen et al., 1994; Fong et al., 1994). However, when all the 
evidence is taken into account, particularly studies emerging from mouse models 
(section 1.5 and Table 1.3), it is clear that the major action of IFN-y is pro- 
atherogenic (Harvey and Ramji, 2005; McLaren and Ramji, 2009). It was therefore 
decided to focus on the pro-atherosclerotic aspects of IFN-y for future studies. MCP- 
1, a key chemokine in this disease, was chosen here for further research with the use 
of pharmacological inhibitors.
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Table 3.3 List of publications utilising THP-1 to study various aspects of  
atherosclerosis
Aspects of atherosclerosis References
Adhesion of monocytes to endothelial cells (Redmond et al., 2009); 
(Guo et al., 2009); 
(Chen et al., 2008); 
(Tikellis et al., 2008)
Cellular apoptosis (Liu et al., 2007a); 
(Berthier et al., 2005); 
(Cappello et al., 2007); 
(Baird et al., 2005); 
(Geng et al., 2003); 
(Inagaki et al., 2002); 
(Liao et al., 2000)
Foam cell formation (Kang et al., 2008); 
(Kang et al., 2006); 
(Hu et al., 2008); 
(Wang et al., 2009); 
(Osto et al., 2008); 
(Ning et al., 2009); 
(Crow et al., 2008); 
(Tian et al., 2009); 
(Wang et al., 2008); 
(Ohwaki et al., 2007)
Immune responses (Dasu et al., 2008); 
(Ibeas et al., 2009); 
(Fuentes et al., 2002); 
Kim, et al. 2008; 
(Holvoet et al., 2006); 
(Figarola et al., 2007); 
(Bonta et al., 2006)
Monocyte migration (Wagsater et al., 2009) 
(Chen and Cheng, 2007); 
(Guo et al., 2009);
(Liu et al., 2008)
NR action (Hao et al., 2009); 
(Inoue et al., 2001); 
(Ning et al., 2009) 
(Liu et al., 2007b); 
(Qiu and Hill, 2008); 
(Hu et al., 2006); 
(Sevov et al., 2006); 
(Seki et al., 2005)
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It has previously been shown that following 24h incubation, IFN-y can promote cell 
death of THP-1 macrophages under certain culture conditions (0.1% (v/v) FCS, 
50pM P-mercaptoethanol and pre-treatment with 100 ng/ml PMA for 2 days) 
(Inagaki et al., 2002). This is clearly not the case in this study. According to the 
trypan blue exclusion assay, approximately 98% of the cells are viable following 
culturing in growth media with 10% FCS, differentiation by treatment with 
160ng/ml PMA for 24h and incubation for 3h with IFN-y (lOOOU/ml). In the light of 
this finding and maximal induction of MCP-1 expression (Figure 3.4), it was 
decided to use this concentration of IFN-y for future studies.
Consistent with previous findings in the J774.2 cell line, pre-incubation of THP-1 
macrophages with apigenin (inhibitor for CK2) and LY294002 (inhibitor for PI3K) 
dramatically attenuated the IFN-y-induced up-regulation of MCP-1 gene expression 
in a concentration dependent manner. These results suggest that similar to mouse 
macrophages, CK2- and PI3K-dependent pathways play crucial roles in the IFN-y- 
stimulated expression of the MCP-1 gene in THP-1 macrophages. The potential 
importance of these pathways in relation to MCP-1 expression have also been 
confirmed previously in human primary monocyte-derived macrophages (Harvey et 
al., 2007), indicating the direct relevance of these studies to conditions in vivo and 
ruling out any potential cell line-specific effects. As detailed above, MCP-1 gene 
expression has been found to be induced by IFN-y in both wild type and STATl-null 
cells, thereby suggesting the potential existence of ST ATI -independent pathways 
regulating its expression (Gil et al., 2001). However, our previous studies showed 
that the action of CK2 and PI3K on MCP-1 expression was mediated, at least in part, 
through the regulation of STAT1 serine727 phosphorylation (Harvey et al., 2007). It 
is at present unclear whether CK2 and PI3K/Akt act directly on STAT1 or through 
other downstream effector kinases.
Despite the existence of numerous studies that have used LY294002 as a specific 
inhibitor for PI3K (Birkenkamp et al., 2000; Nguyen et al., 2001; Choudhury, 2004;
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Harvey, 2006; Venkatesan et al., 2006; Lin et al., 2007), Choi et al. (2004) showed 
that LY294002 at a high concentration (50|iM) could mediate inhibition of IL-1- 
stimulated MCP-1 expression independently of PI3K in phorbol ester-differentiated 
THP-1 macrophages. However, the specific action of LY294002 at concentrations 
used in this study (10-30pM) on PI3K-dependent pathway has previously been 
confirmed in our laboratory. It has been shown that the IFN-y-induced activation of 
Akt was inhibited by LY294002 (Harvey, 2006). Moreover, the role of PI3K/Akt in 
the IFN-y-induced MCP-1 expression has been confirmed via an alternative 
approach in our laboratory. It was shown that transfection of the cells with a DN 
form of Akt resulted in a large decrease in the IFN-y-induced activation of a DNA 
construct containing the MCP-1 promoter linked to the luciferase reporter gene 
(MCP[213]Luc) as well as the IFN-y-mediated activation of a plasmid with three 
tandem ST ATI consensus sites (GAS) upstream of a minimal promoter and the 
luciferase reporter gene (Harvey et al., 2007). In order to further confirm the role of 
the PI3K pathway in IFN-y signalling in human macrophages, the effect of 
LY294002 on the IFN-y-induced STAT1 phosphorylation was investigated in THP- 
1 cells and the results are presented in Chapter 4 (section 4.2.2).
Consistent with previous findings in a range of cell types (Goh et al., 1999; 
Overbergh et al., 2006; Kanda and Watanabe, 2007), IFN-y elicited the 
phosphorylation of STAT1 at Ser727 and Tyr701 in THP-1 macrophages and 
phosphorylation at Ser727 occurred with a more delayed kinetics compared to that 
for tyrosine phosphorylation (Figure 3.9). Phosphorylation at the tyrosine residue is 
known to be obligatory for STAT dimerisaton (Shuai et al., 1994), nuclear 
translocation and subsequent DNA binding activity (Shuai et al., 1993), whereas the 
exact role of serine phosphorylation is relatively poorly understood despite the fact 
that it is essential for maximal transcriptional activity (Wen et al., 1995). Serine 
phosphorylation has been claimed not to contribute to DNA binding (Wen and 
Darnell, 1997), but might be essential for the recruitment of transcriptional co-
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activator, such as CBP/p300 (Sun et al., 2005). The differential function of tyrosine 
and serine phosphorylation might explain the delayed kinetics of phosphorylation of 
serine compared to that of tyrosine. The maximal phosphorylation at both Tyr701 
and Ser727 sites was observed at 30min and 180min respectively. This is consistent 
with an important role for this transcription factor in the regulation of MCP-1 and 
SOCS-1 expression, which is induced maximally after 6h of cytokine treatment 
(Figure 3.3).
In summary, the work presented in this chapter shows that we have successfully 
reproduced and extended the previous findings established in our laboratory using 
J774.2 macrophages to human THP-1 macrophages. First, IFN-y has been shown to 
regulate the expression of MCP-1, SOCS-1 and LPL genes with similar kinetics to 
that found in mouse J774.2 macrophages. Also in support with previous findings, 
CK2- and PI3K-dependent pathways have been demonstrated to play important roles 
in the regulation of MCP-1 expression in human macrophages. Moreover, IFN-y 
induced the phosphorylation of STAT1 at Ser727 and Tyr701 in THP-1 
macrophages in a pattern similar to that observed in mouse macrophages and human 
primary monocyte-derived macrophages. These results thereby suggest that THP-1 
macrophages provide a useful and validated cellular model system for further 
studies of IFN-y signalling pathway.
STATI Ser727 phosphorylation is known to be required for its full transcriptional 
activity (Wen et al., 1995). Unfortunately, the mechanisms responsible for the 
regulation of phosphorylation at this site are poorly understood, particularly in 
macrophages. It is therefore of great interest to identify the exact kinases that act as 
upstream mediators of STAT1 activation and are responsible for serine 
phosphorylation in response to IFN-y. This aspect was the focus of further studies in 
the next chapter.
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4.1 Introduction
STAT1 is one of the most extensively studied transcription factors that are involved 
in IFN-y-stimulated signalling pathways. Activation of STAT1 is largely controlled 
by phosphorylation at Tyr701 and Ser727 (Krause et al., 2006). Our current 
understanding of the mechanisms by which IFN-y mediates STAT1 phosphorylation 
at Ser727 is relatively poor, although several studies have suggested that a number 
of kinases, such as MAPK, PKC-6 and CaMK II are likely to be involved (Nair et al., 
2002; Deb et al., 2003; Overbergh et al., 2006; Kanda and Watanabe, 2007) (see 
section 1.6.2.1). Our previous studies have identified critical roles for CK2 and PI3K 
in the IFN-y-regulated expression of several genes in mouse macrophages, and the 
action of both kinases was mediated, at least in part, through the regulation of 
Ser727 phosphorylation on STAT1 (Mead et al., 2003; Harvey et al., 2007). 
However, contradictory results have also been documented in relation to kinases that 
phosphorylate STAT1 on Ser727. For example, Kovarik et al. (2001) showed that 
the phosphorylation on STAT1 at Ser727 occurred in IFN-y-stimulated mouse 
fibroblasts without a need for p38 MAPK, ERK 1/2 or JNK. In addition, Valledor 
(2008) demonstrated that ERK and JNK selectively regulate the IFN-y-mediated 
gene expression in mouse BMMs independently of STAT1 Ser727 phosphorylation. 
It is thus possible that these kinases exert their role in IFN-y signalling in a cell type- 
specific manner. Potential roles for MAPK, CK2 and PI3K in IFN-y-mediated 
signalling have been detailed in sections 1.7 and 3.1.3-4, and those for PKC-6 and 
CaMK II are discussed below.
4.1.1 PKC-5
PKC-5 belongs to a family of serine/threonine protein kinases (PKC) consisting of 
over 12 iso-enzymes. These are divided into three groups: conventional, novel and
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atypical, based on their structure along with second messenger and co-factor 
requirements. PKC-8 is known as a novel PKC (nPKC), and involved in a diverse 
range of biological responses including cellular growth, apoptosis, immune 
responses and tissue remodeling [see (Dempsey et al., 2000; Harper and Poole, 2007; 
Reyland, 2007) for reviews]. A plethora of studies have proposed important roles for 
PKC-8 in processing of signals triggered by extracellular effectors [see (Gschwendt, 
1999; Rybin et al., 2004) for reviews]. In particular, it has been suggested that PKC- 
8 acts as a downstream effector of the PI3K pathway in the regulation of IFN-y- 
stimulated gene transcription, potentially by mediating STAT1 Ser727 
phosphorylation (Deb et al., 2003). An important role for PKCs in the IFN-y- 
regulated ICAM-1 expression has also been demonstrated in epithelial cells, 
although the specific isoform responsible for this was not conclusively identified 
(Chang et al., 2002). In addition to STATI, PKC-8 has been proposed to activate a 
number of other proteins involved in gene transcription, including STAT3, NFkB 
and p300 (Steinberg, 2004), all of which have previously been reported to mediate 
IFN-y signalling in certain cellular systems (Zhang et al., 1996; Deb et al., 2001; 
Park et al., 2004).
4.1.2 CaMK II
CaMK II is a ubiquitously expressed serine/threonine protein kinase that is central to 
Ca2+ signalling. The mammalian CaMK II family is encoded by four genes (a, P, y 
and 8) with further diversity created by alternative splicing. (Griffith, 2004a). CaMK 
II has a unique holoenzyme structure and autoregulatory properties that allow it to 
produce a prolonged response to transient Ca signals, even after its activator CaM, 
dissociates, and to sense cellular Ca2+ oscillations [see (Hudmon and Schulman, 
2002; Griffith, 2004b) for reviews]. Mouse genetic approaches have provided 
insight into the key function of these kinases, mainly on hippocampal plasticity, 
cortical plasticity, learning and memory (Elgersma et al., 2004). CaMK II is known
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to phosphorylate a wide range of substrates, among which are transcription factors 
such as C/EBPp, CREB and ATF, thereby suggesting a broad role of the kinase in 
the regulation of gene expression (Soderling et al., 2001). Of note, a recent study by 
Nair et al. (2002) showed that CaMK II, along with Ca2+ flux, is required for STAT1 
Ser727 phosphorylation and associated downstream gene transcription in response 
to IFN-y.
4.1.3 Experimental strategy
Work in this chapter was carried out with the aim of determining the potential 
kinases that act upstream of STAT1 in IFN-y signalling and their roles in the IFN-y- 
regulated gene expression and cellular responses in human macrophages. To initiate 
these investigations, it was decided to make use of commercially available 
pharmacological inhibitors designed against various kinases potentially involved in 
IFN-y signalling pathways and screen for their effects on the IFN-y-mediated 
ST ATI phosphorylation. The kinase(s) whose inhibition resulted in the most 
pronounced suppression of STAT1 phosphorylation were selected for future studies. 
The roles of the chosen kinases were firstly confirmed using DN mutants in 
transfection experiments. Moreover, additional pharmacological inhibitors were 
employed wherever necessary. Furthermore, the activation of these kinases by IFN-y 
and their inhibition by the pharmacological agents used was investigated. Finally, 
the studies were extended to the investigation of the role of these pathways in the 
IFN-y-mediated changes in gene expression and cellular responses relevant to 
atherosclerosis (e.g. adhesion of monocytes to endothelial cells) (see Figure 4.1 for 
overall strategy). The inhibitors that were selected for use have been employed 
extensively in many such studies, in a variety of cellular systems. Table 4.1 lists 
some studies that have made use of these pharmacological inhibitors, particularly in 
relation to IFN-y or other cytokine/stimuli-mediated gene/protein expression or
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phosphorylation of proteins important in the regulation of gene expression (e.g. 
STATs).
4.1.4 Selection of genes for study
4.1.4.1 Chemokines
Following screening for kinases involved in the IFN-y-stimulated STAT1 
phosphorylation, their roles in the regulation of gene expression by this cytokine 
was investigated. These kinases could potentially regulate gene expression 
predominantly through the modulation of STAT1, or they may also represent novel 
components of STATI -independent pathways in IFN-y signalling. Therefore, to 
further study the exact roles of these kinases in IFN-y signalling, a number of 
additional genes to MCP-1 and SOCS-1, discussed in the previous chapter (section 
3.1.5), were analysed. Amongst these were the two chemokine genes, MIP-lp and 
IP-10. Crucial roles for these two chemokines in atherosclerosis have been detailed 
in General Introduction (section 1.4.2.4). Similar to MCP-1, the expression of both 
these chemokines has been shown to be up-regulated by IFN-y in a variety of cell 
types (Luster and Ravetch, 1987; Gil et al., 2001; Ramana et al., 2001; Jabuulonska 
et al., 2002). Previous studies have, however, been controversial regarding the 
mechanisms through which IFN-y regulates MIP-lp expression. Ramana et al. (2001) 
showed that the IFN-y-dependent induction of MIP-ip occurs in wild-type mouse 
embryonic fibroblasts but not in STATl-null cells, thereby suggesting that the 
expression of MIP-lp in response to IFN-y requires the presence of STAT1. 
However, these authors observed different results with studies on mouse BMMs, 
where STAT1 was shown not to be obligatory for MIP-ip expression (Gil et al., 
2001). These findings probably reflect cell-specific differences in the mechanism of 
action. In the case of IP-10, the IFN-y-induced gene expression has been shown to 
be impeded in STATl-null cells in both cellular systems, thereby suggesting a 
STAT1-dependent pathway in gene regulation (Gil et al., 2001; Ramana et al., 2001).
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4.1.4.2 ICAM-l
In addition to chemokines, adhesion molecules are another group of proteins that 
largely regulate the recruitment of monocyte/macrophages into the arterial intima 
via transendothelial migration (Engelhardt and Wolburg, 2004). Intercellular 
adhesion molecule-1 (ICAM-l) is an important member of this family of proteins 
and plays crucial roles during the development of atherosclerosis (Blankenberg et al., 
2003). The expression of this molecule is detectable in macrophages, endothelial 
cells and SMCs in human atherosclerotic plaques (Poston et al., 1992). ICAM-l has 
been found to promote the firm adhesion of monocytes, neutrophils, and 
lymphocytes to endothelial cells, principally by binding to the surface membrane p2  
integrin molecule, lymphocyte function associated antigen-1 (LFA-1) and
macrophage antigen-1 (MAC-1) [see (Engelhardt and Wolburg, 2004; Liu et al., 
2004b) for reviews]. The expression of ICAM-l is low in quiescent cells, but 
markedly induced by inflammatory stimuli, such as IL-1, TNF-a and IFN-y (Dustin 
and Springer, 1988; Yang et al., 2005). JAK1/2 and STAT1 have been shown to be 
required for the IFN-y-induced ICAM-l expression in endothelial cells (Chang et al., 
2002, 2004). In keeping with this, Chung et al. (2002) reported that the IFN-y- 
mediated transcription of ICAM-l requires DNA sequences containing two major 
regulatory elements: a GAS sequence and SP1 sequence. Interestingly, Zhou et al. 
(1998) previously demonstrated that the STAT1-associated GAS element in MCP-1 
promoter is required for the IFN-y-induced expression, while SP1-bound GC-rich 
element is dispensible for IFN-y responsiveness but obligatory for constitutive 
expression. It will thus be interesting to know whether a similar mechanism operates 
in the IFN-y-mediated activation of ICAM-l promoter as that required for MCP-1.
4.1.4.3 ICER
The mechanisms underlying the inhibition of gene transcription by IFN-y remain 
largely unclear despite the existence of a large number of the genes that are 
regulated in this manner. Many of these genes are implicated in atherosclerosis, such
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as LPL as discussed in the previous chapter (section 3.1.5.3). ICER has long been 
thought to be responsible for suppressing the expression of several genes regulated 
by IFN-y through cAMP response elements (CREs) (Saavedra et al., 2000). The LPL 
gene for example, the down-regulation of which in response to IFN-y is synergistic 
with cAMP, has putative ICER binding sites in its promoter (Enerback and Gimble, 
1993). ICER is one of the products of the cAMP-response element modulator 
protein (CREM) gene that is produced by internal transcriptional initiation and 
alternative splicing. It belongs to a family of transcription factors that contain the 
basic-leucine zipper (bZIP) domain and mediates transcriptional regulation through 
binding to CREs in the promoter of target genes. ICER lacks a transactivation 
domain and hence represses gene transcription either by heterodimerisation with 
other family members or by competing with them for DNA-binding. Four isoforms 
of ICER (ICER I, ICER Iy, ICER II and ICER Ily), produced by alternative splicing 
of a transcript from the use of an internal promoter, have been discovered and 
appear to be functionally indistinct (Molina et al., 1993; Shaywitz and Greenberg, 
1999; De Cesare and Sassone-Corsi, 2000). Our group has previously found that 
IFN-y produces a dramatic increase in ICER expression in the mouse macrophage 
J774.2 cell line, potentially through the phosphorylation of CREB [or other CRE 
binding proteins] by CK2 (Mead et al., 2003), and this probably represents a 
JAK/STAT1-independent pathway (Harvey, 2006). Exploring the alternative kinases 
involved in such gene regulation could potentially contribute to our knowledge on 
the mechanisms responsible for the IFN-y-mediated inhibition of gene transcription.
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Table 4.1 List of publications utilising pharmacological inhibitors to study signalling pathways regulating cytokine/stimulus-mcdiatcd 
gene/protein expression
Inhibitor Signalling 
Pathway
Cytokine(s) or other 
stimulus Gene(s) or protein(s) analysed Reference
PD98059 MEK/ERK IFN-y B-site APP cleaving enzyme 1 (Cho et al., 2007)
IFN-y 25-hydroxyvitamin D-la-hydroxylase (Overbergh et al., 2006)
IFN-y Procollagen (Ghosh et al., 2006)
IFN-y Inducible cAMP early repressor (Mead et al., 2003)
IFN-y Growth hormone (Gong et al., 2003)
IFN-y CCAAT-enhancer-binding protein p (Salmenpera et al.,
2003)
IFN-y and IL-lp Hepatocyte growth factor (Takami et al., 2005)
IFN-y and leptin Nitric oxide synthase type II (Otero et al., 2007)
IFN-y and LPS Nitric oxide synthase and IL-12 (Zhu et al., 2006)
IFN-y and LPS Inducible NO synthase (Huang et al., 2004)
IFN-y and TNF-a a (2A)-adrenoceptors (Cayla et al., 2008)
IL-17F Interferon-y-inducible protein 10 (Kawaguchi et al., 2007)
IL-lp Growth hormone (Gong et al., 2005)
TNF-a Inter-cellular adhesion molecule 1 and Vascular (Hosokawa et al., 2006)
cell adhesion molecule 1
TNF-a Monocyte chemoattractant protein-1 and inter­ (Ho et al., 2008)
cellular adhesion molecule 1
angiotensin II and Osteopontin (Xie et al., 2004)
IL-lp
U0126 MEK/ERK IFN-y Nitric oxide synthase (Mir et al., 2008)
IFN-y Interferon-y-inducible protein 10 (Dhillon et al., 2008)
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SP600125
IFN-y A disintegrin and metalloproteinase 33 (Ito et al., 2007)
IFN-y Interleukin-17E receptor (Lajoie-Kadoch et al.,
2006)
IFN-y Bicistronic HCV replicon system (Huang et al., 2006)
IFN-y CCAAT-enhancer-binding protein p (Salmenpera et al.,
2003)
IFN-y and PMA Inducible nitric oxide synthase (Han et al., 2003)
IL-17F Interferon-y-inducible protein 10 (Kawaguchi et al., 2007)
LPS Indoleamine 2,3-dioxygenase (Jung et al., 2007)
LPS Class II, major histocompatibility complex (Yaoet al., 2006)
transactivator
LPS Interleukin-6 (Ajuwon et al., 2004)
TNF-a Vascular endothelial growth factor (Kim et al., 2009)
TNF-a Matrix metalloproteinase-9 (Kim et al., 2008)
SAPK/JNK IFN-y and IL-lp 
IFN-y and LPS 
IFN-y and LPS 
LPS 
LPS
LPS
LPS
Hepatocyte growth factor 
Inducible nitric oxide synthase 
Inducible nitric oxide synthase 
Indoleamine 2,3-dioxygenase
Class II, major histocompatibility complex
transactivator
Interleukin-12 p70
Tumor necrosis factor-a
Interleukin-1 p
Tumor necrosis factor-a
Interleukin-6
(Takami et al., 2005) 
(Pawate and Bhat, 2006) 
(Shibata et al., 2006) 
(Jung et a l, 2007)
(Yao et al., 2006)
(Nakahara et al., 2004)
(Zhang et al., 2008)
SB203580
TNF-a Intercellular adhesion molecule 1 
Vascular cell adhesion molecule 1
(Hosokawa et al., 2006)
TNF-a Growth hormone-inducible gene (Buzzelli et al., 2008)
TNF-a Presenilin, nicastrin (Kuo et al., 2008)
TNF-a and Mcl-1 and XIAP (Kato et al., 2008)
granulocyte-
macrophage colony-
stimulating factor
TNF-a Vascular endothelial growth factor (Kim et al., 2009)
TNF-a Matrix metalloproteinase-9 (Kim et al., 2008)
TNF-a Monocyte chemoattractant protein-1 
Intercellular adhesion molecule 1
(Ho et al., 2008)
angiotensin II Osteopontin (Xie et al., 2004)
and IL-1|3
p38 MAPK IFN-y Interferon-Y-inducible protein 10 (Dhillon et al., 2008)
IFN-y CCAAT-enhancer-binding protein p (Salmenpera et al.,
2003)
IFN-y IL-lp Hepatocyte growth factor (Takami et al., 2005)
IFN-y and leptin Nitric oxide synthase type II (Otero et al., 2007)
IFN-y LPS Inducible nitric oxide synthase (Shibata et al., 2006)
IFN-y and LPS Monocyte chemoattractant protein-1 (Yoshimura and
Takahashi, 2007)
IFN-y and LPS Interferon regulatory factor (Koide et al., 2007)
Nitric oxide
Inducible nitric oxide synthase
LPS Indoleamine 2,3-dioxygenase (Jung et al., 2007)
apigenin
LY294002
LPS Class II major histocompatibility complex 
transactivator
(Yaoet al., 2006)
LPS Interleukin-12 p70 
Tumor necrosis factor -a
(Nakahara et al., 2004)
TNF-a Matrix metalloproteinase-9 (Kim et al., 2008)
TNF-a Monocyte chemoattractant protein-1 
Intercellular adhesion molecule 1
(Ho et al., 2008)
CK2 IFN-y
IFN-y
TNF-a
angiotensin II and
IL-lp
calpain
TGF-p
Inducible cAMP early repressor 
Monocyte chemoattractant protein-1 
Manganese superoxide dismutase 
Osteopontin
IkappaBa 
Apolipoprotein E
(Mead et al., 2003) 
(Harvey et al., 2007) 
(Farah et al., 2003)
(Xie et al., 2004)
(Shen et al., 2001) 
(Singh and Ramji, 2006)
PI3K IFN-a Interferon-a target genes (Hjortsberg et al., 2007)
IFN-y Monocyte chemoattractant protein-1 (Harvey et al., 2007)
IFN-y Signal transducers and activators of 
transcription 3
(Fang et al., 2006)
IFN-y Monocyte chemoattractant protein-1 (Venkatesan et al., 2006)
IFN-y Inducible nitric oxide synthase (Hwang et al., 2004)
IFN-y Signal transducers and activators of 
transcription 1 phosphorylation
(Choudhury, 2004)
IFN-y p70 S6 kinase (Lekmine et al., 2004)
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Rottlerin PKC8
IFN-y and leptin Nitric oxide synthase type II (Otero et al., 2007)
IFN-y and LPL Signal transducers and activators of 
transcription-1
(Kota et al., 2005)
IFN-y and LPS Inducible nitric oxide synthase, 
cyclooxygenase-2
(Sheu et al., 2005)
IFN-y and LPS Inducible nitric oxide synthase (Hattori et al., 2003)
IFN-y and LPS Fas/Apo-1 and SP-100 (Kristof et al., 2003)
IL-lp Growth hormone gene (Gong et al., 2005)
LPS Indoleamine 2,3-dioxygenase (Jung et al., 2007)
IFN-y Class II major histocompatibility complex 
transactivator
(Kwon et al., 2007)
IFN-y Signal transducers and activators of 
transcription-1
(Deb et al.,2003)
IFN-y and LPS Nitric Oxide (Springael et al., 2007)
IFN-a Phospholipid scramblase 1 (Zhao et al., 2005)
IFN-a Leukemic CFU-GM progenitors (Kaur et al., 2005)
IFN-a and IFN-p ISRE or GAS elements-controlled genes. (Uddin et al., 2002)
TNF-a Intercellular adhesion molecule 1 
Vascular cell adhesion molecule 1
(Woo et al., 2005)
TNF-a and IL-lp Nephrin (Huwiler et al., 2003)
TGFP Multipass transmembrane protein transporter 
ANK
(Cailotto et al., 2007)
TGFP Fibronectin (Ryer et al., 2006)
TGFP Collagen I (Runyan et al., 2003)
IL-13 15-lipoxygenase (Xu et al., 2004)
IL-6 Signal transducers and activators of 
transcription 3 phosphorylation
(Schuringa et al., 2001)
KN93 CaMK II IFN-y
p-adrenergic receptor 
cytosolic calcium 
G protein-coupled 
receptor
hydrogen peroxide 
hydrogen peroxide
IL-lp
light
phorbol ester
Signal transducers and activators of 
transcription 1 phosphorylation 
Ca2+ release
p38 and activating transcription factor-2 
Focal adhesion kinase
Endothelial NO synthase
Endothelial nitric oxide synthase
Extracellular signal-regulated kinase 1/2
p38 MAPK
Heat shock protein 27
c-Jun
Period gene 
IkB
(Nair et al., 2002)
(Oestreich et al., 2009) 
(Wright etal., 2007) 
(Fan et al., 2005)
(Cai etal., 2004)
(Nguyen et al., 2004)
(Storling et al., 2005) 
(Yokota et al., 2001) 
(Hughes et al., 2001)
Abbreviations: IFN, interferon; IL, interleukin; TNF, tumor necrosis factor; TGF, transforming growth factor; LPS, lipopolysaccharide 
MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; JNK, c-Jun NH2-termina 1 kinase; SAPK, stress-activated 
protein kinase; CK2, casein kinase 2; CaM K, Ca2+/calmodulin-dependent protein kinase; PI3K, phosphoinositide 3-kinase
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A NALYSE THE KINASES  
PO TENTIALLY AC T IM ,  
UPSTREAM  OF ST ATI IN THE  
IFN-y SIGNALLING PATHW AY
I
Screen for candidate kinases responsible for 
the lEN-y-induccd S I ATI phosphorylation
I
P h a r m a c o l o g i c a l  i n h i b i t o r s
Identify the key kinases and analyse them in 
more detail
Confirm the roles of the 
chosen kinases by 
transfection experiments  
using DN mutants
Confirm the role of the 
chosen kinases In use of  
additional 
pha rmacological 
inhibitors
Analyse the roles of the 
chosen kinases in the IFN- 
/-mediated gene expression  
using pharmacological 
inhibitors
Confirm and expand on findings
Analyse the roles of these kinases in 
IEN-'/-mediated changes in monocyte- 
endothelial adhesion
Anah se the activation of these kinases 
in response to IFN-y and the potential 
cross-talk between them
\  T 7 A
P h a r m a c o l o g i c a l  i n h i b i t o r s  P h a r m a c o l o g i c a l  i n h i b i t o r s
Figure 4.1 Experimental strategy
The aim of the experimental strategy was to analyse kinases acting upstream of STAT1 in the IFN- 
y-mediated signalling pathway. This was achieved with the use of pharmacological inhibitors and 
DN mutants combined with analyses of alterations in STAT1 phosphorylation, promoter activation, 
mRNA expression, kinase activity and monocyte-endothelial cell adhesion.
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4.2 Roles of the different kinases in the IFN-y-induced 
STAT1 phosphorylation in macrophages
To identify kinases that are potentially involved in STAT1 phosphorylation, a range 
of pharmacological inhibitors for candidate kinases at a series of concentrations 
were employed. PMA-differentiated THP-1 macrophages were pre-treated with 
individual inhibitors for lh  prior to treatment with IFN-y (lOOOU/ml) for 30min. The 
volume of DMSO added to the cells as a vehicle control was the same as that for the 
highest concentration of each inhibitor used in order to rule out the possibility of the 
effect of DMSO on STAT1 phosphorylation. Following incubation with the 
cytokine, whole cell proteins were extracted using the Laemmli sample buffer 
(section 2.6.2) followed by western blot analysis. Equivalent amount of whole cell 
proteins was subsequently subjected to western blot analysis with specific antibodies 
raised against phospho-STATl Ser727, phospho-STATl Tyr701 and STAT1 p84/91. 
Densitometric analysis of the data was carried out and presented in Figures 4.2-4.4. 
Band intensity for phospho-STATl Ser727 and Tyr701 were normalised to total 
STAT1 protein (p84/91). Results are presented as the IFN-y-induced expression 
levels in the presence of inhibitors (±SD) normalized to induction level stimulated 
by the cytokine (arbitrarily assigned as 1). Where experiments were carried out three 
times or more, a Student’s /-test was used to assess for statistical significance.
In experiments involving the use of inhibitors in THP-1 macrophages, the viability 
of the cells was analysed by the trypan blue exclusion assay. All the results showed 
a negligible proportion of dead cells (2-15%) following treatment with IFN-y in 
combination with each of the inhibitor (Table 4.2), thereby indicating that the 
changes in protein or mRNA expression, if any, were not due to the cell death, but 
because of the specific action of the inhibitor.
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DM DM PD U0126 SP SB rott KN
IFN-y - + + + + + + +
THP-1 
viability (% ) 100 100 98 98 95 97 90 96
Table 4.2 Assessment of viability of THP-1 macrophages following treatm ents 
with inhibitors
PMA-differentiated THP-1 cells were pre-treated for lh  with PD98059 (PD at 
50pM), U0126 (20 pM), SP600125 (SP at 30pM), SB203580 (30pM), rottlerin (rott, 
lOpM) or KN93 (20pM) or DMSO (DM) as negative vehicle control. The cells were 
then either left untreated or exposed to IFN-y (lOOOU/ml) for 30min. The viability of 
the cells was than assessed using the trypan blue exclusion assay. The data is 
obtained from a single experiment.
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4.2.1 Effect of pharmacological inhibitors of MAPK on the IFN-y- 
induced STAT1 phosphorylation
Figure 4.2-A and -B shows that pre-treatment of the cells with PD98059 (ERK 
inhibitor) and SP600125 (JNK inhibitor) attenuated the IFN-y-induced STAT1 
phosphorylation at Ser727 in a concentration-dependent manner. At the highest 
concentration of PD98059 and SP600125 used (50|iM and 30pM respectively), the 
level of phospho-STATl Ser727 was almost reduced to that observed in untreated 
cells. In contrast, the inhibitors had no effect on the IFN-y-induced phosphorylation 
of STAT1 on Tyr701 in DMSO-treated control cells, thereby suggesting that the 
inhibitor did not affect the general phosphorylation status of proteins in the cells in a 
non-specific manner. Overall, the results suggest that ERK and JNK play important 
roles in the IFN-y-mediated phosphorylation of STAT1 at Ser727, but not on Tyr701, 
in human macrophages.
In contrast to the ERK and JNK inhibitors, SB203580, a p38 MAPK inhibitor, was 
found not to impair either Ser727 or Tyr701 phosphorylation of STAT1 stimulated 
by IFN-y (Figure 4.2C), thereby indicating that STAT1 activation by IFN-y in 
human macrophages is potentially independent of p38 MAPK.
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Figure 4.2 Effect of PD98059, SP600125 and SB203580 on the IFN-y-induced phosphorylation of STATI at Ser727 and Tyr701
PMA-differentiated THP-1 macrophages were pre-treated with PD98059 (A), SP600125 (B) or SB203580 (C) at three different concentrations as 
indicated or DMSO (DM) as a vehicle control (volume corresponding to the highest concentration o f the respective inhibitor used). They were 
then cultured in the presence or the absence of IFN-y for 30min. Whole cell protein extracts were prepared and western blot analysis was carried 
out using antibodies specific for pSTATl Tyr701; pSTATl Ser727 and STAT1 p84/91. The graphs show the relative phosphorylation level 
(mean ± SD) of STAT1 at each of these sites normalised to the expression o f the total STAT1 protein, as determined by densitometric analysis, 
from three independent experimental series (the value from IFN-y-treated DMSO control sample was arbitrarily assigned as 1). Asterisks indicate 
significant attenuation o f the IFN-y-induced STAT1 phosphorylation in cells incubated with the DMSO control (***/><0.001; N/S, not significant)
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4.2.2 Effect o f  pharmacological inhibitors o f  CK2 and PI3K on the IFN- 
y-induced STATI phosphorylation
Consistent with our previous findings in the mouse macrophage J774.2 cell line 
(Harvey et al., 2007), a significant attenuation of the IFN-y-induced STAT1 Ser727 
phosphorylation was also observed in human THP-1 macrophages by pre-treatment 
of the cells with the CK2 inhibitor apigenin at 10 and 20pM, and the PI3K inhibitor 
LY294002 at 20 and 30pM (Figure 4.3). Phosphorylation at Tyr701 was not affected 
by either of these inhibitors, thereby suggesting that CK2 and PI3K are specifically 
responsible for the IFN-y-mediated STATI Ser727 phosphorylation.
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Figure 4.3 Effect of apigenin and LY294002 on the IFN-y-induced
phosphorylation of STAT1 at Ser727 and Tyr701
PMA-differentiated THP-1 macrophages were pre-treated with apigenin (A) and 
LY294002 (B) at three different concentrations as indicated or the DMSO control 
(volume corresponding to the highest concentration of the inhibitor was used) as a 
vehicle control. They were then cultured for 30min in the presence or the absence of 
IFN-y. Whole cell protein extracts were prepared and western blot analysis was carried 
out using antibodies specific for pSTATl Tyr701, pSTATl Ser727 and STAT1 p84/91. 
The graphs show the relative phosphorylation level (mean ±  SD) of STAT1 at each of 
these sites normalised to the expression of total STAT1, as determined by densitometric 
analysis from three independent experimental series (value from IFN-y-treated DMSO 
control cells has been arbitrarily assigned as 1). Asterisks indicate significant 
attenuation of the IFN-y-induced STAT1 phosphoiylation in control cells (**P<0.01; 
***p<0 ooi; N/S, not significant)
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4.2.3 Effect of pharmacological inhibitors of PKC-5 and CaMK II on 
the IFN-y-induced STAT1 phosphorylation
Figure 4.4A shows a dramatic inhibition by the PKC-5 inhibitor rottlerin of the IFN- 
y-induced STAT1 phosphorylation at both Ser727 and Tyr701 in a concentration- 
dependent manner. Similar to rottlerin, KN93, an inhibitor of CaMK II, also 
produced a significant inhibition of the phosphorylation of STAT1 at both Ser727 
and Tyr701 sites observed in the presence of IFN-y (Figure 4.4B). However, KN93 
only inhibited the phosphorylation at Ser727 at the highest concentration used 
(20pM) whereas the phosphorylation at Tyr701 was affected to almost equal extent 
by all three concentrations employed. These results suggest that both PKC-5 and 
CaMK II are potentially involved in the IFN-y-induced STAT1 phosphorylation at 
both tyrosine and serine sites.
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Figure 4.4 Effect of rottlerin and KN93 on the IFN-y-induced phosphorylation of
STAT1 at Ser727 and iyr701
PMA-differentiated THP-1 macrophages were pre-treated with rottlerin (A) and KN93 
(B) at three different concentrations as indicated or the DMSO control (volume 
corresponding to the highest concentration of the inhibitor was used). They were then 
cultured for 30min in the presence or the absence of IFN-y. Whole cell protein extracts 
were prepared and western blot analysis was carried out using antibodies specific for 
pSTATl Tyr701, pSTATl Ser727 and STAT1 p84/91. The graphs show the relative 
phosphorylation level (mean ± SD) of STAT1 at each of these sites normalised to the 
expression of total STAT1 as determined by densitometric analysis from three 
independent experimental series (the value from IFN-y-treated DMSO control has been 
arbitrarily assigned as 1). Asterisks indicate significant attenuation by the inhibitors of 
the IFN-y-induced STAT1 phosphorylation observed in control cells (*P<0.05; 
**P<0.01; ***/><0.001; N/S, not significant).
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4.3 Roles of ERK and JNK pathways in IFN-y signalling in 
macrophages
Previous work presented in this chapter has shown that amongst the inhibitors 
screened, the ERK inhibitor PD98059 and the JNK inhibitor SP600125 produced the 
most pronounced inhibition of STAT1 phosphorylation in response to IFN-y at 
Ser727 without affecting that on Tyr701 (section 4.2). It was therefore decided to 
next confirm the roles of ERK and JNK in the IFN-y-mediated STAT1 
transcriptional activity and gene expression by a number of different approaches, 
including on-going use of pharmacological inhibitors and plasmids specifying for 
DN mutants.
4.3.1 Effect of the ERK inhibitor U0126 on the IFN-y-induced STATI 
phosphorylation
To confirm the role of ERK in the IFN-y-regulated STAT1 phosphorylation, a 
concentration-dependent experiment with another ERK inhibitor U0126 was 
performed. As detailed for previous studies, PMA-differentiated THP-1 cells were 
treated with U0126 at a series of concentrations (5, 10 and 20pM) for lh prior to 
further stimulation with IFN-y (lOOOU/ml) for 30min (DMSO was included as a 
vehicle control). Whole cell proteins were subsequently prepared using the Laemmli 
sample buffer and subjected to western blot analysis to monitor STATI 
phosphorylation.
Consistent with previous findings in relation to PD98059 (Figure 4.2A), U0126 
attenuated STATI phosphorylation at Ser727 in a concentration-dependent manner 
(Figure 4.5). Again phosphorylation at Tyr701 was not affected following treatment 
of the cells with the inhibitor. These results support our hypothesis that the ERK 
plays a key role in the IFN-y-mediated STAT1 Ser727 phosphorylation in human 
macrophages.
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Figure 4.5 Effect of U0126 on the IFN-y-induced phosphorylation of STAT1 at Ser727 and Tyr701
PMA-differentiated THP-1 macrophages were pre-treated with U0126 (5, 10 and 20pM) or DMSO (volume equivalent to 20pM of U0126) as a 
vehicle control. They were then cultured for 30min in the presence or the absence of IFN-y. Whole cell protein extracts were prepared and western 
blot analysis was carried out using antibodies specific for: pSTATl Tyr701, pSTATl Ser727 and STAT1 p84/91 (A). The graphs show the relative 
phosphorylation level (mean ±  SD) of STAT1 at either of these sites normalised to the expression of total STAT1 as determined by densitometric 
analysis from three independent experimental series (the value from IFN-y-treated DMSO control has been arbitrarily assigned as 1). Asterisks 
indicate significant attenuation by the inhibitors of the IFN-y-induced ST ATI phosphorylation observed in control cells (**P<0.01; ***P<0.001; 
N/S, not significant).
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4.3.2 Further investigation into the role o f  ERK and JNK on the IFN-y- 
mediated ST ATI phosphorylation in human primary monocyte- 
derived macrophages
Because the experiments so far were carried out on THP-1 macrophages, the action 
of IFN-y and the inhibitors PD98059 and SP600125 on STAT1 phosphorylation in 
human primary monocyte-derived macrophages were investigated.
4,3.2.1 IFN-y induced STAT1 phosphorylation in human primary monocyte- 
derived macrophages
Primary monocytes were isolated from bufify coats of human blood and allowed to 
differentiate in culture over seven days (section 2.3.11). The effect of IFN-y on 
STAT1 Ser727 and Tyr701 phosphorylation was analysed over a 6h time-course 
using western blot analysis. Following differentiation, primary macrophages were 
incubated with IFN-y for periods of 0, 5, 15, 30, 60, 90, 180 and 360min, after 
which whole cell protein was extracted using the Laemmli sample buffer (section 
2.6.2). Western blot and densitometric analysis was carried out as detailed before 
and the results are shown in Figure 4.6.
Human primary macrophages showed the presence of low levels of phospho-STATl 
Ser727 and almost complete absence of phospho-STATl Tyr701. The level of 
phospho-STATl Tyr701 was induced dramatically by IFN-y and reached the highest 
level at 5min following cytokine treatment. This was followed by reduction at 
subsequent time points to reach almost undetectable levels after 180min. The 
phosphorylation at Ser727 of STAT1 occurred with a delayed kinetics compared to 
Tyr701, but was nevertheless induced in a time-dependent manner. After reaching 
the highest level at 90min, there was a gradual decrease in a time-dependent manner. 
These results show that similar to THP-1 macrophages (Figure 3.9), IFN-y induces 
the phosphorylation of STAT1 at both Tyr701 and Ser727. The 30min time point, 
which was chosen for further analysis of STAT1 phosphorylation in THP-1 cells, 
was again selected here for future work on human monocyte-derived macrophages.
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Although there were some differences in total ST ATI levels between various time 
points, this is likely to be specific to this single experiment as previous studies 
consistently showed that IFN-y does not affect the expression of total STAT1 in a 
vast range of cells, including human macrophages (Kovarik et al., 1998; Nguyen et 
al., 2000; Nguyen et al., 2001; Ramsauer et al., 2002; Overbergh et al., 2006; 
Harvey et al., 2007). As only a single experiment was performed, the variation in 
total ST ATI level could represent a technical error during the cellular protein 
extraction. In support to this, our subsequent analysis of the IFN-y-induced STAT1 
phosphorylation in human primary monocyte-derived macrophages showed that the 
total STATI protein levels did not change in response to this cytokine (Figure 4.7).
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Figure 4.6 Tim e-course effect of IFN-y on the phosphorylation of STAT1 at Ser727 
and Tyr701 in human monocyte-derived macrophages
Human monocyte-derived macrophages were treated with IFN-y for the indicated period 
of time and cellular protein extracts were prepared using the Laemmli sample buffer. 
Western blot analysis was carried out using antibodies specific for pSTATl Tyr701, 
pSTATl Ser727 and STAT1 p84/91 (A). Panel B shows the fold induction in the 
phosphorylation level o f STAT1 at each o f these sites normalised to the expression of 
total STAT1 protein levels, as determined by densitometric analysis (Omin control 
assigned as 1) from this single experiment.
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4.3.2.2 Effect of PD98059 and SP600125 on the IFN-y-induced STAT1 
phosphorylation in human primary monocyte-derived macrophages
The choice of concentration of inhibitors used here, PD98059 and SP600125, was 
based on the results in THP-1 cells presented early in this chapter. Figure 4.2A and 
B show that PD98059 at 30pM and SP600125 at 15 and 30|iM produced 60-70% 
inhibition of the IFN-y-induced phospho-STATl at Ser727 levels with less than 5% 
of dead cells compared to DMSO and IFN-y-treated control. Thus, human primary 
monocyte-derived macrophages were pre-treated with PD98059 (30pM), SP600125 
(20pM) or DMSO as a vehicle control. The cells were then cultured in the presence 
or the absence of human IFN-y for 30min. Whole cell protein was extracted and 
western blot analysis was carried out as detailed before. Figure 4.7 shows that as 
found in THP-1 cells (Figure 4.2-A and -B), both inhibitors attenuated the IFN-y- 
induced STAT1 phosphorylation at Ser727. Interestingly, phosphorylation at Tyr701 
was also decreased, in contrast to that found in THP-1 cells (Figure 4.2-A and -B).
Viability of primary macrophages under various treatment was determined by the 
ViaLight® Plus assay (section 2.3.12.2). The results showed a negligible proportion 
of dead cells (5-10%) following treatment with IFN-y in combination with each 
inhibitor (Table 4.3), suggesting that the changes in the phosphorylation level of 
ST ATI at both sites was not due to a toxic effect of the cytokine or the inhibitor.
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Figure 4.7 Effect of PD98059 (PD) and SP600125 (SP) on the IFN-y-induced phosphorylation of STAT1 at Ser727 and Tyr701 in human 
monocyte-derived macrophages
Human monocyte-derived macrophages were pre-treated with PD98059 (30pM) and SP600125 (20pM) or DMSO as a vehicle control. They were 
then cultured in the presence or the absence of IFN-y for 30min. Cellular protein extracts were prepared using the Laemmli sample buffer and 
western blot analysis was carried out using antibodies specific for pSTATl Tyr701, pSTATl Ser727 and STAT1 p84/91 (A). The graphs show the 
relative phosphorylation level (mean ± SD) of STAT1 at either of these sites normalised to the expression of total STAT1 as determined by 
densitometric analysis from three independent experimental series (the value from IFN-y-treated DMSO control has been arbitrarily assigned as 1). 
Asterisks indicate significant attenuation by the inhibitors of the IFN-y-induced STAT1 phosphorylation observed in control cells (*P<0.05; 
**P<0.01; ***P<0.001).
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DMSO ^JDMSCT PD SP
IFN-y - + + +
T H P -t viability (% ) 100 100 89 91
Table 4 3  Assessment of cellular viability of human primary monocyte-derived 
macrophages following treatment with inhibitors and IFN-y
Human primary monocyte-derived macrophages were pre-treated for lh with 
PD98059 (PD at 30pM) or SP600125 (SP at 20pM) or DMSO as negative vehicle 
control. The cells were then either left untreated or exposed to IFN-y (lOOOU/ml) for 
30min. The viability of the cells was than assessed using the ViaLight® Plus assay 
(section 2.3.12.2). The data was obtained from a single experiment.
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4.3.3 Validation of a hepatocyte transfection system for studies on 
STAT1 transcriptional activity
Several studies have shown that macrophage cell lines are relatively difficult to 
transfect at high efficiency with exogenous DNA (Ohtani et al., 1989; Kusumawati 
et al., 1999; Dokka et al., 2000). Therefore, transfection based studies were carried 
out in the human hepatoma Hep3B cell line (section 2.3.3.2) using the SuperFect™ 
method (section 2.5.2). Experiments in our laboratory have demonstrated that this 
cell line can be transfected at high efficiency with exogenous DNA. Our research 
group has also shown that Hep3B cells provide a good model for the cytokine- 
regulated gene expression and responses to IFN-y (Foka et al., 2003; Irvine et al., 
2005; Ali, 2007; Harvey et al., 2007). In addition, Harvey (2006) has demonstrated 
that the level of induction of MCP-1 expression in Hep3B cells by IFN-y and the 
inhibition of this response by LY294002 and apigenin was comparable to that seen 
in macrophages.
In order to further validate the use of this system in the study of STATI 
transcriptional activity in response to IFN-y, western blot analysis was carried out to 
demonstrate the induction of STAT1 phosphorylation by IFN-y and the effect of 
PD98059 on this. Hep3B cells were incubated with IFN-y (lOOU/ml) for periods of 
30, 60 and 180min or left untreated (the optimal concentration of the cytokine used 
in Hep3B cells has been previously determined by our group as lOOU/ml (Harvey, 
2006)), after which whole cell protein was extracted using the Laemmli sample 
buffer (section 2.6.2). Western blotting and analysis of the data was carried out as 
described before and the results are shown in Figure 4.8.
As expected, the phosphorylation of STAT1 at Ser727 was increased by IFN-y over 
the time course, with the maximal level of expression observed at 3h. 
Phosphorylation at Tyr701 was also induced dramatically and declined after 
reaching its highest level at the 30min time point. Thus, the overall pattern of
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STAT1 phosphorylation by IFN-y in Hep3B cells was similar to that observed in 
THP-1 macrophages (Figure 3.9). The Hep3B cell line therefore provides a valuable 
cellular model system for studying IFN-y-regulated ST ATI activation.
The effect of PD98059 on STAT1 phosphorylation in Hep3B cells was also 
investigated by western blot analysis. As for THP-1 macrophages, the cells were 
treated with PD98059 at a series of concentrations (5, 30 and 50 pM) or DMSO 
followed by stimulation with IFN-y (lOOU/ml) for 30min. PD98059 attenuated the 
IFN-y-stimulated STATI phosphorylation at Ser727 in a concentration-dependent 
manner. The overall inhibition by PD98059 was comparable to that in macrophages. 
Unexpectedly, the phosphorylation at Tyr701, which was found not to be inhibited 
by either PD98059 or U0126 in THP-1 cells, was reduced by pre-treatment of 
Hep3B cells with PD98059 at a higher concentration of 50pM (Figure 4.9). This is, 
however, consistent with what was observed in human primary macrophages, where 
STAT1 phosphorylation at both sites was inhibited by pre-treatment with PD98059 
(Figure 4.7). Therefore, in addition to the Ser727 site found in THP-1 cells, ERK 
might also be involved in regulating STAT1 Tyr701 phosphorylation in hepatocytes. 
Given that STAT1 activity is regulated by phosphorylation at both sites, the Hep3B 
cell line, with its high transfection efficiency, provides a useful cellular model 
system for studying the mechanisms underlying the regulation of STAT1 activity in 
response to IFN-y as well as that for MCP-1 promoter activation as previously 
carried out in our laboratory (Harvey et al., 2007).
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Figure 4.8 Effect of IFN-y on the phosphorylation of STAT1 at Ser727 and Tyr701 over time in Hep3B cells
Hep3B cells were treated with IFN-y for the indicated period of time and whole cell protein extracts were prepared. Western blot analysis was 
carried out using antibodies specific for pSTATl Tyr701, pSTATl Ser727 and STAT1 p84/91. The graphs show the fold induction (mean ±  SD) 
in the phosphorylation level of STAT1 at either of these sites normalised to the expression of the total STAT1 protein, as determined by 
densitometric analysis from three independent experimental series (the value for the Omin control point has been arbitrarily assigned as 1). 
Student’s t test was carried out on IFN-y-treated sample versus the Omin control (*P<0.05; **?<0.01; ***?<0.001).
1 68
PSTAT1-Scr727 PSTAT1-Tyr701
PD98059
+ + + + IFN-y
pSTATl-Ser727
pSTATl -Tyr701
STATl-p84/91
N/S N/S ***
DM DM 5 30 50
IFN-y + + + +
DM DM 5 30 50 (pM)
+ + + +
Figure 4.9 Effect of PD98059 on the IFN-y-induced phosphorylation of STAT1 at Ser727 and Tyr701 in Hep3B cells
Hep3B cells were pre-treated with PD98059 (5, 30 and 50pM) as indicated or DMSO as a vehicle control. They were then cultured in the presence or 
the absence of IFN-y for 30min. Whole cell protein extracts were prepared and western blot analysis was carried out using antibodies specific for 
pSTATl Tyr701, pSTATl Ser727 and STAT1 p84/91. The graphs show the relative phosphorylation level (mean ± SD) of STAT1 at either of these 
sites normalised to the expression of the total STAT1 protein, as determined by densitometric analysis from three independent experimental series 
(the value from IFN-y-treated DMSO control has been arbitrarily assigned as 1). Asterisks indicate significant attenuation by PD98059 of the IFN-y- 
induced STAT1 phosphorylation observed in control cells (***P<0.001; N/S, not significant).
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4.3.4 Effect of DN inhibitors of ERK and JNK pathways on the IFN-y- 
induced activation of STAT1 responsive elements and MCP-1 
gene promoter
A potentially important role for ERK and JNK in ST ATI phosphorylation regulated 
by IFN-y has been demonstrated by the concentration-dependent actions of 
pharmacological inhibitors (Figure 4.2-A and -B). In order to confirm the role 
further, co-transfection assays were performed using DN expression plasmids in the 
ERK and JNK cascade.
Previous work in other cell types has demonstrated activation of the MCP-1 gene 
promoter by IFN-y (Valente et al., 1998; Zhou et al., 1998; Zhou et al., 2001). Work 
in our laboratory has established that IFN-y increases the expression of the MCP-1 
gene in the macrophage system and the increase in mRNA levels was not mediated 
by a change in mRNA stability (Harvey, 2006). The regulation of MCP-1 gene 
transcription by IFN-y is thought to be controlled by a key proximal promoter region 
as discussed in section 3.1.5.1 (functional elements of the proximal promoter are 
detailed in Figure 3.2). Previous studies have mapped this region to 213bp upstream 
of the transcriptional start site of the human MCP-1 gene (Valente et al., 1998; Zhou 
et al., 1998; Zhou et al., 2001). The MCP-1 [213]Luc construct contains this region 
cloned into the pGL2-Basic luciferase reporter vector (section 2.5.5.1). In addition 
to the MCP-l[213]Luc construct, GAS-regulated luciferase reporter gene plasmid, 
3xly6e was also included in the study to investigate the consequences of the ERK 
and JNK pathway deficiency on the IFN-y-regulated STAT1 transcriptional activity. 
The inducible expression of the luciferase reporter genes in both plasmids by IFN-y 
has been shown in Hep3B in our laboratory (Harvey, 2006).
Hep3B cells were transfected with 3xly6e or MCP[213]Luc plasmids, and the 
response to IFN-y (lOOU/ml) treatment (6h) was analysed (the optimal time point for 
analysis was identified previously in our laboratory (Harvey, 2006)). The reporter
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construct was co-transfected with a plasmid specifying for a DN mutant for Ras, 
Raf-1, MEK1, ERK1, ERK2 or JNK with the empty plasmid vector pcDNA3 used 
as a control. DN forms of Ras and Raf-1 were included here as they represent 
important upstream components of the ERK pathway (Minden et al., 1994; Ramos, 
2008). Ras has also been reported to contribute to JNK activation in response to 
some stimuli (Minden et al., 1994; Li et al., 1996; Auer et al., 1998). Following co­
transfection and incubation in the absence or the presence of IFN-y for 6h, the cells 
were harvested and extracts prepared for luciferase assay, and the protein 
concentration for each sample was determined (sections 2.5 and 2.6.5). Luciferase 
activity was then normalised to the protein concentration of each sample. We 
normalised the data to protein concentration and not to the activity of another 
internal control plasmid (e.g. CMV-p-galactosidase or RSV-p-galactosidase) 
because in our experience most of these promoters are also responsive to certain 
cytokines or extracellular mediators (Ali, 2007).
Results are presented in Figure 4.10 as the mean relative activity changes (±SD) 
(induction level in the presence of pcDNA3 assigned as 1). A student’s t test was 
performed on the data and the inhibition in promoter activation by all these DN 
mutants was found to be significant, supporting the role of the ERK and JNK 
pathways in the IFN-y-mediated regulation of STAT1-dependent gene transcription, 
including MCP-1.
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4.3.5 The effect of the ERK inhibitor PD98059 on the IFN-y-induced 
gene expression
In order to further confirm and explore the role of the ERK pathway in the IFN-y- 
regulated gene expression in human macrophages, the ERK inhibitor PD98059 was 
again employed to investigate its effect on this cytokine on the expression of several 
key genes implicated in atherosclerosis.
PMA-differentiated THP-1 macrophages were pre-treated with PD98059 at a series 
of concentrations (5, 30 and 50pM) for lh  prior to treatment with IFN-y (lOOOU/ml) 
for 3h. Following incubation with the cytokine, RNA was extracted and RT-PCR 
analysis was carried out for each gene. The optimal PCR condition (Table 2.4) for 
MIP-lp and IP-10 was determined as part of the research carried out during the 
course of these studies (data not shown) and that for ICERI/II and ICAM-1 was 
previously determined in our laboratory by E. Harvey (2006) and Nishi Singh 
(personal communication). Figure 4.11 A shows the PCR products for each gene 
resolved by agarose gel electrophoresis. Densitometric and statistical analysis is 
presented in Figure 4.1 IB. In the case of ICER, the highest molecular weight band, 
representing ICER I, was used for analysis because its expression was much higher 
than ICER II.
The expression of all the genes analysed was induced by incubation of the cells with 
IFN-y. Pre-treatment of the cells with PD98059 inhibited the expression of MCP-1, 
ICAM-1, SOCS-1 and MIP-ip in a concentration-dependent manner. In addition, 
the IFN-y-induced expression of IP-10 was also significantly inhibited in the 
presence of this inhibitor at 50pM. In contrast, the IFN-y-induced expression of 
ICER was not affected by the inhibitor at all the concentrations used. These results 
therefore suggest that the ERK pathway plays a major, but relatively selective role, 
in the regulation of IFN-y-inducible gene expression in human macrophages.
173
Figure 4.11 Effect of PD98059 on the IFN-y-induced expression of MCP-1, 
ICERI/II, ICAM-1, SOCS-1, MIP-lp and IP-10 genes
PMA-differentiated THP-1 cells were pre-treated with PD98059 (5, 30 and 50pM) or 
DMSO as a vehicle control. They were then cultured in the presence or the absence of 
IFN-y for 3h. Total RNA was isolated and subjected to RT-PCR using primers against 
MCP-1, ICER, ICAM-1, SOCS-1, MIP-ip, IP-10 and 28S rRNA. The amplification 
products were analysed by agarose gel electrophoresis (A). The images shown are 
representative of three independent experiments. M denotes the lOObp DNA ladder 
(NEB) (see Appendix I) and -RT shows a reaction in which no reverse transcriptase 
was included for the cDNA synthesis step (RNA from cells incubated with DMSO and 
IFN-y was used). Panel B shows the relative expression (mean ±SD) of the indicated 
gene normalised to the expression of 28S rRNA as determined by densitometric 
analysis from three independent experimental series (IFN-y-treated, DMSO control 
assigned as 1). Statistical comparisons were carried out using the Student’s t test 
between the DMSO and IFN-y-treated control and samples incubated with PD98059 
and IFN-y (*, P<0.05; **, P<0.01; ***, PO.OOl; N/S, not significant).
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4.3.6 The effect of the PKC-6 inhibitor rottlerin on the IFN-y-induced 
gene expression
The potential involvement of PKC-5 in the IFN-y-regulated STAT1 phosphorylation 
at both Ser727 and Tyr701 was demonstrated earlier by the concentration dependent 
inhibition of the response by rottlerin (Figure 4.4A). As a comparison to the effect of 
PD98059 on the IFN-y-mediated regulation o f gene expression (section 4.3.5), 
rottlerin was used to investigate the role o f PKC-5 in such regulation. Key genes 
such as MCP-1, ICAM-1, SOCS-1 and ICERI/II were selected for the study. THP-1 
cells were prepared and treated with the inhibitor (or DMSO) and the cytokine as 
previously described. Rottlerin, at four concentrations (3, 6, 9, 15 pM), was added to 
the cells prior to treatment with IFN-y. Total RNA was extracted and RT-PCR 
analysis was performed for each gene and 28S rRNA. Figure 4.12A shows the PCR 
products for each gene resolved by agarose gel electrophoresis. Densitometric and 
statistical analysis is presented in Figure 4.12B.
The IFN-y-induced expression of MCP-1, SOCS-1, ICAM-1 and ICERI/II was all 
inhibited by rottlerin, to different extent, at each concentration, suggesting a 
potentially more general role for PKC-5 in the IFN-y-mediated regulation of 
macrophage gene expression.
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Figure 4.12 The effect of rottlerin on the IFN-y-induced expression of MCP-1,
ICERI/II, ICAM-1 and SOCS-1 genes
PMA-differentiated THP-1 cells were pre-treated with rottlerin (3, 6, 9 and 15pM) or 
DMSO as a vehicle control. They were then cultured in the presence or the absence of 
IFN-y for 3h. Total RNA was isolated and subjected to RT-PCR using primers against 
MCP-1, ICER, ICAM-1, SOCS-1 and 28S rRNA. The amplification products were 
analysed by agarose gel electrophoresis (A). The images shown are representative of 
three independent experiments. M denotes the lOObp DNA ladder (NEB) and -RT 
denotes a reaction in which no reverse transcriptase was included for the cDNA 
synthesis step (RNA from cells incubated with DMSO and IFN-y was used). Panel B 
shows the relative expression (mean ±SD) of the indicated gene normalised to the 
expression of 28S rRNA as determined by densitometric analysis from three 
independent experimental series (IFN-y-treated, DMSO control assigned as 1). 
Statistical comparisons were carried out using the Student’s t test between the DMSO 
and IFN-y treated control and samples under treatment with rottlerin and IFN-y (*, 
P<0.05; **, PO .O l; ***, PO.OOl).
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4.3.7 Induction of ERK and JNK activity by IFN-y
To further analyse the role of ERK and JNK in IFN-y signalling, it was decided to 
next monitor the change in the ERK and JNK kinase activity in cell extracts in 
response to stimulation of the cells with IFN-y. The kinase activity assay kits, 
obtained from Cell Signalling Technology (section 2.6.6), allows the ERK and the 
JNK activity to be determined via measuring the magnitude of phosphorylation of 
their downstream substrates, transcription factor Elk-1 and c-Jun respectively, by the 
immunoprecipitated kinases. The 30min point was previously chosen to investigate 
the STAT1 phosphorylation in response to IFN-y, and hence was again selected for 
analysing the ERK and JNK activities.
THP-1 cells were treated with IFN-y for 0 and 30min. Cell lysates were prepared 
and used for kinase assays as described in section 2.6.6 according to manufacturer’s 
instruction. Thus, phospho-p42/44/MAPK (Thr202/Tyr204) antibody beads or c-Jun 
fusion protein beads were used to ‘pull-down’ active ERKs and JNKs respectively 
that are present in protein extracts. Addition of ATP results in the phosphorylation 
of the c-Jun substrate by active JNKs present in the sample. In the case of the ERK 
activity assay, the substrate, Elk-1 fusion protein was added with ATP into the 
sample, which was subsequently phosphorylated by active ERK. Phosphorylated 
Elk-1 and c-Jun were detected by western blot analysis using antibodies specifically 
recognising phospho-Elk-l-Ser383 and phospho-c-Jun-Ser63. Western blot analysis 
using p-actin was carried out to ensure the equal amount of whole cell proteins in 
each sample. Densitometric analysis of the data was carried out and presented in 
Figure 4.13. Band intensity for p-Elk-l-Ser383 and p-c-Jun-Ser63 was normalized to 
P-actin. Results are presented as the IFN-y-induced activity levels versus the 
unstimulated control (±SD). The induced phospho-protein level for each substrate 
represents the magnitude of the activity of the respective kinase.
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As shown in Figure 4.13, the cells had low constitutive activity of both kinases in 
the absence of external IFN-y. The activity of ERK was induced almost 3 fold 
following stimulation of the cells with IFN-y for 30min whereas the magnitude of 
induction of JNK was about 1.5 fold. The effect of IFN-y on the ERK activity was 
confirmed by a time-course experiment. THP-1 cells were treated with IFN-y for 0, 
15, 30, 60, 180 and 360min. Cell lysates were prepared and kinase assays were 
performed as discussed above. Figure 4.14 shows that the activity was induced by 
IFN-y in a time-dependent manner and reached its highest level at 60min. The 
phospho-Elkl levels seem at approximately similar levels until the end of the time 
course (6h), although an unusual decrease was observed at the 3h point. This could 
probably be due to a technical error as only a single experiment has been performed. 
Further experiments will be required to confirm this.
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Figure 4.13 The effect of IFN-y on ERK and JNK activities
PMA-differentiated THP-1 cells were treated with IFN-y or left untreated for 30min and 
protein extracts were prepared (section 2.6.6). The ERK and JNK kinase assays were 
carried out using equal amount of proteins and the blotted membranes were probed with 
anti-phospho-Elkl (Ser383) and anti-phospho-c-Jun (Ser63) antibodies as shown in panel A. 
For the analysis o f P-actin levels, 5pg of protein extract for each sample was subjected to 
western blot analysis as described previously (Panel A). Panel B displays the ratio of 
phospho-Elkl:P-actin or phospho-c-Jun:P-actin, normalised to untreated control, which has 
been arbitrarily assigned as 1. The data shown in panel B is the mean (±SD) from three 
independent experimental series. The student’s t test was performed on the IFN-y- 
stimulated samples versus basal activity without treatment with the cytokine (***P<0.001; 
*/><o.05).
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Figure 4.14 The effect of IFN-y on the ERK activity over a time course
PMA-differentiated THP-1 cells were treated with IFN-y for the indicated period of time 
and protein extracts were prepared (section 2.6.6). ERK kinase assays were carried out 
using an equal amount o f protein at each time point and blotted membranes were probed 
with anti-phospho-Elkl (Ser383) antibody as shown in panel A. For the analysis of p-actin 
levels, 5pg of protein extract for each sample was subjected to western blot analysis as 
described previously (Panel A). Panel B displays the ratio of phospho-Elk-1:P-actin, 
normalised to the Omin control which has been assigned as 1. Data is obtained from a single 
experiment.
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4.3.8 Effect of the various pharmacological inhibitors on the IFN-y- 
induced ERK and JNK kinase activity
In addition to ERK and JNK, potential roles for CK2, PKC-8 and PI3K in the IFN-y- 
mediated STAT1 phosphorylation have also been demonstrated previously in this 
chapter (sections 4.2.2-3). Moreover, Choudhury et al. (2004) have shown that PI3K 
acts upstream of MAPK in mediating ST ATI Ser727 phosphorylation in response to 
IFN-y in mouse mesangial cells. It is thus of interest to determine whether CK2, 
PKC-8 or PI3K act upstream of ERK or JNK in mediating IFN-y-stimulated 
responses in human macrophages. To investigate this possibility, it was decided to 
examine the effect o f apigenin, rottlerin and LY294002 on the IFN-y-mediated ERK 
and JNK kinase activities. PD98059 and SP600125 were also included as positive 
controls. THP-1 cells were pre-treated with either apigenin (20pM), rottlerin (10pM), 
LY294002 (30pM), PD98059 (50pM), SP600125 (30pM) or DMSO (vehicle- 
control) for lh  prior to the addition of IFN-y. The cells were then harvested at 30min 
as described previously and the ERK and JNK kinase assays were carried out as 
specified before. The results of these assays are presented in Figure 4.15.
The data clearly show that PD98059 completely abolishes the IFN-y-mediated ERK 
kinase activity in THP-1 cells. It can therefore be concluded that PD98059 is an 
effective ERK inhibitor in THP-1 cells. Interestingly, the ERK activity was not 
inhibited, but instead dramatically enhanced by treatment of the cells with SP600125, 
apigenin and LY294002. This suggests a potential cross-talk between the ERK 
pathway and JNK, CK2 and PI3K pathways. In the case of the IFN-y-mediated JNK 
activity, SP600125 failed to significantly attenuate it. This could potentially be 
explained by the mode of action of SP600125, which acts as a competitor for ATP 
binding to JNK (Bennett et al., 2001). The addition of ATP molecules in the in vitro 
kinase assay probably unexpectedly overcame the competitive association of the 
inhibitor to the ATP-binding pocket, and thereby JNK regained its kinase activity. 
Moreover, the JNK activity was enhanced significantly by treatment of the cells
181
Chapter 4: Roles of ERK and JNK in IFN-y signalling
with PD98059, but not by apigenin, LY294002 or rottlerin, thereby again suggesting 
some sort of cross-talk between the ERK and JNK pathways. To rule out the 
possibility that the failure to suppress the kinase activity by some of these inhibitors 
was due to the lack of their inhibitory activity (e.g. due to storage), the effect of each 
inhibitor on STATI phosphorylation at Ser727 was analysed, and a similar extent of 
suppression was observed as demonstrated before (Figures 4.2 and 4.4).
Cell viability was not impaired by each inhibitor according to the trypan blue 
exclusion assay (Table 4.2), and hence the changes seen in kinase activity were not 
attributable to cell death. Also of note, the p-actin protein levels did not vary in the 
presence of these inhibitors, thereby strongly indicating that the observed effect on 
the ERK and JNK activity was not due to a global change in the cellular protein 
levels by the inhibitors.
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Figure 4.15 The effect of inhibitors on the IFN-y-induced ERK and JNK activities
PMA-differentiated THP-1 cells were pre-treated with each of the specific inhibitors or 
DMSO as a vehicle control for lh  prior to the addition of IFN-y for 30min. Protein 
extracts were prepared and the ERK and JNK kinase assays and P-actin westerns were 
carried out as described in Figure 4.15 (A). For the analysis of phospho-STATl-Ser727 
levels, 1 Opg of protein extract for each sample was subjected to western blot analysis as 
described previously (panel A). Panel B shows the ratio of phospho-Elkl:P-actin and 
phospho-c-Jun: p-actin, normalised to the IFN-y treated DMSO control (assigned as 1). 
The data shown in panel B is the mean (±SD) from three independent experimental 
series. Student’s t test was carried out on samples treated with each inhibitor versus the 
IFN-y-treated, DMSO control sample. Significance of induction (***P<0.001; 
**P<0.01; */><0.05) and significance of inhibition (###P<0.001; N/S not significant) is 
shown. Abbreviations: DM, DMSO; PD, PD98059; SP, SP600125; api, apigenin; LY, 
LY294002; rott, rottlerin.
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4.3.9 Effect of pharmacological inhibitors of ERK and JNK on the IFN- 
y-induced adhesion of monocytes to endothelial cells
Recruitment and adhesion of monocytes to endothelial cells, a key initial event 
during the development of atherosclerosis, is largely mediated by complex 
interactions between different molecules, including cytokines (e.g. IFN-y, 
chemokines), selectins (e.g. L, P and E-selectins), integrins (e.g. pi, p2) and 
adhesion molecules (e.g. ICAM-1, VCAM-1) (section 1.4.2.3). Several groups have 
independently shown that IFN-y promotes such adhesion largely via up-regulation of 
expression of these key molecules (Wang et al., 1994; Chang et al., 2002; Navarro et 
al., 2003; Schroder et al., 2004). A range of cell types have been used in these 
studies, but the regulation of adhesion between THP-1 and human endothelial cells 
by IFN-y has not been studied to our knowledge. IFN-y has been shown to induce 
the expression of a number of chemokines and adhesion molecule in THP-1 cells 
(sections 3.2.1 and 4.3.5), and a similar profile has also been observed in endothelial 
cells (Wong and Dorovini-Zis, 1992; Marfaing-Koka et al., 1995; Harvey et al., 
2007; Kitaya et al., 2007).
It was therefore decided to next investigate the effect of IFN-y on adhesion between 
THP-1 monocytes and HUVEC using CytoSelect™-Leukocyte-endothelium 
adhesion assay kit according to the manufacturer’s protocol (Cell BioLabs Inc.) 
(section 2.8). As suggested by the manufacturer’s instruction, another important pro- 
inflammatory cytokine, TNF-a, was included as a positive control.
The confluent HUVEC monolayer was treated with IFN-y (lOOOU/ml), TNF-a 
(50ng/ml) or left untreated for 6h. The fluorescently-labelled THP-1 cells were then 
added on top of the HUVEC monolayer and allowed to adhere for lh. HUVEC 
alone without any addition of THP-1 were included at each time point as a negative 
control. After washing away the floating cells, the adherent THP-1 cells were 
quantified by florescence measurement. Data are the average fold induction from
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two independent experiments and presented as the IFN-y-induced adhesion levels 
normalized to unstimulated controls. As shown in Figure 4.16, addition of IFN-y or 
TNF-a resulted in no induction in the adhesion between THP-1 and HUVEC at the 
6h point.
U937 is another human monocytic cell line routinely in use in our laboratory 
(Harvey et al., 2007; Harris et al., 2008) and previous work has shown similar 
responses in THP-1 and U937 cells in response to IFN-y actions (Harvey et al., 
2007). U937 has also been successfully employed in similar adhesion assays 
performed by different groups (Weber et al., 1994; Weber et al., 1995; Marx et al., 
1999; Chang et al., 2002). It was therefore decided to use U937 as a cell model to 
investigate the effect of IFN-y on adhesion between monocytes and HUVEC.
4.3,9.1 IFN-y-induced adhesion between U937 and HUVEC
The confluent HUVEC monolayer was treated with IFN-y (lOOOU/ml), TNF-a 
(50ng/ml) or left untreated for the appropriate period of time as indicated in Figure 
4.17. The fluorescently-labelled U937 cells were then added on top of the HUVEC 
monolayer and allowed to adhere for lh. HUVEC alone without any addition of 
U937 were also included at each time point as a negative control. After washing 
away the floating cells, the adherent U937 cells were quantified by florescence 
measurement. Data are the mean (±SD) from three independent experiments and 
presented as the IFN-y-induced adhesion levels normalised to the unstimulated 
control.
The data in Figure 4.17 show that addition of TNF-a result in approximately 3.4- 
and 6-fold induction of adhesion between U937 and HUVEC at 6h and 12h 
respectively, time points at which IFN-y showed minimal effects. The adhesion level 
gradually increased in the presence of IFN-y throughout the subsequent time points 
to reach maximal levels (about 3 fold induction) at 3Oh. This time point was
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therefore selected for future studies. The U937 adhesion decreased marginally 2days 
after stimulation with IFN-y, which is consistent with previous findings between 
human primary monocytes and HUVEC (Wang et al., 1994).
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Figure 4.16 The effect of IFN-y and TNF-a on adhesion between THP-1 and 
HUVEC at the 6h time point
Monolayers o f HUVEC were treated with IFN-y (lOOOU/ml) or TNF-a (50ng/ml) 
for 6h and LeukoTracker™-labelled THP-1 cells were added and allowed to adhere 
for lh. The adherent cells were lysed and quantified by fluorescence measurement at 
485nm/520nm. HUVEC monolayer without the addition of THP-1 cells was used as 
a negative control. The graphs show the average fold induction o f adhesion by 
cytokines at each time point from 2 independent experiments (untreated control 
assigned as 1).
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Figure 4.17 The effect of IFN-y and TNF-a on adhesion between U937 and HUVEC over time
Monolayers o f HUVEC were treated with IFN-y (lOOOU/ml) or TNF-a (50ng/ml) for the indicated 
period o f time and LeukoTracker™-labelled U937 cells were added and allowed to adhere for lh. 
The adherent cells were lysed and quantified by fluorescence measurement at 485nm/520nm. 
HUVEC monolayer without the addition o f U937 cells was used as a negative control. The graphs 
show the mean fold induction (±SD) of adhesion by cytokines at each time point from 3 
independent experiments (untreated control assigned as 1). Student’s t test was carried out on 
samples treated with cytokine versus untreated samples at each time point (***/5<0.001; **P<0.01; 
*P<0.05; N/S, not significant).
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4.3.9.2 Effect of pharmacological inhibitors on the IFN-y-induced adhesion 
between U937 and HUVEC
Previous findings presented in this chapter (sections 4.2.1 and 4.3) suggest crucial 
roles for the ERK and the JNK pathways in mediating IFN-y signalling. In particular, 
suppression of ERK by PD98059 resulted in a reduction of the IFN-y-induced 
expression of MCP-1, IP-10, MIP-lp and ICAM-1, all of which largely contribute to 
the adhesion of monocytes/macrophages to endothelial cells. Moreover, a recent 
study by Lombardi (2008) showed that ERK is required for the synergistic up- 
regulation of IP-10 and fractalkine by IFN-y and TNF-a in human microvascular 
endothelial cells. Fractalkine, like MCP-1, IP-10 and MIP-lp (discussed previously 
in section 4.1.4), is a key chemokine involved in leukocyte recruitment to 
endothelial cells (Schulz et al., 2007). In the light of these findings, we decided next 
to investigate the effect of PD98059 and SP600125 on the IFN-y-mediated adhesion 
of U937 to HUVEC. LY294002 (pharmacological inhibitor of the PI3K pathway) 
was also included for comparative purposes as this inhibitor has previously been 
reported to reverse the IFN-y-stimulated adhesion of primary mouse BMMs to 
polycarbonate membranes in vitro (Navarro et al., 2003). PI3K pathway has also 
been shown to regulate the IFN-y-induced expression of a range of chemokines 
[MCP-1, IFN-inducible T cell a chemoattractant (ITAC), monokine induced by 
IFN-y (Mig) and IP-10] in mouse macrophages by our group (Harvey et al., 2007) 
and the regulation of MCP-1 has been also confirmed in THP-1 cells (Figures 3.7 
and 3.8).
Monolayers of confluent HUVEC were treated with the individual inhibitor or 
DMSO for lh  prior to further incubation with or without IFN-y for 30h. The results 
from the ERK and JNK kinase assays (Figure 4.15) show that the repression of 
either ERK or JNK activity by the respective inhibitor resulted in the induced kinase 
activity of another, and hence the enhanced alternative kinase activity could 
potentially mask the impact of individual inhibitor on cellular adhesion. We
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therefore decided to also include a combination of two inhibitors and analyse their 
joint effects on the IFN-y-mediated monocyte/endothelial cell adhesion. 
Concentrations of 30(iM for PD98059 and 20pM for SP600125 were initially 
selected because these were the concentrations used in human primary monocyte- 
derived macrophages and produced negligible cell death (Sesction 4.3.2). LY294002 
was used at lOpM as this was the concentration previously employed by Navarro et 
al. (2003). The adhesion assay was performed as described before and the results are 
shown in Figure 4.18. Adhesion level in each sample was presented as a percentage 
of that seen in DMSO and IFN-y-treated control cells. The cell viability of HUVEC 
was also determined using the ViaLight assay.
The inhibitors SP600125 and LY294002 attenuated the IFN-y-stimulated adhesion 
between U937 and HUVEC by approximately 20% and 30% respectively. The 
addition of PD98059 however, resulted in a dramatic induction of adhesion by about 
70% compared to DMSO and IFN-y-treated control. As suggested previously, the 
induced adhesion could potentially be due to the enhanced JNK activity in the 
presence of PD98059 (Figure 4.15). These results in isolation suggest that the JNK 
and PI3K pathways potentially regulate the IFN-y-stimulated adhesion of monocytes 
to endothelial cells. The exact role of ERK in the IFN-y-induced adhesion remains 
unclear at present. However, pre-treatment of cells with PD98059 and SP600125 
together resulted in more reduction in adhesion (45%) than that by SP600125 alone 
(20%), thereby suggesting a potential involvement of ERK in the IFN-y-induced 
adhesion of monocytes to endothelial cells.
It is noteworthy that the ViaLight assay carried out on HUVEC (presented as green 
bars in Figure 4.18) showed that incubation with the inhibitor and cytokine for 3lh 
(treatment with inhibitor for lh plus with IFN-y for another 30h) resulted in HUVEC 
viability that was lower than the inhibition levels of adhesion (blue bars in Figure 
4.18). In addition, the total amount of protein (pink bars in Figure 4.18) extracted
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from HUVEC and U937 after variety o f treatments was reduced, possibly because of 
either decreased HUVEC viability or reduced number of U937 adhering to the 
HUVEC monolayer. For comparative purpose, the relative protein amount of each 
sample was presented as a percentage to the IFN-y-treated DMSO control 
(arbitrarily assigned as 100%). These results suggest that the low HUVEC viability 
could have contributed to the decreased adhesion of U937 to HUVEC caused by the 
inhibitors). However, although PD98059 seemed to cause as much HUVEC cell 
death as the other inhibitors, the adhesion between U937 and HUVEC was not 
reduced. It is also important to note that the fluorescent readings are from labelled- 
monocytes, which were incubated for only lh  with cytokine/inhibitor-treated 
HUVEC. It is therefore difficult to come to any firm conclusions on whether the 
reduced adhesion by the inhibitors could be attributed to their actions on specific 
pathways, or simply due to impaired HUVEC viability. It is worth noting that 
HUVEC viability and total amount of protein obtained from HUVEC and U937 cells 
was unaffected by treatment with IFN-y alone (Figure 4.18). The results suggest that 
the induced adhesion of IFN-y-treated cells compared to the unstimulated samples 
was not due to any toxicity of the cytokine.
The high proportion of cell death caused by the inhibitors was probably because of 
the prolonged incubation period (3lh). We thus next decided to investigate the effect 
of these inhibitors on the IFN-y-induced U937 adhesion at much lower 
concentrations and analyse them in a concentration-dependent manner. Another 
ERK inhibitor, U0126 was also included here to provide comparison with PD98059. 
Figure 4.19 shows that with the exception of PD98059, the other three inhibitors 
(U0126, SP600125 and LY294002) attenuated the IFN-y-stimulated adhesion of 
U937 to HUVEC, in a concentration-dependent manner. All these inhibitors at their 
highest concentrations reduced the adhesion by approximately 40% (presented as 
blue bars). However, the ViaLight assay showed that incubation with the inhibitor 
again resulted in low cell viability (presented as a black line in Figure 4.19).
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Interestingly, incubation of the cells with PD98059 produced contrasting results to 
U0126 on adhesion of U937 to HUVEC. The reason behind the opposing action of 
these two specific inhibitors of ERK remains unclear. Therefore, the results suggest 
that it is at present not possible to come to any firm conclusions on the role of each 
kinase analysed on the IFN-y-induced adhesion of U937 to HUVEC. Employment of 
inhibitors might not be the best strategy here because of the prolonged incubation 
period. RNA interference (RNAi) using small interfering RNA (siRNA) form of 
each kinase might facilitate our study on the IFN-y-mediated monocyte/endothelial 
cell adhesion in the future.
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Figure 4.18 The effect o f pharmacological inhibitors on the IFN-y-induced 
adhesion between U937 and HUVEC at the 30h time point along with total 
amount of cellular proteins and viability of HUVEC cells under variety of 
treatments
Monolayers of HUVEC were pre-treated with PD98059 (30pM), SP600125 (20pM), 
LY294002 (lOpM), combination of PD98059 (30pM) and SP600125 (20pM) or 
DMSO for lh, and then incubated with IFN-y (lOOOU/ml) for 30h. LeukoTracker™ - 
labelled U937 cells were added and allowed to adhere to HUVEC monolayers for lh. 
Adherent cells were lysed and quantified by fluorescence measurement at 
485nm/520nm. HUVEC monolayers without any treatment with the inhibitor or 
addition of U937 cells were used as negative controls. Blue bars in figures represent 
the average percentage (± S D ) of adhesion under variety of treatments relative to 
DMSO (DM) plus IFN-y-treated control (assigned as 100%), from four independent 
experiments. Student’s t test was carried out on IFN-y/inhibitor-treated samples versus 
IFN-y-treated DMSO control sample (significance of induction: # F<0.05; significance 
of inhibition: * PO .05, ** FO .O l). Pink bars in figure represent the total amount of 
cellular protein from HUVEC with adhered U937 monocytes under different treatment 
from a single experiment. The value from HUVEC with DMSO and IFN-y-treated 
sample was arbitrarily assigned as 100%. Green bars in figure show the viability of 
HUVEC under different treatments analysed by the ViaLight assay (section 2.3.12.2). 
The value from HUVEC with DMSO and IFN-y treated sample was assigned as 100% 
viable. Luminescence reading was obtained from a single experiment. Abbreviations: 
PD, PD98059; SP, SP600125; LY, LY294002; DM, DMSO
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Figure 4.19 The effect of pharmacological inhibitors on the IFN-y-induced 
adhesion between U937 and HUVEC at the 30h time point along with analysis of 
viability of HUVEC under variety of treatments
Monolayers of HUVEC were pre-treated with PD98059 (0.5, 1 and 3pM), U0126 (1, 2 
and 4pM), SP600125 (0.5, 1 and 3pM), LY294002 (1, 2 and 5pM) or DMSO for lh, 
and then incubated with IFN-y (lOOOU/ml) for 30h. LeukoTracker™-labelled U937 
cells were added and allowed to adhere to the HUVEC monolayer for lh. Adherent 
cells were lysed and quantified by fluorescence measurement at 485nm/520nm. 
HUVEC monolayer without any treatment with the inhibitor or the addition of U937 
cells was used as negative controls. Data were obtained from a single experiment. Blue 
bars in figures represent the percentage of adhesion under variety of treatments relative 
to DMSO plus IFN-y-treated control (assigned as 100%). Black lines in figure show the 
viability of HUVEC under different treatments as determined using the ViaLight assay 
(section 2.3.12.2). The value from HUVEC with DMSO and IFN-y treated sample was 
assigned as 100% viable. Luminescence reading was obtained from a single 
experiment. Abbreviations: PD, PD98059; SP, SP600125; LY, LY294002; DM, 
DMSO
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Chapter 4: Roles of ERK and JNK in IFN-y signalling
4.4 Discussion
4.4.1 Roles of ERK and JNK in the IFN-y-mediated regulation of gene 
expression in human macrophages
An increasing volume of evidence has supported significant roles of MAPK 
pathways in the IFN-y-mediated signalling in an array of cell types. The specific 
MAPK pathways used is thought to be dependent on the cell type and culturing 
conditions (section 1.7.3). Some of these studies suggested that the MAPK pathways 
exert their roles in IFN-y signalling through the regulation of STAT1 Ser727 
phosphorylation (Table 1.4). Consistent with these reports, experiments presented in 
this chapter based on the use of specific pharmacological inhibitors (Figures 4.2-4.4) 
showed that pre-treatment of the cells with the ERK inhibitor PD98059 at 50|iM, 
and the JNK inhibitor SP600125 at 30pM, resulted in the most pronounced 
inhibition of the IFN-y-stimulated STAT1 Ser727 phosphorylation (80% and 73%, 
respectively) when compared to pre-treatment with inhibitors specific to a range of 
other candidate kinases, including CK2, PI3K, PKC-5 and CaMK II (Table 4.4). A 
potentially important role for ERK was again confirmed using another inhibitor of 
this pathway, U0126 (Figure 4.5). In contrast to this, STAT1 phosphorylation at 
Tyr701 was not affected by PD98059, U0126 or SP600125. These data therefore 
strongly suggest potentially key roles for ERK and JNK in the IFN-y-stimulated 
STAT1 activation via regulation of phosphorylation specifically at Ser727. The 
results are in line with some previous findings in THP-1 cells (Overbergh et al., 
2006) and murine demal fibroblasts (Yamana et al., 2009).
To extend the findings obtained using the differentiated THP-1 cell line, the effect of 
PD98059 and SP600125 on the IFN-y-induced STAT1 phosphorylation in human 
primary monocyte-derived macrophages was analysed. The results showed that the 
inhibitors also affect IFN-y signalling in primary human macrophages, with both the 
IFN-y-induced STAT1 Ser727 and Tyr701 phosphorylation being impaired by 
PD98059 and SP600125 (Figure 4.7), These results therefore suggest that along with
195
Chapter 4: Roles of ERK and JNK in IFN-y signalling
the regulation o f STAT1 Ser727 phosphorylation found in THP-1 cells, ERK and 
JNK may also regulate STAT1 activation in response to IFN-y through 
phosphorylation at Tyr701 in primary human macrophages. Despite the different 
effect on Tyr701 phosphorylation, THP-1 and human primary macrophages exhibit 
a conserved action o f ERK and JNK on the IFN-y-stimulated phosphorylation at 
STAT1 Ser727, thereby adding support to the use of THP-1 cells as a useful cellular 
model system for investigating the roles o f ERK and JNK in the regulation of 
STAT1 Ser727 phosphorylation in response to IFN-y in human macrophages.
Table 4.4 Percentage of average suppression from three independent 
experiments of the IFN-y-stimulated STAT1 phosphorylation by each inhibitor 
compared to DMSO treated control cells
Inhibitor (pM) Targeted Kinase Ser727 Tyr701
PD98059 (50) ERK 80% No change
U0126 (20) ERK 38% No change
SP600125 (30) JNK 73% No change
SB203580 (30) P38 No change No change
Apigenin (20) CK2 40% No change
LY294002 (30) PI3K 33% No change
Rottlerin (10) PKC-5 50% 65%
KN93 (20) CaMK II 50% 26%
Absence o f suppression of IFN-y-stimulated STAT1 phosphorylation by pre­
treatment o f the cells with SB203580 (Figure 4.2C) indicates that p38 is not 
obligatory for the IFN-y-mediated STATI -dependent signalling. However, 
SB203580 at 10pM has been reported to induce JNK and ERK activities in human 
erythroleukaemia cell line TF-1( (Birkenkamp et al., 2000). We cannot thus at
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present rule out the possibility, that such increased ERK and JNK activities are also 
occurring in THP-1 macrophages and potentially masking the effect of SB203580 
on STAT1 serine phosphorylation. Indeed, Kovarik et al. (2001) have shown that in 
mouse fibroblast cells, pre-treatment with SB203580 at 5pM further enhances the 
IFN-y-stimulated STATI Ser727 phosphorylation possibly through increasing ERK 
and JNK activities. Moreover, Ramsauer et al. (2002) showed that p38 MAPK 
enhanced the IFN-y-stimulated STAT1-dependent transcription independently of 
Ser727 phosphorylation. Therefore, although it appears that SB203580 failed to 
attenuate the IFN-y-induced STAT1 phosphorylation, further experiments will be 
required to firmly exclude the possible role of p38 MAPK in the regulation of 
STAT1-dependent transcription in response to this cytokine in human macrophages.
As shown in Figure 4.10 and Table 4.5, transfection of the cells with DN forms of 
Ras, Raf-1, MEK1, ERK1, ERK2 and JNK resulted in a large decrease in the IFN-y- 
induced luciferase expression regulated by tandem GAS elements (STAT1 
consensus sites) in the 3xly6e vector, thereby confirming the crucial roles of the 
Ras—Raf-1—MEK—ERK 1/2 pathway along with JNK in the IFN-y-stimulated, 
STAT1-dependent transcriptional activity. Previous studies have demonstrated an 
important role for STAT1 -binding GAS sites in the IFN-y-mediated induction of 
MCP-1 gene expression (Valente et al., 1998; Zhou et al., 1998; Zhou et al., 2001). 
The inhibition observed of the IFN-y-induced activation of MCP-1 promoter in the 
MCP[213]Luc plasmid by these DN mutants further supports a potentially important 
role for Ras—Raf-1—MEK—ERK along with the JNK pathway in the regulation of 
gene transcription downstream of STAT1 in response to this cytokine. It should 
however be noted that the inhibition of the IFN-y-induced MCP[213]Luc activity by 
these DN mutants was much less extensive than that observed for 3xly6e. This 
suggests that an alternative, STAT1-independent signalling pathway might operate 
alongside a ST ATI -dependent mechanism or in its absence, in the regulation of 
MCP-1 expression by IFN-y. This assumption might explain the finding by Gil et al.
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(2001) that MCP-1 expression is inducible by IFN-y in both wild type and STAT1- 
deficient macrophages. The exact STAT1-independent mechanisms underlying the 
IFN-y-induced MCP-1 expression are not fully understood. It is however worth 
noting that the increased expression o f STAT3 in STAT1-deficient mouse 
embryonic fibroblasts has been shown to mediate the induction of SOCS-3 
expression by IFN-y (Ramana et al., 2005). More work will be needed to determine 
whether a similar STAT3-dependent mechanism operates to maintain the induction 
of MCP-1 expression by IFN-y in the absence o f STAT1.
Table 4.5 The average percentage inhibition of 3xly6e and MCP[213]Luc 
activity from three independent experiments by co-transfection of cells with 
each DN expression plasmid in the presence of IFN-y
Ras Raf-1 MEK1 ERK1 ERK2 JNK
3xly6e 71 67 62 70 85 56
MCP[213]Luc 34 30 35 24 47 28
The role o f ERK in the IFN-y-mediated, ST ATI -dependent gene expression was 
also confirmed by RT-PCR experiments. Pre-treatment o f the cells with PD98059 
inhibited the mRNA expression of MCP-1, M IP-lp, IP-10, ICAM-1 and SOCS-1 in 
a concentration-dependent manner (Figure 4.11). STAT1-dependent pathway has 
been shown to mediate the regulation of all these genes by IFN-y (sections 3.1.5 and
4.1.4). Taken together with previous data on the effect o f PD98059 on the IFN-y- 
induced STAT1 Ser727 phosphorylation along with co-tranfection experiments 
using DN plasmids (Figures 4.2 and 4.10), the results suggest that the ERK pathway 
regulates STAT1-dependent gene expression in response to IFN-y, at least in part, 
through the modulation o f STAT1 phosphorylation at Ser727.
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Gough et al. (2007) recently proposed a JAK1/STAT1-independent role for 
MEK/ERK in the regulation of IFN-y response genes in mouse embryonic 
fibroblasts. It would be of interest to know whether this is also the case in human 
macrophages. As shown in Figure 4.11, pre-treatment of the cells with PD98059 
failed to suppress the IFN-y-induced ICERI/II expression, which has been shown to 
be potentially regulated through a JAK/STAT1-independent pathway (Harvey, 
2006). Thus at least on the basis of the limited genes that we have studied in human 
macrophages, ERK appears to regulate the IFN-y-mediated gene expression 
predominantly via its action on STAT1 activity. However, STAT1-independent 
pathways have also been shown to be involved in the regulation of MCP-1 and MIP- 
ip expression by IFN-y (sections 3.1.5 and 4.1.4). We can therefore not rule out the 
possibility that ERK could regulate the expression of these two genes via a STAT1- 
independent mechanism alongside with its action on STAT1 activity.
The ERK and the JNK activity was shown to be induced by the addition of IFN-y by 
about 3- and 1.5-fold respectively at the 30min time point (Figure 4.13), thereby 
further confirming the function of these two kinases in mediating IFN-y signalling. 
The kinetics of ERK activity (Figure 4.14) in the presence of IFN-y is consistent 
with the previous data presented in section 3.2.5, where the IFN-y-mediated STAT1 
Tyr701 and Ser727 phosphorylation reached its peak at 30-60min and 3h 
respectively. The kinase activity assays further support that ERK and JNK pathways 
may act upstream of STAT1 in mediating IFN-y signalling in macrophages.
4.4.2 Roles of CK2 and PI3K in the IFN-y-mediated induction of 
ST ATI phosphorylation
Pre-treatment of the cells with apigenin (CK2 inhibitor) at 20pM and LY294002 
(PI3K inhibitor) at 30pM resulted in 40% and 33% inhibition, respectively, of the 
IFN-y-induced STAT1 phosphorylation at Ser727, while the phosphorylation at
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Tyr701 was unaffected (Figure 4.2 and Table 4.4). CK2 and PI3K might thus play 
an important role in the regulation of STAT1 activity specifically through the 
modulation of phosphorylation at Ser727 in response to IFN-y. The results are 
consistent with previous findings in mouse macrophages (Harvey, 2006) and in 
mouse embryonic fibroblasts (Nguyen et al., 2001). The data are also in keeping 
with previous results on the effect of these two inhibitors on the IFN-y-induced 
MCP-1 expression presented in Chapter 3 (Figures 3.5-3.8). Overall, CK2 and PI3K 
probably exert their roles in regulating IFN-y-dependent gene expression in human 
macrophages via modulating STAT1 Ser727 phosphorylation.
As discussed earlier in Chapter 3 (section 3.3), although LY294002 at 50|iM has 
been reported to inhibit the IL1-induced MCP-1 expression, through a PI3K- 
independent mechanism (Choi et al., 2004), work in our laboratory has previously 
confirmed the specific action of LY294002 at the concentrations used in this study 
(10-30|iM) on the PI3K/Akt-dependent pathway (Harvey, 2006). Harvey (2007) has 
also demonstrated that a DN form of Akt, a key PI3K downstream effector, largely 
suppressed the IFN-y-induced luciferase activity from 3xly6e and MCP[213]Luc 
plasmids. Therefore, the results presented in this study add further support to the 
potential role of the PI3K/Akt pathway in the regulation of IFN-y-mediated MCP-1 
expression along with ST ATI phosphorylation. To further confirm such role, siRNA 
for Akt available in our laboratory could facilitate our investigation via RNAi- 
mediated knock-down approaches.
4.4.3 Roles of PKC-6 and CaMK II in the IFN-y-mediated induction of 
ST ATI phosphorylation
Inhibitors for PKC-5 (rottlerin) at lOpM and CaMK II (KN93) at 20pM attenuated 
the IFN-y-induced ST ATI Ser727 phosphorylation by approximately 50% in both 
cases (Figure 4.4, Table 4.4). The results on PKC-5 are in line with previous 
findings in human acute promyelocytic leukemia cell line NB-4 (Deb et al., 2003)
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and in the mouse macrophage cell line RAW264.7 (Kwon et al., 2007), while the 
observed results on CaMK II are consistent with previous studies in the mouse 
fibroblasts cell line NIH3T3 (Nair et al., 2002). However, although these three 
studies all demonstrated insensitivity of STATI Tyr701 phosphorylation to rottlerin 
and KN93, results in this thesis clearly show that these two inhibitors suppress 
STATI Tyr701 phosphorylation by 65% and 26% respectively (Table 4.4). It thus 
appears that in THP-1 macrophages, PKC-8 and CaMK II regulate IFN-y-mediated 
signalling pathway through modulation of STAT1 phosphorylation at both Tyr701 
and Ser727 sites. The discrepancy observed in the THP-1 cell line with the human 
promyelocytic leukemia cell line NB-4, mouse macrophage cell line RAW264.7 and 
the mouse fibroblast cell line NIH3T3 could probably reflect species- and cell type- 
specific action of the kinases, although additional experiments via different 
approaches will be required to confirm the role of these two kinases in THP-1 cells. 
Moreover, rottlerin has also been shown to prevent the IFN-y-induced expression of 
all the marker genes analysed, including MCP-1, ICAM-1, SOCS-1 and ICERI/II in 
a dose-dependent manner. The results thereby suggest a potentially general role for 
PKC-8 in the IFN-y-mediated induction of gene expression in human macrophages, 
via modulating the phosphorylation of STAT1 at Tyr701 and Ser727.
In the light of a recent report by Rybin (2008) that showed that PMA activates and 
phosphorylates PKC-8 at Tyr311, it is possible that in PMA-differentiated THP-1 
cells used during the course of this study, PMA and IFN-y could synergistically 
phosphorylate PKC-8, which in turn stimulates the phosphorylation of STAT1 at 
Ser727 and Tyr701 sites. Inhibition of PKC-8 tyrosine phosphorylation by rottlerin 
(Soltoff, 2001) might result in the inhibition of ST ATI phosphorylation at both sites 
(Figure 4.20). Further approaches such as the use of DN mutants or siRNA against 
PKC-8 are required to further confirm the role of this kinase in IFN-y signalling.
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rottlerin
I
Figure 4.20 Potential synergistic actions of IFN-y and PMA on PKC-5 activity 
and phosphory lation of its potential downstream effector STAT1
In the hypothetical pathway, PMA and IFN-y synergistically induce tyrosine 
phosphorylation o f PKC-5, which could in turn phosphorylate STAT1 at Ser727 and 
Tyr701. Rottlerin, a specific inhibitor o f PKC-5, represses the tyrosine 
phosphorylation o f the kinase. Abbreviations: PMA, phorbol 12-myristate 13-acetate; 
IFN, interferon; PKC, protein kinase C; STAT, signal transducers and activators of 
transcription; Y, Tyr701; S, Ser727; p, phosphorylation
4.4.4 Cross-talk between ERK, JNK and other kinases in IFN-y- 
stimulated signalling pathways
A number o f previous studies have demonstrated potential functional interactions 
between kinases acting upstream of STAT1 in response to IFN-y. For example, Deb 
(2003) suggested a JAK— PI3K— PKC-5 pathway in stimulating STAT1 Ser727 
phosphorylation in human acute promyelocytic leukemia cell line NB-4. Similarly, a 
PI3K— MAPK— STAT1 (Ser727) pathway has been demonstrated by Choudhury et 
al. (2004) in rat glomerular mesangial cells. Studies in this thesis on the effect of a 
number of kinase inhibitors on the ERK and JNK activities in THP-1 cells also 
suggest potential interactions (Figure 4.15). For example, whilst the IFN-y-induced 
ERK activity was not attenuated following inhibition o f JNK, CK2, PI3K or PKC-5,
2 0 2
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it was enhanced further by inhibitors of JNK, CK2 and PI3K. A similar result was 
obtained for the IFN-y-induced JNK activity, which was not suppressed by 
inhibitors specifying for CK2, PI3K or PKC-8, but induced by the ERK inhibitor 
PD98059 (Figure 4.15). Birkenkamp et al. (2000) have previously shown a similar 
phenomenon in human erythroleukaemia cell line TF-1 where inhibition of p38 
MAPK by SB203580 could enhance NFkB transcriptional activity associated with 
increased phosphorylation of ERK 1/2 and JNK.
One of the most likely explanations for such further enhancement of kinase activities 
is functional redundancy between signalling pathways, so that blocking one pathway 
might ultimately lead to increased activity of other routes to maintain a fully 
functional cellular response. As IFN-y is a key player in the immune system, such 
redundancy in its signalling might represent an essential safety mechanism to ensure 
the maintenance of the whole immune system during the failure of one element 
(Thrane et al., 2007).
4.4.5 Roles of ERK and JNK in the IFN-y-induced adhesion of 
monocytes to endothelial cells
Work presented in this chapter has shown significant roles of ERK and JNK 
pathways in mediating the IFN-y-induced gene expression, many of which are 
largely involved in the adhesion of monocytes/macrophages to endothelial cells. It is 
therefore possible that the ERK and the JNK pathways also contribute to the IFN-y- 
induced adhesion of monocytes to endothelial cells (Figure 4.17). Consistent with 
this notion, pre-treatment of the cells with U0216 (ERK inhibitor), SP600125 (JNK 
inhibitor) and combination of PD98059 (ERK inhibitor) and SP600125 attenuated 
the adhesion of U937 to HUVEC in response to the cytokine. PD98059 alone, 
however, did not inhibit, but instead, induced such adhesion (Figures 4.18 and 4.19). 
The exact underlying reason for the opposite effect of PD98059 and U0126 in such
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adhesion is not clear at present, although we suspect that the differences in 
molecular mechanisms used by these two inhibitors might play a role. In addition, 
keeping with a previous study by Navarro et al. (2003), the PI3K pathway inhibitor, 
LY294002 was also shown to reverse the IFN-y-stimulated adhesion of monocytes 
to endothelial cells.
It is worth noting that as addition of each inhibitor resulted in a low viability of 
HUVEC (Figures 4.20 and 4.21), we cannot rule out the possibility that the reduced 
adhesion may be due to decrease viability o f HUVEC. Interestingly, although pre- 
treatment of HUVEC with PD98059 resulted in viability that was comparable to the 
other inhibitors, the adhesion was increased. It is therefore difficult to come to any 
firm conclusions on whether the inhibition of adhesion was due to the specific action 
of the inhibitors or because of reduced HUVEC viability. The low viability of 
HUVEC is probably due to the prolonged period of incubation (31h), and alternative 
approaches will thus be required in the future to confirm these results. For example, 
siRNA form of each kinase might provide valuable alternative to the use of 
pharmacological inhibitors. Our laboratory has recently adapted the adenovirus- 
mediated small hairpin RNA (shRNA) knock-down approach, which could be 
employed in the study of adhesion assay in the future.
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Chapter 5: Effects of the therapeutic agents on IFN-y 
signalling
5.1 Introduction
As detailed in the General Introduction (section 1.8), the NRs, PPARs and LXRs are 
recently emerging as crucial regulators o f inflammation, and compelling evidence 
suggests that ligand-dependent activation of these NRs exert profound 
anti-inflammatory and protective effects in atherosclerotic development [see (Repa 
and Mangelsdorf, 2002; Barish, 2006; Bensinger and Tontonoz, 2008; Nomiyama and 
Bruemmer, 2008) for reviews]. Although statins are prescribed as 
cholesterol-lowering drugs, animal studies and clinical trails have recently confirmed 
that in addition to the cholesterol-lowering effects, statins also exert their 
athero-protective roles via cholesterol-independent effects, so called ‘pleiotropic 
effects’. These effects are largely dependent on their anti-inflammatory and 
immunosuppressive actions [see (Mach, 2002b, 2003; Kronmann et al., 2007) for 
reviews].
As detailed in the General Introduction (section 1.5), IFN-y is a key pro-inflammatory 
cytokine regulating atherosclerotic development, and a large number of studies have 
suggested that these therapeutic agents target inflammation by repressing the 
IFN-y-mediated expression of inflammatory response genes in macrophages [see 
(Straus and Glass, 2007; Rigamonti et al., 2008) for reviews]. To date, the molecular 
mechanisms underlying the anti-inflammatory actions of PPAR and LXR ligands 
along with statins remain largely unclear, particularly in relation to the 
IFN-y-dependent signalling and the JAK-STAT pathway. Therefore, investigating the 
molecular basis of the anti-inflammatory actions of these therapeutic agents in the 
IFN-y-mediated signalling and the JAK-STAT pathway could potentially lead to the
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identification of novel targets for therapeutic intervention of atherosclerosis. Work in 
this chapter was carried out with the aim of analysing the potential effects of PPARs 
and LXRs ligands along with statins on the IFN-y-regulated gene expression and their 
impact on the IFN-y-mediated signalling and cellular responses in human 
macrophages.
5.1.1 Experimental strategy
PMA-differentiated THP-1 macrophages were employed again as discussed in 
previous chapters. To initiate the investigation, two types of statins (lovastatin and 
simvastatin) and synthetic agonists for PPAR-y (BRL49653), -a (GW7647) and LXRs 
(TO901317) were initially employed to screen for their effects on the IFN-y-mediated 
expression of a range of inflammatory genes. Lovastatin and simvastatin were chosen 
here because they are two of the most commonly used statins for treating 
hypercholesterolemia and have both been employed for investigating the effect of 
statins on IFN-y-mediated inflammatory gene expression in macrophages (Mach, 
2002a; Veillard et al., 2006; Lee et al., 2007b; Lee et al., 2008). Anti-inflammatory 
effect of both statins in vivo has also been confirmed in animal studies (Chauhan et al., 
2004; Ulivieri et al., 2008; Winkler et al., 2009). Anti-inflammatory and 
athero-protective roles of PPARa ligands, such as GW7647 and PPARy ligands, such 
as BRL49653 (also called ‘rosiglitazone’) have been consistently confirmed in mouse 
models of atherosclerosis (Collins et al., 2001; Chen et al., 2001b; Duez et al., 2002; 
Zuckerman et al., 2002; Li et al., 2004) (see Table 1.6 for a list of animal studies). On 
the other hand, contradictory results for the effect of PPAR5 ligands in atherosclerotic 
lesion development have been reported. Li et al. (2004) showed that the PPARS ligand 
GW0742 had no effect on atherosclerotic lesion size in the LDLR-deficient male mice. 
In contrast, the same ligand has been reported to reduce the lesion size in LDLR-/- 
female mice (Graham et al., 2005). Although the exact reason for these contrary 
findings remains unclear at present, the gender of the mice might have played an
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important role. Due to the potential complexity of the mechanisms underlying the 
PPAR5 ligands, we decided to initiate our investigation on the potential roles of 
PPARs on IFN-y responses with only PPAR-a and -y, excluding PPAR6 in the work 
presented in this study. TO901317 is a commonly used synthetic agonist for the LXRs 
and has been widely used to investigate the anti-inflammatory and anti-atherogenic 
effects of LXRs activation in animal models (Dai et al., 2007; Ou et al., 2008; Peng et 
al., 2008). In addition, TO901317 has been routinely used for studies on THP-1 
macrophage in our laboratory (Huwait, 2008).
Following screening for the effects of these compounds on the IFN-y-induced gene 
expression, their potential impact on IFN-y-dependent signalling was also confirmed 
by analysing their effects on the IFN-y-induced STAT1 phosphorylation at Ser727 and 
Tyr701. In addition to the synthetic agonists for PPARs and LXRs as discussed above, 
endogenous ligands for PPARy and LXRs were also included. 15d-PGJ2 is a widely 
used naturally occurring PPARy ligand and several studies have demonstrated that it 
shows greater transrepression activity on inflammatory gene expression than the 
various types of synthetic PPARy agonists (Jiang et al., 1998; Ricote et al., 1998; 
Chawla et al., 2001). In the case of the LXRs, the endogenous ligand 
22(R)-hydroxycholesterol (22R) was selected as it is one of the most commonly used 
ligand for activating these NRs (Joseph et al., 2003; Piraino et al., 2006), and has been 
routinely used with studies on THP-1 macrophages in our laboratory (Greenow, 2004; 
Huwait, 2008). In addition, LXRs are known to form functional heterodimers with 
RXRs to bind to the LXRE in the promoter of target genes and activate their 
transcription (Rizzo and Fiorucci, 2006). It has been shown that LXR/RXR can be 
activated by ligands for both LXR and RXR, either separately or in synergy (Aranda 
and Pascual, 2001). It was thus decided to also include the agonist for RXRs 
(9-czs-retinoic acid [9cRA]) and analyse the individual and combinatorial effect of 
22R and 9cRA on the IFN-y-induced STAT1 phosphorylation.
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The effect of statins and agonists for PPARy and LXRs on the IFN-y-mediated gene 
expression and the activation of STAT1 response element were again confirmed using 
DNA constructs MCP[213]Luc and 3xly6e in transfection experiments, as discussed 
in Chapter 4. Finally, the studies were extended to the investigation of the effect of 
PPAR and LXR ligands on the IFN-y-mediated changes in a key cellular response 
relevant to atherosclerosis, the adhesion of monocytes to endothelial cells, as 
discussed in Chapter 4 (see Figure 5.1 for the overall strategy).
It is worth noting that in order to prevent the potential interference by fatty acids and 
other lipids that might exist in FCS, which could possibly activate PPARs and LXRs, 
delipidated FCS was used in experiments employing these NRs. Numerous 
laboratories have employed delipidated serum for such studies (Costet et al., 2003; 
Quinn et al., 2005; Beyea et al., 2007). Serum delipidation has been routinely carried 
out in our laboratory and not been found to show any deleterious effect on cellular 
viability and cytokine responses (Huwait, 2008).
5.1.2 Selection of genes for study
In order to analyse the potential effect of statins and agonsits for PPARs and LXR in 
the IFN-y-induced gene expression, the genes employed in previous chapters, 
including MCP-1, IP-10, MIP-lp, ICAM-1, SOCS-1 and ICER, were selected here 
again for further investigation. In addition, the major histocompatibility complex 
(MHC) class II activator (CIITA) was included. MHC class II molecules are directly 
involved in the activation of T lymphocytes and in the control of the immune response. 
Most of the cells do not express MHC-II constitutively and become MHC-II positive 
upon activation by IFN-y (Mach et al., 1996). This complex regulation is under the 
control by CIITA (Steimle et al., 1994). Aberrant class II MHC expression is 
associated with inflammatory diseases, including rheumatoid arthritis and multiple 
sclerosis (Mach et al., 1996).
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The expression of CIITA is cell type-specific and tightly controlled by four 
independent promoters in humans (pi, pH, pill and pIV). CIITA type I isoform is 
specifically and constitutively expressed in dendritic cells. By contrast, CIITA type III 
is mainly expressed by B lymphocytes and can be induced by IFN-y in fibroblasts, 
endothelial cells and B lymphocytes. CIITA type IV is the major IFN-y-inducible 
isoform expressed by a variety of cell types (Buttice et al., 2006). pIV has several 
important c/s-acting elements including GAS, E-box and IRE. The GAS and E-box 
elements are bound cooperatively by activated STAT-la and upstream regulatory 
factor-1 (USF-1) respectively. Activated STAT-la also induces the expression of 
IRF-1, which then binds IRE in pIV (Piskurich et al., 2006). Histone acetylation at the 
CIITA pIV is increased following IFN-y stimulation (Lee et al., 2008). Brg-1, which is 
needed to mediate chromatin remodelling, is also functionally required for CIITA 
gene transcription (Ni et al., 2005). In addition to pIV, other CIITA promoters can also 
be used to direct IFN-y-inducible CIITA transcription in macrophages, such as pi 
(LeibundGut-Landmann et al., 2004). A number of studies have shown that statins 
inhibit IFN-y-induced CIITA expression (Kwak et al., 2000; Sadeghi et al., 2001; 
Mach, 2002a; Youssef et al., 2002; Lee et al., 2008). In particular, Youssef (2002) 
showed that statins are not selective for pIV, but inhibit IFN-y-inducible CIITA 
transcription in general. Therefore, CIITA pill and pIV genes were selected here for 
work detailed in this chapter.
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Figure 5.1 Experimental Strategy
The aim of the experimental strategy was to analyse the effect of a variety of potential therapeutic agents, including statins, agonists of PPAR-a 
and -y along with LXRs on the IFN-y-mediated signalling pathways. This was achieved by the analysis of the effects of these agents on the 
IFN-y-induced gene expression, ST ATI phosphorylation and transactivation, MCP-1 promoter activation and monocyte-endothelial adhesion.
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5.2 Effects of statins on IFN-y signalling
5.2.1 Effects of statins on the IFN-y-induced gene expression
PMA-differentiated THP-1 macrophages were pre-treated with lovastatin (5, 10 and 
20pM) or simvastatin (1, 5 and lOpM) for lh  as indicated below (Figures 5.2 and 5.3) 
prior to treatment with IFN-y (lOOOU/ml) for 3h. The concentrations of simvastatin 
and lovastatin employed were based on previous studies (Kwak et al., 2000; Kwak et 
al., 2001; Chung et al., 2002; Luan et al., 2003; Bruegel et al., 2006; Veillard et al., 
2006). The volume of DMSO, which was added to the cells as a negative control, was 
the same as that for the highest concentration of the respective statin used in order to 
rule out the possibility of the effect of DMSO on gene expression. Following 
incubation for 3h with the cytokine, RNA was extracted and RT-PCR analysis was 
carried out for each gene. The optimal PCR conditions for CIITA pill and pIV (Table
2.4) were determined as part of research carried out during the course of these studies 
(data not shown). Figures 5.2 (A) and 5.3 (A) show the PCR products for each gene 
resolved by agarose gel electrophoresis. Densitometric and statistical analysis is 
presented in panel B of Figures 5.2 and 5.3.
Figure 5.2 shows that lovastatin has no effect on the IFN-y-induced expression of all 
the genes analysed. In contrast, simvastatin inhibits the IFN-y-induced expression of 
several genes analysed, including MCP-1, ICAM-1, SOCS-1 and CIITA pIV. The 
effect of simvastatin on the expression of MCP-1, ICAM-1 and SOCS-1 appears to be 
concentration-dependent. However, simvastatin shows no effect on the expression of 
MIP-ip, ICER sand CIITA pill (Figure 5.3). Simvastatin thus shows gene-specific 
effects on the IFN-y-induced gene expression in human macrophages. Taken together, 
the results from these RT-PCR experiments suggest that different types of statins 
might have distinct actions on the IFN-y-regulated macrophage gene expression. In 
addition, the constant expression of control genes (Figures 5.2 and 5.3) suggests that 
these statins at the concentrations analysed do not have a global effect on cellular
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gene transcription.
In experiments described in this chapter involving the use of therapeutic agents on 
THP-1 macrophages, the viability of the cells was analysed by the trypan blue 
exclusion assay. All the results showed a negligible proportion of dead cells (< 10%) 
following treatment with IFN-y in combination with each of the agent at the highest 
concentration employed (Table 5.1), indicating that the changes in mRNA or protein 
expression, if any, were not due to cell death, but because of the specific action of the 
relevant agent.
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Figure 5.2 Effect of lovastatin on the IFN-y-induced mRNA expression of genes
PMA-difFerentiated THP-1 macrophages .were pre-treated for lh  with lovastatin (5,10 
and 20pM) or DMSO as a vehicle control. The cells were then cultured for 3h in the 
presence or the absence of IFN-y. Total RNA was isolated and subjected to RT-PCR 
using primers against MCP-1, ICER, ICAM-1, SOCS-1, IP-10 and 28S rRNA. The 
amplification products were analysed by agarose gel electrophoresis and the images 
shown are representative of three independent experiments. M denotes the lOObp 
DNA ladder (Appendix I); -RT indicates a reaction in which no reverse transcriptase 
was used during the cDNA synthesis step (RNA was from cells incubated with DMSO 
and IFN-y). Panel B shows the relative expression (mean ±SD) of the indicated gene 
normalised to the expression of 28S rRNA as determined by densitometric analysis 
from three independent experimental series (IFN-y-treated, DMSO control assigned as 
1). Statistical comparisons were carried out using the Student’s t test between the 
DMSO and IFN-y treated control and samples under treatment with lovastatin and 
IFN-y (N/S, not significant).
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Figure 5 3  Effect of simvastatin on the IFN-y-induced mRNA expression of genes
PMA-differentiated THP-1 macrophages were pre-treated for lh  with simvastatin (1,5 
and lOpM) or DMSO as a vehicle control. The cells were then cultured for 3h in the 
presence or the absence of IFN-y. Total RNA was isolated and subjected to RT-PCR 
using primers against MCP-1, ICER, ICAM-1, SOCS-1, MIP-ip, CIITA pill, CIITA 
pIV and P-actin. The amplification products were analysed by agarose gel 
electrophoresis and the images shown are representative o f three independent 
experiments (A). M denotes the lOObp DNA ladder (NEB). Panel B shows the relative 
expression (mean ±SD) of the indicated gene normalised to the expression of P-actin as 
determined by densitometric analysis from three independent experimental series 
(IFN-y-treated, DMSO control assigned as 1). Statistical comparisons were carried out 
using the Student’s t test between the DMSO and IFN-y treated control and samples 
under treatment with simvastatin and IFN-y (* P<0.05; ** P<0.01; *** P<0.001; N/S, 
not significant).
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(A)
DM DM LVS SMS BRL 15d GW TO
IFN-y - + + + + + + +
THP-1 
viability' (%) 100
100 98 99 96 90 96 97
(B)
DM DM 22R 9cRA 22R+9cRA
IFN-y - + + + +
THP-1 
viability (% )
100 100 95 92 90
Table 5.1 Assessment of viability of THP-1 m acrophages under various treatm ents
PMA-differentiated THP-1 cells were pre-treated for 2h with lovastatin (LVS at 20pM), 
simvastatin (SMV at lOpM), BRL49653 (BRL at 20pM), 15d-PGJ2 (15d at lOpM), 
GW7647 (GW at 5pM) or TO901317 (TO at lOpM) (A), or 24h with 
22(R)-hydroxycholesterol (22R, 2pg/ml), 9-cis retinoic acid (9cRA at lOpM) or 
combination o f both (B), or DMSO (DM) as negative vehicle control. The cells were then 
either left untreated or exposed to IFN-y (lOOOU/ml) for 30min. The viability of the cells 
was than assessed using the trypan blue exclusion assay. The data were obtained from a 
single experiment.
215
fChapter 5: Effects of the therapeutic agents on IFN-y signalling
5.2.2 Effects of statins on the IFN-y-induced STAT1 phosphorylation
Lovastatin and simvastatin at a series of concentrations were employed again to 
investigate whether statins exert their effects on IFN-y signalling through modulation 
of STAT1 phosphorylation. PMA-differentiated THP-1 macrophages were pre-treated 
with the respective statin for lh  prior to stimulation with IFN-y (lOOOU/ml) for 30min. 
The volume of DMSO added to the cells as a vehicle control was the same as that for 
the highest concentration of each statin used in order to rule out the possibility of the 
effect of DMSO on STAT1 phosphorylation. Following incubation with the cytokine, 
whole cell proteins were extracted and western blot analysis was carried out as 
described before in Chapter 4. Densitometric analysis of the data was carried out and 
presented in Figure 5.4 Band intensity for phospho-STATl Ser727 and Tyr701 were 
normalised to total STAT1 (p84/91). Results are presented as the IFN-y-induced 
expression levels in the presence of statins (±SD) normalised to the induction levels 
stimulated by the cytokine, which was arbitrarily assigned as 1. Student’s t test was 
used to assess for statistical significance.
As shown in Figure 5.4 (A), lovastatin showed no statistically significant effect on the 
IFN-y-induced STAT1 phosphorylation at either Ser727 or Tyr701. This is consistent 
with previous data from RT-PCR experiments which show that the IFN-y-induced 
expression of marker genes analysed was not affected by lovastatin. These results 
together suggest that lovastatin probably does not target IFN-y signalling, at least at 
the level of genes analysed in this study and the JAK-STAT pathway in THP-1 
macrophages. Figure 5.4 (B) shows that simvastatin did not affect the IFN-y-induced 
STAT1 phosphorylation. Having shown that simvastatin inhibits the IFN-y-induced 
expression of some of the genes analysed (Figure 5.3), the results thereby suggest that 
simvastatin might affect the IFN-y-induced expression of these genes independently 
of STATl phosphorylation. Moreover, the addition of simvastatin did not affect the 
phospho-STATl status in the absence of IFN-y, thereby suggesting that simvastatin 
does not target the constitutive phosphorylation of STATl in THP-1 macrophages.
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Figure 5.4 Effect of lovastatin and simvastatin on the IFN-y-induced 
phosphorylation of STATl at Ser727 and Tyr701
PMA-difFerentiated THP-1 macrophages were pre-treated for lh  with lovastatin (A) 
and simvastatin (B) at three different concentrations as indicated or DMSO (DM, equal 
volume as the highest concentration of the respective statins) as a vehicle control. The 
cells were then cultured for 30min in the presence or the absence of IFN-y. Cell protein 
extracts were prepared using the Laemmli sample buffer and western blot analysis was 
carried out using antibodies specific for pSTATl Tyr701, pSTATl Ser727 and STATl 
p84/91. The graphs show the relative phosphorylation level (mean ± SD) of STATl at 
each of these sites normalised to the expression of the total STATl protein, as 
determined by densitometric analysis, from three independent experimental series (the 
value from IFN-y-treated DMSO control sample was arbitrarily assigned as 1). 
Student’s t test was carried out on samples treated with each type o f statin versus 
IFN-y-treated, DMSO control sample (N/S, not significant).
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5.2.3 Effects of simvastatin on the IFN-y-induced activation of ST ATI 
responsive elements and MCP-1 gene promoter
To further confirm the effect of simvastatin on the IFN-y-mediated regulation of gene 
expression and to investigate its impact on STAT1 transcriptional activity, transfection 
assays were performed using plasmids containing luciferase reporter gene regulated 
by STAT1 responsive, GAS elements (3xly6e) and the MCP-1 gene promoter 
(MCP[213]Luc) as described previously in Chapter 4 (section 4.3.4). Following 
transfection with 3xly6e or MCP[213]Luc plasmids, Hep3B cells were incubated with 
simvastatin at three different concentrations (1, 5 or lOpM) or DMSO for lh. The 
cells were subsequently incubated for 6h in the absence or the presence of IFN-y after 
which cell extracts were prepared for luciferase reporter activity assays. Results are 
presented in Figure 5.5 as mean relative activity changes (±SD) (IFN-y-treated DMSO 
control arbitrarily assigned as 1). Simvastatin significantly inhibited the 
IFN-y-induced activation of MCP-1 gene promoter in a concentration-dependent 
manner, and also attenuated the activation of 3xly6e at lOpM. These results suggest 
that the inhibitory effect of simvastatin on the IFN-y-induced expression of genes, 
such as MCP-1, is at least in part, modulated through the regulation of STAT1 
transcriptional activity.
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D M S O  1}jM 5 |j M 1 0 jjM
I F N -y -  +  -  +  +  - +
MCP [213]
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Figure 5.5 Effect of sim vastatin on the stim ulation of STAT1 responsive elements 
and the MCP-1 gene prom oter activity by IFN-y
Hep3B cells were transfected with plasmids 3xly6e or MCP[213]Luc. Following lh 
incubation with simvastatin (1, 5 and 10p.M) or DMSO, transfected cells were 
incubated for 6h in the absence or the presence o f IFN-y after which cell extracts were 
prepared for luciferase reporter activity assay. Luciferase counts were normalised to 
protein concentration and presented as the mean relative activation (±SD) in response to 
IFN-y, in relation to unstimulated samples, from three independent experiments. The 
data was further normalised to the relative activation of IFN-y-treated DMSO control 
sample (arbitrarily assigned as 1). Student’s t test was carried out on samples treated 
with simvasatin versus IFN-y-stimulated DMSO control sample (***, P<0.001; N/S, 
not significant).
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5.3 Effects of PPAR-y agonists on IFN-y signalling
5.3.1 Effects o f  PPAR-y agonists on the IFN-y-induced gene expression
PMA-differentiated THP-1 macrophages were pre-treated for 2h with the PPAR-y 
agonist BRL49653 at a series of concentrations (5, 10 and 20pM) prior to treatment 
with IFN-y (lOOOU/ml) for 3h. The concentrations and the pre-incubation period 
employed here were based on previous research (Li et al., 2000b; Chawla et al., 2001; 
Crosby et al., 2005). RNA was subsequently extracted and RT-PCR was carried out 
for each gene as detailed before. Figure 5.6 (A) shows the PCR products for each gene 
resolved by agarose gel electrophoresis. Densitometric and statistical analysis is 
presented in panel B of the figure.
BRL49653, in a concentration-dependent manner, attenuated the IFN-y-induced 
expression of MCP-1, IP-10, SOCS-1 and CIITA pill, but had no effect on the 
expression of ICERI/II, ICAM-1 and CIITA pIV. The results suggest that BRL49653 
selectively inhibits IFN-y-regulated gene expression in a gene-specific manner in 
THP-1 macrophages. The expression of genes in the absence of the cytokine shows no 
change following treatment of BRL49653 (20|iM), thereby suggesting that the agonist 
has no impact on the constitutive expression of the genes analysed.
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Figure 5.6 Effect of BRL49653 on the IFN-y-induced mRNA expression of genes
PMA-differentiated THP-1 macrophages were pre-treated for 2h with BRL49653 (5, 
10 and 20pM) or DMSO as a vehicle control. The cells were then cultured for 3h in the 
presence or the absence of IFN-y. Total RNA was isolated and subjected to RT-PCR 
using primers against MCP-1, ICER, ICAM-1, SOCS-1, IP-10, CIITA pill, CIITA pIV 
and 28S rRNA. The amplification products were analysed by agarose gel 
electrophoresis and the images shown are representative of three independent 
experiments (A). M denotes the lOObp DNA ladder (Appendix I) and -R T  indicates a 
reaction in which no reverse transcriptase was added during the cDNA synthesis step 
(RNA was from cells incubated with DMSO and IFN-y). Panel B shows the relative 
expression (mean ±SD) of the indicated gene normalised to the expression of 28S 
rRNA as determined by densitometric analysis from three independent experimental 
series (IFN-y-treated, DMSO control assigned as 1). Statistical comparisons were 
carried out using the Student’s t test between the DMSO and IFN-y treated control and 
samples under treatment with BRL49653 and IFN-y (* P<0.05; ** PO .O l; *** 
P<0.001; N/S, not significant).
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5.3.2 Effects of PPARy agonists on the IFN-y-induced STAT1 
phosphorylation
In addition to BRL49653, the endogenous PPAR-y ligand, 15d-PGJ2 was also 
included to investigate the effect of PPAR-y activation on the IFN-y-mediated STATl 
phosphorylation. PMA-differentiated THP-1 macrophages were pre-treated for 2h 
with PPAR-y agonists BRL49653 (5, 10 or 20pM) or 15d-PGJ2 (1, 5 or lOpM) prior 
to treatment with IFN-y (lOOOU/ml) for 30min. The concentrations of 15d-PGJ2 used 
were based on previous studies (Castrillo et al., 2000; Straus et al., 2000; Chen et al., 
2003). Whole cell proteins were then extracted and western blot analysis was carried 
out as detailed before. Results are presented as the IFN-y-induced expression levels in 
the presence of BRL49653 or 15d-PGJ2 (±SD) normalized to the induction levels 
stimulated by the cytokine, which was arbitrarily assigned as 1.
Figure 5.7 shows that neither BRL49653 or 15d-PGJ2 significantly affected the 
IFN-y-mediated STATl phosphorylation in THP-1 macrophages. Given the potential 
gene-specific action of BRL49653 on the IFN-y-induced mRNA expression (Figure 
5.6), the results suggest that PPAR-y agonists selectively target the IFN-y-regulated 
gene expression via mechanism(s) independent of STATl phosphorylation.
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Figure 5.7 Effect of BRL49653 and 15d-PGJ2 on the IFN-^-induced 
phosphorylation of STATl on Ser727 and iyr701
PMA-differentiated THP-1 macrophages were pre-treated for 2h with BRL49653 (A) 
and 15d-PGJ2 (B) at three different concentrations as indicated, or DMSO (DM, equal 
volume as the highest concentration of the respective agonist) as a vehicle control. The 
cells were then cultured for 30min in the presence or the absence o f IFN-y. Cell protein 
extracts were prepared using the Laemmli sample buffer and western blot analysis was 
carried out using antibodies specific for pSTATl Tyr701, pSTATl Ser727 and STATl 
p84/91. The graphs show the relative phosphorylation level (mean ± SD) of STATl at 
each of these sites normalised to the expression of the total STATl protein, as 
determined by densitometric analysis, from three independent experimental series (the 
value from IFN-y-treated DMSO control sample was arbitrarily assigned as 1). 
Student’s t test was carried out on samples treated with each type of agonist versus 
IFN-y-treated, DMSO control sample (N/S, not significant).
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5.3.3 Effects of PPAR-y agonists on the IFN-y-induced STATl 
phosphorylation in human primary monocyte-derived 
macrophages
To rule out the possibility that the absence of an effect of PPAR-y agonists on the 
IFN-y-mediated STATl phosphorylation is a peculiar property of the differentiated 
THP-1 cell line, the effect of these agonists on STATl phosphorylation in human 
primary monocyte-derived macrophages was investigated.
Primary monocyte-derived macrophages were prepared as described in Chapter 4 
(section 4.3.2). These cells were pre-treated with BRL49653 (20pM) or 15d-PGJ2 
(10|iM) for 2h prior to further incubation for 30min in the presence or the absence of 
IFN-y. Cellular protein was then subjected to western blot analysis. Densitometric and 
statistical analysis of the data was carried out as detailed before. Consistent with 
previous results in THP-1 macrophages (Figure 5.7), neither of these ligands was 
found to affect the IFN-y-induced STATl phosphorylation in human primary 
monocyte-derived macrophages (Figure 5.8).
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Figure 5.8 Effect of BRL49653 (BRL) and 15d-PGJ2 (15d) on the IFN-y-induced phosphorylation of STATl at Ser727 and Tyr701 in human 
monocyte-derived macrophages
Human monocyte-derived macrophages were pre-treated for 2h with BRL49653 (20pM) or 15d-PGJ2 (lOpM) or DMSO (DM) as a vehicle control.
The cells were then incubated for 30min in the presence or the absence of IFN-y. Cell protein extracts were prepared using the Laemmli sample buffer 
and western blot analysis was carried out using antibodies specific for pSTATl Tyr701, pSTATl Ser727 and STATl p84/91 (A). The graphs show the 
relative phosphorylation level (mean ± SD) of STATl at each of these sites normalised to the expression of the total STATl protein, as determined by 
densitometric analysis, from three independent experimental series (the value from IFN-y-treated DMSO control sample was arbitrarily assigned as 1). 
Student’s t test was carried out on samples treated with each type of agonist versus IFN-y-treated, DMSO control sample (N/S, not significant).
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5.3.4 Effects of PPAR-y agonists on the IFN-y-induced activation of 
STATl responsive elements and MCP-1 gene promoter
As detailed before, Hep3B cells were transfected with 3xly6e or MCP[213]Luc 
plasmids and subsequently pre-treated for 2h with BRL49653 or 15d-PGJ2 at three 
different concentrations or DMSO. Following further incubation for 6h in the absence 
or the presence of IFN-y, cell extracts were prepared for luciferase reporter activity 
assay. Figure 5.9 shows that BRL49653 significantly inhibited the IFN-y-mediated 
activation of STATl responsive elements (GAS) in the 3xly6e plasmid at all the three 
concentrations analysed, and also attenuated the activation of MCP-1 promoter by this 
cytokine at 10 and 20pM. Moreover, 15d-PGJ2 was also found to inhibit the 
activation of MCP-1 promoter at all the three concentrations used and to repress the 
activation of 3xly6e at 5 and lOpM. These results support the inhibitory effect of 
PPAR-y agonists on the IFN-y-induced expression of genes, including MCP-1, at least 
in part through the modulation of STATl transcriptional activity.
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Figure 5.9 Effect of BRL49653 and 15d-PGJ2 on the activation of STATl 
responsive elements and MCP-1 prom oter activity by IFN-y
Hep3B cells were transfected with plasmids 3xly6e or MCP[213]Luc. Following 2h 
incubation with the respective agonist at three different concentrations or DMSO, 
transfected cells were treated with IFN-y or left untreated for 6h after which cell 
extracts were prepared for luciferase reporter activity assay. Luciferase counts were 
normalised to protein concentration and presented as the mean relative activation 
(±SD) in response to IFN-y, in relation to unstimulated controls, from three 
independent experiments. The data was further normalised to the relative activation of 
IFN-y-treated DMSO control sample (arbitrarily assigned as 1). Student’s t test was 
carried out on samples treated with PPAR-y agonist versus IFN-y-stimulated DMSO 
control sample (*♦*, PO.OOl; **, P<0.01; *, P<0.05; N/S, not significant)
IFN-y
IFN -y
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5.4 Effects of PPARa agonists on IFN-y signalling
5.4.1 Effects of PPARa agonists on the IFN-y-induced gene expression
The experiments were carried out exactly as described in section 5.3.1, except that the 
cells were treated with the PPARa agonist GW7647 (0.5, 1 or 5pM) instead of 
BRL49653. Semi-quantitative RT-PCR of MCP-1, ICER, ICAM-1, SOCS-1, IP-10, 
CIITA pill and pIV and p-actin was carried out and the results are presented in Figure 
5.10. The same concentrations of GW7647 have previously been used by other 
laboratories (Gupta et al., 2001; Seimandi et al., 2005; Bento-Abreu et al., 2007; 
Ramanan et al., 2008).
With the exception of ICAM-1, GW7647 was found to attenuate the IFN-y-induced 
expression of all the other genes analysed including MCP-1, ICERI/II, SOCS-1, IP-10, 
CIITA pill and pIV (Figure 5.10). The inhibition occurred in a 
concentration-dependent manner. The results thereby suggest a potential gene-specific 
action of GW7647 in IFN-y signalling. No observable changes of gene expression 
occurred after the addition of GW7647 (5pM) in the absence of IFN-y, thereby 
suggesting that GW7647, like BRL49653, does not affect the constitutive expression 
of genes analysed in THP-1 macrophages.
228
Figure 5.10 Effect of GW7647 on the IFN-y-induced mRNA expression of genes
PMA-differentiated THP-1 macrophages were pre-treated for 2h with GW7647 (0.5,1 
or 5pM) or DMSO (DM) as a vehicle control. The cells were then cultured for 3h in the 
presence or the absence of IFN-y. Total RNA was isolated and subjected to RT-PCR 
using primers against MCP-1, ICER, ICAM-1, SOCS-1, IP-10, CIITA pin , CIITA pIV 
and p-actin. The amplification products were analysed by agarose gel electrophoresis 
and the images shown are representative of three independent experiments (A). M 
denotes the lOObp DNA ladder (Appendix I); -RT indicates a reaction in which no 
reverse transcriptase was used during the cDNA synthesis step (RNA was from cells 
incubated with DMSO and IFN-y). Panel B shows the relative expression (mean ±SD) 
o f the indicated gene normalised to the expression of P-actin as determined by 
densitometric analysis from three independent experimental series (IFN-y-treated, 
DMSO control assigned as 1). Statistical comparisons were carried out using the 
Student’s t test between the DMSO and IFN-y treated control and samples under 
treatment with GW7647 and IFN-y (* P<0.05; ** PO .O l; *** PO.OOl; N/S, not 
significant).
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5.4.2 Effects of PPARa agonists on the IFN-y-induced STATl 
phosphorylation
GW7646 was employed again to investigate its effect on the IFN-y-induced STATl 
phosphorylation. The experiments and the analyses of the data were carried out 
exactly as detailed in section 5.3.2, except that the cells were pre-treated for 2h with 
GW7647 instead of BRL49653.
Figure 5.11 clearly demonstrates that GW7647 had no effect on the IFN-y-induced 
STATl phosphorylation at either Ser727 or Tyr701, thereby suggesting that the 
agonist targets the IFN-y-induced gene expression via mechanism(s) distinct from 
phosphorylation of STATl.
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Figure 5.11 Effect of GW7647 on the IFN-y-induced phosphorylation of STATl at Ser727 and Tyr701
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PMA-differentiated THP-1 cells were pre-treated for 2h with GW7647 at three different concentrations as indicated or DMSO (equal volume as GW7647 
at 5pM) as a vehicle control. The cells were then cultured for 30min in the presence or the absence of IFN-y. Cell protein extracts were prepared using 
the Laemmli sample buffer and western blot analysis was carried out using antibodies specific for pSTATl Tyr701, pSTATl Ser727 and STATl p84/91. 
The graphs show the relative phosphorylation level (mean ± SD) of STATl at each of these sites normalised to the expression of the total STATl protein, 
as determined by densitometric analysis, from three independent experimental series (the value from the IFN-y-treated, DMSO control sample was 
arbitrarily assigned as 1). Student’s t test was carried out on samples treated with GW7647 versus IFN-y-treated, DMSO control sample (N/S, not 
significant).
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5.5 Effects of LXR agonists on IFN-y signalling
5.5.1 Effects of LXR agonists on the IFN-y-induced gene expression
The experiments and the analyses of the data were carried out exactly as described in 
section 5.3.1, except that the cells were pre-treated for 2h with the non-steroidal LXR 
agonist TO901317 instead of BRL49653. The concentration of TO901317 has been 
previously determined in our laboratory (Huwait, 2008).
Figure 5.12 shows that pre-treatment of THP-1 macrophages with TO901317 at lOpM 
resulted in a slight, but significant inhibition of the IFN-y-induced expression of 
MCP-1 and CIITA pIV, but had no effect on that of other genes analysed, including 
ICAM-1, SOCS-1, ICER, IP-10 and CIITA pill. The results suggest a selective effect 
ofT0901317 on the IFN-y-regulated gene expression.
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Figure 5.12 Effect of TO901317 on the IFN-y-induced mRNA expression of genes
PMA-differentiated THP-1 macrophages were pre-treated for 2h with TO901317 (1,5 
or 10pM) or DMSO as a vehicle control. The cells were then cultured for 3h in the 
presence or the absence of IFN-y. Total RNA was isolated and subjected to RT-PCR 
using primers against MCP-1, ICER, ICAM-1, SOCS-1, IP-10, CIITA pill, CIITA pIV 
and 28S rRNA. The amplification products were analysed by agarose gel 
electrophoresis and the images shown are representative of three independent 
experiments (A). M denotes the lOObp DNA ladder (Appendix I); -RT denotes a 
reaction in which no reverse transcriptase was present during the cDNA synthesis step 
(RNA was from cells incubated with DMSO and IFN-y). Panel B shows the relative 
expression (mean ±SD) of the indicated gene normalised to the expression of p-actin as 
determined by densitometric analysis from three independent experimental series 
(IFN-y-treated, DMSO control assigned as 1). Statistical comparisons were carried out 
using the Student’s t test between the DMSO and IFN-y treated control and samples 
under treatment with TO901317 and IFN-y (* P<0.05; *** PO.OOl; N/S, not 
significant).
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5.5.2 Effects of LXR agonists on the IFN-y-induced STATl 
phosphorylation
TO901317 was again employed here to analyse the effect of ligand-dependent 
activation of LXRs on the IFN-y-induced STATl phosphorylation. The experiment 
and the analyses of the data were carried out exactly as detailed in section 5.3.2, 
except that the cells were pre-treated for 2h with TO901317 instead of BRL49653.
Figure 5.13 (A) shows that TO901317 had no effect on the IFN-y-induced STATl 
phosphorylation at either Ser727 or Tyr701, thereby suggesting that the agonist targets 
the IFN-y-induced gene expression via mechanism(s) distinct from phosphorylation of 
STATl at Ser727 and Tyr701.
In addition to TO901317, naturally occurring ligands for LXRs (22R) and RXRs 
(9cRA) were also included here. To analyse the potentially synergistic and individual 
effects of 22R and 9cRA on the IFN-y-induced STATl phosphorylation, the cells were 
pre-treated with combination of 22R (2jig/ml) and 9cRA (10pM) or the individual 
ligands for 24h prior to the addition of IFN-y for a further 30min. The concentration 
of 22R and 9cRA and the pre-incubation period were previously determined in our 
laboratory (Huwait, 2008) and also have been employed by other research groups 
(Costet et al., 2000; Laffitte et al., 2001). The ligand 22(S)-hydroxycholesterol (22S) 
(2pg/ml), an inactive enantiomer of 22R, was included as a control because it binds to 
but does not activate the LXRs (Janowski et al., 1999). Western blot analysis was 
carried out as described before.
Figure 5.13 (B) shows that pre-treatment of THP-1 macrophages with 22R and 9cRA 
individually or together significantly attenuated the IFN-y-induced phosphorylation at 
both Ser727 and Tyr701. The most pronounced inhibition was obtained with 
combination of these ligands. These results thus suggest that the ligand-dependent 
activation of LXRs and RXRs could suppress the IFN-y-mediated signalling
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individually or in combination. Pre-treatment of 22S showed no effect on the 
IFN-y-induced phosphorylation, thereby suggesting that the observed effect by 22R 
was specific to LXR activation.
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Figure 5.13 Effect of TO901317,22R, 9cRA and 22R+9cRA on the IFN-y-induced
phosphorylation of STATl at Ser727 and iyr701
PMA-differentiated THP-1 cells were pre-treated for 2h with TO901317 (1,5 or 10}iM), 
24h with 22R (2pg/ml), 9cRA (lOpM), 22R+9cRA, or DMSO (DM, equal volume as 
highest concentration of respective agent) as a vehicle control. 22S (2pg/ml) was 
included as a negative control for 22R. The cells were then cultured for 30min in the 
presence or the absence of IFN-y. Cell protein extracts were prepared using the 
Laemmli sample buffer and western blot analysis was carried out using antibodies 
specific for pSTATl Tyr701, pSTATl Ser727 and STATl p84/91. The graphs show 
the relative phosphorylation level (mean ± SD) of STATl at each of these sites 
normalised to the expression of the total STATl protein, as determined by 
densitometric analysis, from three independent experimental series (the value from 
IFN-y-treated DMSO control sample was arbitrarily assigned as 1). Student’s t test was 
carried out on samples treated with each type of ligand versus IFN-y-treated, DMSO 
control sample (*P<0.05; **P<0.01; ***P<0.001; N/S, not significant).
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5.5.3 Effect of LXR and RXR agonists on the IFN-y-induced STATl 
phosphorylation
To further confirm the effect of ligand-activated LXR/RXR in IFN-y-induced STATl 
phosphorylation, the combinatorial action of 22R and 9cRA on both the constitutive 
along with the IFN-y-induced STATl phosphorylation was analysed. The previous 
studies shown in Figure 5.13B were restricted only to IFN-y-treated cells. Consistent 
with previous data, combination of 22R and 9cRA significantly inhibited the 
IFN-y-induced STATl phosphorylation at Ser727 and Tyr701 (Figure 5.14A). 
However, the ligands had no effect on STATl phosphorylation in the absence of the 
cytokine, thereby suggesting that the action of LXR/RXR was specific to the 
IFN-y-inducible phosphorylation of STATl.
The inhibitory effect of 22R and 9cRA was again confirmed by 
concentration-response experiments that showed that the IFN-y-induced STATl 
phosphoryaltion at both sites was inhibited by combination of 22R and 9cRA in a 
concentration-dependent manner (Figure 5.14B).
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Figure 5.14 Effect of 22R and 9cRA on the IFN-y-induced phosphorylation of 
STAT1 at Ser727 and Tyr701
PMA-differentiated THP-1 cells were pre-treated for 24h with 22R (2pg/ml) and 9cRA 
(lOpM) (A), or 22R (1,2 or 5pg/ml) and 9cRA (lOpM) (B) or DMSO (equal volume as 
the highest concentration of the respective agents) as a vehicle control. 22S (2pg/ml) 
was included as a negative control for 22R. The cells were then cultured for 30min in 
the presence or the absence of IFN-y. Cell protein extracts were prepared using the 
Laemmli sample buffer and western blot analysis was carried out using antibodies 
specific for pSTATl Tyr701, pSTATl Ser727 and STAT1 p84/91. The graphs show 
the relative phosphorylation level (mean ± SD) of STAT1 at each of these sites 
normalised to the expression of the total STAT1 protein, as determined by 
densitometric analysis, from three independent experimental series (the value from 
IFN-y-treated DMSO control sample was arbitrarily assigned as 1). Student’s t test was 
carried out on samples treated with the agonists versus IFN-y-treated, DMSO control 
sample (*/><0.05; **P<0.01; ***P<0.001; N/S, not significant).
237
wK)
*+voo
K>
C / 3
C/5 ■a "O NH
H C/5 C/5
> H H
H
$ i j 4
T3 M
00 C/5
rt
VO ■i^1 “14
o K»
Relative Expression
+ o
pi
C / 5
g
C / 5
-4
1^
K)K>
+VO
C/5
00
■o
C/5§
■o
C/5
1
i
C/5ni
Ki
*3
2!
4
*32!
-4
Relative Expression
4-J
*o
C /3
3
C /3
■t4K>-a
Relative Expression Relative Expression
2
•a
C / 5
H
>
H
i - - .■
* '-ao* h-k
N
/S
T3
C /3
3
<1o
Chapter 5: Effects of the therapeutic agents on IFN-y signalling
5.5.4 Effects of LXR and RXR agonists on the IFN-y-induced ST ATI 
phosphorylation in human primary monocyte-derived 
macrophages
We next decided to confirm the action of LXR/RXR on the IFN-y-induced STAT1 
phosphorylation in human primary monocyte-derived macrophages to rule out the 
possibility that the effect of 22R and 9cRA observed previously (Figures 5.13 and 
5.14) was a peculiar property of the differentiated THP-1 cell line. The human 
primary macrophages were prepared and the experiments were carried out as 
described in section 5.3.3 except that the cells were pre-treated for 24h with 
combination of 22R (2pg/ml) and 9cRA (lOpM) instead of the PPARy agonists for 2h. 
Statistical analysis of the data was performed as detailed before.
Figure 5.15 shows that pre-treatment of the cells with combination of 22R and 9cRA 
significantly attenuated the IFN-y-induced STAT1 phosphorylation in human 
monocyte-derived macrophages, thereby suggesting that the inhibitory effect of 22R 
with 9cRA on IFN-y signalling was not specific to the THP-1 cell line but probably a 
general property to human macrophages.
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Figure 5.15 Effect of 22R with 9cRA on the IFN-y-induced phosphorylation of STAT1 at Scr727 and Tyr701 in human monocyte-derived 
macrophages
Human monocyte-derived macrophages were pre-treated for 24h with 22R (2pg/ml) with 9cRA (lOpM) or DMSO as a vehicle control. The cells were 
then cultured for 30min in the presence or the absence of IFN-y. Cell protein extracts were prepared using the Laemmli sample buffer and western blot 
analysis was carried out using antibodies specific for pSTATl Tyr701, pSTATl Ser727 and STAT1 p84/91. The graphs show the relative phosphorylation 
level (mean ± SD) of STAT1 at each of these sites normalised to the expression of the total STAT1 protein, as determined by densitometric analysis, from 
three independent experimental series (the value from IFN-y-treated DMSO control sample was arbitrarily assigned as 1). Student’s t test was carried out 
on samples treated with ligands versus IFN-y-treated, DMSO control sample (***/><0.001).
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5.5.5 Effects of LXR and RXR agonists on the IFN-y-induced activation
of STAT1 responsive elements and MCP-1 gene promoter
The action of 22R with 9cRA on the IFN-y-mediated activation of STAT1 
transactivation and MCP-1 gene promoter was also confirmed using GAS-regulated 
reporter plasmid, 3xly6e, and the MCP-1 promoter reporter plasmid MCP[213]Luc in 
transfection experiments. The experiments and data analysis were performed as 
detailed in section 5.3.4 except that the transfected Hep3B cells were treated for 24h 
with 22R and 9cRA instead of PPARy agonists for 2h.
Figure 5.16 shows that 22R and 9cRA together significantly suppress the 
IFN-y-induced STAT1 transcriptional activity and MCP-1 promoter activation, 
thereby supporting the action of ligand-dependent activation of LXR/RXR on 
IFN-y-mediated STAT1 tranactivation and MCP-1 transcription.
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Figure 5.16 Effect of 22R+9cRA on the IFN-Y-stimulated activation of STAT1 responsive elements and MCP-1 gene promoter
Hep3B cells were transfected with plasmids 3xly6e or MCP[213]Luc. Following 24h incubation with combination of 22R (2pg/ml) and 9cRA 
(lOpM) or DMSO, transfected cells were treated with IFN-y or left untreated for 6h after which cell extracts were prepared for luciferase reporter 
activity assay. Luciferase counts were normalised to protein concentration and presented as the mean relative activation (±SD) in response to IFN-y, 
in relation to unstimulated samples, from three independent experiments. The data was further normalised to the relative activation of 
IFN-y-treated DMSO control sample (arbitrarily assigned as 1). Student’s t test was carried out on samples treated with agonists versus 
IFN-Y-stimulated DMSO control (***/><0.001).
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5.6 Effects of therapeutic agents on the IFN-y-induced 
adhesion of monocytes to endothelial cells
Numerous studies have demonstrated that PPAR ligands inhibit the adhesion of 
leukocytes to endothelial cells and the recruitment of leukocytes to the site of 
inflammation (Li et al., 2004; Ahmed et al., 2006; Lee et al., 2007a; Straus and Glass,
2007). Such an effect is thought to correlate with the transrepression action of PPARs 
on a range of molecules contributing to the adhesion and recruitment, such as 
chemokines and adhesion molecules [see (Straus and Glass, 2007; Bensinger and 
Tontonoz, 2008; Rigamonti et al., 2008) for reviews]. Our results show that addition 
of ligands for PPAR-a and -y, as well as LXR agonists suppress the IFN-y-induced 
expression of a key chemokines, MCP-1 (Figures 5.6, 5.10 and 5.12). We thus 
decided to investigate the effect of PPAR and LXR ligands on the IFN-y-induced 
adhesion of U937 to endothelial cells using the PPARy agonists (BRL49653 and 
15d-PGJ2) and the LXR ligands (22R with 9cRA). We again employed the
t*w
CytoSelect Leukocyte-endothelium adhesion assay system as detailed in Chapter 4 
(section 4.3.9). The adhesion assay and analysis of the data was carried out as 
described before except that the HUVEC monolayer was pre-treated with BRL49653, 
15d-PGJ2 or 22R with 9cRA for 2h, instead of the inhibitors for lh.
Figure 5.17 shows that 15d-PGJ2 and the combination of 22R with 9cRA significantly 
inhibited the IFN-y-induced adhesion of U937 to HUVEC by approximately 50% and 
20% respectively. The addition of BRL49653, however, resulted in an induction of 
adhesion by about 60% compared to DMSO and IFN-y-treated control. Such opposite 
effect of 15d-PGJ2 and BRL49653 in leukocyte adhesion to endothelial cells has also 
been observed by another research group (Rival et al., 2002), although the exact 
underlying reasons currently remain unclear. The results in isolation suggest that the 
PPARy agonist, 15d-PGJ2, and the LXR agonists, 22R and 9cRA, inhibited the 
IFN-y-induced adhesion of monocytes to endothelial cells.
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It is noteworthy that the cellular viability assays (ViaLight and MTT assays) carried 
out on HUVECs (presented as black and blue lines in Figure 5.17) showed that 
incubation with the agonists and the cytokine for 32h (treatment with agonists for 2h 
plus with IFN-y for another 30h) resulted in a low HUVEC viability. The data 
suggests that the low HUVEC viability could also contribute to the decreased 
adhesion of U937 to HUVEC caused by the agonists 15d-PGJ2 along with 22R and 
9cRA. However, although the addition of BRL49653 seemed to result in as much 
HUVEC cell death as the other agonists, the adhesion of U937 to HUVEC was 
induced. It is therefore difficult to come to any firm conclusions on whether the 
reduced adhesion by the agonists could be attributed to their actions on the 
IFN-y-mediated cellular inflammatory response, or simply be due to reduced HUVEC 
viability.
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Figure 5.17 The effects of therapeutic drugs on the IFN-y-induced adhesion 
between U937 and HUVEC and analysis of viability of HUVEC under variety of 
treatments
Monolayers o f HUVEC were pre-treated with BRL49653 (20pM), 15d-PGJ2 (10 pM) 
or 22R (2pg/ml) with 9cRA (lOpM) for 2h and further stimulated with IFN-y 
(lOOOU/ml) for 30h. LeukoTracker™-labelled U937 cells were added and allowed to 
attach to the HUVEC monolayer for 1 h. Adherent cells were lysed and quantified by 
fluorescence measurement at 485nm/520nm. HUVEC monolayers without treatment, 
or addition o f U937 cells (No U937) were used as negative controls. Statistical 
analysis was performed from three independent experiments. Blue bars show the 
percentage o f adhesion (m ean±SD ) under variety o f treatments relative to DMSO 
(DM) plus IFN-y-treated control (assigned as 100%). Student’s t test was carried out 
on ligands treated samples versus IFN-y treated DMSO control sample (significance 
o f induction: #, P<0.05; significance o f inhibition: *, P O .05; **, R<0.01; ***, 
P 0 .0 0 1 ; N/S, not significant). Green and black lines in the figure show the viability 
o f HUVEC under various treatments using ViaLight assay and MTT assays 
respectively. The value from HUVEC with DMSO and IFN-y treated sample was 
assigned as 100% viable. Results o f MTT assay (mean +  SD) are representative of 
three independent experiments. Luminescence reading of ViaLight assay was 
obtained from single experiment.
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5.7 Discussion
5.7.1 Effects of statins on IFN-y signalling
Numerous studies have demonstrated the suppressive effect of statins on 
stimuli-mediated expression of inflammatory response genes, many of which are 
directly involved in atherosclerosis [see (Liao, 2005; Jasinska et al., 2007; Lahera et 
al., 2007) for reviews]. In particular, many types of statins, such as simvastatin and 
lovastatin, have been shown to inhibit the IFN-y-induced gene expression, including 
chemokines, adhesion molecules and proteins essential for immune responses in a 
range of vascular cells, such as monocytes/macrophages, endothelial cells and smooth 
muscle cells (Kwak et al., 2001; Chung et al., 2002; Townsend et al., 2004; Buttice et 
al., 2006; Montecucco et al., 2009) (see Table 1.9 for a list of studies). Consistent with 
these previous findings, work presented in this chapter clearly shows that 
pre-treatment of THP-1 macrophages with simvasatin inhibits the IFN-y-induced 
expression of MCP-1, ICAM-1, OITA pi V and SOCS-1 in a concentration-dependent 
manner, thereby suggesting an anti-inflammatory and immunomodulatory effect of 
simvastatin in human macrophages (Figure 5.3). In contrast to CIITA pIV, the 
expression of CIITA pill was not affected by simvastatin, thereby suggesting a 
promoter-specific action of simvastatin on the IFN-y-induced CIITA expression. 
Several studies have demonstrated that simvastatin suppresses the IFN-y-induced 
CIITA pIV expression in macrophages and endothelial cells (Kwak et al., 2001; 
Sadeghi et al., 2001; Mach, 2002a; Lee et al., 2008), while Buttice et al. (2006) 
showed that simvastatin did not affect either CIITA pill or pIV in response to IFN-y in 
human aortic smooth muscle cells. These results together suggest that simvastatin 
may repress the IFN-y-stimulated expression of CIITA in a promoter- and 
cell-type-specific manner.
Figure 5.4B shows that simvastatin at concentrations that inhibited the IFN-y-induced 
gene expression failed to attenuate STATl phosphorylation at either Ser727 or Tyr701,
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thereby suggesting the involvement of a STAT1 phosphorylation-independent 
mechanism for the simvastatin-mediated repression. In addition, as shown in Figure 
5.5, pre-treatment of the cells with simvastatin resulted in a decrease in the 
IFN-y-induced luciferase expression regulated by STAT1 consensus sites (GAS) in the 
3xly6e vector and the activation of MCP-1 gene promoter. As summarised in Table 
5.2, simvastatin inhibits the IFN-y-induced expression of MCP-1, ICAM-1, CIITA 
pIV and SOCS-1. As detailed before in sections 3.1.5 and 4.1.4, the expression of 
these genes has been shown to be mediated, at least in part, by a STAT1-dependent 
pathway in response to IFN-y. These results therefore suggest that simvastatin 
probably inhibits the expression of these genes by attenuating the STAT1 
transcriptional activity in response to IFN-y, but without targeting STAT1 
phosphorylation.
In contrast to simvastatin, lovastatin was found not to affect the IFN-y-induced gene 
expression (Figure 5.2) or STAT1 phosphorylation (Figure 5.4A). Such differential 
effect of different types of statins has been previously documented. For example, 
Sugiyama et al. (2000) showed that simvastatin, but not pravastatin, induces the bone 
morphogenetic protein-2 expression in human osteosarcoma cells. Moreover, in 
contrast to our findings in THP-1 macrophages, Chung et al. (2002) and Townsend et 
al (2004) have shown that lovastatin suppresses the IFN-y-induced expression of 
genes, such as ICAM-1, TNF-a and CD40, by attenuating STAT1 phosphorylation at 
Ser727 in endothelial, smooth muscle and microglial cells. These results together 
suggest that statins probably exert their anti-inflammatory effects in a cell type- and 
statin type-specific manner.
5.7.2 Effects of PPARy agonists on IFN-y signalling
As detailed in the General Introduction (section 1.8.1), inhibitory effects of PPAR 
agonists on the cytokine-stimulated inflammatory responses in vascular cells are well 
documented [see (Marx et al., 2004; Pascual and Glass, 2006; Ricote and Glass, 2007)
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for reviews]. In particular, numerous studies have shown that the ligand-activated 
PPARy represses the IFN-y-induced expression of a large range of inflammatory 
response genes, such as chemokines (e.g. IP-10) and inflammatory mediator 
molecules (e.g. COX2) (see Table 1.7 for a list of IFN-y-induced inflammatory 
response genes repressed by PPARs). Consistent with these findings, Figure 5.6 shows 
that pre-treatment of THP-1 macrophages with BRL49653 inhibited the 
IFN-y-induced expression of MCP-1, IP-10, CIITA pill and SOCS-1. It should be 
noted that both simvastatin and BRL49653 repressed the expression of MCP-1 and 
SOCS-1 in response to IFN-y (Figure 5.2 and 5.6). Interestingly, the 
anti-inflammatory properties of statins have been previously shown to be mediated, at 
least in part, by activation of PPARy, through a mechanism involving the generating 
of endogenous PPAR ligands (e.g. 15d-PGJ2) (Yano et al., 2007). It is thus tempting 
to speculate that the repressive effect of simvastatin on the IFN-y-induced expression 
of MCP-1 and SOCS-1 is probably mediated by the action of PPARy, although more 
detailed studies will be required to confirm this. Park et al. (2003) previously 
demonstrated that BRL49653 inhibited the IFN-y-induced expression of MCP-1 and 
IP-10 by inducing the transcription of SOCS-1, and thus activating the 
SOCS-dependent negative regulation of IFN-y signalling in mouse astrocytes. This is 
unlikely to be the case in THP-1 macrophages as the expression of SOCS-1 is 
inhibited by BRL49653, thereby suggesting an alternative mechanism underlying the 
repressive action of this agent.
A number of studies have previously shown that the PPARy agonist, 15d-PGJ2, exerts 
its transrepression activity on the IFN-y-mediated inflammatory gene expression by 
inhibiting STAT1 phosphorylation in mouse macrophage, mesangial cells and 
insulinoma cells (Chen et al., 2003; Weber et al., 2004; Panzer et al., 2008). We 
however found that in THP-1 and human primary monocyte-derived macrophages, 
both 15d-PGJ2 and BRL49653 have no effect on the IFN-y-induced STAT1 
phosphorylaiton at either Ser727 or Tyr701 (Figures 5.7 and 5.8). Therefore, the 
PPARy agonits probably exert their anti-inflammatory effects through a cell type- and
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potentially species-specific-mechanisms.
Table 5.2 Sum m ary of the repressive effects of therapeutic agents on the 
IFN-y-induced gene expression
MCP-1 IP-10 MIP-ip ICAM-1
CIITA
pill
CIITA
pIV
SOCS-1 ICER
Lovastatin - - / - / / - -
Simvastatin 4 / - 1 - 4 4 ->
BRL49653 4 1 / - 4 - 4 -
GYV7647 1 1 / -> I 1 4 4
TO901317 1 - / - - 4 -> -
•, no effect; [ ,  inhibition; /, not investigated
Abbreviations: MCP; monocyte chemoattractant protein; IP; interferon-gamma-induced 
protein; MIP; macrophage inflammatory protein; ICAM, intercellular adhesion molecule; 
CIITA; MHC class II activator; SOCS, suppressors o f cytokine signaling; ICER; inducible 
cAMP early repressor
Although PPARy agonists seem not to target STAT1 phosphorylation, both BRL49653 
and 15d-PGJ2 attenuated the IFN-y-induced activation of STAT1 response elements 
(3xly6e construct) and MCP-1 gene promoter (MCP[213]Luc) (Figure 5.9). As 
summarised in Table 5.2, the IFN-y-inducible expression of MCP-1, IP-10 and 
SOCS-1 was also inhibited by addition o f BRL49653. In addition, the expression of 
all these genes in response to IFN-y has been previously shown to be mediated, at 
least in part, through a STAT1-dependent pathway. Taken together, these results 
suggest that BRL49653 attenuates the IFN-y-induced expression of MCP-1, IP-10 and 
SOCS-1 by targeting STAT1 transcriptional activity without affecting STAT1 
phosphorylation.
5.7.3 Effects of PPARa agonists on IFN-y signalling
Figure 5.10 shows that the PPARa agonist GW7649 inhibited the IFN-y-induced
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expression of all the genes analysed except ICAM-1 (Table 5.2). Such a repressive 
activity of PPARa agonist on pro-inflammatory cytokine-induced gene expression in 
macrophages is consistent with some previous studies (Shu et al., 2000; Souissi et al., 
2008). In addition, statins have been suggested to exert their pleiotropic effects, at 
least in part, through a PPARa-dependent pathway (Paumelle et al., 2006). It is worth 
noting that both simvastatin and GW7647 attenuated the IFN-y-induced expression of 
MCP-1, IP-10, SOCS-1 and CIITA pIV, thereby suggesting that simvastatin might 
also inhibit the expression of these genes via the repressive activity of PPARa.
Similar to what was observed for the PPARy agonist BRL49653, the IFN-y-induced 
STAT1 phosphorylation was not affected by GW7647 (Figure 5.11). These data 
suggest that GW7647 exerts its transrepression activity through mechanisms different 
from modulation of STAT1 phosphorylation. In contrast to our findings in THP-1 
macrophages, Jee et al (2005) showed that PPARa agonists inhibit the LPS-induced 
STAT1 phosphorylation and transactivation in rat brain glial cells. PPARa agonists 
thus probably exert their transrepression activity through mechanisms depending on 
the stimuli and the cell type.
5.7.4 Effects of LXR agonists on IFN-y signalling
As shown in Figure 5.12 and Table 5.2, the synthetic LXR agonist TO901317 
significantly attenuated the IFN-y-induced expression of MCP-1 and CIITA pIV. Such 
slight but reproducible effects confirm the anti-inflammatory and immunomodulatory 
actions of LXR agonists as previously suggested by numerous studies [see (Pascual 
and Glass, 2006; Rizzo and Fiorucci, 2006; Bensinger and Tontonoz, 2008) for 
reviews]. Although the expression of these three genes in response to IFN-y is known 
to be mediated by STAT1-dependent signalling, the IFN-y-induced phosphorylation of 
this transcription factor was not affected by TO901317 (Figure 5.13), thereby 
suggesting the existence of a mechanism independent of STAT1 phosphorylation. 
Previous studies have proposed several mechanisms by which TO901317
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transrepresses pro-inflammatory stimuli-induced gene expression, such as targeting of 
the NFkB and AP-1-dependent pathways (Castrillo et al., 2003; Ogawa et al., 2005; 
Piraino et al., 2006; Zhang-Gandhi and Drew, 2007). However, to our knowledge, 
there have been no published reports showing that the agonist represses inflammatory 
gene expression by targeting STAT1 activity.
In contrast to TO901317, the endogenous LXR ligand, 22R, and the RXR ligand, 
9cRA, attenuated the IFN-y-induced STAT1 phosphorylation in THP-1 macrophages 
individually or in combination (Figures 5.13B and 5.14). LXRs are known to form 
heterodimers with RXRs in order to bind to LXRE in the promoter of target genes to 
activate transcription (Aranda and Pascual, 2001). In addition, the heterodimer can be 
activated by ligands for both LXRs and RXRs, either separately or in synergy (Aranda 
and Pascual, 2001). Consistent with this, Figure 5.13B shows that 22R together with 
9cRA inhibited the IFN-y-induced STAT1 phosphorylation to a greater extent than the 
inhibitory effect of individual agonist. In addition to STAT1 phosphorylation, 22R and 
9cRA inhibited the activation of STAT1 response elements and MCP-1 gene promoter 
in response to IFN-y (Figure 5.16). To our knowledge, this is the first time that a 
ligand-dependent activation of LXR has been shown to repress the IFN-y-induced 
gene expression by inhibiting STAT1 phosphorylation and transactivation.
In contrast to its essential role in the LXR-mediated activation of gene transcription, 
LXREs have not been identified in the proximal promoters of LXR-repressed 
inflammatory genes (Castrillo et al., 2003; Ogawa et al., 2005; Terasaka et al., 2005; 
Zelcer and Tontonoz, 2006). Moreover, as discussed in the General Introduction 
(section 1.8.2), ligand-dependent activation of LXRs is thought to suppress 
inflammatory gene expression by transrepression (Pascual and Glass, 2006). In 
contrast to transcriptional activation, which involves the binding of LXRs to specific 
LXREs in the promoter or enhancer regions of target genes, transrepression operates 
through a mechanism independent of LXRE binding. It remains unclear whether the 
repression of gene expression by LXR requires heterodimerisation with RXR (Glass
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and Ogawa, 2006). Therefore, although 9cRA has been clearly shown to inhibit the 
IFN-y-induced STAT1 phosphorylation individually or in combination with 22R, the 
exact role of RXR in the 22R/9cRA-mediated inhibition of the IFN-y-induced STAT1 
phosphorylation and transactivation remains poorly understood. LXR/RXR, 
PPAR/RXR and Famesoid X receptor (FXR)/RXR are known as ‘permissive 
heterodimer’, as demonstrated by the finding that an RXR ligand, such as 9cRA 
stimulates the transcriptional activity of the heterodimers. In addition to PPARs and 
LXRs, FXRs are also recently emerging as anti-inflammatory NRs (Li et al., 2007; 
Wagner et al., 2008; Zhang et al., 2009). Therefore, in addition to its potential action 
on LXR/RXR, the 9cRA-mediated repression of IFN-y-induced STAT1 
phosphorylation could also be because of its action on FXR/RXR and PPAR/RXR. It 
should however be noted that such potential effect of 9cRA on other NR does not 
contradict a specific effect of LXRs on IFN-y responses because the LXR-dependent 
effects have been further confirmed using the synthetic ligand TO901317 (Figures 
5.12 and 6.12) and LXR expression plasmids (Figure 6.17A) (see Chapter 6 for 
details).
It is becoming increasingly clear that non-genomic actions by NR ligands are an 
important aspect in their regulation of gene expression. Non-genomic actions of NR 
ligands are the actions that do not initially have a direct effect on gene transcription, 
but rather often involve the rapid generation of intracellular second messengers 
through the activation of various signal transduction cascades. Some of the 
non-genomic actions of steroids are mediated by classical NRs, while the others are 
thought to be mediated by novel, non-classical membrane receptors, the biological 
properties of which remain to be thoroughly investigated [see (Losel and Wehling, 
2003; Wehling and Losel, 2006) for reviews]. Work in our laboratory has recently 
suggested such non-genomic actions for 22R and 9cRA in THP-1 macrophages by 
demonstrating that these ligands together regulate ABCA1 and apoE expression in 
THP-1 macrophages through pathways involving Akt, PKC and JNK/SAPK (Huwait,
2008). Results presented in the previous chapter have demonstrated important roles
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for MAPK (i.e. ERK and JNK) and PKC in the IFN-y-regulated gene expression. 
Interestingly, Yao et al. (2006) have recently shown that ERK and p38 MAPK 
negatively regulate the IFN-y-induced expression of the CIITA gene in macrophages. 
It is thus of interest to find out whether these LXR/RXR ligands negatively regulate 
the IFN-y-induced gene expression in macrophages through non-genomic actions by 
activation of signal transduction cascades, such as ERK.
5.7.5 Effects of therapeutic agents on the IFN-y-induced adhesion of 
monocytes to endothelial cells
PPAR and LXR ligands are known to exert their athero-protective roles largely 
through inhibition of the recruitment of leukocytes to the site of inflammation (Straus 
and Glass, 2007; Nomiyama and Bruemmer, 2008). Suppressive effects of PPAR 
ligands in adhesion of monocytes to endothelial cells, and the subsequent 
transmigration have been documented (Marx et al., 1999; Ahmed et al., 2006; Barish 
et al., 2008). Consistent with these previous findings, pre-treatment of HUVEC with 
the endogenous PPARy ligand 15d-PGJ2 and the endogenous LXR/RXR ligands 22R 
and 9cRA attenuated the IFN-y-induced adhesion of U937 monocytes to monolayers 
of HUVEC. In contrast to 15d-PGJ2, a synthetic PPARy agonist BRL49653 did not 
inhibit, but instead induced such adhesion (Figure 5.17). This finding is consistent 
with a previous study (Rival et al., 2002), which demonstrated that BRL49653 
increases the adhesion of U937 to the endothelial EA.Hy926 cell line, while another 
PPAR y agonists 15d-PGJ2 decreased it. A similar phenomenon has been also 
observed with PPARa ligands. Fenofibrate has been shown to inhibit the adhesion of 
U937 to endothelial EA.Hy926 cells while another PPARa activator fenofibric acid 
induces it (Rival et al., 2002). These results suggest that distinct type of PPAR ligands 
might have different effect on cellular responses. However, the exact underlying 
reasons for such opposite effects of 15d-PGJ2 and BRL49653 in leukocyte adhesion 
to endothelial cells remain unclear at present.
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It is worth noting that as the addition of 15d-PGJ2 or 22R together with 9cRA resulted 
in a low viability of HUVEC (Figure 5.17), we cannot rule out the possibility that the 
reduced adhesion may be due to decreased viability of HUVEC. Interestingly, 
although pre-treatment of HUVEC with BRL49653 resulted in viability that was 
comparable to the other ligands, the adhesion was increased. It is therefore difficult to 
come to any firm conclusions on whether the inhibition of adhesion was due to 
specific action of 15d-PGJ2 and 22R/9cRA or because of reduced HUVEC viability. 
As suggested in Chapter 4 (section 4.3.9), the low viability of HUVECs is probably 
due to the prolonged period of incubation (32h). Alternative approaches will therefore 
be required in the future for such studies. For example, Marx et al. (1999) have 
demonstrated that the TNF-a-induced adhesion of U937 monocytes to human 
saphenous vein endothelial cells (HSVEC) was inhibited by the PPARa agonist 
fenofibrate without an effect on viability and protein synthesis of these cells despite 
the incubation period of over 32h. Therefore, the use of HSVEC instead of HUVEC 
provides one potential approach.
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Chapter 6: Investigation of mechanisms underlying the 
inhibitory effects of therapeutic agents on IFN-y signalling 
6.1 Introduction
Work presented in Chapter 5 has shown that PPAR and LXR ligands exert 
significant inhibitory effects on the IFN-y-induced expression of several genes in 
human macrophages, at least in part, by inhibition of STATI -dependent 
transcriptional activation. As discussed in the General Introduction (section 1.8), 
although previous studies have proposed a number of trans-repression models for 
the actions of PPAR and LXR ligands, such as competition for a limiting amount of 
co-activators or prolonged recruitment of co-repressors, the exact mechanisms 
underlying the NR-dependent repression remain largely unclear, particularly in 
relation to IFN-y actions and the JAK-STAT pathway.
6.1.1 Nucleo-cytoplasmic translocation of STAT1
ST AT proteins are latent transcription factors that mainly reside in the cytoplasm 
before activation. Although immunofluorescence microscopy shows a 
predominantly cytoplasmic localisation of most STATs in resting cells, it is well 
recognised that inactive STATs are constantly shuttling between the nucleus and the 
cytosol via a carrier-independent mechanism. In addition to this, the export receptor 
CRM 1-dependent export also operates constitutively (Andrews et al., 2002; Zeng et 
al., 2002), although it only plays a minor role in the overall flux rate of STATs 
(Marg et al., 2004). Carrier-dependent nuclear import has so far not been reported 
for the inactive STAT1 protein (Figure 6.1 A).
As detailed in the General Introduction (section 1.6), the binding of IFN-y to its 
cognate receptors leads to the activation of JAK1 and JAK2, and the tyrosine 
phosphorylation of STAT1 (Tyr701). This process, commonly termed STAT1
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activation triggers the dimerisation of STAT1 and, subsequently, fast and efficient 
translocation into the nucleus, where they bind to STAT1 response elements (e.g. 
GAS) and activate transcription of IFN-y-inducible genes [see (Darnell, 1997; Stark 
et al., 1998) for reviews]. Dimerisation has been shown to reduce the carrier-free 
nuclear import of activated STAT1, and switch to carrier-dependent translocation 
(Sekimoto et al., 1997; Marg et al., 2004). STATs contain nuclear localisation 
signals (NLSs), which interact with importin a5. This then binds to importin p which 
docks the ST AT complex to nuclear pores and initiate its translocation into the 
nucleus. Only STAT dimers that have two intact NLS elements, one from each 
monomer, are able to bind to importin a5 (Sekimoto et al., 1996; Sekimoto et al., 
1997; Fagerlund et al., 2002). Nuclear import and retention are two separate steps 
leading up to nuclear accumulation, with non-specific DNA binding of activated 
STAT1 being sufficient for nuclear retention. Critical for nuclear accumulation of 
STAT1 and the subsequent nuclear export is the point of STAT1 tyrosine 
dephosphorylation, as activated STAT1 is incapable of leaving the nucleus (Meyer 
et al., 2003). It has been demonstrated that DNA binding protects STAT1 from 
dephosphorylation in a DNA sequence-specific manner (Meyer et al., 2003), and 
hence reveals a critical role for non-specific DNA binding in the nuclear retention of 
STAT1 (Vinkemeier, 2004) (Figure 6.1B).
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A. Resting Cells
Cytosol
Nucleus
B. IFN-y-stimulated Cells
Cytosol
Nucleus
Figure 6.1 Schematic representation of STAT1 nucleo-cytoplasmic cycling in 
resting cells (A) and during IFN-y stimulation (B) [Taken from (Meyer et al., 
2003; Vinkemeier, 2004)]
Carrier-independent cycling is depicted with blue arrows and carrier-dependent 
translocation with yellow arrows. The red bar represents the export block of 
phosphorylated ST AT I dimers. Phosphorylation and dimerisation are indicated (+P). 
The reverse reaction (dephosphorylation) is indicated (-P). Arrow widths are 
proportional to their corresponding flux rate.
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6.1.2 Co-activator competition transrepression model for activated NRs
NRs, such as PPARs and LXRs, and many of the transcription factors that drive 
inflammatory responses require an overlapping set of co-activator proteins 
(Huuskonen et al., 2004; Ricote and Glass, 2007). Previous studies have identified a 
large number of such co-regulators, including the pi 60 family proteins (such as 
steroid receptor co-activator-1 (SRC-1)) and the CBP/p300 (Lee et al., 2000; 
Huuskonen et al., 2004). Upon ligand binding, the activation function (AF)-2 
subdomain of NRs undergo a conformation change, which allows the direct 
interaction with the p i60 family co-activators (e.g. SRC-1). These co-activators can 
also interact with CBP/p300 proteins via a separate domain. Additionally, direct 
interaction between CBP/p300 with NRs has also been reported, which may enhance 
complex formation (Aranda and Pascual, 2001). Furthermore, SRC-1 has been 
reported to recruit additional co-factors, such as CARM1 and p300/CBP-associated 
factors (PCAF), to target gene promoters. Once these complexes have been 
assembled, the histone acetylase activities of CBP/p300 and PCAF, and the histone 
methyltransferase activity of co-activator-associated arginin methyltransferase-1 
(CARM1) serve to remodel the chromatin architecture at target gene promoters, thus 
promoting transcriptional activation (Darimont et al., 1998; Leo and Chen, 2000). 
SRC-1 proteins have also been shown to be involved in transactivation by several 
transcription factors, including AP-1, NFkB, serum response factor (SRF) and p53 
(Lee et al., 2001). CBP and p300 are evolutionary conserved proteins that serve as 
co-activators for different types of transcription factors, including AP-1, MyoD, 
NFkB, Pit-1 and STATs by potentiating their transcriptional activity (Shikama et al., 
1998).
Several studies have shown that competition for a limiting amount of co-activators, 
such as SRC-1 and CBP/p300 in cells could, at least in part, be responsible for the 
antagonistic actions of NR ligands on activities of transcription factors. For example,
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Li et al. (2000b) have shown a strong correlation between PPARy interaction with 
co-activators and the repression of the iNOS promoter in response to ligand binding. 
This is the so called co-activator competition transrepression model for NRs 
(Pascual and Glass, 2006). As discussed in the General Introduction (section 1.8), 
PPARs and LXRs have been shown to repress IFN-y responses by antagonising the 
actions of various signalling cascades, such as NFkB-, JAK/STAT1- and AP-1- 
dependent pathways. Noteworthily, Giri et al. (2004) have shown that the PPARy 
agonist, 15d-PGJ2, inhibits the IFN-y and LPS-induced NFicB-dependent pathway 
by reducing the recruitment of p300 to the promoter of target genes. It is thus of 
great interest to know whether the co-activator competition model is also used for 
the inhibitory actions of PPARs and LXRs on IFN-y-stimulated gene transcription, 
especially through the classical JAK-STAT pathway.
6.1.3 Experimental strategy
Work in this chapter was carried out with the aim of investigating the potential 
mechanisms by which statins and PPAR and LXR ligands inhibit the IFN-y- 
stimulated signalling pathways as detailed in the previous chapter. Simvastatin, 
PPARy agonists (BRL49653 and 15d-PGJ2), PPARa agonists GW7647, synthetic 
LXR agonist TO901317 and the endogenous LXR/RXR ligands 22R and 9cRA 
were selected for further studies because they were previously shown to mediate the 
inhibition of IFN-y-induced gene expression and cellular responses in human 
macrophages (Figures 5.2-7). Previous work presented in Chapter 5 has suggested 
that simvastatin, PPAR-a and -y agonists and TO901317 exert their repressive 
activities on the IFN-y-induced gene expression, at least in part, by inhibiting 
ST ATI transactivation but without affecting ST ATI phosphorylation (section 5.7). 
We therefore decided to investigate the potential mechanisms underlying such 
repressive activities with emphasis on STAT1-dependent pathways. First, we 
decided to investigate the effects of these therapeutic agents on nucleo-cytoplasmic
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shuttling of activated STAT1 in response to IFN-y. This was achieved by analysing 
the amounts of phospho-Tyr701 STAT1 in nuclear and cytoplasmic fractions using 
western blot analysis. In addition, the effect o f these therapeutic agents on the IFN- 
y-induced binding of STATI to GAS elements in the MCP-1 promoter was 
investigated using EMSA analysis.
In order to investigate whether PPAR and LXR ligands repress the IFN-y-induced 
ST ATI transcriptional activity by competing for limiting amounts of the co­
activators p300 and SRC-1 in cells, we first decided to carry out co-transfection 
assays using the plasmid containing luciferase reporter gene driven by STAT1 
response elements (3xly6e) and expression plasmids for p300 and SRC-1. 
Furthermore, the hypothesis that repression can be caused by competition among 
different transcription factors for limiting amounts of essential co-activators predicts 
that mutations affecting co-activator binding and/or transactivation should also 
affect repression (Li et al., 2000b). To test this hypothesis, we examined the effects 
of deletions in the AF-2 subdomain of LXR on the ligand-dependent repression of 
IFN-y-mediated activation of STAT1 response elements and MCP-1 promoter by 
transient transfection assays. DNLXR-a, which contains the full length sequence of 
LXR-a lacking the AF-2 subdomain, was therefore employed in this study (Kocarek 
et al., 2002). AF-2 is known to be required for the recruitment of co-activators to 
NRs and serve as an adapter surface for interactions with other molecules necessary 
for transcriptional activation ((Barettino et al., 1994; Bourguet et al., 2000). Point 
mutations in the AF-2 domain has been shown to abolish transcriptional activation 
(Svensson et al., 2003).
Finally, as shown in the previous chapter (Figures 5.14-17), the LXR ligand, 22R 
and the RXR ligand, 9cRA, repress the IFN-y-induced STAT1 phosphorylation and 
transactivation. In order to further investigate the roles of LXR-a and -(3 isoforms in 
the 22R and 9cRA-mediated repression, co-transfection assays were employed again
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using the 3xly6e plasmid and expression vectors for LXR isoforms. Figure 6.2 
summaries the overall experimental approach.
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Figure 6.2 Experimental Strategy
The aim of the experimental strategy was to investigate the potential mechanisms 
underlying the therapeutic agents (statins, agonists of PPAR-a and -y and 
LXRs)-mediated inhibition of IFN-y signalling pathways. This was achieved by 
analysis of the effects of these agents on the IFN-y-induced nuclear accumulation of 
phospho-STATl Tyr701 and STAT1 binding to MCPGAS elements. In addition, for 
analysis of whether agonists for PPARs and LXRs repress IFN-y signalling by 
competition with transcription factors for limiting amounts o f co-activators, transient 
transfection assays were performed using expression plasmids for p300 and SRC-1 and 
a DN plasmid for LXR-a lacking the AF-2 subdomain (DNLXR-a). Dependence of 
LXR agonists-mediated inhibition on LXR isoforms was also investigated by transient 
transfection assays using expression plasmids for LXR-a and -p.
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6.2 Investigation into the effects of therapeutic agents on 
the IFN-Y-induced nuclear and cytoplasmic amounts of 
activated STAT1
6.2.1 Nuclear and cytoplasmic amounts of activated STAT1
The effect of IFN-y on the nuclear and cytoplasmic amounts of activated ST ATI 
was analysed over a 3h time course by western blot analysis. Such an approach has 
been used previously by other research group to analyse the nuclear accumulation of 
STAT1 (Haspel et al., 1996; Meyer et al., 2002). PMA-differentiated THP-1 
macrophages were incubated with IFN-y (lOOOU/ml) for periods of 30min and 3h or 
left untreated. Nuclear and cytoplasmic fractions were subsequently prepared using 
the nuclear extract kit (Active Motif, Rixensart, Belgium) according to the 
manufacturer’s instructions (section 2.6.4). Western blot analysis was carried out on 
both nuclear and cytoplasmic extracts using antibodies against phopho-STATl 
Tyr701, total STAT1 (p84/91), nucleolin and P-actin. Nucleolin and P-actin are 
primarily presented in the nucleus and cytoplasm respectively, and have frequently 
been used as constitutive controls for nuclear and cytoplasmic fractions (McHugh et 
al., 1991; Morimoto et al., 2002; Akiyama et al., 2003; Padilla et al., 2004). We thus 
monitored the expression of nucleolin and p-actin by western blot analysis to ensure 
the integrity of nuclear and cytoplasmic fractions. Densitometric analysis of the data 
was carried out and presented as mean fold induction (±SD) relative to nuclear 
sample at Omin (arbitrarily assigned as 1). Student’s t test was carried out on the 
samples treated with IFN-y for 30 and 180min versus the untreated control sample 
for nuclear and cytoplasmic fractions respectively.
Figure 6.3 shows that the nuclear amount of phopho-STATl Tyr701 was at almost 
undetectable levels in the Omin control cells, and increased dramatically following 
incubation with IFN-y to reach the highest level at 3 Omin and declined at 180min. A 
similar induction was also observed in the cytoplasmic amount of phospho-STATl 
Tyr701. In contrast, the nuclear and cytoplasmic amounts of total ST ATI remained
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unchanged throughout the time-course. The induction of phospho-STATl Tyr701 
and the unchanged amount of total STATI p84/91 was consistent with previous 
findings using whole cell extracts (Figure 3.11). These results suggest that IFN-y 
rapidly induces the amount of phospho-STATl Tyr701 in the nucleus and the 
cytosol. It is worth noting that the expression of nucleolin and p-actin was 
predominantly detected in the nuclear and cytoplasmic fractions respectively, 
thereby demonstrating the intergity of nuclear and cytoplasmic fractions.
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Figure 6.3 Effect o f IFN-y on nuclear and cytoplasmic amounts of STAT1 over 
time
PMA-differentiated THP-1 cells were treated with IFN-y for the indicated period of 
time and nuclear (N), and cytoplasmic (C) extracts were prepared (section 2.6.4). 
Western blot analysis was carried out using antibodies specific for pSTATl Tyr701, 
STAT1 p84/91, nucleolin and p-actin (A). Panel B shows the fold induction (mean 
±SD) of the levels o f phospho-STATl Tyr701 and STAT1 p84/91 proteins relative 
to the Oh control (assigned as 1) from three independent experimental series. 
Student’s t test was carried out on samples treated with IFN-y for 30 and 180min 
versus Oh control sample for nuclear and cytoplasmic fractions, respectively (nuclear 
fraction: ***P<0.001, N/S not significant; cytoplasmic fraction: M#P<0.001; n/s 
not significant).
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6.2.2 Effect o f  simvastatin on the IFN-y-induced nuclear and 
cytoplasmic amounts o f  activated ST A TI
In the previous chapter, simvastatin was shown to inhibit the IFN-y-induced gene 
expression through modulation of STAT1 transactivation without affecting the 
phosphorylation of the protein (Figures 5.2 and 5.5-6). We thus decided to 
investigate the effect of simvastatin on the IFN-y-induced nuclear and cytoplasmic 
amounts of phospho-STATl Tyr701.
PMA-differentiated THP-1 macrophages were pre-treated for lh  with simvastatin at 
10pM, prior to further incubation with IFN-y (lOOOU/ml) for 3 Omin. The volume of 
DMSO added to the cells as a vehicle control was the same as that for simvasatatin 
in order to rule out the possibility of the effect of DMSO on nuclear translocation of 
STAT1. Nuclear and cytoplasmic fractions were prepared and western blot analysis 
was carried out as described before (section 6.2.1). Only the expression of phospho- 
STATl Tyr701 was monitored because it is the form that can be actively imported 
into the nucleus. Densitometric analysis of the data was carried out and presented in 
Figure 6.4. Results are presented as IFN-y-induced nuclear and cytoplasmic amounts 
of phospho-STATl Tyr701 in the presence of simvastatin (±SD) in relation to the 
nuclear and cytoplasmic amounts of phospho-STATl in response to this cytokine 
respectively. The value from DMSO-treated sample stimulated with IFN-y was 
arbitrarily assigned as 1. Student’s t test was carried out on the simvastatin and 
cytokine-treated sample versus IFN-y-induced level of phospho-STATl in nucleus 
and cytoplasm respectively.
Figure 6.4 clearly shows that pre-treatment of the cells with simvastatin had no 
effect on either the nuclear or cytoplasmic amounts of phospho-STATl Tyr701 in 
the presence of IFN-y.
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Figure 6.4 Effect of simvastatin on the amount of phospho-STATl in nucleus and cytoplasm
PMA-differentiated THP-1 cells were pre-treated for lh with simvastatin (lOpM) prior to further treatment with IFN-y for 30min. DMSO (DM) 
was used as a vehicle control. Nuclear (N) and cytoplasmic (C) extracts were prepared using Nuclear Extract Kit (section 2.6.4). Western blot 
analysis was carried out using antibodies specific for pSTATl Tyr701, nucleolin and P-actin (A). Panel B shows the relative expression (mean 
±SD) of phospho-STATl Tyr701 in both nuclear and cytoplasmic extracts from three independent experimental series (the value from nuclear 
extracts for IFN-y-treated DMSO control has been arbitrarily assigned as 1). Student’s t test was carried out on nuclear and cytoplasmic 
fractions of samples treated with simvastatin versus nuclear and cytoplasmic fractions respectively of IFN-y-stimulated DMSO control sample 
(nuclear fraction: N/S not significant; cytoplasmic fraction: n/s not significant).
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6.2.3 Effect of PPARy agonists on the IFN-y-induced nuclear and 
cytoplasmic amounts of activated ST ATI
PPARy agonists have been shown to attenuate the IFN-y-induced gene expression 
by suppressing STAT1 transactivation without targeting phosphorylation. We thus 
investigated the effect of PPARy agonists (15d-PGJ2 and BRL49653) on nuclear 
and cytoplasmic amounts of phospho-STATl Tyr701.
The experiments were carried out exactly as described before (section 6.2.2) except 
that the cells were pre-treated for 2h with 15d-PGJ2 (lOpM) and BRL49653 (20pM) 
instead of simvastatin for lh. Densitometric and statistical analysis of the data was 
carried out as detailed before (section 6.2.2) and presented in Figure 6.5. The results 
show that neither BRL49653 nor 15d-PGJ2 affected the IFN-y-induced nuclear or 
cytoplasmic amounts of phospho-STATl Tyr701.
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Figure 6.5 Effect of PPARy agonist on the IFN-y-induced amount of phospho-STATl in the nucleus and the cytoplasm
PMA-differentiated THP-1 cells were pre-treated for 2h with BRL49653 (BRL, 2 0 j l a M )  or 15d-PGJ2 (15d, lOpM) prior to further treatment with 
IFN-y for 3Omin. DMSO (DM) was used as a vehicle control. Nuclear (N) and cytoplasmic (C) extracts were prepared using the Nuclear Extract 
Kit (section 2.6.4). Western blot analysis was carried out using antibodies specific for pSTATl Tyr701, nucleolin and P-actin (A). Panel B 
shows the relative expression (mean ±SD) of phospho-STATl Tyr701 in both nuclear and cytoplasmic extracts from three independent 
experimental series (the value from nuclear extract of IFN-y-treated DMSO control has been arbitrarily assigned as 1). Student’s t test was 
carried out on nuclear and cytoplasmic extract samples treated with PPAR-y agonist versus IFN-y-stimulated DMSO control sample (nuclear 
fraction: N/S not significant; cytoplasmic fraction: n/s not significant).
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6.2.4 Effect of PPARa agonist on the IFN-y-induced nuclear and 
cytoplasmic amounts of activated STAT1
In the previous chapter, the PPARa agonist GW7647 was shown to inhibit the IFN- 
y-induced gene expression but not the phosphorylation of STAT1 (Figures 5.11-12). 
We thus investigated the effect of GW7647 on the IFN-y-induced level of phospho- 
STATl Tyr701 in the nucleus and the cytoplasm.
The experiments and data analyses were carried out exactly as described before 
(section 6.2.3) except that the cells were treated for 2h with GW7657 (5pM) instead 
of PPARy agonists. Figure 6.6 shows that GW7647 failed to affect the amounts of 
phospho-STATl Tyr701 in the nucleus or the cytoplasm in response to IFN-y.
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Figure 6.6 Effect of PPARa agonists on the IFN-y-induced amount of phospho-STATl in the nucleus and the cytoplasm
PMA-differentiated THP-1 cells were pre-treated for 2h with GW7647 (5pM) prior to further treatment with IFN-y for 30min. DMSO (DM) was 
used as a vehicle control. Nuclear (N) and cytoplasmic (C) extracts were prepared (section 2.6.4) and western blot analysis was carried out using 
antibodies specific for pSTATl Tyr701, nucleolin and p-actin (A). Panel B shows the relative expression (mean ±SD) of phospho-STATl 
Tyr701 in both nuclear and cytoplasmic extracts from three independent experimental series (the value from nuclear extract of IFN-y-treated 
DMSO control has been arbitrarily assigned as 1). Student’s t test was carried out on nuclear and cytoplasmic extract samples treated with 
GW7647 versus IFN-y-stimulated DMSO control sample (nuclear fraction: N/S not significant; cytoplasmic fraction: n/s not significant).
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Figure 6.7 Effect of LXR agonists on the IFN-y-induced amount of phospho-STATl in nucleus and cytoplasm
PMA-differentiated THP-1 cells were pre-treated for 2h with TO901317 (TO, 10pM) (A), or for 24h with the endogenous LXR ligands 
(LXR) 22R (2|ig/ml) and 9cRA (IOjjM ) prior to further treatment with IFN-y for 30min. DMSO (DM) was used as a vehicle control. 
Nuclear (N) and cytoplasmic (C) extracts were prepared (section 2.6.4). Western blot analysis was carried out using antibodies specific 
for pSTATl Tyr701, nucleolin and P-actin (A). Panel B shows the relative expression (mean ±SD) of phospho-STATl at Tyr701 in both 
nuclear and cytoplasmic extracts from three independent experimental series (the value from nuclear extract o f IFN-y-treated DMSO 
control has been arbitrarily assigned as 1). Student’s / test was carried out on nuclear and cytoplasmic extract samples treated with LXR 
agonists versus IFN-y-stimulated DMSO control sample (nuclear fraction: **P<0.001; cytoplasmic fraction: n/s, not significant).
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6.3 Investigation into the effects of therapeutic agents on 
the IFN-Y-induced protein binding to MCP-1 promoter
6.3.1 IFN-y induced protein binding to the GAS element on the MCP-1 
promoter
The effect of IFN-y on the binding of protein to the GAS element on the MCP-1 
gene promoter was investigated over a 3h time course using EMSA. PMA- 
differentiated THP-1 macrophages were incubated with IFN-y for periods of 30 and 
180min or left untreated and nuclear fractions were prepared using the Nuclear 
Extract Kit (Active Motif, Belgium) according to the manufacturer’s instructions 
(section 2.6.4). The EMSA probes MCPGAS (Table 2.10), containing the GAS 
element of the human MCP-1 promoter, was radiolabelled and incubated in a protein 
binding reaction with nuclear protein extracts as described in section 2.7. The 
resulting DNA-protein complexes were resolved on a 4% non-denaturing 
polyacrylamide gel and visualised by exposure to X-ray film (section 2.7). A 
representative image from three independent experiments is shown in Figure 6.8. 
IFN-y treatment of THP-1 macrophages resulted in the formation of at least six 
DNA-protein complexes (C l-6). With the exception of C4, they were induced at 
varying extent following treatment o f cells with IFN-y for 30min and 3h. These 
results indicate that IFN-y rapidly induces the binding of proteins to the MCP-1 
GAS element in THP-1 macrophages.
The specificity of the DNA-protein interactions was next examined by competition- 
and antibody/supershift-EMSA (section 2.7.4). The nuclear extracts from IFN-y 
treated cells at 30min were employed for the analysis. For competition-EMSA, the 
extracts were pre-incubated with a 250-fold molar excess of unlabelled MCPGAS, 
ST ATI and NFkB consensus binding site probes (Table 2.10). Antibody supershift- 
EMSA analysis was carried out using a ST ATI specific antibody (Santa Cruz, CA). 
Pre-incubation with the non-immune serum (NIS) served as a control. Subsequent
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EMSA was carried out exactly as described previously. The representative image 
from three experiments is shown in Figure 6.8.
Protein binding of all complexes (C l-6) was competed out completely by an excess 
of the unlabelled MCPGAS probe and to a lesser extent by the unlabelled STAT1 
consensus probe, but not by a consensus sequence for NFkB (Table 2.10). The 
competition analysis suggests that the formation of all complexes (C l-6) is specific 
to MCPGAS element and STATI protein was necessary for the formation of these 
complexes. Moreover, pre-incubation of the extracts with the anti-STATl antibody 
resulted in the formation of a slower migrating antibody-protein-DNA supershift 
complex (denoted ssSTATl in Figure 6.8). Formation of complexes C l-2, but not 
C3-6 was inhibited in the presence of the anti-STATl antibody, thereby indicating 
that C l-2 were likely to represent STAT1-DNA complexes. Cl and C2 probably 
represent DNA binding by STAT1 splice variant-a (p91) and -p (p84) respectively. 
On the other hand, pre-incubation of the extracts with the NIS did not affect the 
formation of any complexes (C l-6), thereby suggesting that the formation of 
antibody-protein-DNA supershift complex (ssSTATl) is STATI specific. Together, 
these data suggest that STAT1, in nuclear protein extracts from IFN-y-treated THP-1 
macrophages, does specifically bind to the MCPGAS probe. As the binding of 
ST ATI (C l-2) to MCPGAS reached the highest level at 30min and declined at 
180min, the 30min time point was selected for future EMSA.
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Figure 6.8 IFN-y-induced formation of MCPGAS-protein complexes
PMA-differentiated THP-1 macrophages were treated with IFN-y for 0, 30 and 
180min and nuclear extracts were prepared. EMSA was carried out using the 
radiolabelled probe MCPGAS. The nuclear extracts prepared from the IFN-y-treated 
cells (3Omin) were employed for competition and supershift EMSA. Competition 
assays were carried out using a 25Ox molar excess o f unlabelled GAS, STAT1 and 
NFkB consensus sequences. Antibody supershift-EMSA was carried out using 
ST ATI specific antibody (Santa Cruz, CA). Pre-incubation with non-immune serum 
(NIS) served as a negative control. Results are representative of three independent 
experiments, ss denotes supershift; FP denotes free probes
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6.3.2 Effect of simvastatin on the IFN-y-induced STAT1 binding to 
MCPGAS
We next decided to investigate the effect of simvastatin on the IFN-y-induced 
STAT1 binding to MCPGAS. PMA-differentiated THP-1 macrophages were pre­
treated for lh  with simvastatin (lOpM) prior to incubation with IFN-y (lOOOU/ml) 
for 3Omin. The volume of DMSO added to the cells as a vehicle conrol were the 
same as that for simvastatin in order to rule out the possibility that the results are due 
to the presence of DMSO. Nuclear extracts were prepared and subsequently 
subjected to EMSA using MCPGAS probe as described before (section 6.3.1). A 
representative image from three independent experiments is shown in Figure 6.9A. 
Densitometric analysis was carried out by measuring the intensity of C l-2 in each 
sample and then presenting the sum value of these data in Panel B, normalised to the 
IFN-y-treated DMSO control. The results show that pre-treatment of the cells with 
simvastatin did not affect the binding of ST ATI to MCPGAS.
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Figure 6.9 Effect of simvastatin on the IFN-y-induced STAT1 binding to MCPGAS
PMA-differentiated THP-1 macrophages were pre-treated for lh  with simvastatin (10pM) or DMSO (DM) as a vehicle-control. They were then 
either stimulated with IFN-y for 3 Omin or left untreated. Nuclear extracts were prepared as before and used for EMSA using the radiolabelled 
MCPGAS consensus probe (A). The free probe has been run out of the gel. Densitometric analysis (determined by measuring the intensity of 
C l-2 in each sample and then calculating the sum value) is presented in Panel B, normalised to the IFN-y-treated DMSO control. The results 
shown in Panel B are the mean ratio ± SD from three independent experimental series (***P<0.001, compared to the DMSO-treated control, n/s 
compared to the IFN-y-treated DMSO control).
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6.3.3 Effect of PPARy agonists on the IFN-y-induced STAT1 binding to 
MCPGAS
BRL49653 and 15d-PGJ2 were used to investigate the effects of PPARy agonists on 
the IFN-y-induced binding of STAT1 to MCPGAS. The experiments and analysis of 
the data were carried out exactly as described in section 6.3.2 except that the cells 
were pre-treated for 2h with BRL49653 (20pM) or 15d-PGJ2 (lOpM) instead of 
simvastatin for lh. A representative image from three independent experiments is 
shown in Figure 6.10A. Densitometric and statistical analysis was carried out as 
described before and presented in Panel B. The results show that neither BRL49653 
or 15d-PGJ2 suppressed the IFN-y-mediated formation of STAT1 -MCPGAS 
complexes.
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Figure 6.10 Effect of PPARy agonists on the IFN-y-induced STAT1 binding to MCPGAS
PMA-differentiated THP-1 macrophages were pre-treated for 2h with the BRL49653 (BRL, 20pM), 15d-PGJ2 (15d, 10pM) or DMSO (DM) as 
a vehicle-control. They were then either stimulated with IFN-y for 3Omin or left untreated. Nuclear extracts were prepared as before and used for 
EMSA analysis using the radiolabelled MCPGAS consensus probe (A). The free probe has been run out of the gel. Densitometric analysis 
(determined by measuring the intensity of C l-2 in each sample and then calculating the sum value) of these data is presented in Panel B, 
normalised to the IFN-y-treated DMSO control. The results shown in Panel B are the mean ratio ± SD from three independent experimental 
series (***/,<0.001, compared to the DMSO-treated control; n/s compared to the IFN-y-treated DMSO control).
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6.3.4 Effect of PPARa agonists on the IFN-y-induced STAT1 binding 
to MCPGAS
GW7647 was used to investigate the effect of PPARa agonist on STAT1 binding to 
MCPGAS in response to IFN-y. Experiments and analysis of the data was carried 
out exactly as described in section 6.3.3 except that the cells were pre-treated for 2h 
with GW7647 (5pM) instead of PPARy agonists. Figure 6.11 A shows a 
representative image from three independent experiments. Densitometric and 
statistical analysis were carried out as described before and presented in Panel B. 
GW7647 was found not to affect the binding of STAT1 to MCPGAS in response to 
IFN-y.
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Figure 6.11 Effect of PPARa agonists on the IFN-y-induced STAT1 binding to MCPGAS
PMA-differentiated THP-1 macrophages were pre-treated for 2h with the GW7647 (GW, 5pM) or DMSO (DM) as a vehicle-control. They were 
then either stimulated with IFN-y for 3Omin or left untreated. Nuclear fractions were prepared as before and used for EMSA analysis using the 
radiolabelled MCPGAS probe (A). The free probe has been run out of the gel. Densitometric analysis (determined by measuring the intensity of 
C l-2 in each sample and then calculating the sum value) of these data is presented in Panel B, normalised to the IFN-y-treated DMSO control. 
The results shown in Panel B are the mean ratio ± SD from three independent experimental series (***P<0.001, compared to the DMSO-treated 
control, n/s compared to the IFN-y-treated DMSO control).
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6.3.5 Effect of LXR agonists on the IFN-y-induced STAT1 binding to 
MCPGAS
The synthetic LXR agonist TO901317 and the endogenous LXR/RXR ligands 22R 
and 9cRA were used to investigate the effect of LXR ligands on the IFN-y-induced 
STAT1 binding to MCPGAS. PMA-differentiated THP-1 macrophages were pre­
treated for 24h with combination of 22R (2pg/ml) and 9cRA (lOpM) or 2h with 
TO901317 (lOpM) prior to treatment with IFN-y for 30min. EMSA and analysis of 
the data was carried out exactly as described in section 6.3.4. Figure 6.12 shows 
representative images from three independent exprimental series (left panel). 
Densitometric and statistical analysis was carried out and presented in the right 
panel. The results show that both TO901317 and combination of 22R and 9cRA 
signficantly attenuated the binding of STAT1 to MCPGAS in response to IFN-y.
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Figure 6.12 Effect of LXR agonists on the IFN-Y-induced STAT1 binding to MCPGAS
PMA-differentiated THP-1 macrophages were pre-treated for 24h with 22R (2pg/ml) and 9cRA (10pM) (A), or for 2h with 
TO901317 (TO, 10pM) (B), with DMSO (DM) employed as a vehicle-control. The cells were then either stimulated with IFN-y for 
30min or left untreated. Nuclear extracts were prepared as before and used for EMSA using the radiolabelled MCPGAS probe. The 
images are representative of three independent experiments (left panel). The free probe has been run out of the gel. Densitometric 
analysis (determined by measuring the intensity of C l-2 in each sample and then calculating the sum value) of these data is presented 
in the right panel, normalised to the IFN-y-treated DMSO control. The results shown in the right panels are the mean ratio (± SD) 
from three independent experiments (***P<0.001, compared to the DMSO-treated control. #P<0.05 compared to the IFN-y-treated 
DMSO control).
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6.4 Investigation into whether the therapeutic agents 
mediate repression of IFN-y signalling by competition 
for a limiting amount of co-activators in cells
6.4.1 Investigation into whether PPARy agonists mediate the inhibition 
of the IFN-y-induced activation of 3xly6e by competition for a 
limiting amount of co-activators
In order to investigate whether PPARy agonists-mediated inhibition of IFN-y 
signalling occurs by competition with transcription factors for a limiting amount of 
co-activators in the cells, co-transfection assays were carried out using expression 
plasmids for the co-activators SRC-1 and p300. As described in the previous chapter 
(section 4.3.4), Hep3B cells were co-transfected with the GAS-regulated reporter 
plasmid, 3xly6e, and DNA constructs specifying for the constitutive expression of 
p300 or SRC-1 with the empty plasmid vector pcDNA3 used as a control. The cells 
were pre-treated for 2h with BRL49653 (20pM), 15d-PGJ2 (lOpM) or DMSO as 
vehicle control prior to treatment with IFN-y (lOOU/ml) for 6h. Cell extracts were 
subsequently prepared for luciferase reporter activity assays.
Figure 6.13 shows that the expression of p300 significantly enhanced the IFN-y- 
induced activation of 3xly6e, but did not affect the repressive effect mediated by 
either BRL49653 or 15d-PGJ2. These results suggest that the co-activator p300 is 
likely to be required for STAT1 transactivation mediated by the cytokine, but the 
PPARy agonists-dependent repression of the IFN-y-mediated STAT1 transactivation 
is independent of the amount of p300 in the cells.
Figure 6.14 shows that the expression of SRC-1 did not affect either the IFN-y- 
stimulated activity of ST ATI response elements or the suppressive effect mediated 
by PPARy agonists. These results thus suggest that in contrast to p300, SRC-1 is not 
involved in STAT1 transactivation in response to IFN-y and the PPARy agonists- 
mediated repression of the IFN-y-induced STAT1 transactivation is independent of 
the amount of SRC-1 in the cells.
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Figure 6.13 Effect of transfection of p300 expression plasmid on the PPARy agonists-mediated inhibition of IFN-y-stimulated activity of 
STAT1 responsive elements
Hep3B cells were co-transfected with 3xly6e and an expression plasmid for p300 or pcDNA3 as the empty vector control. Following 2h 
incubation with BRL49653 (BRL, 20pM), 15d-PGJ2 (15d, lOpM) or DMSO control (DM), transfected cells were treated with IFN-y for 6h after 
which cell extracts were prepared for luciferase reporter activity assays. Luciferase counts were normalised to protein concentration and 
presented as the mean relative activation (±SD) in response to IFN-y, in relation to unstimulated controls, from three experiments (each carried 
out in triplicate). The data was further normalised to the relative activation of IFN-y-treated cells transfected with pcDNA3 (arbitrarily assigned 
as 1). Student’s t test was carried out on samples transfected with the p300 plasmid versus IFN-y-stimulated pcDNA3 transfected samples 
(**P<0.01; *P<0.05; N/S, not significant)
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Figure 6.14 Effect of transfection of SRC-1 expression plasmid on the PPARy agonists-mediated inhibition of IFN-Y-stimuIated activity 
of STAT1 responsive elements
Hep3B cells were co-transfected with 3xly6e and an expression plasmid for SRC-1 or pcDNA3 as empty vector control. Following 2h 
incubation with BRL49653 (BRL, 20pM), 15d-PGJ2 (15d, lOpM) or DMSO control (DM), transfected cells were treated with IFN-y for 6h after 
which cell extracts were prepared for luciferase reporter activity assay. Luciferase counts were normalised to protein concentration and 
presented as the mean relative activation (±SD) in response to IFN-y, in relation to unstimulated controls, from three experiments (each carried 
out in triplicate). The data was further normalised to the relative activation of IFN-y-treated cells transfected with pcDNA3 (arbitrarily assigned 
as 1). Student’s t test was carried out on samples transfected with the SRC-1 plasmid versus IFN-y-stimulated pcDNA3 transfected samples 
(N/S, not significant)
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6.4.2 Investigation into whether LXR/RXR agonists mediate the 
inhibition of the IFN-y-induced activation of 3xly6e by 
competition for limiting amount of co-activators
In addition to PPARy agonists, we next investigated whether the LXR ligands- 
dependent repression of the IFN-y-induced STAT1 transactivation occurs by 
competition for a limiting amount of co-activators in the cells. The experiments and 
the analysis of the data were carried out exactly as described in section 6.4.1 except 
that the cells were pre-treated for 24h with 22R with 9cRA instead of PPARy 
agonists for 2h.
Figure 6.15 shows that similar to previous findings (Figures 6.13-14), the expression 
of p300, but not SRC-1, further enhanced STATI transactivation in response to IFN- 
y, thereby confirming that p300, but not SRC-1, is required for the STAT1- 
dependent pathway in response to the cytokine. In addition, neither the p300 nor the 
SRC-1 expression plasmids reversed the 22R and 9cRA-mediated inhibition of the 
IFN-y-induced ST ATI transactivation, thereby suggesting that the suppressive effect 
of LXR/RXR ligands on the IFN-y-stimulated STAT1-dependent pathway is 
independent of the amount of p300 or SRC-1 in the cells.
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Figure 6.15 Effect of transfection of p300 and SRC-1 expression plasmids on the LXR ligands-mediated inhibition of IFN-y-stimulated 
activity of ST ATI responsive elements
Hep3B cells were co-transfected with 3xly6e and expression plasmids for p300 or SRC-1, or pcDNA3 as an empty vector control. Following 
24h incubation with 22R (2pg/ml) and 9cRA (lOpM) or the DMSO control (DM), transfected cells were treated with IFN-y for 6h after which 
cell extracts were prepared for luciferase reporter activity assay. Luciferase counts were normalised to protein concentration and presented as the 
mean relative activation (±SD) in response to IFN-y, in relation to unstimulated controls, from three experiments (each carried out in triplicate). 
The data was further normalised to the relative activation of IFN-y-treated cells transfected with pcDNA3 (arbitrarily assigned as 1). Student’s t 
test was carried out on samples transfected with the p300 or SRC-1 expression plasmids versus IFN-y-stimulated pcDNA3 transfected samples 
(**J°<0.01; N/S, not significant)
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6.4.3 Effect of DN plasmids for LXR on the ligands-mediated inhibition 
of the IFN-y-induced activation of 3xly6e and MCP-1 gene 
promoter
The hypothesis that repression can be caused by competition among transcription 
factors for a limiting amount of co-activators predicts that deficiency in co-activator 
recruitment and/or transcriptional activation by LXRs should also affect repression 
(Li et al., 2000b). In order to further investigate whether 22R and 9cRA mediate the 
inhibition of IFN-y signalling via a mechanism dependent on competition for 
limiting amounts of co-activators, we examined the effects of deletion of the AF-2 
subdomain of LXR on the ligand-dependent repression of the IFN-y-mediated 
activation of STAT1 response elements and MCP-1 promoter by transient 
transfection assays. AF-2 is required for the recruitment of co-activators to NRs and 
mutation in AF-2 abolishes transcriptional activation (Barettino et al., 1994; 
Bourguet et al., 2000; Svensson et al., 2003). The DN mutant plasmid (DNLXR-a) 
employed in this study contains the full length sequence of LXR-a lacking the AF-2 
subdomain in the pSG5 expression vector (Kocarek et al., 2002).
Hep3B cells were co-transfected with 3xly6e or MCP[213]Luc and DNLXR-a with 
the empty plasmid vector pSG5 used as a control. Results are presented in Figure 
6.16 as mean relative activity (±SD) relative to the induction level in the presence of 
pSG5 (arbitrarily assigned as 1). Consistent with previous findings (Figure 5.17), 
Figure 6.16 shows that pre-treatment of the cells with 22R and 9cRA significantly 
inhibited the IFN-y-induced STAT1 transactivation and MCP-1 promoter activity. In 
addition, consistent with our results on co-transfection assays using expression 
plasmids for p300 and SRC-1 (Figure 6.15), transfection of the cells with DNLXR-a 
does not reverse the 22R and 9cRA-mediated inhibition. These results thereby lend 
further support to our conclusion that 22R and 9cRA attenuate IFN-y signalling via 
mechanisms independent of competition with transcription factors for a limiting 
amount of co-activators in the cells.
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Figure 6.16 Effect of transfection with DNLXR-a on the LXR ligands-mediated 
inhibition of IFN-y-stimulated activity of ST ATI responsive elements and MCP- 
1 promoter
Hep3B cells were co-transfected with 3xly6e or MCP[213]Luc and DNLXR-a. pSG5 
was used as an empty vector control. Following 24h incubation with 22R (lpg/ml) and 
9cRA (5gM) or DMSO as vehicle control, transfected cells were incubated in the 
absence or the presence of IFN-y for 6h after which cell extracts were prepared for 
luciferase reporter activity assay. Luciferase counts were normalised to protein 
concentration and presented as the mean relative activation (±SD) in response to IFN-y, 
in relation to unstimulated controls, from three experiments (each carried out in 
triplicate). The data was further normalised to the relative activation of IFN-y-treated 
cells transfected with pSG5 (arbitrarily assigned as 1). Student’s / test was carried out 
on samples transfected with DNLXR-a plasmids versus IFN-y-stimulated pSG5 
transfected samples in the presence of the ligands (N/S, not significant). The statistical 
analysis was also carried out on the ligands treated samples transfected with pSG5 
versus IFN-y-stimulated DMSO control (**P<0.01; ***P<0.001).
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6.5 Effect of expression plasmids for LXR on the 22R and 
9cRA-mediated inhibition of IFN-y signalling
In order to investigate whether the 22R and 9cRA-mediated inhibition of IFN-y 
signalling occurs in an LXR-dependent manner, co-transfection assays were 
performed using expression plasmids for LXRs. Hep3B cells were co-transfected 
with 3xly6e or MCP[213]Luc and expression plasmids for LXR-a or -p with the 
empty plasmid vector pSG5 used as a control. Results are presented in Figure 6.17 
as the mean activity (±SD) relative to the induction level in the presence of pSG5 
(arbitrarily assigned as 1).
Figure 6.17A shows that consistent with previous findings (Figure 5.7), treatment of 
the cells with 22R and 9cRA inhibited the induction of luciferase activity driven by 
STAT1 response elements in response to IFN-y. In addition, transfection with 
expression plasmids for LXR-a and -p dramatically suppressed the IFN-y-induced 
activity of ST ATI response elements (GAS), in the absence or the presence of 22R 
and 9cRA. These results thus suggest that the repressive effect on the IFN-y- 
stimulated ST ATI transactivation mediated by 22R and 9cRA was dependent on 
both LXR isoforms, a and p.
In contrast to 3xly6e, Figure 6.17B shows that transfection with expression plasmids 
of LXR-a and -p did not affect the induction of MCP-1 gene promoter activity in 
response to IFN-y with or without treatment of 22R and 9cRA. On the other hand, 
consistent with the data shown in Figures 5.7 and 6.16, pre-treatment of the cells 
with 22R and 9cRA inhibited the IFN-y-induced activation of MCP-1 promoter. 
These results thereby suggest that the 22R and 9cRA-mediated repressive effect on 
the IFN-y-induced activation of MCP-1 gene promoter occurs in a manner 
independent of LXR.
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Figure 6.17 Effect of transfection with expression plasmids for LXR-a or -p on 
the LXR ligands-mediated inhibition of IFN-y-stimulated STAT1 responsive 
elements and MCP-1 promoter activity
Hep3B cells were co-transfected with 3xly6e (A) or MCP[213]Luc (B) and 
expression plasmids for LXR-a or -p. pSG5 was used as an empty vector control. 
Following 24h incubation with 22R (1 pg/ml) and 9cRA (5pM) or DMSO as vehicle 
control, transfected cells were incubated in the absence or the presence o f IFN-y for 
6h after which cell extracts were prepared for luciferase reporter activity assay. 
Luciferase counts were normalised to protein concentration and presented as the 
mean relative activation (±SD) in response to IFN-y, in relation to unstimulated 
controls, from three experiments (each carried out in triplicate). The data was 
further normalised to the relative activation o f IFN-y-treated cells transfected with 
pSG5 (arbitrarily assigned as 1). Student’s t test was carried out on samples 
transfected with over-expression plasmids versus the IFN-y-stimulated pSG5 
transfected samples in the absence or the presence o f the ligands respectively 
(***p<0.ooi; ** P<0.01; N/S, not significant).
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6.6 Discussion
6.6.1 M echanisms underlying the repressive actions o f  simvastatin on IFN-y 
signalling
Upon stimulation with IFN-y, translocation of phosphorylated STATI at Tyr701 into the 
nuclear compartment is a crucial event for transducing the external signals into the 
nucleus and stimulation of transcription of target genes. Figure 6.3 clearly demonstrated a 
dramatic induction of phospho-STATl Tyr701 level in response to IFN-y at 30min and 
3h points in both nuclear and cytoplasmic extracts. The level and kinetics of induction 
was consistent with our previous finding using whole cell proteins from THP-1 
macrophages (Figure 3.11). Although immunofluorescence microscopy images show a 
predominantly nuclear localisation of STATs in cells stimulated with IFN-y in previous 
studies (Sekimoto et al., 1996; McBride et al., 2002; Meyer et al., 2002; Lodige et al., 
2005), western blot analysis of total STAT1 protein shows a similar intensity of bands in 
nuclear and cytoplasmic fractions (Figure 6.3). Other research groups have also used 
western blot analysis to investigate the nucleocytoplasmic distribution of STAT1 in 
response to IFN-y (Haspel et al., 1996; Meyer et al., 2002). In particular, Mayer et al. 
(2002) have demonstrated that western blot analysis was unable to detect significant 
accumulation of STAT1 and phospho-STATl in nucleus in response to IFN-y, which is 
consistent with our findings. This is probably because of the dynamic nature of STAT1 
localisation driven by a constant nucleo-cytoplasmic carrier-free shuttling at any given 
time point (Vinkemeier, 2004) (Figure 6.1). However, despite these limitations, western 
blot analysis provide a good insight into the effect of IFN-y and these therapeutic agents 
on the nuclear levels of phospho-STATl and thus the potential effect of these compounds 
on the accumulation of activated STAT1 in nucleus. Nevertheless, the precise effects of 
these therapeutic agents on IFN-y-mediated STATI nuclear accumulation need be 
confirmed using alternative approaches, such as immunofluoresence microscopy analysis.
Our results in the previous chapter (Figures 5.3-5) show that simvastatin exerts its 
repressive effect on the IFN-y-induced gene expression, but does not affect STAT1
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phosphorylation in response to this cytokine. EMSA shows that simvastatin does not 
affect the binding of STAT1 to GAS elements in response to IFN-y (Figure 6.9). These 
results together suggest that simvastatin attenuates the IFN-y-induced gene expression by 
mechanisms independent of inhibition of STAT1 phosphorylation or DNA binding 
activity. This conclusion is consistent with a previous study showing that simvastatin 
attenuates the IFN-y-induced promoter activation of CIITA gene, but does not affect 
STAT1 phosphorylation or DNA binding in response to this cytokine in human 
microvascular endothelial cells (Sadeghi et al., 2001).
Western blot analysis of phospho-STATl Tyr701 in nuclear and cytoplasmic fractions 
shows that simvastatin does not affect the nuclear and cytoplasmic levels of activated 
STAT1 in the presence of IFN-y (Figure 6.4). This is consistent with findings that 
simvastatin does not affect the IFN-y-stimulated STAT1 phosphorylation in whole cell 
protein extracts (Figure 5.5B). We therefore suspect that simvastatin does not affect the 
IFN-y-stimulated nuclear accumulation of activated STAT1. Consistent with our 
hypothesis, Sadeghi et al. (2001) have previously shown that simvastatin does not affect 
the IFN-y-stimulated nuclear localisation of STAT1 in human microvascular endothelial 
cells using combination of western blot and immunoflorescence microscopy. Similar 
approaches could therefore be adopted to confirm such effect of simvastatin in THP-1 
macrophages.
6.6.2 M echanism s underlying the repressive action o f  PPAR agonists on 
IFN-y signalling
Figure 6.10 shows that PPARy agonists do not have any effect on the binding of STAT1 
to GAS elements in response to IFN-y in THP-1 macrophages. Work presented in the 
previous chapter (Figures 5.7-10) shows that PPARy agonists attenuate the IFN-y- 
induced gene expression, at least in part, through the inhibition of STAT1 transcriptional 
activity without targeting ST ATI phosphorylation. These results together suggest that 
PPARy agonists repress the IFN-y-induced STAT1-mediated pathway via mechanism
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independent of STAT1 phosphorylation or DNA binding. However, several previous 
studies show contradictory results. For example, Chen et al. (2003) and Panzer et al. 
(2008) have demonstrated the inhibitory action of PPARy agonists on the IFN-y- 
dependent STAT1 phosphorylation and DNA binding activities in the mouse macrophage 
RAW264.7 cell line and the mouse mesangial cells respectively. Such actions have also 
been confirmed in the rat insulinoma RINm5F cell line (Weber et al., 2003, 2004). 
Although the exact reasons for the differences between our results and other studies are 
unclear at present, the cell type- and species-specific actions of PPARy agonists might 
have played a role. Indeed, although PPARs have emerged as important regulators of 
macrophage function in both human and murine species, a number of species-specific 
differences in terms of mechanism have been reported (Rigamonti et al., 2008). For 
example, PPARy activation has been found to decrease the rate of cholesterol 
esterfication in THP-1 macrophages by reduction of acyl-CoA cholesterol 
acyltransferase-1 (ACAT-1) mRNA expression (Hirakata et al., 2004). However, in 
murine macrophages PPARy has been reported to decrease cholesterol esterfication 
without affecting AC AT mRNA level (Li et al., 2004). Such species-specificity of 
PPARs actions indicate that the validation of pharmacological compounds will need to be 
assessed in humanised model, such as human primary cells, and ultimately in large-scale 
clinical trails.
Consistent with the results that show that PPARy agonists do not attenuate the IFN-y- 
stimulated ST ATI phosphorylation in whole cell extracts (Figure 5.8), western blot 
analysis shows that these agonists do not have any effect on the IFN-y-induced amounts 
of phospho-STATl Tyr701 in the nucleus or the cytoplasm (Figure 6.5). The unchanged 
level of phospho-STATl in the nucleus in isolation suggests that PPARy agonists are 
unlikely to affect the nuclear accumulation of activated STATI in response to IFN-y. 
However, additional experiments using alternative technique such as 
immunoflourescence microscopy will be required to confirm the hypothesis.
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Direct interaction of CBP/p300 and STAT1 has been reported to play essential roles in 
the JAK-STAT1 pathway induced by IFN-y and the normal response of macrophages to 
this cytokine (Zhang et al., 1996; Horvai et al., 1997; Bouhet et al., 2009). Consistent 
with these previous findings, transfection of the cells with expression plasmids for p300 
was found to further enhance the STAT1 transactivation induced by IFN-y (Figure 6.13). 
In contrast to p300, transfection with an expression plasmid for SRC-1 did not affect the 
fold induction of ST ATI transactivation in response to this cytokine (Figure 6.14). 
Additionally, several previous studies have shown that PPARs repress the activities of 
transcription factors, such as AP-1 and NFkB by competing for limiting amounts of 
shared coactivators (Kamei et al., 1996; Li et al., 2000b; Gervois et al., 2001). Figures 
6.13-14 show that the expression of p300 and SRC-1 by transfection of the cells with 
expression plasmids for these co-activators failed to restore the PPARy agonists-mediated 
inhibition of IFN-y-induced ST ATI transactivation. These results thereby suggest that the 
PPARy agonists-mediated repression of IFN-y-induced STATI transactivation occurs in 
a p300- and SRC-1-independent manner. The results are consistent with a previous study 
that shows that the PPAR-dependent repression of both AP-1- and NFicB-niediated gene 
expression is independent of the amount of CBP in the cells (Delerive et al., 1999a). The 
basis for the different results between our study and previous research supporting the co­
activator competition model of PPARs (Kamei et al., 1996; Li et al., 2000b; Gervois et al., 
2001) is not clear at present. As in most of the cases, conclusions regarding the roles of 
co-regulators have been based on the use of transient reporter assays involving over­
expression of various co-factors that restore repressive effects of PPAR agonists, some 
researchers have called for studies focusing on the regulation of endogenous genes in a 
normal chromatin context to further confirm the exact roles of these co-regulators in 
PPAR agonists-mediated transrepression (Ricote and Glass, 2007).
The molecular mechanisms underlying the repressive actions of PPARa agonists in 
relation to IFN-y signalling are poorly understood due to limited research on this aspect. 
The studies presented in the previous chapter show that PPARa agonist inhibits IFN-y-
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induced gene expression independently of STAT1 phosphorylation. Figure 6.6 shows that 
the PPARa agonist GW7647 does not affect the nuclear and cytoplasmic level of 
activated STAT1 in response to IFN-y. Moreover, the IFN-y-induced STAT1 binding to 
GAS elements is also unaffected by the PPARa agonist. These results thereby indicate 
that the PPARa agonist GW7647 exerts its repressive action on IFN-y signalling 
independent of STAT1 phosphorylation or DNA binding activity, and without reducing 
the nuclear or cytoplasmic amounts of activated STAT1.
As detailed in the General Introduction (section 1.8), Pascual et al. (2005) and Ghisletti et 
al. (2007) have recently independently shown that in mouse primary macrophages 
SUMOylation of PPARy in response to the ligands prevents the clearance of co-repressor 
complexes by LPS and maintains the repressed state of the inflammatory genes. 
Interestingly, a parallel SUMOylation-dependent mechanism has also been shown to act 
in LXR-mediated transrepression (Ghisletti et al., 2007). It will therefore be of great 
interest to find out whether SUMOylation of PPARs or LXRs is also required for 
transrepression of IFN-y signalling.
6.6.3 M echanism s underlying the repressive actions o f  LXR agonists in 
IFN-y signalling
Western blot analysis of phospho-STATl Tyr701 in nuclear and cytoplasmic fraction 
from THP-1 macrophages shows that the natural LXR and RXR ligands 22R and 9cRA 
together inhibit the IFN-y-induced amounts of activated ST ATI in the nucleus, but not in 
the cytoplasm (Figure 6.7B). The reduced nuclear levels of phospho-STATl in isolation 
suggest that 22R together with 9cRA decreases the IFN-y-stimulated nuclear amount of 
activated STAT1. In addition, pre-treatment of the cells with 22R and 9cRA also 
inhibited the IFN-y-induced binding of STAT1 to GAS elements on the MCP-1 gene 
promoter (Figure 6.12A). Nuclear import and retention are known as two steps leading to 
the nuclear accumulation of activated STATI and DNA binding has been shown to be 
critical for nuclear retention of this transcription factor (section 6.1.1). The reduced DNA
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binding activity of STAT1 could therefore result in from its increased dephosphorylation, 
and subsequently nuclear export. Moreover, results presented in the previous chapter 
have shown that 22R and 9cRA together inhibited the IFN-y-induced tyrosine 
phosphorylation of STATI (Figures 5.15-16). As only the tyrosine phsophorylated 
STAT1 is capable of being actively translocated into the nucleus, inhibition of tyrosine 
phosphorylation may lead to the reduced cytoplasmic to nuclear translocation of activated 
STAT1. These results together suggest that the reduced nuclear amount of phospho- 
STATl Tyr701 is likely to be a net result of its inhibited nuclear importation and 
increased exportation. However, it is worth nothing that the degree of inhibition of the 
amount of phospho-STATl Tyr701 in the nucleus is of similar extent to the decrease 
observed at the level of whole cell proteins (Figure 5.15). The possibility therefore 
remains that the reduced nuclear level of phospho-STATl is merely because of the 
inhibition of phosphorylation itself, and that the reduced phosphorylation is simply due to 
the increased dephosphorylation rate of ST ATI in the nucleus. Alternative approaches 
such as immunoflorescence microscopy analysis will need to confirm the exact effect of 
these ligands on the IFN-y-mediated STATI nuclear accumulation.
In contrast to these endogenous ligands, the synthetic LXR agonist TO901317 had no 
effect on the IFN-y-induced amount of activated STAT1 in both the nucleus and the 
cytoplasm (Figure 6.7A). The results are consistent with previous findings using whole 
cell extracts (Figure 5.14). Interestingly, similar to the combinatorial effect of 22R and 
9cRA, TO901317 was shown to inhibit STAT1 binding to GAS elements. These results 
thereby suggest that synthetic and endogenous agonists of LXR may exert their 
repressive actions on IFN-y signalling through distinct mechanisms.
Transfection of the cells with expression plasmids for p300 and SRC-1 failed to 
overcome the 22R and 9cRA-mediated inhibition of IFN-y-induced STAT1 
transactivation, thereby suggesting that the repressive actions of activated LXR is 
independent of the amounts of co-activators p300 and SRC-1. The hypothesis that
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repression can be caused by competition between different transcription factors for 
limiting amounts of essential shared coactivators predicts that mutations in LXRs 
affecting co-activator binding and/or transactivation should also affect transrepression. 
Therefore, the DNLXR-a plasmid was employed in the investigations. The plasmid 
contains the full sequence of LXR-a, but lacks the AF-2 subdomain, which is required for 
the recruitment of co-activators and transcriptional activation (Barettino et al., 1994; 
Bourguet et al., 2000; Kocarek et al., 2002). Figure 6.16 shows that transfection of the 
cells with DNLXR-a does not restore the 22R and 9cRA-mediated inhibition of the IFN- 
y-induced ST ATI transactivation and MCP-1 promoter activity. These results thereby 
confirm further that the LXR-mediated transcriptional inhibition occurs via mechanisms 
different from competition for limiting amounts of shared co-activators in the cells.
It is worth noting that a number of alternative factors might also contribute to the results 
of the co-transfection assays using DNLXR-a. First, as only DNLXR-a was included in 
this assay, the inhibitory effect of another isoform, LXR-(3 in the cells could possibly 
mask the impact of the dysfunction of LXR-a. Moreover, the expression of LXR-a has 
been shown to be induced by natural and synthetic LXR agonists in multiple human cell 
types, including macrophages and the hepatoma Hep3B cell line (Laffitte et al., 2001; 
Blaschke et al., 2006). 22R and 9cRA-mediated induction of LXR-a expression could 
possibly overcome the DN effect of the LXR-a mutant. Therefore, more work will be 
needed to decipher the exact reason(s) why the 22R and 9cRA-mediated inhibition was 
not affected by transfection of the cells with DNLXR-a.
In the absence or the presence of 22R and 9cRA, transfection of the cells with expression 
plasmids for LXR-a and -p significantly inhibited the IFN-y-induced STAT1 
transactivation (Figure 6.17A). Additionally, consistent with our previous findings 
(Figure 5.17), the inhibition in cells transfected with LXR plasmids and treated with these 
ligands occurred to a greater extent than cells transfected with the LXR plasmids alone. 
These results thereby suggest that 22R and 9cRA attenuate IFN-y signalling in LXR-
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dependent manner. Interestingly, transfection with LXR-a and -p expression plasmids 
does not affect the IFN-y-induced promoter activity of the MCP-1 gene, despite the fact 
that the activation of the MCP-1 promoter was largely inhibited by the ligands, 22R and 
9cRA (Figures 5.17 and 6.17B). These results therefore suggest that the LXR ligands 
probably exert the repressive effect on MCP-1 expression in an LXR-independent 
manner. Moreover, the finding that LXR expression plasmids attenuated the IFN-y- 
stimulated STATI transactivation but not MCP-1 expression is consistent with previous 
studies that demonstrated a sustained expression of MCP-1 in response to IFN-y in 
STATl-null macrophages (Gil et al., 2001; Ramana et al., 2002). STAT3 has previously 
been shown to be activated in response to IFN-y and drive the transcription of certain 
STAT1 response genes in STATl-null cells (Qing and Stark, 2004; Ramana et al., 2005). 
The existence of STAT1 alternative factor(s) may play a role to maintain MCP-1 
expression in cells transfected with LXR expression plasmids, which reduce the ST ATI 
transactivation. However, we cannot rule out the possibility that the complexity of the 
MCP-1 gene promoter (Figure 3.2) compared to the artificial STAT1 responsive elements 
might also contribute to the different responses observed on the activation of 3xly6e and 
MCP[213] plasmids to over-expression of LXR-a or -p in the cells. Further studies will 
be required to understand the exact molecular basis of the discrepancy between STATI 
transactivation and MCP-1 promoter activation.
As discussed in the previous chapter, the NR ligands could exert their non-genomic 
actions by activation of intracellular signalling cascades (e.g. MAPK-dependent pathway) 
through modes either dependent on the classical NRs or novel membrane receptors 
(section 5.7.4). As discussed above, LXR ligands potentially inhibit the IFN-y-mediated 
gene expression, at least in part, in a manner independent of the corresponding receptor. 
It will be of interest to find out whether the non-genomic effects are responsible for this 
NR-independent action of LXR ligands. More work will be required to address this issue.
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Overall, our results suggest that 22R and 9cRA together attenuate the IFN-y signalling 
pathway, at least in part, in a manner dependent on LXR and by inhibition of STAT1 
phosphorylation and DNA binding activity, which may together result in decreased 
nuclear accumulation of activated STAT1. Additionally, the LXR-mediated inhibition 
occurs via mechanisms different from competition with transcription factors for shared 
co-activators. LXR-independent mode of action by the ligands might also contribute to 
the IFN-y-mediated gene expression. On the other hand, the synthetic LXR agonist 
TO901317 inhibits the IFN-y-induced gene expression by attenuating STAT1 DNA 
binding activity without affecting STAT1 phosphorylation in either the nucleus or the 
cytoplasm.
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7.1 Mechanisms underlying the IFN-y-mediated regulation of 
gene expression
Atherosclerosis, an underlying cause of CAD, is an inflammatory disorder 
orchestrated by cytokines. The pro-inflammatory cytokine IFN-y is a key regulator of 
atherogenesis and is involved in all the major steps in the pathogenesis of this disease. 
The cellular actions and the downstream signalling mechanisms of this important 
inflammatory mediator have attracted great interest. Extensive studies in last decade 
have identified a pivotal role for the JAK-STAT pathway in relation to IFN-y 
signalling. However, many aspects of IFN-y-activated JAK-STAT-dependent 
signalling remain unclear, particularly in relation to the mechanisms involved in the 
phosphorylation of STAT1 at Ser727, which warrants further studies. The work 
detailed in this thesis has used several different approaches to delineate the 
mechanisms underlying the IFN-y-mediated regulation of gene expression and cellular 
responses, with particular emphasis on identifying potential targets that may lend 
themselves to therapeutic intervention of atherosclerosis. The majority of this work 
has been carried out in macrophages as these cells have a key role in the pathology of 
atherosclerosis and are an important target for the action of IFN-y. It was hoped that 
such studies will not only enhance our understanding of IFN-y signalling associated 
with atherosclerosis but, in the long term, may also identify potentially novel 
therapeutic avenues.
Experiments based on the use of pharmacological inhibitors against potential 
mediators of IFN-y signalling identified a key role for ERK and JNK in the 
phosphorylation of STAT1 Ser727 in response to this cytokine. The crucial role of 
these kinases in IFN-y-activated signalling was subsequently substantiated through the 
use of kinase assays, and transfection experiments using DN mutants. The work also
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identified important roles for other kinases (CK2, PI3K, PKC-5 and CaMKII) in the 
IFN-y-mediated regulation of expression of a range of model genes in macrophages. 
These kinases were found to mediate the regulation of gene expression in response to 
IFN-y, at least in part, through modulation of STAT1 Ser727 phosphorylation.
7.1.1 R oles o f  ERK and JNK in the IFN-y-mediated signalling pathway 
in macrophages
The ERK inhibitors (PD98059 and U0126) and the JNK inhibitor (SP600125) 
markedly inhibited the phosphorylation of STAT1 at Ser727 in response to IFN-y in 
THP-1 macrophages. These results strongly suggest key roles for ERK and JNK in the 
IFN-y-stimulated activation of STAT1 via regulation of phosphorylation at Ser727. 
The important roles of these two kinases in mediating the IFN-y-stimulated STAT1 
phosphorylation were also extended to human primary monocyte-derived 
macrophages and human hepatocytes through the use of pharmacological inhibitors. 
These results thereby suggest that the use of ERK and JNK as key regulators of 
STAT1-dependent signalling occurs in both human macrophages and hepatocytes.
Transfection based assays, in Hep3B cells, confirmed that ERK and JNK, as well as 
other key components (Ras, Raf-1 and MEK1) of these pathways were also involved 
in the IFN-y-induced STAT1 transactivation. The inhibition also occurred at the level 
of IFN-y-induced activation of MCP-1 promoter as determined by the use of DN 
mutants in transfection assays. RT-PCR experiments further confirmed a crucial role 
of ERK in the regulation of gene expression downstream of STAT1 in response to this 
cytokine. Thus, the ERK inhibitor, PD98059 inhibited the IFN-y-induced expression 
of MCP-1, MIP-ip, IP-10, SOCS-1 and ICAM-1, all of which have previously been 
shown to be primarily regulated through a STATl-dependent pathway by this cytokine. 
These results together suggest that ERK and JNK-dependent pathways regulate the 
IFN-y-mediated gene expression associated with atherosclerosis, at least in part 
through the modulation of STATl phosphorylation in human macrophages,
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particularly at Ser727. Consistent with our findings, Overbergh et al. (2006) have 
shown that in PMA-differentiated THP-1 macrophages, ERK is responsible for the 
IFN-y-induced expression of 1,25-dihydroxy vitamin D3, through regulation of STATl 
Ser727 phosphorylation. In addition, JNK has been shown to regulate the expression 
of MCP-1 in response to IFN-y and LPS by modulation of STATl Ser727 
phosphorylation in murine dermal fibroblast (Yamana et al., 2009). However, whether 
ERK and JNK activate STATl through downstream effector kinases or by a direct 
action remains to be determined.
In addition to STATl-dependent mechanisms, alternative pathways have also been 
previously reported to regulate the expression of MCP-1 and MIP-lp genes in 
response to IFN-y (Gil et al., 2001; Ramana et al., 2001). We can therefore not rule 
out the possibility that ERK and JNK are also involved in STATl-independent 
pathways along with its action on STATl activity. Indeed, Gough et al. (2007) have 
recently demonstrated that ERK 1/2 is activated independently of the JAK1-STATl 
signalling pathway and is responsible for the IFN-y-induced expression of iNOS gene 
in murine embryonic fibroblasts. The possibility therefore remains that these two 
kinases utilise different mechanism for each of these genes.
Results from kinase assays add further support to the important roles of these two 
kinases in IFN-y-dependent signalling. Treatment of the cells with IFN-y resulted in a 
3- and 1.5-fold induction in the activity of ERK and JNK respectively, which was 
consistent with the kinetics of STATl phosphorylation and induction of gene 
expression in response to this cytokine.
It is worth noting that recent studies have shown that pharmacological inhibitors for 
ERK1/2 (e.g. PD98059 and U0126) can also attenuate the activation of MEK5 and 
subsequently ERK5, although higher concentrations are required (Mody et al., 2001). 
In HeLa cells, the concentrations of these inhibitors required for inhibiting the ERK5
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pathway (lOOpM for PD90859 and lOpM for U0126) is 10-fold higher than that 
required for inhibiting ERK1/2 (lOpM for PD98059 and lpM for U0126) (Mody et al., 
2001). We have shown in human macrophages and hepatocytes that PD98059 (at 5, 
30 and 50pM) and U0126 (at 5, 10 and 20pM) inhibited the IFN-y-induced STATl 
phosphorylation at all these concentrations. Inhibition of the IFN-y-induced gene 
expression by PD98059 at these concentrations has also been demonstrated.
7.1.2 R oles o f  other kinases in IFN-y-mediated signalling pathways in 
macrophages
In addition to ERK and JNK, work presented in this thesis has identified important 
roles for other kinases in the IFN-y-mediated signalling pathway in relation to STATl 
phosphorylation. These kinases include CK2, PI3K, PKC-8 and CaMKII.
Previous studies in our laboratory have identified critical roles for CK2 and PI3K in 
the IFN-y-regulated expression of several genes in mouse macrophages (Harvey et al., 
2007). Work detailed in this study have extended the investigation into human 
macrophages and confirmed important roles of these two kinases in IFN-y signalling 
in THP-1 macrophages. Consistent with previous findings in mouse macrophages, 
pre-treatment of THP-1 macrophages with inhibitors for CK2 (apigenin) and PI3K 
(LY294002) attenuated the IFN-y-induced expression of MCP-1 and STATl 
phosphorylation at Ser727, without affecting that at Tyr701. Previous findings by our 
research group based on RT-PCR analysis of a number of marker genes, along with 
gene expression profiling, have shown that CK2 and PI3K are involved in the 
regulation of a range of genes important for inflammation and atherosclerosis in 
response to IFN-y in mouse macrophages (Harvey et al., 2007). These results together 
suggest an important role for CK2 and PI3K in the regulation of IFN-y responsive 
gene expression in macrophages, at least in part, via modulation of STATl 
phosphorylation at Ser727.
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Inhibitors for PKC-5 (rottlerin) and CaMKII (KN93) have both been shown to 
attenuate the IFN-y-induced STATl phosphorylation at Tyr701 and Ser727, thereby 
suggesting that these two kinases mediate the IFN-y-induced STATl activity via 
regulation of phosphorylation at Tyr701 and Ser727. The key roles of PKC-5 in the 
IFN-y-mediated regulation of gene expression was also demonstrated by RT-PCR 
analysis that showed that rottlerin inhibited the expression of MCP-1, ICAM-1, 
SOCS-1 and ICERI/II in the presence of this cytokine. Similar roles of these two 
kinases in IFN-y signalling have been previously demonstrated by other research 
groups. PKC-5 has been shown to regulate the expression of some IFN-y-mediated 
gene (e.g. CIITA) through modulation of STATl Ser727 phosphorylation in human 
leukaemia cell line (Deb et al., 2003) and mouse macrophage cell line RAW264.7 
(Kwon et al., 2007). CaMKII has also been shown to be required for the 
IFN-y-mediated STATl Ser727 phosphorylation in mouse fibroblasts (Nair et al., 
2002).
4
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7.2 Mechanisms underlying the inhibitory effects of
therapeutic agents on IFN-y signalling
Ligands for NRs, PPARs and LXRs, as well as cholesterol-lowering drugs, statins 
have recently been found to exert profound anti-inflammatory and protective effects 
in the development of atherosclerosis. Despite their well established significance in 
inflammatory responses and potential clinical benefits in atherosclerosis, the 
molecular mechanisms underlying such anti-inflammatory and athero-protective 
effects remain poorly understood, particularly in relation to IFN-y actions and the 
JAK-STAT pathway. Work presented in this thesis has used several different 
approaches to decipher the molecular basis of repression of IFN-y-induced gene 
expression by these therapeutic agents, with particular focus on their actions on the 
JAK-STAT pathway. The majority of this work was carried out in macrophages as 
these cells are an important target for the anti-inflammatory actions of PPARs and 
LXRs, as well as the pleiotropic effects of statins. It was hoped that such studies will 
not only enhance our understanding of the molecular mechanisms underlying the 
anti-inflammatory and atheroprotective effects of these agents, but may also benefit 
the development of effective and safe therapeutic intervention of this disease in the 
future. The results of these studies are summarised in Table 7.1 and detailed in 
following sections.
7.2.1 M echanism s underlying the PPARs-mediated inhibitory effects on 
IFN-y signalling
Pre-treatment of the cells with the PPARy agonist (BRL49653) attenuated the 
IFN-y-induced expression of MCP-1, IP-10, MIP-lp, CIITA pill and SOCS-1. 
Similarly, the PPARa agonist (GW7647) prevented the expression of these genes 
along with CIITA pIV and ICERI/II. The inhibitory effect of PPARy agonists 
(BRL49653 and 15d-PGJ2) on the IFN-y-stimulated transcription of the MCP-1 gene 
was also confirmed by transient transfection assays. The study was subsequently 
extended to delineate the potential mechanisms.
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Table 7.1 Summary of results from investigation of the mechanisms underlying
the inhibitory effects of therapeutic agents on the IFN-y-activated,
STATl-dependent signalling pathway
NR
targeted
MCP-1
promoter
activation
STAT1
trans
-activation
STAT1
phosphorylation
Nuclear 
amount of 
activated 
STAT1
STAT1
DNA
binding
activity
Simvastatin i
BRL49653 PPARy
15d-PGJ2 PPARy
GW7647 PPARa
TO901317 LXR
22R+9cRA LXR i i 1 i
—►, no effect; inhibition; /, not investigated
Abbreviations: STAT, signal transducers and activators of transcription; MCP, monocyte
chemoattractant protein; 22R, 22(R)-hydroxycholesterol; 9cRA, 9- c i s  retinoic acid; PPAR, peroxisome 
proliferators-activated receptor; LXR, liver X receptor; NR, nuclear receptor
Transient transfection assays showed that PPARy agonists (BRL49653 and 15d-PGJ2) 
attenuated the IFN-y-induced STAT1 transactivation. Western blot analysis showed 
that none of the PPARs agonists employed in this study (BRL49653, 15d-PGJ2 and 
GW7647) affected the IFN-y-stimulated STAT1 phosphorylation or nuclear amount of 
activated STAT1. EMSA analysis additionally showed that these compounds failed to 
affect the STAT1 DNA binding activity. The results therefore suggest that the PPARy 
agonists prevent the IFN-y-induced gene expression, at least in part, by inhibiting 
STATl-dependent pathway, without affecting STAT1 phosphorylation, DNA binding 
activity or nuclear amount of activated STAT1. Transfection of the cells with 
expression plasmids for p300 or SRC-1 failed to restore the PPARy agonists-mediated 
inhibition of IFN-y-stimulated STAT1 transactivation, thereby suggesting that PPARy 
agonists-mediated transrepression of STAT1 transcriptional activation potential is 
independent of the amount of p300 or SRC-1 in the cells.
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7.2.2 M echanisms underlying the LXRs-m ediated inhibitory effects on 
IFN-y signalling
RT-PCR analysis showed that treatment of the cells with the LXR agonist TO901317 
resulted in a slight but reproducible inhibition of the IFN-y-induced expression of 
MCP-1 and CIITA pIV. The LXR agonist-dependent repression of MCP-1 gene 
transcription was also confirmed by transfection assay using endogenous LXR/RXR 
ligands 22R and 9cRA. In addition, these ligands together attenuated the 
IFN-y-stimulated STAT1 transactivation. These results together suggest the LXR 
ligands attenuate the expression of IFN-y response genes, at least in part, via their 
inhibitory actions on the STAT1 transcriptional activation potential. Further studies 
focused at delineating the potential mechanisms involved in the inhibitory actions of 
LXR ligands on STATl-dependent signalling.
Western blot analysis and EMSA showed that 22R and 9cRA attenuated the 
IFN-y-stimulated STAT1 phosphorylation and binding to GAS element. Moreover, 
western blot analysis on nuclear and cytoplasmic fractions showed that these ligands 
reduced the amount of phospho-STATl Tyr701 in the nucleus, but not in the 
cytoplasm. It has been widely accepted that IFN-y stimulates the nuclear 
accumulation of activated STAT1 (section 6.1.1) and such accumulation can be 
visualised using immunoflurescence microscopy (Higashi et al., 2003). The reduced 
amount of phospho-STATl in the nucleus thereby suggests a potential inhibitory 
effect of 22R and 9cRA on nuclear accumulation of activated STAT1. Such inhibition 
is probably as a result of inhibited STAT1 phosphorylation and DNA binding activity, 
which decrease the nuclear import of activated STAT1 and increase the nuclear export 
of dephosphorylated STAT1 respectively. However, we, at present, do not rule out the 
possibility that the reduced amount of phospho-STATl in the nucleus is merely 
because of the inhibition of its phosphorylation, and vice versa, that the reduced 
phosphorylation is simply due to the increased dephosphorylation rate of STAT1 in 
nucleus. More work will therefore be required to confirm the exact role of LXR
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ligands on STAT1 nucleo-cytoplasmic translocation.
Over-expression of co-activators p300 and SRC-1 did not restore the inhibition of the 
IFN-y-induced STAT1 transactivation by 22R and 9cRA, thereby suggesting that the 
LXR ligands mediate the inhibition of STAT1 transcriptional activation potential 
through mechanisms independent of competition for co-activators p300 and SRC-1 in 
the cells. In addition, transfection of the cells with DNLXRa does not overcome the 
22R and 9cRA-mediated inhibition of IFN-y-induced STAT1 transactivation and 
MCP-1 promoter activation. The DNLXRa is known to be deficient in recruitment of 
co-factors. Work previously carried out in our laboratory has confirmed that 
transfection of the cells with DNLXRa attenuates the LXR ligands-mediated 
activation of the ABCA1 promoter (Huwait, 2008). These results therefore add further 
support to the notion that the 22R and 9cRA-mediated transrepression of IFN-y 
signalling occurs through mechanisms distinct from competition for a limiting amount 
of co-activators in the cells.
Transient transfection assays using expression plasmids specifying for LXR-a and -p 
showed that 22R and 9cRA attenuated the IFN-y-stimulated, STATl-dependent 
signalling in a manner dependent on LXR isoforms. In the absence of LXR ligands, 
transfection of the cells with expression plasmids specifying for LXR-a and ~P 
dramatically inhibited the IFN-y-stimulated STAT1 transactivation. In addition, the 
inhibition was more extensive in the presence of LXR ligands. In contrast, 
transfection with these expression plasmids did not affect the IFN-y-induced 
activation of MCP-1 promoter in the presence or the absence of 22R and 9cRA, 
thereby suggesting that the LXR ligands potentially inhibit MCP-1 gene expression 
through an LXR-independent mechanism.
The exact molecular basis for the discrepancy observed between STAT1 
transactivation and MCP-1 promoter activation remains to be determined. However,
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taking together all the findings on LXR ligands-mediated inhibition of IFN-y 
responses and the potential underlying mechanisms identified during the course of this 
study, we propose a model (Figure 7.1) here that provides a potential explanation. 
According to this model, in the absence of the LXR ligand, over-expressed LXRs (as 
a result of transfection with expression plasmids in this case) attenuate the 
IFN-y-stimulated STAT1 transactivation. Previous studies have suggested the 
potential roles of factors independent of STAT1 in the IFN-y-mediated regulation of 
MCP-1 (Gil et al., 2001; Ramana et al., 2002). More recently, STAT3 has been found 
to be activated and replace the STAT1 in the STAT1-deficient cells to mediate the 
transcription of certain genes in response to IFN-y (Qing and Stark, 2004; Ramana et 
al., 2005). It is thus tempting to speculate that as a result of inhibition of STAT1 
transcriptional activity by LXRs, other factors become activated and mediates the 
transcription of the MCP-1 in response to IFN-y (Figure 6.17B). This might explain 
why the activation of MCP-1 promoter remained unchanged following transfection 
with the LXR expression plasmids in the absence of the ligands, despite the marked 
inhibition of STAT1 transactivaiton (Figure 6.17). Following stimulation with the 
ligands, activated LXRs inhibit STAT1 phosphorylation and transactivation. In 
addition to its LXR-dependent mode of action, the LXR ligands could potentially 
modulate other factors, and thereby MCP-1 gene transcription, in a non-genomic 
manner that is potentially independent of LXRs. As a result, these LXR-dependent 
and -independent actions of ligands lead to a reduction of the IFN-y-induced MCP-1 
expression (Figure 7.1C). This model is consistent with our findings that MCP-1 
promoter activation is inhibited by 22R and 9cRA, and that MCP-1 expression is 
decreased by TO901317. Overall, according to this model, the LXR agonists could 
exert their transrepression on IFN-y responsive gene, via both LXR-dependent and 
-independent mechanisms. In contrast, the inhibitory action of LXR agonists on 
STAT1 transactivation is primarily dependent on LXR isoforms. Such dual actions of 
the ligands could potentially explain the discrepancies between STAT1 transactivation
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and MCP-1 expression, as well as the different responses of MCP-1 expression to 
LXR ligands and over-expression of LXRs in the cells.
Non-genomic actions are increasingly being recognised as important contributors to 
the effects of ligands of NR in the regulation of cellular responses. One of the 
important features of non-genomic action is that it occurs rapidly, usually in the 
seconds to minutes range (Losel and Wehling, 2003). As observed in this study, the 
inhibitory effect of 22R and 9cRA on STAT1 phosphorylation, nuclear level, DNA 
binding activity and transactivation occurs at the 30min point following treatment of 
THP-1 macrophages with these ligands. Such a rapid response implies the potential 
involvement of non-genomic actions in the modulation of STAT-dependent pathway 
by LXR ligands. More work will be needed to confirm this hypothesis. Moreover, in 
addition to classical NRs, novel non-classical, membrane-associated receptors are 
emerging as key players for the NR ligands in mediating the non-genomic actions in 
some cases (Wehling and Losel, 2006). It will be thus of great interest to delineate 
whether a non-genomic action is involved in such transrepression.
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(B) In the cells with action ol l x k s , hut without l a k  ligands
MCP-1STAT1
over-expressed
LXR
STAT1 alternative factors
(C) In the cells stimulated with LXR ligands
LXR- dependent
LXR ligands
LXR- independent X Non-genomic action
MCP-1STAT1
LXR
STAT1 alternative factors
Figure 7.1 A putative model of LXR-dependent and -independent actions of ligands on IFN-y-j 
and gene expression
IFN-y activates STAT1, which in turn mediates the expression of MCP-1 (A). The over-e: 
IFN-y-stimulated STAT1 transactivaiton. As a result, STAT1 alternative factors become activated ai 
the transcription of MCP-1 gene. Expression of MCP-1 thus remains unchanged (B). LXR ligands p< 
IFN-y responsive gene expression through LXR-dependent and -independent mechanisms (the 
non-genomic action). On one hand, the ligands activate the LXRs, which in turn repress the ST 
potential. On the other hand, the ligands could also target the alternative factors independently of LXP 
MCP-1 is thus reduced as a result of both STATl-dependent and independent pathways being inhibite 
I, activation or expression inhibited; — expression remained; solid arrow, positive regulation; solid z 
dot arrow, pathway being inhibited
Abbreviations: LXR, liver X receptor; MCP, monocyte chemoattractant protein; STAT, signal transducer and ai
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7.2.3 M echanism s underlying the simvastatin-mediated inhibitory 
effects on IFN-y signalling
RT-PCR analysis has clearly shown that simvastatin inhibits the IFN-y-induced 
expression of MCP-1, IP-10, MIP-1(3, ICAM-1, SOCS-1 and CIITA pIV, but not 
CIITA pill, thereby suggesting a selective action on IFN-y responsive gene expression. 
The inhibitory effect of simvastatin on MCP-1 transcription was further confirmed 
using transient trasfection assays that showed that the IFN-y-induced MCP-1 
promoter activation was reduced by simvastatin. Transfection assays additionally 
demonstrated a decrease in STAT1 transactivation in the presence of IFN-y following 
treatment of the cells with simvastatin. These results together suggest that simvastatin 
mediates the inhibition of the IFN-y responsive gene expression, at least in part, by 
attenuating STAT-1-dependent pathway. Further studies were therefore focused on the 
mechanisms underlying such an inhibitory effect of simvastatin.
Western blot analysis using whole cell extracts along with nuclear and cytoplasmic 
proteins showed that simvastatin does not affect the IFN-y-stimulated STAT1 
phosphorylation or nuclear amount of Tyr701 phospho-STATl. EMSA also indicated 
that simvastatin had no effect on the IFN-y-induced STAT1 DNA binding activity. 
These results together suggest that simvastatin exerts the inhibitory effect on 
IFN-y-induced gene expression by attenuating STAT-1 transactivation without 
affecting the phosphorylation, nuclear accumulation or DNA binding activity of this 
transcription factor. More work will therefore be required to elucidate the exact 
mechanisms by which simvastatin inhibits IFN-y signalling.
Previous studies have suggested that statins attenuate the expression of many 
inflammatory response genes, such as iNOS and MCP-1, via PPARs (Paumelle et al., 
2006; Yano et al., 2007). Interestingly, we noticed that simvastatin and the PPARy 
agonist (BRL49653) both inhibited the IFN-y-induced expression of MCP-1 and 
SOCS-1, while simvastatin and the PPARa agonist (GW7647) both inhibited the
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expression of MCP-1, SOCS-1 and CIITA pIV. It is thus tempting to speculate that the 
inhibitory effects of simvastatin on the expression of these genes are probably 
mediated via PPARs. The cross-talk between statins and PPARs may thus represent a 
potential avenue for future work as a result of this study.
A recent study by Montecucco et al. (2009) has shown that simvastatin inhibits 
C-reactive-protein (CRP)-induced chemokine secretion and expression of ICAM-1 in 
human primary monocytes, as well as the chemotactic migration of these cells through 
the attenuation of the ERK1/2 pathway. Activation of the ERK1/2 pathway has been 
shown to be responsible for the expression of a range of inflammatory response genes 
(i.e. MCP-1, IP-10, MIP-ip and ICAM-1) in response to IFN-y in this study (Chapter 
4). It would thus be of great interest to identify whether a similar ERK-dependent 
mechanism is also involved in the inhibitory effect of simvastatin on IFN-y-induced 
gene expression.
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In summary, the work presented in this thesis has been successful in enhancing our 
understanding of the signalling cascades by which IFN-y regulates gene expression, in 
relation to STATl-dependent pathway, as well as the molecular basis underlying the 
statin- and agonists for NRs (PPARs and LXRs)-mediated inhibition of IFN-y 
responsive gene expression in THP-1 macrophages. The major key findings are as 
follows:
1. Kinases, including ERK, JNK, CK2, PI3K, PKC8 and CaMKII play 
important roles in the stimulation of STAT1 Ser727 phosphorylation in 
response to IFN-y;
2. ERK and JNK-dependent pathways play key roles in the IFN-y-stimulated 
STAT1 transactivation and MCP-1 promoter activity;
3. ERK acts as an important mediator in the regulation of gene expression (i.e. 
MCP-1, MIP-ip, IP-10, ICAM-1 and SOCS-1) in response to IFN-y;
4. ERK and JNK activity is induced by IFN-y by about 3- and 1.5-fold 
respectively;
5. PPARa agonist inhibits IFN-y-induced gene expression (e.g. MCP-1) without 
affecting STAT1 phosphorylation, DNA binding activity or nuclear amount of 
activated STAT1;
6. PPARy agonists inhibit the IFN-y-induced gene expression (e.g. MCP-1), at 
least in part, by attenuating STATl-dependent pathway without affecting 
STAT1 phosphorylation, DNA binding activity or nuclear amount of 
activated STAT1;
7. LXR agonists inhibit the IFN-y-induced gene expression (e.g. MCP-1), at 
least in part, by attenuating STATl-dependent pathway through reduction of
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STAT1 phosphorylation, DNA binding activity and potentially nuclear 
accumulation;
8. Inhibition of IFN-y responsive gene transcription by agonists for PPARy and 
LXRs does not occur via competition for a limiting amount of shared 
co-activators, SRC-1 or p300 with transcription factors in the cells;
9. LXR agonists-mediated inhibition of the IFN-y-stimulated STAT1 
transactivation occurs in a mode dependent of NR LXRs, while the inhibition 
of MCP-1 gene transcription occurs, at least in part, independently of LXRs;
10. Simvastatin inhibits the IFN-y-induced gene expression (i.e. MCP-1), at least 
in part, by attenuating the STATl-dependent pathway without affecting 
STAT1 phosphorylation, DNA binding activity or nuclear amount of 
activated STAT1.
The different pathways for the IFN-y-mediated regulation of gene expression in 
human macrophages and the actions of agonists for PPARs and LXRs, as well as 
statins on these pathways are illustrated in Figure 7.2.
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Figure 7.2 Different pathways in the IFN-y-mediated regulation of gene 
expression and the putative model for the actions of statins, PPARs and LXRs on 
these pathways, particularly in relation to ST ATI transcriptional activity
A number o f kinases, including ERK, JNK, CK2, PI3K, PKC5 and CaMKII play 
crucial roles in the IFN-y-mediated regulation o f gene expression, at least in part, 
through modulation o f STAT1 transcriptional activity (black solid arrows). The 
putative roles for these kinases in STAT1-independent pathways are denoted as black 
dot arrows and require further study. Agonists for PPARs and LXRs inhibit the 
IFN-y-induced gene expression (e.g. MCP-1). Ligand-dependent PPARy (pink) and 
LXR (red) exert the inhibitory effects by attenuating STAT1 transcriptional activity. 
Additionally, LXR ligands may also target alternative factors) to STAT1 in an 
LXR-independent manner. Statins (green) inhibit the IFN-y-induced gene expression 
(e.g. MCP-1) through novel mechanisms, probably via potentiating the 
transrepression o f PPAR-y and -a, or attenuating the ERK pathway. Such putative 
actions o f statins (represented as green dot arrows) are derived from previous 
publications (see text) and require further evaluation in human macrophages, 
positive regulation; -1, antagonism; — , putative action
Abbreviations: IFN, interferon; IFN-yR, interferon-gamma receptor; ERK, extracellular 
signal-regulated kinase; JNK, c-Jun N-terminal kinase; PKC, protein kinase C; PI3K, 
phosphoinositide 3-kinase; PPAR, peroxisome proliferator-activated receptor; LXR, liver X 
receptor; LXR L, LXR ligand; MCP, monocyte chemoattractant protein; STAT, signal 
transducer and activator of transcription
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7.3 Future work
A number of avenues for further investigation are highlighted by the results of this 
study. These can be divided into investigation of the general roles of ERK and JNK, 
along with other potential kinases in the regulation of gene expression and cellular 
responses by IFN-y, and the continued in depth analysis of the mechanisms involved 
in the inhibitory effects of the therapeutic agents on IFN-y signalling.
7.3.1 Future investigations into the roles of ERK and JNK in the 
regulation of gene expression by IFN-y
The initial step in the continued investigation of the roles of ERK and JNK along with 
other kinases in the regulation of IFN-y-mediated gene expression in macrophages is 
to extend the studies by other approaches such as siRNA/shRNA-mediated 
knockdown. It is also of great interest to confirm some of our findings on cells from 
ERK-, JNK- or other kinase-deficient mice.
To investigate the potential role of ERK5-dependent pathway in the IFN-y-mediated 
STAT1 transcriptional activity and gene expression, it would be necessary to extend 
the studies via the use of DN approaches used for studies in this thesis or by specific 
knock-down of ERK5 or its upstream kinase MEK5 with siRNA/shRNA. The 
phosphorylation state and kinase activity of ERK5 in response to the cytokine would 
also need to be monitored.
The role of Ser727 in the regulation of STAT1 activity is at present unclear but 
appears to be associated with the recruitment of co-factors such as MCM5, BRCA1 
and CBP/p300 (Zhang et al., 1998; Ouchi et al., 2000; Sim et al., 2005). Chromatin 
immunoprecipitation (ChIP) assays is an elegant technique that allows the 
determination of which co-factors are involved in the transcriptional regulation of a 
certain gene (e.g. MCP-1). Briefly, ChIP involves: the cross-linkage of proteins, 
including regulatory factors, to chromatin using formaldehyde; chromatin
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fragmentation; immunoprecipitation of the protein of interest; reversal of 
cross-linking; followed by PCR analysis using primers specific for the section of 
promoter region of interest. The results of these investigations would verify whether 
these sequences bind to co-regulator proteins and reveal any potential gene-specific 
differences. Recruitment of CBP/p300 to STAT1 target gene promoters in response to 
IFN-y has previously been demonstrated by Sun et al. (2005) using this technique. 
ChIP assays have also been employed in our laboratory to determine the binding of 
STAT1 and Spl to the MCP-1 gene promoter (Harvey, 2006). It thus could be used to 
determine the recruitment of STAT1 and specific co-regulators on the promoter of 
genes that have been identified to be regulated through ERK and JNK pathways. The 
effect of blockage of these two pathways on the recruitment of these factors could 
also be investigated. Blockage of ERK and JNK could be achieved by 
pharmacological inhibitors, DN mutants, siRNA or the use of cells derived from 
ERK- or JNK-knockout mice.
As discussed earlier, although it has been clearly shown that ERK and JNK mediate 
the regulation of IFN-y responsive gene expression, at least in part, through the 
modulation of STAT1 phosphorylation in human macrophages, we do not rule out the 
possibility that these two kinases may also regulate gene expression through 
alternative STAT1 -independent pathways. For example, STAT3 has been shown to 
replace STAT1 in STATl-null cells to drive the transcription of certain genes, such as 
SOCS-3 and CEBP5 in response to IFN-y (Qing and Stark, 2004; Ramana et al., 
2005). Amongst the genes analysed in this study, the expression of MCP-1 and 
MIP-ip has been shown to be induced by IFN-y in both wild type and STATl-null 
macrophages (Gil et al., 2001). The study therefore could initially extend to 
investigation of the role of STAT3 in the regulation of MCP-1 and MIP-ip expression 
in the STATl-null cells. STAT3 phosphorylation and the effect of STAT3-knockdown 
by siRNA on gene expression in STATl-null cells might be two of the potential 
approaches for future study. The effect of blockage of ERK and JNK on the potential
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STAT3 transcriptional activity could then be investigated.
Cross-talk between different signalling pathways is relatively common in the 
regulation of gene expression in response to IFN-y as discussed in Chapter 4 (section 
4.4.4). It is thus important that further studies are carried out in relation to the 
potential cross-talk between the ERK/JNK pathways and others, such as CK2, PI3K, 
PKC5 and CaMKII pathways. Such studies could involve analysis of the activation of 
a particular pathway (e.g. ERK) in cells where the action of key components of other 
signalling pathways has been inhibited either by the use of pharmacological agents, 
siRNA-mediated knockdown or use of macrophages from knockout mice.
Adhesion assays conducted in this study have shown that the inhibitors for ERK, JNK 
and PI3K prevent the IFN-y-stimulated adhesion of monocytes to endothelial cells. It 
is, however, difficult to come to any firm conclusions on the exact roles of these 
kinases in the adhesion process due to the reduced viability of endothelial cells as a 
result of incubation with the inhibitors for a prolonged period of time. It is thus of 
particular importance to further confirm the results through alternative approaches. 
SiRNA/shRNA-mediated knockdown of each kinase might represent one potential 
approach instead of the use of pharmacological inhibitors.
I
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7.3.2 Future investigation into the mechanisms underlying the inhibitory 
effects of the therapeutic agents on IFN-y signalling
Although most of the actions of PPAR or LXR agonists are mediated through the 
corresponding NR, we have noticed that a number of previous studies on 
transrepression by these agonists on IFN-y-mediated gene expression have suggested 
some NR-independent effects (see Table 1.7 for a list of studies). In addition, it 
remains to be determined what the exact role of RXR is in the 22R/9cRA-mediated 
inhibition of IFN-y responses as discussed above. It is therefore essential that this is 
investigated before detailed studies on the mechanisms underlying transrepression are 
carried out. This could be achieved through the analysis of the actions of the agonists 
on mRNA expression of marker genes and/or STAT1 phosphorylation/transactivation 
in cells where the expression of the corresponding NR has been knocked down by 
RNAi approaches.
EMSA analysis has shown that the activation of LXRs, but not PPARs or simvastatin 
inhibits the STAT1 DNA binding in vitro. It will therefore be of interest to confirm 
whether this is also the case in vivo using ChIP assays. Such analysis could then be 
extended to a range of genes, in order to discriminate between potentially global 
effects and those that are likely to be promoter-specific.
Initial studies on the nucleo-cytoplasmic translocation using western blot analysis 
suggest that activation of LXR inhibits the IFN-y-induced nuclear accumulation of 
activated phospho Tyr701 STAT. LXR agonists have also been shown to attenuate the 
STATl phosphorylation at Tyr701 site. The possibility therefore remains that the 
reduced nuclear amounts of Tyr701 phospho-STATl observed is merely due to 
inhibition of STATl phosphorylation. To further confirm the effect of these potential 
therapeutic agents on nuclear accumulation of STATl, immunoflorescence analysis 
should be carried out as used in numerous publications studying the 
nucleo-cytoplasmic cycling of STATl (Begitt et al., 2000; Meyer et al., 2003; Sadzak
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I et al., 2008). For this, the cells are pre-treated with the corresponding agent and 
subsequently stimulated with IFN-y for the appropriate period of time (the optimal 
time point should be determined from initial experiments). STATl in fixed cells could 
then be visualised by indirect immunofloresence microscopy using an anti-STATl 
antibody and fluorescently-labelled secondary antibody [e.g. Cy3-labelled goat 
anti-rabbit antibody (Jackson ImmunoResearch, Cambridge, UK)]. Confocal 
microscopy available in our university is a powerful tool that could produce images 
with high resolution to study the location of the protein and dynamic processes in the 
cells.
Both PPAR-y and LXRs are subjected to SUMOylation. Such SUMOylation and 
NCoR-dependent mechanism has been found to be responsible for transrepression of 
LPS-induced expression of certain genes in mouse macrophages (Pascual et al., 2005; 
Ghisletti et al., 2007). It is thus of particular interest to probe whether this is also 
important for transrepression of IFN-y signalling. The study could involve 
investigating the effect of RNAi-mediated knockdown of the rate-limiting, 
E2-conjugating enzyme Ubc9, that is required for SUMOylation of target proteins 
(Hay, 2005). The read-out could mainly be changes in mRNA expression of key 
downstream targets by PCR analysis. To further test the ligand-dependent 
SUMOylation of NRs, both in vitro and in vivo approaches could be used. In vitro 
SUMOylation reactions could be carried out by adding recombinant SUMO and Ubc9 
to in v/Zro-translated NRs [see (Ghisletti et al., 2007) for details]. The NRs can be 
synthesized in vitro directly from PCR products using commercially available in vitro 
translation kits, such as PROTEINscript™ II (Ambion/Applied Biosystems, 
Warrington, UK). For in vivo SUMOylation assays, the plasmids specifying for 
FLAG-tagged NR is transfected into cells in the absence or presence of those for 
Myc-tagged SUMO-1, -2 or -3. Protein extracts are subjected to western blot analysis 
using anti-FLAG antibodies where the appearance of higher molecular weight is 
indicative of potential SUMOylation, and the presence of SUMO moiety can be
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confirmed by western blot using anti-Myc antibodies (see (Pascual et al., 2005; 
Ghisletti et al., 2007) for details).
Ant-inflammatory effects of statins have been suggested to be mediated through 
PPAR-dependent pathways (Paumelle and Staels, 2007). In order to investigate the 
importance of each PPAR isoform in statins-dependent inhibition of IFN-y-induced 
gene expression, RNAi-mediated knockdown of corresponding PPAR isoforms could 
be carried out. The changes in statins-mediated inhibition of the IFN-y response 
marker genes could be then monitored using PCR. It would also be of interest to 
evaluate whether there is a synergistic action of statins and PPAR ligands on IFN-y 
signalling. This could be achieved by investigating the IFN-y-induced gene expression, 
STATl phosphorylaiton or transactivation in response to statins and PPAR ligands 
individually and in combination.
A recent study suggested that statins inhibit the CRP-induced inflammatory gene 
expression by attenuating the ERK pathway (Montecucco et al., 2009). In order to 
evaluate whether this is also the case in IFN-y signalling, the study could be initially 
extended to investigate the effect of statins on IFN-y-induced ERK activity. The effect 
of knockdown of ERK (e.g. by RNAi) on statins-mediated inhibition of gene 
expression could also been studied mainly using RT-PCR analysis.
i
325
Chapter 7: General Discussion
7.4 Implications for the treatment of atherosclerosis
Recent studies have demonstrated the selective targeting of protein kinases as a 
therapeutic approach, and it is a common procedure to use small inhibitor molecules 
(Daub et al., 2004; Buschbeck, 2006; Roberts and Der, 2007). Indeed, potential 
therapeutic strategies have been investigated in relation to the treatment of 
inflammatory diseases that involve the inhibition of ERK- or JNK-dependent 
signalling (Bennett, 2006; Schuh and Pahl, 2009). Further research into these 
pathways could lead to the development of specific therapeutics without undesired 
side effect. The identification of the molecular mechanisms underlying the 
anti-inflammatory effects of agonists for PPARs and LXRs, as well as statins, in 
relation to IFN-y responses provides additional targets for therapeutic intervention.
Chemokines and adhesion molecules are key inflammatory mediators that play pivotal 
roles in the recruitment of inflammatory cells to lesion sites, a crucial early step in 
atherogenesis (section 1.4). Previous studies have demonstrated that the deficiency of 
several chemokines or adhesion molecules in mouse models of atherosclerosis 
protects against lesion formation (Collins et al., 2000; Cybulsky et al., 2001; Ni et al., 
2001; Inoue et al., 2002b). The broad-spectrum inhibitor of chemokines has also been 
investigated for a potential treatment of inflammatory diseases with some success 
(Grainger and Reckless, 2003; Johnson et al., 2004). The identification of 
ERK-dependent pathways in the regulation of chemokine and adhesion molecule 
expression by IFN-y in macrophages suggests a beneficial, athero-protective effect of 
specific inhibition of ERK signalling. The suggestion of potential role for ERK in the 
IFN-y-induced adhesion of monocytes to endothelial cells adds further support to the 
potential therapeutic significance of this signalling pathway for atherosclerosis. The 
inhibition of ERK activity by specific pharmacological inhibitors has previously been 
suggested as a potential therapeutic strategy in pulmonary inflammatory disease 
(Duan et al., 2004; Schuh and Pahl, 2009). Investigation into therapeutic strategies for
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treatments of cancer that involves the inhibition of ERK-dependent signalling have 
led to great success and have been taken into phase I or II clinical trials (Rinehart et 
al., 2004; LoRusso et al., 2005; Roberts and Der, 2007; Adjei et al., 2008). It is 
possible that these may be applied to atherosclerosis.
The requirement of JNK in IFN-y responses suggests that signalling through this 
kinase may also provide a target for therapeutic intervention of atherosclerosis. 
SP600125 has been used to attenuate disease progression in a number of rodent 
models of pulmonary inflammatory disorders, including single and chronic allergen 
challenge in rats (Eynott et al., 2003; Eynott et al., 2004) and mouse (Nath et al., 
2005). Based on the numerous findings on crucial roles of JNK in immune and 
inflammatory responses, it has been assumed that JNK inhibitors might reduce 
leukocyte infiltration as well as the expression of chemokines in pulmonary cells 
(Bennett, 2006), consistent with our findings in macrophages in this study. The 
therapeutic strategy based on the use of low molecular weight compounds, such as 
SP600125, may thus also be applicable to atherosclerosis.
The findings in this study clearly demonstrated that the agonists for PPAR-a and -y, as 
well as statins, inhibit the IFN-y-induced chemokine and CIITA gene expression. The 
results add direct support to the crucial anti-inflammatory and possibly 
immono-modulatory actions of these therapeutic agents and indicate the potential 
therapeutic benefits for these agents for the treatment of atherosclerosis, and possibly 
other inflammatory diseases. Although the underlying mechanisms are at present 
unclear, compelling evidence from animal and clinical studies has indicated that 
PPARa (fibrates) and PPARy (TZD) could exert cardio-protective effects through 
their anti-inflammatory actions (Sidhu et al., 2003; Yue et al., 2003; Wang et al., 2005; 
Yu et al., 2007; Bulhak et al., 2009). The potentially beneficial pleiotropic effects of 
statins on atherosclerosis are undergoing a number of clinical trials and preliminary 
studies have generated promising results (Davignon and Leiter, 2005).
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Despite the potentially important therapeutic benefits of these agents, these drugs 
possess a number of deleterious side effects, which have not only restrained their 
clinical use but have also led to the unsuccessful clinical development of many PPAR 
agonists (Rubenstrunk et al., 2007; Shearer and Billin, 2007). Therefore, one of the 
excellent strategies for the development of PPAR agonists-derived drugs for the 
treatment of atherosclerosis would be to preferentially transrepress inflammatory 
genes in key atheroma cells, instead of transactivating detrimental metabolic genes, 
thereby retaining their athero-protective actions without undesired side effects. Our 
findings on the anti-inflammatory actions of these therapeutic agents in relation to 
IFN-y responses in macrophages suggests that inhibition of IFN-y-induced 
pro-inflammatory gene expression provide potentially valuable therapeutic target for 
the development of next generation of cell-type- and target gene-type-selective PPAR 
agonists. A newly synthesised PPARy ligand MBX-102/JNJ39659100 with selective 
activity has shed light on the development of such therapeutic drugs. This new type of 
ligand has been shown to act as a selective PPARy activator with weak transactivation 
but robust transrepression activity and therefore exhibits full therapeutic activity 
without the classical PPARy side effects (Gregoire et al., 2009). Likewise, the 
development of cell-type- or tissue-selective statins could potentially be a better 
therapeutic approach without the undesired side effects.
The inhibitory effects of LXR ligands on the IFN-y-mediated responses provide 
further evidence that these agonists could protect against the development of 
atherosclerosis, not only due to their well-appreciated roles in promoting reverse 
cholesterol transport but also their potential function in the regulation of immune and 
inflammatory responses. LXR ligands therefore may be valuable candidates for the 
development of novel therapeutic approaches for the treatment of inflammatory 
conditions beyond atherosclerosis. Indeed, the potential therapeutic benefits of LXR 
ligands for the treatment of pulmonary inflammation have been previously 
demonstrated in cultured macrophages and mouse models in vivo (Birrell et al., 2007;
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Smoak et al., 2008).
The activation by the LXRs of de novo lipogenesis and associated elevation of plasma 
VLDL-triglyceride levels represents a major challenge for pharmaceutical 
development of ideal LXR agonists for the treatment of atherosclerosis (Grefhorst et 
al., 2002). One of the potential strategies to minimise the side effects of LXR ligands 
is the identification of target gene-selective or tissue-selective LXR agonists. Our 
results clearly demonstrate the inhibitory effects of LXR ligands on IFN-y signalling, 
via targeting STATl-dependent pathway in macrophages, thereby suggesting that 
STATl-mediated IFN-y signalling in macrophages provides specific targets for the 
development of novel therapeutic approaches.
7.5 Concluding remarks
From the work presented in this thesis, it is clear that IFN-y mediates the regulation of 
STATl-dependent pathway in macrophages via several signalling cascades. The 
IFN-y-dependent signalling and the target genes studied have important functions in 
the pathogenesis o f atherosclerosis. Moreover, the studies presented in this thesis also 
identified crucial anti-inflammatory actions of agonists for PPARs and LXRs, as well 
as statins on IFN-y-mediated responses in macrophages. A complete understanding of 
the molecular mechanisms involved in the key signalling pathways and the 
anti-inflammatory effects of these therapeutic agents will hopefully lead to the 
development of new therapeutic strategies to combat this disease.
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DNA molecular weight markers
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I —  610B 
- 5 Q 9 0  
- 4 0 7 2
- 3 0 5 4
I —  2 0 3 6  
- 1 6 3 6
- 1 0 1 8
5 0 6 , 5 1  7 
3 9 6  
I— 3 4 4  
2 9 8
2 2 0  
2 0 1  
154  
1 34
7=;
J ° - 19D 9 1 6 2  
0 1 4 47 1 2 6
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Cat No. N3231S/N3231L
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0.5pg/lane
Cat No. 15615-016
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Full-range Ranbow™  M olecular Weight M arkers
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25
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12% SDS-PAGE gel 
Cat. No. RPN800 (GE healthcare)
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Appendix II
Plasmid vectors
|S .i^ 8 8 § o £ S S
xxcqoqiuujcozxx<
Sm al
pcDNA3
5.4 kb
•Tth111l
SaiyXDal
There is an ATG upstream 
of the Xba I site. Bsml
BamHI
3 STFIT s ite s  from the Ly6e promoter 
BamHI
6060 bp
3xLy6e pZLuc—TK 
6060 bp 
(Tags not. drawn to scale) 
(Insert not drawn to scale)
390
Appendix
Amp' poly{A) signai
(tor background reduction)
Sma i 
Kpnl 
Sac I M>u\ 
N m  I 
Xhol Bgn I 
Hind ill
tori cri2744
2738
Sa/I
SamH
poiy(A) signal 
{for luc reporter)
SV40
2043 p m  I
Ssp J 2138 2256
Xfrif? 11933
Sea 1 
1814
Sph 12699
Nae 12758 
Nhe I 2789
pSP64 Poly\A) 
Vector
(3,030bp)
PvuW
285
B g\ J  
1454
SP8 i 1
Hnd 111 7
m i 20
Sa!\ 22
Acc 1 23
II 24
;® al 28
SamHI 34
Am 1 39
Sma 1 41
Sac I 50
(dA:dT)g0
EeoR I 88
 start
391
CS
Q6
VA
0^
.2A
Appendix
C^[Cl>'P<b^O— E q  -C: -c; o t : i £ :  m|  ^ : a . ^  cosq |
Comments for pCEP4: 
10186 nucleotides
Sal I
EcoRV
pCEP4
10.2 kb
f l_ o r ig in , 
fimpR_promoter, / {
\\ f
\ 4716
4323
CflG_enhancer 
Nctel 567
CRF
flm picillin—
,lacZ_a ,
M13_pUC_fuid_primer , CMV_immearly_prc
M13 Fon»ard20_priin«r<>'V-f»>d_prifner
Spel 332 CMV_promoter
SacI 901
: pCE P_ fwd_pr imer 
EK
H indiII 994 
Notl 1001 
EagI 1001 
EcoRI 1008 
B g lll 1020 
EcoRV 1028 
Kpnl 1036 
S a il 1039 
Xbal 1045 
BamHI 1051 
Smal 1057
I
A
pBR322_origin
enhancer 
SV40_promoter 
SV40_origin 
SV40pro F_prlmer 
StuI 2022 
Xhol 2045 
' . T7_promoter
M13_pliC_rev_primer
lac_promoter
hGH_Pfl_terminator 
flgel 1603 
pBflBE_3_primer
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Appendix III
t-Test
Mean 1 = r\
Mean 2 = X2 
Variance = acf
nl »2
i _x\~x2
t-Table
A difference between two means is significant (at the given probability level) if the calculated 
t value is greater than the value given in this table. A probability of p = 0.05 (95% probability 
of making a correct statement) is usually acceptable for biological work.
When comparing two means, the number o f degrees o f freedom is (nl + n2)-2, where n l is the 
number o f replicates o f treatment 1, and n2 is the number o f replicates of treatment 2 (adapted 
from http://helios.bto.ed.ac.uk/bto/statistics/tress4a.html#Student,s%20t-test).
m m
P-Value 0.1 0.05 0.01 o © ©
1 6.31 12.71 63.66 636.62
2 2.92 4.30 9.93 31.60
3 2.35 3.18 5.84 12.92
4 2.13 2.78 4.60 8.61
5 2.02 2.57 4.03 6.87
6 1.94 2.45 3.71 5.96
7 1.89 2.37 3.50 5.41
8 1.86 2.31 3.36 5.04
9 1.83 2.26 3.25 4.78
10 1.81 2.23 3.17 4.59
Standard deviation 1 = a  j 
Standard deviation 2 = a 2
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